class;term;comment
material entity;rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine;
material entity;T. gondii recombinant vaccine vector rBCGpMV361-TgCyP;
material entity;S. pneumoniae pspA-rBCG Vector Vaccine;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group W-135 / meningococcal polysaccharide vaccine group Y Injectable Solution [Menquadfi];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [Mencevax Acwy];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [Menveo];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Mastaflu];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Invivac];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [Menactra];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [ACWY Vax];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Begrivac];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Imuvac];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Enzira];
material entity;Bordetella pertussis BPZE vectored vaccine;
material entity;Actinobacillus pleuropneumoniae HS93Tox-/pIG-T1K vectored vaccine;
material entity;pCR3.1-VS-HSP65-TP-GRP6-M2;
material entity;Autologous TriMix-DC Melanoma Vaccine;A dendritic cell vaccine consisting of dendritic cells (DCs) electroporated with mRNA encoding three adjuvants, CD40 ligand (CD40L), a constitutively active TLR4, and CD70 (all together termed TriMix). coelectroporated with full-length mRNA encoding MAGE-A3, MAGE-C2, Tyrosinase and gp100. and linked to DC-LAMP, with potential immunostimulating activity. Upon vaccination, the DCs may stimulate the immune system to mount an antigen-specific cytotoxic T-lymphocyte (CTL) response against the melanoma antigens. This may decrease cellular proliferation of melanoma cells expressing these antigens. Electroporation with the adjuvants CD40L and TLR4 allows for the generation of mature and active DCs. electroporation with CD70 provides a costimulatory signal to CD27+ naive T cells thereby supporting T-cell proliferation and inhibiting T-cell apoptosis.
material entity;AE-Poxine;
material entity;Aeromonas hydrophila LSA34 vector vaccine WED/pUTDgap;
material entity;SL3261 expressing T. spiralis Ag30;
material entity;VMCL;
material entity;SRL172;
material entity;smallpox vaccine;
material entity;Newcastle disease virus lysate;
material entity;meningococcal group B vaccine 0.3 MG/ML Injectable Suspension;
material entity;meningococcal group A polysaccharide 0.008 MG/ML / meningococcal group C polysaccharide 0.008 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.008 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.008 MG/ML Intramuscular Solution;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution [Mengivac A + C];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution [AC Vax];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution [Mengivac];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injection [ACWY Vax];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [Nimenrix];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injection [Nimenrix];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injection [Menveo];
material entity;rSPV-PCV2-cap;
material entity;BCG-DHTM;
material entity;pcDNA3-MCC/ST;
material entity;mRNA-electroporated dendritic cells encoding gp100 and tyrosinase as melanoma vaccine;
material entity;short overlapping peptides and full-length recombinant protein;
material entity;Multivalent immunotherapeutic vaccine;The approach focuses on the use of five primary patient derived melanoma cells (MEL-2, MEL-V, 3MM, KFM, and GLM-2). These cells display differential in vitro migratory and invasive properties as well as have the ability to form solid tumors when implanted into BALB/c nude mice. The retention of the innate phenotype of these primary patient derived cells together with the expression of a multitude repertoire of melanoma associated antigens offers a novel opportunity to target melanoma so as to avoid immune evasion
material entity;diphtheria toxoid vaccine, inactivated / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Meningitec];
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection [Meningitec];
material entity;Haemophilus B Conjugate Vaccine / meningococcal group C polysaccharide Injectable Solution [Menitorix];
material entity;diphtheria toxoid vaccine, inactivated / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Menjugate];
material entity;meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Boostrix];
material entity;meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Bexsero];
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate];
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB];
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection;
material entity;Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L;
material entity;Herpes Simplex Virus 2 DNA Vaccine encoding gD;
material entity;Avian pneumovirus DNA Vaccine expressing the F gene;
material entity;Classical Swine Fever Virus DNA Vaccine pcDNA/E2 with TRIF;
material entity;Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2;
material entity;Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk] Box of 25 by Gerke;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Mevita;
material entity;influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide Injectable Solution [Menitorix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Mtk;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Mastaflu];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Orifarm Leverkus;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Intramuscular Solution [Menactra];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Veron;
material entity;influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide Injection [Menitorix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Emra-Med;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Enzira];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Eurim-Pharm;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Begrivac];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Gerke;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Invivac];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Kohlpharma;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Imuvac];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [ActHIB];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Axicorp;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML [Menjugate];
material entity;E. maxima DNA vaccine pcDNA-Gam56;
material entity;Murine cytomegalovirus DNA vaccine pgM-pgN;
material entity;Hepatitis D DNA vaccine pcDNA3p27/Ad5F35p27;
material entity;T. gondii DNA vaccine pVAX-TgMIC13;
material entity;Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML;
material entity;IBDV DNA vaccine pCAGVP243-IL-18;
material entity;Bordetella pertussis fimbriae 2/3 vaccine, inactivated;
material entity;IBDV DNA vaccine pCAGoptiVP2/rVP2;
material entity;Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML;
material entity;P. multocida DNA vaccine pcDNA-OMPH + pcDNA-OMPA;
material entity;Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML;
material entity;IBV DNA vaccine pVAX1-16S1/M/N;
material entity;L. major DNA vaccine pcLACK + IL-22;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated;
material entity;T. cruzi DNA vaccine encoding TSA-1 and Tc24;
material entity;Bordetella pertussis toxoid vaccine, inactivated;
material entity;T. gondii DNA vaccine ROP8-pVAX-1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Cc;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Menjugate];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Emra-Med;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Meningitec];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Europharma;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection [Meningitec];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax] Box of 1 by Boehringer Ingelheim;
material entity;meningococcal group B vaccine Injectable Suspension [Bexsero];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax] Box of 1 by Sanofi;
material entity;meningococcal group B vaccine Injectable Solution [Bexsero];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Aca Mueller;
material entity;meningococcal group B vaccine Injectable Suspension [Trumenba];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Axicorp;
material entity;meningococcal group B vaccine Injectable Suspension [Boostrix];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Prefilled Syringe [Mencevax Acwy];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide Injection [Mengivac A + C];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3 by European;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide Injection [AC Vax];
material entity;Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML;
material entity;BVDV DNA vaccine encoding E2;
material entity;Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML;
material entity;P. multocida DNA vaccine pcDNA-OMPH/OMPA;
material entity;Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML;
material entity;Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML;
material entity;E. rhusiopathiae DNA vaccine pcD-ACSC;
material entity;influenza virus DNA vaccine p-Beta-actinH7HA;
material entity;influenza virus DNA vaccine pCMVH5HA;
material entity;influenza virus DNA vaccine pCAGGHA;
material entity;influenza virus DNA vaccine pCAGGoptiHA;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y / tetanus toxoid vaccine, inactivated;
material entity;Haemophilus B Conjugate Vaccine / meningococcal group C polysaccharide;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine;
material entity;meningococcal group C polysaccharide / tetanus toxoid vaccine, inactivated;
material entity;influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide;
material entity;Meningococcal Polysaccharide Vaccine, Groups A & C;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y;
material entity;PRRSV DNA vaccine pIRESorf7/IL-2;
material entity;PRRSV DNA vaccine pIRESorf5/IL-2;
material entity;avian influenza virus DNA vaccine pCMV-HA;
material entity;avian influenza DNA vaccine pCMV-M;
material entity;PRRSV DNA vaccine pIRESorf5/IFN-Gamma;
material entity;PRRSV DNA vaccine pCA-U-optiGP5;
material entity;Chinese S. japonicum DNA vaccine SjC23;
material entity;Chinese S. japonicum DNA vaccine SjC23-Hsp70;
material entity;DNA vaccine expressing the E2 protein;
material entity;B. burgdorferi DNA vaccine encoding strain B31 OspA;
material entity;PRRSV DNA vaccine pCI-ORF5/ORF6;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML [Meningitec];
material entity;meningococcal group A polysaccharide 0.008 MG/ML / meningococcal group C polysaccharide 0.008 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.008 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.008 MG/ML [Menactra];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML [ActHIB];
material entity;meningococcal group B vaccine 0.3 MG/ML [Boostrix];
material entity;meningococcal group B vaccine 0.3 MG/ML [Bexsero];
material entity;Haemophilus capsular oligosaccharide 0.015 MG/ML;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML [Menjugate];
material entity;diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML [Meningitec];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injection;
material entity;Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21;
material entity;DNA vaccine expressing PspA;
material entity;pCgap DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase;
material entity;B16 melanoma DNA vaccine pSin-mTRP-1;
material entity;PsaA DNA Vaccine;
material entity;Hepatyrix vaccine;
material entity;H. rhabdovirus DNA Vaccine encoding N and G;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML;
material entity;Marburg virus recombinant vector vaccine MBGV GP/MBGV NP;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [Recombivax];
material entity;N. meningitidis DNA vaccine P3A;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [Recombivax];
material entity;influenza virus DNA vaccine M2-DNA/M2-Ad;
material entity;pneumococcal capsular polysaccharide type 4 vaccine;
material entity;Leptospira interrogans DNA vaccine pTARGET/ LigBrep;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [Heplisav-B];
material entity;Leptospira interrogans DNA vaccine ompL1-pcDNA3.1(+);
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection;
material entity;Laryngotracheitis DNA Vaccine encoding gB;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection;
material entity;SIV recombinant vector vaccine rAd5/rLCMV;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML;
material entity;H. pylori DNA vaccine pcDNA3.1-hspB;
material entity;H. pylori DNA vaccine pcDNA3.1-hspA;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Veron;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Emra-Med;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by HVD;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Merck;
material entity;Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.05 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by MSD;
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Sanofi;
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Axicorp;
material entity;Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Cc;
material entity;Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10 by Merck;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Emra-Med;
material entity;Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Gerke;
material entity;Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.005 MG;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.25 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Veron;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.25 MG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Recombivax];
site;vaccination site;The site that is the part of the host body and the entrance point where a vaccine is administered.
material entity;HSV 2 DNA vaccine pVAX-HSV-2gD-HSP70;
material entity;pneumococcal capsular polysaccharide type 8 vaccine;
material entity;RHDV DNA vaccine pcDNA-VP60;
material entity;pneumococcal capsular polysaccharide type 33F vaccine;
material entity;pneumococcal capsular polysaccharide type 3 vaccine;
material entity;HRSV DNA vaccine DRF-412;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Recombivax];
material entity;BRSV DNA vaccine VCL-Fb;
material entity;Hepatitis B Surface Antigen Vaccine Injection [Recombivax];
material entity;Y. pestis DNA vaccine YscF-2;
material entity;Recombivax Injectable Product;
material entity;Hantavirus DNA vaccine pWRG/HTN-M;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Recombivax];
material entity;Duck hepatitis virus 1 DNA vaccine pSCA/VP1;
material entity;P. aeruginosa DNA vaccine pGACAG-OprF/OprI;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [Recombivax];
material entity;P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA;
material entity;BCG Vaccine (by Organon Teknika);
material entity;P. aeruginosa DNA vaccine pGACAG-PcrV;
material entity;1 ML Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML Injection;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10 by Merck;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10 by Sanofi;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML;
material entity;COVID-19 vaccine Injectable Solution;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe;
material entity;influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide Injectable Solution;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Kohlpharma;
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus;
material entity;Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck;
material entity;Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Sanofi;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injection;
material entity;Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.05 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10;
material entity;Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.005 MG;
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.005 MG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Sanofi;
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.05 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Eurim-Pharm;
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Orifarm Leverkus;
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG/ML;
material entity;Diphtheria-Tetanus-Poliovirus-Haemophilus B-Hepatitis B vaccine;
material entity;B. pertussis DNA vaccine pcDNA/S1;
material entity;Diphtheria Toxoid-Pertussis-Poliovirus vaccine;
material entity;A. pleuropneumoniae DNA vaccine pcDNA-apxIA/pcDNA-apxIIA;
material entity;Fluvax vaccine;For the prevention of influenza caused by Influenza Virus, Types A and B. For the Southern Hemisphere 2017 season, the vaccine is indicated for use only in persons aged 5 years and over.
material entity;Dengue Virus DNA Vaccine expressing prM/E proteins;
material entity;seasonal Influenza A27:H29 vaccine;
material entity;B. abortus DNA vaccine pVF278;
material entity;Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML;
material entity;S. aureus DNA vaccine pClfaSrtD13;
material entity;M. avium DNA vaccine DNA-Av35/p2AIL12;
material entity;pneumococcal capsular polysaccharide type 1 vaccine;
material entity;B. anthracis DNA Vaccine expressing PA;
material entity;human H1N1 influenza monovalent vaccine;A monovalent vaccine used to protect against H1N1 influenza virus.
material entity;S. aureus DNA vaccine encoding Efb, FnbpA, ClfA, Cna;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Veron;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.5 MG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Aca Mueller;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.008 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Axicorp;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Merck;
material entity;meningococcal group C polysaccharide 0.008 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Mtk;
material entity;meningococcal group B vaccine 0.3 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Orifarm Leverkus;
material entity;meningococcal group C polysaccharide 2.5 MG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Sanofi;
material entity;meningococcal group C polysaccharide 0.5 MG;
material entity;meningococcal group A polysaccharide 0.008 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Gerke;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by HVD;
material entity;meningococcal group A polysaccharide 2.5 MG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Kohlpharma;
material entity;meningococcal group A polysaccharide 0.5 MG;
material entity;pneumococcal capsular polysaccharide type 12F vaccine;
material entity;Dengue Virus DNA Vaccine encoding NS1;
material entity;pneumococcal capsular polysaccharide type 11A vaccine;
material entity;Dengue Virus DNA Vaccine D1ME-VRP;
material entity;pneumococcal capsular polysaccharide type 14 vaccine;
material entity;pneumococcal capsular polysaccharide type 2 vaccine;
material entity;E. tarda DNA vaccine pCE18;
material entity;pneumococcal capsular polysaccharide type 19F vaccine;
material entity;C. pneumoniae DNA vaccine pHSP-60;
material entity;pneumococcal capsular polysaccharide type 22F vaccine;
material entity;E. tarda DNA vaccine pCEsa1;
material entity;pneumococcal capsular polysaccharide type 20 vaccine;
material entity;E. tarda DNA vaccine pCE6;
material entity;pneumococcal capsular polysaccharide type 17F vaccine;
material entity;Foot-and-Mouth Disease Virus Cationic Microparticle-coated DNA Vaccine;
material entity;pneumococcal capsular polysaccharide type 15B vaccine;
material entity;Foot-and-Mouth Disease Virus DNA Vaccine pSinCMV-Vac-MEG990;
material entity;pneumococcal capsular polysaccharide type 19A vaccine;
material entity;C. trachomatis DNA vaccine pWRG7079::MOMP;
material entity;pneumococcal capsular polysaccharide type 18C vaccine;
material entity;FMDV DNA Vaccine encoding P1 and non-structural proteins 2A, 3C, and 3D;
material entity;Feline immunodeficiency virus recombinant vector vaccine FIV-Delta-RT;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Mtk;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.05 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Haematogmbh;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Gerke;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.005 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by HVD;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Kohlpharma;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Merck;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Cc;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.5 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Emra-Med;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.008 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Aca Mueller;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Eurim-Pharm;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Axicorp;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Europharma;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 2.5 MG;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 2.5 MG;
material entity;Hepatitis A virus-Typhoid vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [Recombivax];
material entity;H. pylori DNA vaccine poipA;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injection;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 20000 UNT/ML;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Product;
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Injection;
material entity;Infanrix Penta;A combination vaccine against diphtheria, tetanus, pertussis, hepatitis B, and poliovirus.
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain;
material entity;Hepatitis B Surface Antigen Vaccine Injection [Heplisav-B];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 10;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 10;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML [Epaxal];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML [Havpur];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Ambirix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution;
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Injection [Zostavax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML [Zostavax];
material entity;Streptococcus pneumoniae capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;pneumococcal capsular polysaccharide vaccine;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [Zostavax];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML [Hepatyrix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML [Hepatyrix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix];
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Engerix-B];
material entity;P. yoelii DNA vaccine pDIP/PyCSP. 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML;
material entity;REV DNA vaccine VP22/gag and VP22/env;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection;
material entity;pneumococcal capsular polysaccharide type 9N vaccine;
material entity;Infectious Bursal Disease Virus DNA Vaccine expressing VP2;
material entity;pneumococcal capsular polysaccharide type 7F vaccine;
material entity;Infectious Bronchitis Virus DNA Vaccine encoding S1, N, and M;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML;
material entity;Japanese encephalitis virus DNA Vaccine pCJ-3/E encoding E;
material entity;pneumococcal capsular polysaccharide type 5 vaccine;
material entity;Japanese encephalitis virus DNA Vaccine P-JEV;
material entity;pneumococcal capsular polysaccharide type 6B vaccine;
material entity;IBV DNA vaccine pVAX1-N;
material entity;HRSV DNA vaccine pND-G;
material entity;pneumococcal capsular polysaccharide type 23F vaccine;
material entity;H. rhabdovirus DNA Vaccine encoding G;
material entity;Flu-Imune;A trivalent inactive influenza virus vaccine.
material entity;IBV DNA vaccine pVAX-S1 with GM-CSF adjuvant;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML [Havrix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Twinrix Paediatric];
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injectable Suspension [Twinrix Adult];
material entity;Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injectable Suspension [Twinrix Paediatric];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection;
material entity;meningococcal group B vaccine Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension [Hepatyrix];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe;
material entity;meningococcal group B vaccine Injectable Solution;
material entity;hepatitis A vaccine (inactivated) strain HM175 / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Suspension [ViATIM];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [Twinrix];
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injection;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Twinrix Adult];
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injectable Suspension;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Intramuscular Solution;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Prefilled Syringe;
material entity;influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide Injection;
material entity;1 ML Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML Injection [Vivaxim];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide Injection;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Prefilled Syringe;
material entity;pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML;
material entity;Infanrix Quinta;A combination vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b (Hib).
material entity;Human cytomegalovirus DNA vaccine pcGB;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B];
material entity;SHIV DNA vaccine encoding env and gag;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B];
material entity;P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B];
material entity;GSK1437173A;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B];
material entity;SHIV(Ba-L) DNA vaccine encoding env and gag;
material entity;QIV Dresden;A quadrivalent influenza vaccine against two influenza A strains and two influenza B strains.
material entity;P. yoelii DNA vaccine pPyHsp60-VR1012;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML;
material entity;P. berghei DNA vaccine encoding PbCSP;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Engerix-B];
material entity;P. berghei DNA vaccine CSP-3p28;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection;
material entity;P. yoelii DNA vaccine encoding MSP1;
material entity;P. yoelii DNA vaccine encoding PySSP2;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe Box of 1;
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Injectable Solution;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML;
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Twinrix Adult];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML [Vaqta];
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Twinrix Paediatric];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe;
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Twinrix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injectable Solution;
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Injectable Solution [Ambirix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10;
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Injectable Solution [Twinrix Adult];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe Box of 1;
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Injectable Solution [Twinrix Paediatric];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe Box of 10;
material entity;Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Ambirix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML [Vaqta];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML [Epaxal];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal];
material entity;Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;L1 protein, Human papillomavirus Vaccine;
material entity;Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML;
material entity;Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 20;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 50;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 20;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 50;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution [Vaqta];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution [Vaqta] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML [Vaqta];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 1;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Mtk;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension Box of 1;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Axicorp;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1 by Glaxosmithkline;
material entity;T. gondii irradiated sterilised tachyzoites;A Live attenuated vaccine irradiated sterilised tachyzoites that immunizes against Toxoplasma gondii trypmastigote.
material entity;T. gondii LDH1 and LDH2 mutant vaccine;A Live attenuated vaccine with LDH1 and LDH2 mutant that immunizes against Toxoplasma gondii trypmastigote.
material entity;T. gondii GRA17 mutant vaccine;A Live attenuated vaccine with GRA17 mutant that immunizes against Toxoplasma gondii trypmastigote.
material entity;UV-attenuated Toxoplasma gondii with DSCG adjuvant;A Live attenuated vaccine with DSCG adjuvant that immunizes against Toxoplasma gondii trypmastigote.
material entity;Pertussis Vaccine Injectable Solution;
material entity;Neisseria meningitidis 0.5 MG/ML;
material entity;Pertussis Vaccine 600 UNT/ML;
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML;
material entity;acellular pertussis vaccine, inactivated Injectable Solution;
material entity;Diphtheria Toxoid-Pertussis-Haemophilus B-Hepatitis B vaccine;
material entity;Pertussis Vaccine Injectable Suspension [Acel-P];
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML;
material entity;Pertussis Vaccine Injectable Suspension [Boostrix];
material entity;N. caninum Killed Protozoa Vaccine;A Inactivated vaccine that immunizes against Neospora caninum protozoa.
material entity;CTLVECNS;A Inactivated vaccine that immunizes against Toxoplasma gondii trypmastigote.
material entity;PfSPZ;A Live attenuated vaccine PfSPZ that immunizes against Plasmodium falciparum sporozoite.
material entity;RH-AMA1KO;A Live attenuated vaccine RH-AMA1KO that immunizes against Toxoplasma gondii trypmastigote.
material entity;p52(-)/p36(-) GAP;A Live attenuated vaccine p52(-)/p36(-) GAP that immunizes against Plasmodium falciparum sporozoite.
material entity;Pb(PfCS@UIS4);A Live attenuated vaccine Pb(PfCS@UIS4) that immunizes against Plasmodium falciparum sporozoite.
material entity;G. lamblia vaccine encoding a1-giardin;A Live attenuated vaccine encoding a1-giardin that immunizes against Giardi lamblia trophozoite.
material entity;G. lamblia vaccine using attenuated Salmonella vaccine expressing VSPH7;A Live attenuated vaccine expressing VSPH7 that immunizes against Giardi lamblia trophozoite.
material entity;G. lamblia bivalent DNA vaccine encoding a1-giardin and CWP2;A Live attenuated vaccine encoding a1-giardin and CWP2 that immunizes against Giardi lamblia trophozoite.
material entity;G. lamblia vaccine encoding a-enolase;A Live attenuated vaccine encoding a-enolase that immunizes against Giardi lamblia trophozoite.
material entity;EAU DNA vaccine IRBP-DNA encoding IRBP;
material entity;EAE DNA vaccine pZZ/MBP68-85 encoding MBP;
material entity;Autoimmune diabetes DNA vaccine pCMV-1/rGAD65 encoding GAD;
material entity;Autoimmune diabetes DNA vaccine pND2-SGAD55;
material entity;Glypican-3-derived peptide vaccine for human hepatocellular carcinoma;An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells.
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 25;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 10 by Glaxosmithkline;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 10;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 20 by Glaxosmithkline;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 20;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension Box of 25;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix] by Glaxosmithkline;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix];
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix] Box of 25 by Glaxosmithkline;
material entity;Adjuvant arthritis DNA vaccine CII encoding type II collagen;
material entity;Insulin-dependent diabetes mellitus DNA vaccine JwGAD65 + IL-4;
material entity;Autoimmune diabetes DNA vaccine pND2-GAD65-BAX encoding GAD and BAX;
material entity;Pristane-induced arthritis DNA vaccine DNA-hsp65 encoding Mycobacterium leprae 65-kDa heat shock protein;
material entity;Adjuvant arthritis DNA vaccine pCMV3.65 encoding HSP65;
material entity;B. burgdorferi DNA vaccine pCMV-ZS7/TPA encoding OspC from Borrelia burgdorferi sensu lato;
material entity;Herpes simplex virus DNA vaccine pCI-gB encoding gB;
material entity;West Nile virus DNA vaccine pCBWN encoding prM and E;
material entity;C. tetani DNA vaccine pcDNA3tetC encoding fragment C;
material entity;Herpes simplex virus DNA vaccine pSIN-gB encoding gB;
material entity;Adjuvant arthritis DNA vaccine pcDNA-CCOL2A1 encoding type II collagen;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 50;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 25;
material entity;0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P];
material entity;0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] by Glaxosmithkline;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 50 by Glaxosmithkline;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 20;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 50;
material entity;0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 25 by Glaxosmithkline;
material entity;B. anthracis DNA vaccine LF pDNA encoding LF;
material entity;B. anthracis DNA vaccine pDNA encoding PA;
material entity;H. rhabdovirus DNA vaccine pHRV-G encoding HIRRV and VHSV G proteins;
material entity;E. acervulina DNA vaccine 3-1E;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix] Box of 25;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 20;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 5;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 5;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 20 by Sanofi;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] by Sanofi;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 5 by Sanofi;
material entity;Optaflu;A vaccine against flu (influenza) in adults, especially in those who run an increased risk of experiencing associated complications in case they fall ill with flu.
material entity;Prostate cancer DNA vaccine hPSMAt encoding PSMA;
material entity;Trihibit;A vaccine for Diphtheria, haemophilus influenzae, pertussis, and tetanus diseases.
material entity;Prostate cancer DNA vaccine pcDNA3-STEAP encoding six-transmembrane epithelial antigen;
material entity;Virivac;A combined live virus vaccine used to prevent measles, mumps, and rubella.
material entity;Prostate cancer DNA vaccine pVax-PSA;
material entity;TD-Rix;A vaccine used to prevent diphtheria and tetanus in individuals over 6 years of age.
material entity;Prostate cancer DNA vaccine rPSMAt encoding PSMA;
material entity;Mumpsvax II;
material entity;Melanoma DNA vaccine hTRP2 encoding TRP-2;
material entity;Rabie-Vax;A vaccine for indivuduals who at risk or recently exposed to rabies.
material entity;Melanoma recombinant vector vaccine rVVmTRP-1 encoding TRP-1;
material entity;Tetracoq;An adsorbed diphtheria, tetanus, pertussis and inactivated poliomyelitis vaccine.
material entity;Neuroblastoma DNA vaccine HuDsec;
material entity;Rudivax vaccine;
material entity;Melanoma DNA vaccine pUB-TRP-2 encoding a fusion protein linking murine ubiquitin (UB) to the N-terminus of the full-length mTRP-2;
material entity;Melanoma DNA vaccine gp75 DNA encoding melanosomal membrane glycoproteins, gp75 Vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Aca Mueller;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Axicorp;
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25 by Mtk;
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3 by Emra-Med;
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML [Infanrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3 by Kohlpharma;
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix] Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3 by Mtk;
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1 by Eurim-Pharm;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1 by Kohlpharma;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1 by Mtk;
material entity;acellular pertussis vaccine, inactivated 0.008 MG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25 by Emra-Med;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 5;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 5;
material entity;Hib-Imune;Active immunization against Haemophilius influenzae type b in recommended routinely for children at 24 months of age and for children at 15 months of age enrolled in child care facilities.
material entity;M-M-R I;A vaccine used to protect against measles, mumps, and rubella for 12-15 month-old individuals.
material entity;Prostate cancer DNA vaccine psig-3P-Fc encoding 3P(hPSM, hPAP, or hPSA)-Fc fusion protein;
material entity;FP85A;A TB vaccine that uses attenuated fowlpox strain FP9 to express mycobacterial mycolyl transferase Ag85A.
material entity;Chinese S. japonicum DNA vaccine pVAX/SjFABP encoding FABP;
material entity;Chinese S. japonicum DNA vaccine pCMV-Sjc97 encoding paramyosin;
material entity;Chinese S. japonicum DNA vaccine SjCTPI-Hsp70;
material entity;Chinese S. japonicum DNA vaccine SjCTPI;
material entity;Certiva vaccine;A vaccine against diphtheria, tetanus, and pertussis.
material entity;T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain);
material entity;OmniHIB vaccine;A Haemophilus influenzae type B conjugate vaccine manufactured by GSB.
material entity;Prostate cancer DNA vaccine pmPSCA encoding PSCA;
material entity;T. gondii DNA vaccine T.g.HSP70;
material entity;T. gondii DNA vaccine pVR1020-GRA1;
material entity;MVA85A;
material entity;Prostate cancer DNA vaccine encoding PSCA;
material entity;Prostate cancer DNA vaccine PSCA-HSP encoding PSCA and HSP;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1 by Glaxosmithkline;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Mtk;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Haematogmbh;
material entity;acellular pertussis vaccine, inactivated Injectable Solution [Acel P Lederle];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by HVD;
material entity;acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution Box of 5;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Kohlpharma;
material entity;acellular pertussis vaccine, inactivated Injectable Solution [Tussoglobin];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Mevita;
material entity;acellular pertussis vaccine, inactivated Injectable Solution [Pac Merieux];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Emra-Med;
material entity;acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution [Tussoglobin];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 1 by Novartis;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Eurim-Pharm;
material entity;acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Gerke;
material entity;acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution [Tussoglobin] Box of 1;
material entity;acellular pertussis vaccine, inactivated 160 MG/ML [Tussoglobin];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Cc;
material entity;acellular pertussis vaccine, inactivated 160 MG/ML;
material entity;BCG Vaccine SSI;Pharmacotherapeutic group (ATC code): J 07 AN 01.
material entity;VEE virus recombinant vector vaccine RAd/VEEV#3 encoding TC-83;
material entity;VEE virus recombinant vector vaccine RAd/VEEV#2;
material entity;Carcinoma DNA vaccine pVAX/E2A;
material entity;Cancer DNA vaccine p.DOM-AH1 encoding fragment C;
material entity;IHNV DNA vaccine pCDNA-G encoding G;
material entity;VEE virus recombinant vector vaccine RAd/VEEV;
material entity;VEE virus DNA vaccine VEEV IA/B parent encoding structural genes;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Eurim-Pharm;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML [Covaxis];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Haemophilus B Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine Injection [Infanrix Hexa];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by GSK;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Kohlpharma;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML [Pediacel];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Glaxosmithkline;
material entity;2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Kohlpharma;
material entity;2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution [Tussoglobin] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Mtk;
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Haemophilus B Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine Injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Emra-Med;
material entity;2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution Box of 5;
material entity;0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P] by Lederle Products;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25 by Mtk;
material entity;2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution [Tussoglobin];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Emra-Med;
material entity;2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution;
material entity;Colorectal cancer DNA vaccine pCEA/HBsAg encoding carcinoembryonic antigen and hepatitis B surface antigen;
material entity;B-cell lymphoma DNA vaccine VCL-1642.XXX encoding a chimeric immunoglobulin molecule onsisting of tumor-specific variable (Id) regions;
material entity;B16 melanoma DNA vaccine pSin-hTRP-1 encoding TRP-1;
material entity;Rabiesvax vaccine;
material entity;Melanoma DNA vaccine pN4a-MAGE-1-GM;
material entity;Rabipur vaccine;A vaccine used to help prevent rabies infection in people who either have been, or are at risk of being bitten, licked or scratched by an animal infected with rabies virus.
material entity;Melanoma DNA vaccine pNL3-MAGE-1-GM;
material entity;diphtheria, tetanus and whole cell pertussis vaccine;
material entity;Lung metastasis DNA vaccine pCEP4-MUC1 encoding MUC1;
material entity;Lymerix;LYMErix [Lyme Disease Vaccine (Recombinant OspA)] is a noninfectious recombinant vaccine developed and manufactured by SmithKline Beecham Biologicals. The vaccine contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus.
material entity;Melanoma DNA vaccine SINCp c-muMUC18 encoding MCAM/MUC18;
material entity;Tevax vaccine;An inactIve vaccine used to prevent tetanus.
material entity;Melanoma DNA vaccine TA2M encoding tyrosinase peptides;
material entity;B16 melanoma DNA vaccine pCMV-hTRP-1 encoding TRP-1;
material entity;Hexavax;a hexavalent vaccine that has been withrawn on June 2012 by the European commission
material entity;Melanoma DNA vaccine pCR3.1-VS-HSP65-TP-GRP6-M2 encoding 6 tandem repeats of GRP;
material entity;Cholera Vaccine, USP;An active immunization against cholera, indicated only for individuals traveling to or residing in countries where cholera is endemic or epidemic.
material entity;Melanoma DNA vaccine VR-S8/VR-IL2/AD-S8 encoding survivin;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3 by Kohlpharma;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3 by Mtk;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1 by Emra-Med;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25 by Emra-Med;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25 by Mtk;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3 by Emra-Med;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax];
material entity;1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 20;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Mtk;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML [Repevax];
material entity;1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Waymade;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis] Box of 10;
material entity;1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 10 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis];
material entity;Genhevac B;This absorbed recombinant hepatitis B vaccine is indicated for active immunization against hepatitis B virus infection caused by all known subtypes in subjects of any age considered at risk of exposure to the virus.
material entity;Melanoma DNA vaccine VR1012/mPmel17;
material entity;Rabivac vaccine;A human diploid cell vaccine against rabies, a viral infectious disease.
material entity;Melanoma DNA vaccine hugp100 encoding gp100;
material entity;Meruvax I;HPV77/DE5 strain
material entity;WEE virus DNA vaccine pVHX-6 encoding 26S;
material entity;rVSV-ZEBOV;
material entity;Vaccinia virus DNA vaccine wtD8L;
material entity;ISS 1018 CpG ODN vaccine adjuvant;A CpG DNA vaccine adjuvant that is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity.
material entity;Vaccinia virus DNA vaccine 4pox;
material entity;VEE virus DNA vaccine encoding 26S;
material entity;HPV-16 L1 VLP;A human paillomavirus vaccine that has the vaccine antigen ingredient of monovalent non-infectious, L1 recombinant HPV-like particles (VLP).
material entity;Vaccinia virus DNA vaccine tPA-D8L;
material entity;Vaccinia virus DNA vaccine A33R from strain IHD-J;
material entity;Hepatitis B surface antigen vaccine;A Hepatitis B virus vaccine that uses recombinant Hepatitis B surface antigen as the antigen
material entity;B. anthracis DNA vaccine PA83 furin;
material entity;Vaccinia virus DNA vaccine pWRG/L1R;
material entity;HEPLISAV-B vaccine;A Hepatitis B surface antigen viral vaccine that utilizes a cytidine-phosphate-guanosine oligodeoxynucleotide (CpGODN) 1018, as an adjuvant.
material entity;Vaccinia virus DNA vaccine B5R;
material entity;B. anthracis DNA vaccine pCPA;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Mtk;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Orifarm Leverkus;
material entity;Pertussis Vaccine Injectable Suspension;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Gerke;
material entity;Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Glaxosmithkline;
material entity;Pertussis Vaccine 600 UNT/ML Injectable Suspension;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Kohlpharma;
material entity;Pertussis Vaccine Injectable Solution [Pertuvac];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Mevita;
material entity;Pertussis Vaccine Injectable Solution [Pa Vaccinol];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Aca Mueller;
material entity;Pertussis Vaccine 15000000000 UNT/ML Injectable Suspension Box of 5;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Axicorp;
material entity;Pertussis Vaccine 15000000000 UNT/ML Injectable Suspension;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Emra-Med;
material entity;Pertussis Vaccine 600 UNT/ML [Acel-P];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Eurim-Pharm;
material entity;Pertussis Vaccine 15000000000 UNT/ML Injectable Suspension Box of 5 by Aventis;
material entity;Pertussis Vaccine 15000000000 UNT/ML;
material entity;Diphtheria-Tetanus-Whole Cell Pertussis-Haemophilus b vaccine;A combination vaccine with whole cell that protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.
material entity;avian influenza virus DNA vaccine pH5HA;
material entity;J-Vax;An inactivated Japanese encephalitis vaccine (JVax *) for use by certain travelers to and expatriates in Asia.
material entity;M. marinum pCMV-85A;
material entity;Diphtheria-Tetanus-Acellular Pertussis-Haemophilus b vaccine;A combination vaccine that protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.
material entity;avian influenza virus DNA vaccine pNP;
material entity;Oral Poliovirus vaccine;
material entity;avian influenza virus DNA vaccine pN1NA encoding N1 neuraminidase;
material entity;IPNV DNA vaccine pEGFP-N1-SegA and pEGFP-N1-VP2;
material entity;FeLV DNA vaccine gag/pol and env;
material entity;IHNV DNA vaccine pIHN-G encoding glycoproteins;
material entity;VHSV DNA vaccine pVHS-G encoding glycoproteins;
material entity;Sindbis virus DNA vaccine encoding E2;
material entity;VEE virus DNA vaccine pSTU-TRDF encoding VEEV E3-E2-6K;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Mevita;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Eurim-Pharm;
material entity;0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Gerke;
material entity;0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Haematogmbh;
material entity;0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim] by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Kohlpharma;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Aca Mueller;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Axicorp;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Cc;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Emra-Med;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Veron;
material entity;Dengue virus DNA vaccine sC encoding prM and E;
material entity;YF 17DD-YFV;A YF-17DD vaccine t hat is manufactured by Bio-Manguinhos
material entity;Dengue virus DNA vaccine sB encoding E;
material entity;Stamaril vaccine;It is live attenuated YFV vaccine strain 17D manufactured in China, France, Senegal, and the USA. In powder and solvent for suspension for injection in pre-filled syringe.
material entity;ACWY Vax vaccine;a licensed N. meningitidis vaccine that includes meningococcal polysaccharides from Groups A, C, Y and W-135 combined, and is manufactured by GSK.
material entity;Dengue virus DNA vaccine sABC encoding prM and E;
material entity;MRKAd5 HIV-1 gag/pol/nef;The MRK adenovirus type 5 human immunodeficiency virus type 1 clade B gag/pol/nef vaccine is a replication-incompetent adenovirus type 5-vectored vaccine that elicits cell-mediated immunity against conserved human immunodeficiency virus proteins.
material entity;S. mansoni DNA vaccine Sm-p80-pcDNA3 encoding the large subunit of S. mansoni calpain;
material entity;S. mansoni DNA vaccine pcDNA/GPXbb encoding glutathione-S-peroxidase, GPX;
material entity;YF-17DD vaccine;A Yellow fever virus vaccine that uses the live attenated 17DD strain.
material entity;Dengue virus DNA vaccine sA encoding prM and E from Dengue Virus 4;
material entity;YF-17D vaccine;A Yellow fever virus vaccine that uses the live attenated 17D strain.
material entity;Melanoma DNA vaccine xenogeneic DNA encoding murine tyrosinase;
material entity;Chinese S. japonicum DNA vaccine pVIVO2-IL12-Sj23 encoding Sj23 and IL-12;
material entity;VPM1002;A TB vaccine that recombinant BCG strain with the replacment of its urease C encoding gene with the listeriolysin encoding gene from Listeria monocytogenes.
material entity;S. mansoni DNA vaccine pcDNA/CTSOD encoding SOD;
material entity;recombinant BCG vaccine;A TB vaccine that uses BCG as vaccine vector.
material entity;S. mansoni DNA vaccine Sm23-pcDNA encoding Sm23;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Kohlpharma;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Emra-Med;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Emra-Med;
material entity;Pertussis Vaccine 0.016 MG/ML [Boostrix];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Eurim-Pharm;
material entity;Pertussis Vaccine 0.016 MG/ML;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Gerke;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Gerke;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Glaxosmithkline;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Waymade;
material entity;acellular pertussis vaccine, inactivated Injectable Suspension [Repevax];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Aca Mueller;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Aca Mueller;
material entity;acellular pertussis vaccine, inactivated Injectable Suspension [Pediacel];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Axicorp;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Axicorp;
material entity;Bordetella Pertussis Fimbriae Serotype 2 And 3 Antigen;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Cc;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Cc;
material entity;Bordetella Pertussis Filamentous Haemagglutinin Antigen;
material entity;acellular pertussis vaccine, inactivated Injectable Suspension;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Orifarm Leverkus;
material entity;acellular pertussis vaccine, inactivated Injectable Suspension [Infanrix];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Veron;
material entity;acellular pertussis vaccine, inactivated Injectable Suspension [Covaxis];
material entity;LIPO-5;LIPO-5 is a therapeutic HIV vaccine made up of lipopeptides, Study Names: VRI02/ANRS 149 LIGHT. NCT01492985
material entity;B. anthracis DNA vaccine pIMS-120 encoding PA;
material entity;B. anthracis DNA vaccine pTPA-P;
material entity;Imuvac vaccine;
material entity;Human papillomavirus DNA vaccine hCRTE6E7L2 DNA encoding CRT linked to E6, E7 and L2;
material entity;licensed influenza vaccine;
material entity;Dengue virus DNA vaccine p1012D2ME encoding prM and E from DEN 2 New Guinea C strain;
material entity;B. anthracis DNA vaccine pLAMP1-PA63;
material entity;B. anthracis DNA vaccine pTPA-PA63;
material entity;non-small cell lung cancer vaccine;A cancer vaccine against non-small cell lung cancer (NSCLC)
material entity;Dengue virus DNA vaccine pE1D2 encoding E from Dengue Virus 2 strain New Guinea C;
material entity;Dengue virus DNA vaccine D1ME encoding prM and E;
role;clinical trial vaccine role;A vaccine role that indicates a clinical trial status of a vaccine
material entity;Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein;
material entity;CV9201;A non-small cell lung cancer mRNA-derived vaccine that contains modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities.
material entity;Dengue virus DNA vaccine pcTPANS1 encoding NS1 fused to the tissue plasminogen activator signal sequence;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Emra-Med;
material entity;Pertussis Vaccine 0.025 MG;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Kohlpharma;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 50;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Mtk;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 1 by Kohlpharma;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Mtk;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution [Vaqta];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Orifarm Leverkus;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 50;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution [Vaqta] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Veron;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 25;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Aca Mueller;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 20;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Haematogmbh;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Orifarm Leverkus;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Kohlpharma;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 25;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Mevita;
material entity;Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 20;
material entity;Bordetella pertussis pertactin vaccine, inactivated;
material entity;Acetone-Dried Typhoid Vi Polysaccharide vaccine;A polysaccharide vaccine to prevent typhoid caused Salmonella typhi. Acetone is used to inactivate culture, and dried.
material entity;Spring Summer Encephalitis Vaccine;A tick-borne encephalitis virus vaccine used to prevent subtype Far Eastern tick-borne encephalitis virus (formerly known as Russian Spring Summer encephalitis virus).
material entity;Hepatitis A virus-Typhoid vaccine foreign to USA;A vaccine to protect individuals against infections caused by hepatitis A virus and typhoid fever bacteria.
material entity;inactivated acellular pertussis vaccine;
material entity;Pneumococcal vaccine foreign to USA;
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine foreign to USA;A Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine manufactured outside of the U.S
material entity;Meningococcal Conjugate and Haemophilis B Vaccine foreign to USA;A Meningicoccal Conjugate and Haemophilis B Vaccine manufactured outside of the U.S.
material entity;Meningococcal Conjugate and Haemophilis B Vaccine;An active immunizing combination agent that is used to prevent infection caused by certain groups of meningococcal bacteria and Haemophilus influenza type b (Hib) bacteria.
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] by Glaxosmithkline;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Veron;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe Box of 1;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe Box of 10;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Mevita;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by MZG;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Orifarm Leverkus;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 50;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 10;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 20;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 20 by Glaxosmithkline;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 50;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 50 by Glaxosmithkline;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] by Glaxosmithkline;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 10;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 10 by Glaxosmithkline;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 20;
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus-ACT-Hib vaccine;A vaccine that contains ActHIB and protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, and Haemophilus influenzae type b.
material entity;Adenovirus Type 7;An oral vaccine against adenovirus serotype 7.
material entity;Quatro Virelon;Active immunization against tetanus, diphtheria, pertussis, and poliomyelitis for individuals between 3 months and 6 years of age.
material entity;Tritanrix;Active immunzation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards
material entity;Diphtheria-Tetanus-Pertussis-Hepatitis B vaccine;
material entity;Adenovirus Type 4;An oral vaccine against adenovirus serotype 4.
material entity;DTP-ActHIB;A vaccine used to prevent diphtheria, tetanus, pertussis, and Haemophilus type B infections.
material entity;MR-VAX II;A live virus vaccine for immunization against measles and rubella.
material entity;Imovax ID;A vaccine used to develop immunity to rabies.
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Mevita;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Emra-Med;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Gerke;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Eurim-Pharm;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Haematogmbh;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Gerke;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Kohlpharma;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Haematogmbh;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Aca Mueller;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Veron;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Cc;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Aca Mueller;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Emra-Med;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Axicorp;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Cc;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Mtk;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Orifarm Leverkus;
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine foreign to USA;A Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine manufactured outside of the U.S.
material entity;Diphtheria-Tetanus-Poliovirus vaccine foreign to USA;A Diphtheria-Tetanus-Poliovirus vaccine manufactured outside of the U.S.
material entity;seasonal influenza virus vaccine foreign to USA;A seasonal Influenza virus vaccine manufactured outside of the U.S.
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus vaccine foreign to USA;A Diphtheria-Tetanus-Pertussis-Poliovirus vaccine manufactured outside of the U.S.
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine foreign to USA;A Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine manufactured outside of the U.S
material entity;Hepatitis B vaccine foreign to USA;A Hepatitis B vaccine manufactured outside of the U.S.
material entity;HIB Polysaccharide foreign to USA;A Haemophilis influenzae Type b capsular polysaccharide vaccine manufactured outside of the U.S.
material entity;TDAP;A vaccine that protects adolescents and adults from tetanus, diphtheria, and pertussis.
material entity;Mumps-Rubella Vaccine foreign to USA;A Mumps-Rubella vaccine manufactured outside of the U.S.
material entity;Measles virus vaccine foreign to USA;A measles virus vaccine manufactured outside of the U.S.
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Emra-Med;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Kohlpharma;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Mtk;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Gerke;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Aca Mueller;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Kohlpharma;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Orifarm Leverkus;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Orifarm Leverkus;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Veron;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Veron;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Aca Mueller;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Cc;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Emra-Med;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Kohlpharma;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Mtk;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Mevita;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by MZG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Mtk;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 1 by Stada;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 10;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Sanofi;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal];
material entity;Fluzone 2015-2016 vaccine;
material entity;Ditanrix;a Diphthpheria-Tetanus Absorbed vaccine for children 7 years of age and adults.
material entity;Revaxis vaccine;Revaxis is a Diphtheria, Tetanus and Poliomyelitis (inactivated) vaccine manufactured by Sanofi Pasteur. This vaccine helps boost protection against diphtheria, tetanus and poliomyelitis (polio).
material entity;Moraten vaccine;A more attenuated measles vaccine that targets measles virus strain Moraten.
material entity;Rotashield vaccine;A rotavirus vaccine against severe diarrheal disease.
material entity;Orimune vaccine;monovalent vaccine agianst poliomyelitis for infants 6-12 weeks of age, all immunized children up to 18 years of age, and high risk adults.
material entity;Fluogen;Influenza virus vaccine is used to prevent infection caused by influenza virus types A and B.
material entity;Pnu-Imune vaccine;
material entity;P. falciparum RTS,S/AS01;A malaria vaccine that consists of hepatitis B surface antigen virus-like particles, incorporating a portion of the Plasmodium falciparum-derived circumsporozoite protein and a liposome-based adjuvant.
material entity;injection form;
material entity;intramuscular solution;
material entity;drug package;
generically dependent continuant;drug brand name;An information content entity that specifies a family of drug products containing a specific active ingredient.
material entity;Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine;
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML;
material entity;injectable suspension;
material entity;injectable solution;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Eurim-Pharm;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1;
material entity;influenza A virus (H3N2) antigen;
material entity;influenza B virus antigen;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta];
material entity;Fluzone 2015-2016 Injectable Product;
material entity;Influenza A virus (H1N1) antigen;
material entity;yellow fever virus strain 17D-204 live antigen;
material entity;influenza B virus B/Austria/1359417/2021 antigen;
material entity;influenza A virus A/Victoria/2570/2019 (H1N1) antigen;
material entity;influenza B virus B/Washington/02/2019 antigen;
material entity;influenza B virus B/Michigan/01/2021 antigen;
material entity;influenza A virus A/Kansas/14/2017 (H3N2) antigen;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen;
material entity;influenza A virus A/Sydney/5/2021 (H1N1) antigen;
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 80;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 2;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 100;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 50;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 20;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 80;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 20;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 10;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 1;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 2;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML;
material entity;influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML;
material entity;influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML;
material entity;influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML;
material entity;influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML;
material entity;influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML;
material entity;hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML [Prehevbrio];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen;
material entity;influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML;
material entity;influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen;
material entity;influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML;
material entity;influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML;
material entity;influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML;
material entity;influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML;
material entity;influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML;
material entity;PRRSV DNA vaccine GST-ORF5 encoding GP5;
material entity;Newcastle disease virus DNA vaccine pCAGF encoding the F protein;
material entity;Lymphocytic choriomeningitis virus DNA vaccine pCMV-NP;
material entity;Rabies virus DNA vaccine pSG5rab.gp;
material entity;IHNV DNA vaccine pCMV4-G;
material entity;Foot and mouth disease DNA vaccine pWRMHX encoding a minimal self-cleaving ribozyme;
material entity;Murine cytomegalovirus DNA vaccine pcDNA-89 encoding pp89;
material entity;IHNV DNA vaccine pCMV4-N encoding the nucleoprotein;
material entity;1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Organon;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 100;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Cc;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Merck;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by MSD;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 1;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 50;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Veron;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Axicorp;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol];
material entity;Human papillomavirus DNA vaccine Pe7(pcDNA3-Sig/sE7/LAMP) encoding E7;
material entity;Human papillomavirus DNA vaccine VlJns-Ll encoding L1;
material entity;Leishmania donovani cen1 mutant vaccine;
material entity;Ebola virus recombinant VSVΔG-GP encoding GP;
material entity;Ebola virus recombinant rAD-GP encoding GP;
material entity;Plasmodium FabB/FabF mutant vaccine;
material entity;VHSV DNA vaccine pCMV-vhsG encoding glycoprotein G;
material entity;Leishmania infantum HSP70 II mutant vaccine;
material entity;Ebola virus recombinant vector vaccine EBO7 encoding GP from SEBOV and ZEBOV;
material entity;Human papillomavirus DNA vaccine E7IR;
material entity;Western equine encephalomyelitis virus PE2/E1 mutant vaccine;
material entity;Human papillomavirus DNA vaccine CRT/E7 DNA;
material entity;Western equine encephalomyelitis virus PE2/E1 or E2 mutant vaccine;
material entity;Ebola virus DNA vaccine GP DNA;
material entity;Western equine encephalomyelitis virus PE2/E2 mutant virus;
material entity;Human papillomavirus DNA vaccine E7SH DNA;
material entity;Human papillomavirus DNA vaccine pC16-L1 encoding L1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 3 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 3 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [Tetasorbat];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [Tetabulin];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [Tet Aktiv];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [Tetanol];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 20 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [Tetamun];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [T Medevax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Merck;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [T Immun];
material entity;1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Organon;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [T Wellcovax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [T Vaccinol];
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [Clostet];
material entity;P. yoelii p36/p52 mutant vaccine;
material entity;P. berghei p36p mutant vaccine;
material entity;VHSV DNA vaccine pCMV-vhsN encoding nucleocapsid protein N and glycoprotein G;
material entity;influenza virus DNA vaccine pBK-SFV-NP;
material entity;influenza virus DNA vaccine pHA/NP147-155 encoding NP147-155;
material entity;influenza virus DNA vaccine HA-DNA;
material entity;influenza virus DNA vaccine pBK-SFV-HA;
material entity;influenza virus DNA vaccine pRSV-NP encoding the coding sequence from influenza virus A/PR/8/34.;
material entity;influenza virus DNA vaccine pIRES/HA/IL-12p35 + pIRES/NA/IL-12p40;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 10;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol];
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 20;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 2;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel];
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] Box of 25;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 20;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 10;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix];
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension;
material entity;influenza virus DNA vaccine A/NP;
material entity;influenza virus DNA vaccine d1TTFC-NP encoding NP;
material entity;influenza virus DNA vaccine HA DNA;
material entity;influenza virus DNA vaccine NP DNA;
material entity;Y. pestis DNA vaccine F1-V DNA;
material entity;T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2;
material entity;Bovine herpesvirus 1 recombinant vector vaccine BHVl/BRSVG;
material entity;Bovine herpesvirus 1 DNA vaccine pRSVgIV;
material entity;influenza virus DNA vaccine NA-DNA;
material entity;T. gondii DNA vaccine pSAG1-ROP2-SAG2;
material entity;influenza virus DNA vaccine H5 DNA;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 20;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 2;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 25;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat];
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 50;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 10;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat] Box of 10;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux];
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 20;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 10;
material entity;Bovine herpesvirus 1 recombinant vector vaccine rLaSota/gDFL encoding gD;
material entity;Bovine herpesvirus 1 DNA vaccine pMASIAtgB encoding a truncated, secreted form of gB;
material entity;Bovine herpesvirus 1 recombinant vector vaccine rLaSota/gDF encoding gD;
material entity;protein vaccine stabilizer;a vaccine stabilizer that is a protein.
material entity;Herpes simplex virus DNA vaccine gBDNA encoding gB;
material entity;lactose vaccine stabilizer;a vaccine stabilizer that is specifically made by a lactose.
material entity;Herpes simplex virus DNA vaccine gB-DNA encoding gB;
material entity;Alkest TW 20 vaccine stabilizer;a polysorbate 20 vaccine stabilizer that is Alkest TW20.
material entity;sugar vaccine stabilizer;a vaccine stabilizer that is specifically made by a sugar.
material entity;Herpes simplex virus DNA vaccine gD-2 encoding gD;
material entity;bovine serum albumin vaccine additive;a protein vaccine stablizer that is specifically bovine serum albumin.
material entity;M. tuberculosis DNA vaccine DNAAg85A encoding a single immunogenic M.tb Ag;
material entity;sucrose vaccine stabilizer;a vaccine stabilizer that is specifically made by a sucrose.
material entity;Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27;
material entity;amino acid vaccine stabilizer;a vaccine stabilizer that is generated based on amino acids.
material entity;Herpes simplex virus DNA vaccine Delta-gB-2 encoding gB;
material entity;gelatin;Gelatin is a mixture of peptides and proteins produced by partial hydrolysis of collagen extracted from the skin, boiled crushed bones, connective tissues, organs and some intestines of animals such as domesticated cattle, chicken, and pigs.(wikipedia)
material entity;Coxsackievirus DNA vaccine pCMV/VPl encoding VP1;
material entity;Hepatitis B DNA vaccine pCMV-S2.S encoding the HBV(ayw Strain) envelope protein.;
process;host immune factor-induced control of intracellular replication of live attenuated vaccine;
material entity;M. tuberculosis DNA vaccine (containing the ESAT-6, MPT-64, MPT-83, and KatG constructs);
process;host susceptibility gene response to vaccine adverse event;a vaccine-induced host gene response that represents a vaccine adverse event response associated with a host susceptibility gene.
material entity;M. tuberculosis DNA vaccine encoding Ag85B, MPT64 and MPT83;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Orifarm Leverkus;
material entity;BCG, live, Connaught strain;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20 by Sanofi;
material entity;Engerix-B Injectable Product;
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Eurim-Pharm;
material entity;hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML;
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Europharma;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) and tetanus toxoid conjugate vaccine;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Gerke;
material entity;hepatitis B virus subtype ADW2 HBsAg surface protein antigen;
material entity;0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution;
material entity;hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Axicorp;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injection [ActHIB];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Cc;
material entity;Meningococcal-Tetanus Vaccine;
material entity;ActHIB Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Emra-Med;
material entity;Meningococcal-Haemophilis B-Tetanus Vaccine;
material entity;vaccine conjugate protein;The conjugate protein is a part of a conjugate vaccine and acts as a carrier protein that is covalently attached to a vaccine antigen with poor antigenicity (e.g., a polysaccharide). A conjugate protein is able to induce T-cell-dependent immune responses and stimulate the production of immune memory.
process;vaccine-induced herd immunity;when the vaccination of a significant portion of a population (or herd), in contagious diseases that are transmitted from individual to individual, chains of infection are likely to be disrupted, so the large numbers of a population are immue or less susceptible to the disease.
material entity;Lassa fever virus recombinant vector vaccine V-LSG/N encoding the glycoprotein and the nucleoprotein;
process;RB51 induced protection against B.suis;
material entity;T. cruzi DNA vaccine pUB-ASP-2;
material entity;Lymphocytic choriomeningitis virus vaccine;A viral vaccine against infection of a Lymphocytic choriomeningitis virus.
material entity;T. cruzi DNA vaccine encoding ASP-2;
material entity;Schistosoma vaccine;A protozoan vaccine against Schistosoma infection
material entity;Lassa fever virus recombinant vector vaccine V-LSG encoding the glycoprotein;
material entity;Schistosoma mansoni vaccine;A protozoan vaccine against Schistosoma mansoni
material entity;T. cruzi DNA vaccine pTS encoding T. cruzi antigens;
material entity;neomycin residual;an antibiotics vaccine residual that has the antibiotics of neomycin.
material entity;Rabies virus DNA vaccine encoding the ERA glycoprotein;
material entity;Tween 20 vaccine stabilizer;a polysorbate 20 vaccine stabilizer that is Tween 20.
material entity;Rabies virus DNA vaccine pCMV-intA-rabies encoding glycoprotein G;
material entity;Sindbis virus vaccine;A viral vaccine against infection of an Sindbis virus.
material entity;T. cruzi DNA vaccine encoding TSA-1, ASP-1, ASP-2;
material entity;protective vaccine antigen;the vaccine antiegn that induces protective immune response.
material entity;Leishmania major DNA vaccine KMP-11;
material entity;Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Tenivac];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML [Varivax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis] by Sanofi;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Tenivac];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis];
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Tenivac];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tenivac];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis] Box of 10 by Sanofi;
material entity;Tenivac Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20 by Veron;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML;
material entity;Hepatitis B Surface Antigen Vaccine Injection [Engerix-B];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller;
material entity;BCG, live, Montreal strain;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Tenivac];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution;
material entity;Haemophilus capsular oligosaccharide;
site;intragastric route;A route of administration that located in the stomach, so that the material is taken into body through stomach directly.
material entity;HIV recombinant vector vaccine MVA-gag encoding gag;
material entity;SIV DNA vaccine pSIVgag and pmacIL-15 encoding SIV core protein;
process;intragastric vaccination;vaccination that occurs in the intagastric route.
material entity;HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost;
site;intragastric injection route;An intragastric route that has a vaccine injection site located in stomach.
material entity;HIV DNA vaccine pHIS-SHIV-B;
material entity;Toxoplasma gondii mic2 mutant vaccine;
material entity;SIV DNA vaccine pVacc4 encoding env from mac239;
material entity;P. yoelii UIS3 mutant vaccine;
material entity;HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag;
material entity;Toxoplasma gondii OMPDC/UP mutant vaccine;
material entity;HIV DNA vaccine pCMN160;
material entity;Toxoplasma gondii OMPDC mutant vaccine;
material entity;HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6);
material entity;Human cytomegalovirus DNA vaccine VCL-CB01 encoding phosphoprotein 65 and gB;
material entity;Classical swine fever virus DNA vaccine pCI-gp55;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Axicorp;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Revaxis];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Repevax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3 by Mtk;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Td-Pur];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Aca Mueller;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Td-Impfstoff Merieux];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Covaxis];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Mtk;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Clostet];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Pediacel];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 20 by Mtk;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix];
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [Tetatoxoid];
process;intradermal vaccination;vaccination process that occurs in intradermal route.
material entity;human serum albumin vaccine additive;a protein vaccine stablizer that is specifically human serum albumin.
material entity;Hepatitis B DNA vaccine pCMV-HBs encoding HBsAg;
role;vaccine stabilizer role;a role inheres in vaccine component when added into vaccine's formulation, it tends to inhibit the reaction between two or more other vaccine substances in the final vaccine formulation. it also helps to protect the vaccine from adverse conditions such as the freeze-drying process or heat.
material entity;Hepatitis B DNA vaccine pS encoding major envelope proteins;
material entity;gelatin vaccine stabilizer;a vaccine stabilizer that is gelatin.
material entity;human serum albumin;the serum albumin that is part of human
material entity;Hepatitis B DNA vaccine pCEA/HBsAg encoding CEA and HBsAg;
process;vaccine reconstitution;A vaccine prepration process that mixes vaccine lyophilized powder and diluent liquid. The process forms a vaccine that can be used for administration. This term can also be considered as a child term of OBI term 'material combination'.
material entity;Hepatitis B DNA vaccine pRc/CMV-HBs(S) encoding HBsAg;
process;subcutaneous vaccination;vaccination process that occurs in the subcutaneous route
material entity;Duck hepatitis B DNA vaccine pcDNA I-S encoding small S proteins;
role;vaccine emulsifier role;a role inheres in the vaccine component when it is added into vaccine's formulation, it tends to stabilizes an emulsion by increasing its kinetic stablity.
material entity;M. tuberculosis DNA vaccine pcDNA3.1+/Ag85A DNA encoding Ag85A;
material entity;lyophilized vaccine powder;a vaccine powder that is freeze-dried and lyophilized.
material entity;influenza virus DNA vaccine pDNA encoding M2 and NP;
material entity;HIV recombinant vector vaccine MVA.HIVA encoding env and rev;
process;oral vaccination;vaccination process that occurs in oral route.
material entity;Hepatitis B DNA vaccine PLGA-CTAB-DNA encoding the small envelope gene;
process;intranasal vaccination;vaccination process that occurs in intranasal route
material entity;HIV DNA vaccine VlJns-tPA-gp120;
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML [ActHIB];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injection [Twinrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Orifarm Leverkus;
material entity;Diphtheria-Tetanus-Poliovirus-Influenza B vaccine;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Twinrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated Prefilled Syringe [Tetanol];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Veron;
material entity;0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection [ActHIB];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Aca Mueller;
material entity;Diphtheria-Tetanus-Haemophilus b vaccine;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Twinrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Tetravac];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Europharma;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Tetasorbat];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Gerke;
material entity;tetanus toxoid vaccine, inactivated Prefilled Syringe [Clostet];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [T-Immun Immuno];
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Tetamun];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Cc;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Tetanus-Impfstoff Merieux];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension [Tetanol];
process;RB51 induced protection against B. ovis;
material entity;Fluzone Quadrivalent - Southern Hemisphere Formulation;
material entity;Fluzone Quadrivalent;
material entity;Gardasil 9 vaccine;
material entity;Flucelvax Quadrivalent;
material entity;FluLaval Tetra;
material entity;FluLaval Quadrivalent;
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 1 by Glaxosmithkline;
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 3 by Glaxosmithkline;
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 1 by Boehringer Ingelheim;
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML Injectable Solution;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3 by Emra-Med;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3 by Glaxosmithkline;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain);
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3 by Kohlpharma;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3 by Mtk;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 10 by Glaxosmithkline;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection [M-M-R II];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 25 by Emra-Med;
material entity;M-M-R II Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 25 by Mtk;
material entity;Boostrix-Polio;
material entity;Adacel-Polio;
material entity;influenza A (H1N1) 2009 Monovalent Vaccine (GlaxoSmithKline);
process;RB51 induced immune response without protection;
process;RB51 induced immune protection;
material entity;Trumenba vaccine;
material entity;Nimenrix vaccine;
material entity;influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted by GSK;
material entity;Vaxchora vaccine;
material entity;Tri-Immunol;This vaccine is given to provide protection against diphtheria, tetanus, and pertussis in children between 6 weeks and 7 years old.
material entity;Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10 by Glaxosmithkline;
material entity;Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25 by Emra-Med;
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Glaxosmithkline;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Kohlpharma;
material entity;prefilled syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Mtk;
material entity;Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Waymade;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 by Glaxosmithkline;
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 by Glaxosmithkline;
material entity;drug dose form;A material entity of a drug based on their general physical form and how they are administered.
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Emra-Med;
material entity;injectable product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Eurim-Pharm;
material entity;Hepatitis D virus vaccine;A viral vaccine that protects against infection with Hepatitis D virus.
material entity;viral haemorrhagic septicaemia virus vaccine;A viral vaccine against infection of a viral haemorrhagic septicaemia virus.
material entity;Marburg virus DNA vaccine MARV GP encoding GP;
material entity;Infectious pancreatic necrosis virus vaccine;A viral vaccine against infection of an infectious pancreatic necrosis virus.
material entity;B. anthracis DNA vaccine PA;
material entity;Mycobacterium marinum vaccine;A vaccine that protects against Mycobacterium marinum.
material entity;Marburg virus DNA prime/boost vaccine DNA/rAd5-GP encoding GP from strain Angola;
process;augmented protection and cellular immunity using host protein as adjuvant;an vaccine-induced host response that shows augmented protection and cellular immunity after a host protein is used as adjuvant.
material entity;Marburg virus recombinant vector vaccine CAdVax-Panfilo;
process;percutaneous vaccination;Administration of a drug by the way of absorption through the skin, usually for systemic action. The route allows sustained therapeutic plasma drug levels and avoids first pass effect. Simplicity of administration tends to result in high patient compliance.|YL
material entity;Ebola virus recombinant vector vaccine Ad-CMVZGP encoding the glycoprotein;
site;percutaneous route;
material entity;Ebola virus recombinant adenovirus vaccine AdC7-ZGP encoding GP;
process;intravesical vaccination;The injection of a given substance directly into the bladder via a urethral catheter instead of being injected under the skin.
material entity;Ebola virus DNA vaccine DNA/rAd5 encoding ZEBOV and SEBOV antigens;
site;intravesical route;
material entity;Ebola virus recombinant vector vaccine Ad-CAGoptZGP encoding the envelope glycoprotein;
role;vaccine conjugate role;A role inheres in a material eneitity that union itself chemically with a relative weak vaccine antigen to form a new whole that can create an effective miinuogen. The
material entity;Ebola virus recombinant vector vaccine pVSVXN2-Delta-G/ZEBOVsGP encoding GP;
material entity;Lassa fever virus recombinant vector vaccine YFV17D/LASV-GPC encoding the glycoprotein precursor;
material entity;Gardasil 9 Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma;
material entity;Gardasil 9 prefilled syringe;
material entity;0.5 ML L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML Injection [Gardasil 9];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 10;
material entity;L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML [Gardasil 9];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax];
material entity;0.5 ML L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML Prefilled Syringe [Gardasil 9];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 20;
material entity;Gardasil 9 injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Gerke;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 10 by Sanofi;
material entity;Varivax Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Veron;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 20;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [Varivax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Aca Mueller;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 10 by Sanofi;
material entity;L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Axicorp;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] by Sanofi;
material entity;L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 20 by Sanofi;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel];
material entity;Flublok Quadrivalent;
material entity;Lymphoma DNA vaccine V-Alpha-V-Beta-V-Beta-FrC;
material entity;Bexsero vaccine;
material entity;B. melitensis DNA vaccine p-ialB;
process;RB51 induced host immune response;
material entity;P. falciparum recombinant vector vaccine MVA.ME-TRAP;
process;RB51 induced protection against B.abortus;
material entity;B. melitensis DNA vaccine pCI-Omp31;
material entity;Murid herpesvirus 1 vaccine;A viral vaccine that protects against infection with Murine Cytomegalovirus (or called murid herpesvirus 1).
material entity;B. abortus DNA vaccine pcDNA3-SOD encoding Cu-Zn SOD;
process;RB51 induced protection against B.Melitensis;
material entity;B. melitensis DNA vaccine p-Omp25;
process;RB51 induced protection against B.canis;
material entity;B. melitensis DNA vaccine pCIBLSOmp31 encoding BLSOmp31 (fusion protein);
material entity;Marburg virus DNA vaccine DNA-GP encoding GP;
material entity;Bovine viral diarrhea virus 2 vaccine;viral vaccine that is used to protect against Bovine viral diarrhea virus 2 infection
material entity;B. abortus DNA vaccine pcDNA3.1-p39-L7/L12 encoding p39-L7/L12 fusion protein;
material entity;Monkeypox virus vaccine;viral vaccine that is used to protect against Monkeypox virus infection
material entity;Marburg virus recombinant vector vaccine MBGV GP;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injection [M-M-R II];
material entity;L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Glaxosmithkline;
material entity;L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Kohlpharma;
material entity;L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Mtk;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML [M-M-R II];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Waymade;
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck;
material entity;L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Veron;
material entity;L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Emra-Med;
material entity;L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck;
material entity;L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Orifarm Leverkus;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Veron;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Veron;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Veron;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Veron;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med;
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain Injectable Suspension;
material entity;yellow fever virus strain 17D-204 live antigen Injectable Suspension;
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix];
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution;
material entity;rabies virus vaccine flury-lep strain Injection;
material entity;Japanese encephalitis virus vaccine, inactivated Prefilled Syringe;
material entity;Japanese encephalitis virus vaccine, inactivated Injectable Suspension;
material entity;L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Prefilled Syringe;
material entity;L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Prefilled Syringe;
material entity;vaccine against disease;a grouping class for vaccines for specific diseases
material entity;vaccine against infectious disease;Vaccine against an infectious disease caused by specific pathogen(s).
material entity;Plasmodium falciparum MSA2;
material entity;transmission-blocking vaccine;A vaccine that prevents or reduce the transmission of a disorder within a target host or among a population by inducing or modifying specific adaptive immune responses against the antigens present in the vaccine.
material entity;IL-12-MOP (CTX-1796) vaccine adjuvant;Nucleic acid vaccine adjuvant that targets on cytokine receptor to induce a Th1-based response.
material entity;Bl-Eng2 vaccine adjuvant;Vaccine adjuvant that is primarily composed of protein and actives innate immune pathways to induce a mixed Th1/Th2 response.
material entity;Bl-Eng2+Adjuplex vaccine adjuvant;Combination vaccine adjuvant contains both Bl-Eng2 and adjuplex vaccine adjuvants and is able to induce a mixed Th1/Th2 response.
material entity;vaccine by platform type;a grouping class for vaccines for specific platforms
material entity;canvaxgen;Gene expressing a protein which serves, either in whole or in part, as an antigen within a cancer vaccine.
material entity;P. falciparum pfCelTos protein vaccine;
material entity;C. jejuni PorA protein vaccine;
material entity;BOOSTRIX vaccine 0.5 ML Prefilled Syringe;
material entity;BOOSTRIX vaccine Prefilled Syringe;
material entity;S. agalactiae BipA Protein Vaccine;
material entity;C. muridarum Tarp subunit vaccine;
material entity;J5dLPS/OMP;
material entity;tetanus toxoid vaccine, inactivated 2 LFU/ML;
material entity;influenza A virus (H5N1) antigen;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 50;
material entity;BCG, live, Tice strain 50 MG;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 10;
material entity;powder for oral suspension;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 1;
material entity;oral suspension;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 20;
material entity;oral tablet;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 100;
material entity;oral capsule;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 100;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 50;
material entity;oral;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 20;
material entity;BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS;
material entity;Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML;
material entity;Ovine Ecthyma live virus vaccine by Colorado Serum Company CZ Veterinaria;
material entity;Biothrax Injectable Product;
material entity;Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine-Erysipelothrix Rhusiopathiae-Haemophilus Parasuis Bacterin (USDA: 49V9.20);
material entity;Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine-Haemophilus Parasuis Bacterin (USDA: 49Q9.20);
material entity;BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS 0.1 MG/ML [Biothrax];
material entity;West Nile Virus DNA Vaccine (USDA: 1995.D0);
material entity;Ovine Ecthyma live virus waccine by Texas Agricultural Experiment Station;
material entity;BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS 0.1 MG/ML;
material entity;Canine Parainfluenza Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 47A9.20);
material entity;tetanus toxoid vaccine, inactivated 2000 IU/ML;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 50;
material entity;influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 50;
material entity;influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 25;
material entity;influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 25;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 10;
material entity;influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension;
material entity;influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML [Tetravac];
material entity;yellow fever virus strain 17D-204 live antigen 2000 UNT/ML [Stamaril];
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 10;
material entity;influenza B virus antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac];
material entity;influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML;
material entity;influenza A virus A/Indonesia/05/2005 (H5N1) antigen 0.0075 MG/ML;
material entity;T. gondii DNA vaccine encoding MIC8;
material entity;Biothrax Injectable Suspension;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol];
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 10;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 1;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno];
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension Box of 10;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno] Box of 10;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 50;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 20;
material entity;Recombinant NY-ESO-1 Protein vaccine adjuvanted with Imiquimod;
material entity;Group A streptococcal recombinant fusion peptide Vaccine;
material entity;Mutagrip Vaccine with P40 Adjuvant;
material entity;Inactivated split Mem 71 Virus with SPT adjuvant;
material entity;P. falciparum MSP4 with AFCo1 Adjuvant;
material entity;Anthrax vaccine adsorbed with Squalene adjuvant;
material entity;Recombinant Colorectal cancer antigen GA733 Vaccine;
material entity;Synthetic OMP1 Vaccine;
material entity;Inactivated HIV-2 Vaccine with PMMA;
material entity;L. donovani Recombinant Ld-Gamma-GCS in NIV system Vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 20;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Aca Mueller;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 10;
material entity;influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Emra-Med;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Gerke;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML [Td-Pur];
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML [Td-Impfstoff Merieux];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Mevita;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix];
material entity;influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Mtk;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML [Covaxis];
material entity;influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML;
material entity;influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML [Revaxis];
material entity;influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML [Repevax];
material entity;influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML;
material entity;HIV-2 DNA vaccine;
material entity;Synthetic MUC1 Peptide Vaccine;
material entity;Recombinant PA with Poly(I:C) Adjuvant;
material entity;Recombinant NY-ESO-1 ISCOMATRIX Vaccine;
material entity;C. muridarum PmpG-1, PmpE/F-2, and MOMP Proteins Vaccine;
material entity;Recombinant Tir Protein Vaccine;
material entity;recombinant S gene Hepatitis B Vaccine with rIFN-gamma;
material entity;attenuated Listeria expressing cancer antigen vaccine;
material entity;inactivated H1N1(2009) vaccine with AF03 adjuvant;
material entity;Y. pestis F1 antigen Vaccine with Flagellin;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 10;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 1 by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 20;
material entity;influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 10;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50 by Mtk;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 5;
material entity;influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Gerke;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 50;
material entity;influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax];
material entity;influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Mtk;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] Box of 10;
material entity;influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML;
material entity;influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML;
material entity;BVDV Inactivated Vaccine;
material entity;BHV1 gD subunit vaccine;
material entity;Cancer Vaccine using E7 protein of human papillomavirus 16 and Quil-A;
material entity;Cancer Vaccine using E7 protein of human papillomavirus 16 and Algammulin;
material entity;Inactivated PMV-3 Vaccine with Specol;
material entity;P. multocida rOmpH Vaccine;
material entity;Rotavirus Chimeric VP6 protein Vaccine;
material entity;B. anthracis rPA Vaccine with Rehydragel HPA adjuvant;
material entity;S. aureus IsdB subunit vaccine (V710);
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Axicorp;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Cc;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution Box of 1;
material entity;influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50 by Mtk;
material entity;tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin] Box of 1;
material entity;influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML [Tetamun];
material entity;hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Aca Mueller;
material entity;tetanus toxoid vaccine, inactivated 4 LFU/ML;
material entity;hepatitis A virus strain CR 326F antigen, inactivated;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 250 UNT/ML [Tetabulin];
material entity;influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Mtk;
material entity;tetanus toxoid vaccine, inactivated 250 UNT/ML;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin];
material entity;influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution;
material entity;influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 2000 IU/ML Injectable Solution;
material entity;influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML;
material entity;E. maxima oocysts with Arlacel A vaccine;
material entity;rHA with IL-7 adjuvant;
material entity;rHA with IL-2 adjuvant;
material entity;HBsAg Liposomal MTP-PE Vaccine;
material entity;gp140, Gag and Tat Protein Vaccine with MF59;
material entity;gp120 recominant with GMDP adjuvant;
material entity;V3 VLPs with Gamma inulin adjuvant;
material entity;rHA with IL-1Beta adjuvant;
material entity;microbial eukaryotic vaccine;A vaccine that targets against a microbial eukaryote caused disease.
material entity;gp120 recominant with MDP adjuvant;
material entity;Tetanus Toxoid with Stearyl Tyrosine;
material entity;Tetanus Toxoid with Calcium Phosphate;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Cc;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Mtk;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10;
material entity;influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun] Box of 10;
material entity;influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Aca Mueller;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML [Boostrix];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Axicorp;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML;
material entity;influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10;
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Gerke;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1;
material entity;influenza A virus (H3N2) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun];
material entity;influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Mevita;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML;
material entity;hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML [Vaqta];
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun] Box of 10;
material entity;influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun] Box of 1;
material entity;influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML;
material entity;Mycobacterium tuberculosis mce-3 mutant vaccine;
material entity;M2 mutant from influenza A vaccine;
material entity;Bovine Respiratory Syncytial Virus recombinant vector vaccine BHVl/BRSVG encoding the G protein;
material entity;African Swine Fever Virus 9GL mutant vaccine;
material entity;Brucella abortus S19 vjbR mutant vaccine;
material entity;Recombinant B. abortus AsnC protein with CFA/IFA adjuvant;
material entity;Recombinant B. abortus CobB protein with CFA/IFA adjuvant;
material entity;Aflunov;
material entity;Focetria;
material entity;Fluad vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Aca Mueller;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Axicorp;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Cc;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3 by Boehringer Ingelheim;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML [Tetasorbat];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML [Tetanus-Impfstoff Merieux];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax];
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML [Pediacel];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 2 by Boehringer Ingelheim;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML [Tetanol];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 20 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML [T Wellcovax];
material entity;influenza virus DNA vaccine pIRES/NA/GM-CSF encoding NA;
material entity;influenza virus DNA vaccine pIRES/HA/GM-CSF encoding HA;
material entity;influenza virus DNA vaccine pIRES/NA expressing NA;
material entity;influenza virus DNA vaccine pIRES/HA encoding HA;
material entity;influenza virus DNA vaccine pIRES/NA/IL-2 encoding NA;
material entity;influenza virus DNA vaccine pIRES/HA/IL-2 expressing HA;
material entity;influenza virus DNA vaccine p188 encoding H7;
material entity;influenza virus DNA vaccine BacPAKHA encoding EqfKY HA;
material entity;influenza virus DNA vaccine pCMV/H7;
material entity;influenza virus DNA vaccine pCMV/Hl encoding H1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Mtk;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Orifarm Leverkus;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Veron;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Aca Mueller;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Emra-Med;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Eurim-Pharm;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Mtk;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Orifarm Leverkus;
material entity;P. falciparum MSA-2 subunit vaccine;
material entity;LEISH-F1+MPL-SE vaccine;
material entity;pneumococcal polysaccharide conjugate vaccine serotype 1 (PNC-1);
material entity;HIV-1 gp120 with mCT E112K;
material entity;HSV glycoproteins subunit vaccine;
material entity;live TC-83 VEE Vaccine with DHEA;
material entity;rgp120 HIV Vaccine with immunoliposomes;
material entity;MVA/IL-15/5Mtb vaccine;
material entity;Hepatitis B surface antigen (HBsAg) with JVRS-1000;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Orifarm Leverkus;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B] Box of 1 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 1 by Glaxosmithkline;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 2;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 10 by Glaxosmithkline;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 2;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 10 by Glaxosmithkline;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 1 by Glaxosmithkline;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 1 by GSK;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 10 by Glaxosmithkline;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur];
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux];
material entity;Brucella melitensis mucR mutant vaccine;
material entity;MDA-modified human apo B-100 peptide Vaccine;
material entity;Mycobacterium tuberculosis mce-2 mutant vaccine;
material entity;Tick-borne Encephalitis Virus C protein mutant vaccine;
material entity;YopE(67-77) Protein Vaccine;
material entity;pVAX-P1 DNA vaccine;
material entity;human apo B-100 peptide-2 protein vaccine;
material entity;HIV recombinant gp160 Protein Vaccine;
material entity;P. yoelii TyCS-VLP Vaccine;
material entity;B. anthracis PA protein Vaccine with TMDP;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10 by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Mtk;
material entity;tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution [Tetanol];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 80 UNT/ML [Infanrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B] Box of 1 by Merieux;
material entity;tetanus toxoid vaccine, inactivated 5.33 UNT/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Boehringer Ingelheim;
material entity;tetanus toxoid vaccine, inactivated 5.33 UNT/ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 8 UNT/ML [Tetanol];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 5.33 UNT/ML Injectable Solution Box of 1;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 50;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 5;
material entity;Fluarix Quadrivalent 2018-2019 vaccine Prefilled Syringe;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2018-2019];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria 2015-2016];
material entity;Afluria 2015-2016 Injectable Product;
material entity;Afluria 2015-2016 Prefilled Syringe;
material entity;afluria 2015-2016 vaccine Injectable Suspension;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen;
material entity;Fluarix Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe;
material entity;Afluria 2015-2016 vaccine;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML;
material entity;Afluria 2015-2016 0.5 ML Prefilled Syringe;
material entity;Afluria 2016-2017 Injectable Product;
material entity;Afluria 2016-2017 vaccine;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 20;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 20;
material entity;Afluria 2017-2018 Injectable Product;
material entity;Afluria 2017-2018 vaccine;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML [Afluria 2017-2018];
material entity;Afluria 2016-2017 vaccine Injectable Suspension;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Afluria 2016-2017];
material entity;afluria 2016-2017 vaccine 0.5 ML Prefilled Syringe;
material entity;Afluria 2016-2017 vaccine Prefilled Syringe;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2016-2017];
material entity;Fluarix Quadrivalent 2018-2019 Injectable Product;
material entity;Fluarix Quadrivalent 2017-2018 vaccine Prefilled Syringe;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2017-2018];
material entity;Fluarix Quadrivalent 2018-2019 vaccine;
material entity;Fluarix Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe;
material entity;Fluarix Quadrivalent 2016-2017 vaccine 0.5 ML Prefilled Syringe;
material entity;Fluarix Quadrivalent 2016-2017 vaccine Prefilled Syringe;
material entity;Fluarix Quadrivalent 2017-2018 Injectable Product;
material entity;Fluarix Quadrivalent 2017-2018 vaccine;
material entity;equine rhinopneumonitis-influenza vaccine;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2018-2019];
material entity;equine EEV and WEV encephalomyelitis-influenza vaccine-tetanus toxoid;
material entity;Afluria Quadrivalent 2018-2019 Injectable Product;
material entity;equine EEV and WEV encephalomyelitis-influenza-West Nile virus vaccine-tetanus toxoid;
material entity;Afluria Quadrivalent 2018-2019 vaccine Prefilled Syringe;
material entity;horse encephalomyelitis EEV, VEV, and WEV combination vaccine;a viral vaccine against horse EEV, WEV, and VEE viral infections
material entity;Afluria Quadrivalent 2018-2019 vaccine Injectable Suspension;
material entity;Afluria Quadrivalent 2018-2019 vaccine;
material entity;equine EEV and WEV encephalomyelitis vaccine-tetanus toxoid;
material entity;Afluria Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 250;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 100;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 100;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 250;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10;
material entity;equine EEV and WEV encephalomyelitis-rhinopneumonitis-influenza vaccine-tetanus toxoid;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin;
material entity;Flulaval Quadrivalent 2016-2017 vaccine;
material entity;Canine Distemper-Hepatitis-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin;
material entity;Afluria Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe;
material entity;Feline Immunodeficiency-Leukemia Virus Vaccine;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2016-2017];
material entity;equine EEV and WEV encephalomyelitis-rhinopneumonitis vaccine-tetanus toxoid;
material entity;Flulaval Quadrivalent 2016-2017 Injectable Product;
material entity;persons aged 25--64 years with medical conditions at higher risk for influenza-related complications;
material entity;Feline Leukemia-Chlamydia Psittaci Vaccine;
material entity;FluLaval Quadrivalent 2015-2016 Injectable Product;
material entity;retroviral vaccine vector;a viral vaccine vector that uses a retroviral strain
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Vaccine;
material entity;FluLaval Quadrivalent 2015-2016 vaccine;
process;inactivation;inactivation is a processual entity that produces inactive material.
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine;
material entity;FluLaval Quadrivalent 2015-2016 vaccine Injectable Suspension;
material entity;Rous sarcoma virus vaccine vector;
material entity;Feline Rhinotracheitis-Calici-Chlamydia Psittaci Vaccine;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [FluLaval Quadrivalent 2015-2016];
material entity;FluLaval Quadrivalent 2016-2017 vaccine Injectable Suspension;
material entity;equine EEV and WEV encephalomyelitis-rhinopneumonitis-influenza-West Nile Virus vaccine-tetanus toxoid;
material entity;Flulaval Quadrivalent 2016-2017 vaccine 0.5 Prefilled Syringe;
material entity;persons aged 6 months--24 years;
material entity;horse EEV, VEV, WEV encephalomyelitis-West Nile Virus Vaccine-Tetanus Toxoid;
material entity;Flulaval Quadrivalent 2016-2017 vaccine Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 100;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 250;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1;
material entity;MVTT vaccine vector;a vaccinia virus vector that uses the MVTT vaccine strain as the vector. MVTT is an attenuated vaccine strain.
material entity;Lawsonia intracellularis vaccine;a bacterial vaccine against Lawsonia intracellularis infection
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Vaccine;
material entity;Flulaval Quadrivalent 2017-2018 Injectable Product;
material entity;swinepox virus vaccine vector;a poxvirus vaccine vector that uses a swinepox virus as the vector
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine;
material entity;Flulaval Quadrivalent 2017-2018 vaccine;
material entity;Modified Vaccinia Ankara (MVA) virus vaccine vector;a vaccinia virus vector that uses the Modified Vaccinia Ankara (MVA) virus.
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Vaccine;
material entity;ORF virus vaccine vector;a poxvirus vaccine vector that uses an ORF virus which is a parapoxvirus.
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Vaccine;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2017-2018];
material entity;Afluria 2017-2018 vaccine Prefilled Syringe;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract;
material entity;Afluria 2017-2018 vaccine Injectable Suspension;
material entity;horse EEV, VEV, WEV encephalomyelitis and West Nile Virus vaccine;
material entity;Afluria 2018-2019 vaccine;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Afluria 2017-2018 vaccine 0.5 ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 100;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 250;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine;
material entity;Afluria Quadrivalent 2016-2017 Formula Injectable Product;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine;
material entity;Afluria 2018-2019 vaccine 0.5 ML Prefilled Syringe;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira CanicolaGrippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Afluria 2018-2019];
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract;
material entity;Afluria 2018-2019 Injectable Product;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parvovirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract;
material entity;Afluria 2018-2019 vaccine Prefilled Syringe;
material entity;Canine Distemper-Adenovirus Type 2-Measles-Parainfluenza Vaccine;
material entity;afluria 2018-2019 vaccine Injectable Suspension;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira CanicolaGrippotyphosa-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Afluria Quadrivalent 2016-2017 Formula Prefilled Syringe;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract;
material entity;Afluria Quadrivalent 2016-2017 Formula Influenza Virus Vaccine Injectable Suspension;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin;
material entity;Afluria Quadrivalent 2016-2017 Formula vaccine;
material entity;Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine;
material entity;Afluria Quadrivalent 2016-2017 Formula 0.5 ML Prefilled Syringe;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2016-2017 Formula];
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 3;
material entity;canine parainfluenza-bordetella bronchiseptica vaccine;
material entity;canine parvovirus vaccine-leptospira canicola icterohaemorrhagiae bacterin;
material entity;Afluria Quadrivalent 2017-2018 vaccine Prefilled Syringe;
material entity;Canine Distemper-Adenovirus Type 2-Parvovirus-Rabies Vaccine;
material entity;Afluria Quadrivalent 2017-2018 Injectable Product;
material entity;Canine Distemper-Hepatitis-Parainfluenza Vaccine;
material entity;Afluria Quadrivalent 2017-2018 vaccine;
material entity;Canine Distemper-Measles Vaccine;
material entity;Afluria Quadrivalent 2017-2018 vaccine Injectable Suspension;
material entity;Canine Distemper-Parvovirus Vaccine;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2017-2018];
material entity;Morupar;A Measles-Mumps-Rubella vaccine that is manufactured by Sanofi Aventis.
material entity;Bovine Rhinotracheitis-Respiratory Syncytial Virus Vaccine;
material entity;Fluvirin 2015-2016 Injectable Product;
quality;bacterial vaccine organism live attenuated;a live attenuated quality of a bacterial vaccine strain.
material entity;Bovine Rhinotracheitis-Virus Diarrhea Vaccine;
material entity;Fluvirin 2015-2016 vaccine;
quality;viral vaccine organism live attenuated;a live attenuated quality of a virus vaccine strain.
material entity;Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Campylobacter Fetus-Leptospira CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Fluvirin 2015-2016 vaccine Injectable Suspension;
material entity;Vectormune FP-ND;
material entity;Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluvirin 2015-2016];
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML [PedvaxHIB];
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin;
material entity;PedvaxHIB Injectable Product;
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Pomona Bacterin;
material entity;classical swine fever virus vaccine;
material entity;Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Vaccine;
material entity;PedvaxHIB vaccine Injection;
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML [YF-Vax];
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 25;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10 by Statens Serum Institut;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 25;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed];
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 3;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed] by Aventis;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 50;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension;
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO];
material entity;0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension;
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO];
material entity;0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension [Neisvac C];
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO];
material entity;0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension [Neisvac C] by Pfizer;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution;
material entity;0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection [ActHIB];
material entity;live attenuated Marek's disease virus vaccine;A live attenuated vaccine that protects against Marek's disease virus.
material entity;Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid;
material entity;live attenuated Newcastle disease virus vaccine;A live attenuated viral vaccine that protects aganist Newcastle disease virus infection.
material entity;Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin;
material entity;Fluvirin 2015-2016 vaccine Prefilled Syringe;
material entity;live attenuated avian reovirus vaccine;an avian reovirus vaccine that using live attenauted reovirus.
material entity;inactivated avian influenza vaccine;an avian influenza vaccine that uses inactivated viral organism
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Fluvirin 2017-2018 vaccine;
material entity;vesicular stomatitis virus vaccine vector;a viral vaccine vector that uses a vesicular stomatitis virus (VSV) as the vector.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin;
material entity;Fluvirin 2016-2017 vaccine 0.5 ML Prefilled Syringe;
material entity;AquaVac Furuvac;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica Bacterin;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluvirin 2017-2018];
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine;
material entity;Fluvirin 2017-2018 Injectable Product;
material entity;Advent;
material entity;Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Hardjo-Pomona Bacterin;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluvirin 2016-2017];
material entity;live attenuated feline panleukopenia virus vaccine;a feline panleukopenia virus vaccine where the virus used is live attenuated.
material entity;Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Pomona Bacterin;
material entity;Fluvirin 2016-2017 Injectable Product;
material entity;Megan Vac1;Megan Vac1 is a Salmoneela vaccine that consists of a double gene-deleted S. enterica serovar Typhimurium strain and is designed for protection of broilers to reduce Salmonella contamination.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine;
material entity;Fluvirin 2016-2017 vaccine Prefilled Syringe;
material entity;BCG vaccine vector;a bacterial vaccine vector that uses TB vaccine BCG as the vector.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Fluvirin 2016-2017 vaccine Injectable Suspension;
material entity;Fluvirin 2016-2017 vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin;
material entity;Fluvirin 2015-2016 vaccine 0.5 ML Prefilled Syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 1 by Baxter;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5 by Statens Serum Institut;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension by Statens Serum Institut;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20 by Statens Serum Institut;
material entity;Leishmania tarentolae vaccine vector;a parasite vaccine vector using a live attenuated Leishmania tarentolae strain.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Campylobacter Fetus-Haemophilus Somnus-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin;
material entity;autologous dendritic cell melanoma vaccine;
material entity;Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.21);
material entity;Fluzone Quadrivalent 2018-2019 vaccine Injectable Suspension;
material entity;Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.22);
material entity;Fluzone Quadrivalent 2018-2019 vaccine 0.5 ML Injection;
material entity;Porcine Reproductive & Respiratory Syndrome-Parvovirus Reproductive Form, Modified Live & Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4P19.20);
material entity;Fluzone Quadrivalent Pediatric Dose for 6-35 Months of Age 2018-2019 Vaccine 0.25 ML Prefilled Syringe;
material entity;Comirnaty vaccine;A SARS-CoV-2 RNA vaccine formed from a lipid nanoparticle-formulated trimerized SARS-CoV-2 receptor-binding domain
material entity;avian encephalomyelitis-chicken anemia virus-fowl pox vaccine;
material entity;Fluzone Quadrivalent 2018-2019 Vaccine Prefilled Syringe;
material entity;Fluzone Quadrivalent 2018-2019 Injectable Product;
material entity;Infectious Salmon Anemia Virus Killed Virus Vaccine-Aeromonas Salmonicida-Vibrio Anguillarum-Ordalii-Salmonicida Bacterin (USDA: 4A45.20);
material entity;Fluzone Quadrivalent 2018-2019 vaccine Injection;
material entity;Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.20);
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2018-2019];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection Box of 5;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution by Aventis;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Booster];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Booster] Box of 5;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Vaccine];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] by Novartis;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Glaxosmithkline;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Sanofi;
material entity;avian encephalomyelitis-fowl pox vaccine;
material entity;influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML;
material entity;avian encephalomyelitis-fowl pox-laryngotracheitis vaccine;
material entity;Fluzone Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe;
material entity;SARS-CoV-2 protein;
material entity;avian encephalomyelitis-fowl pox-Mycoplasma gallisepticum vaccine;
material entity;avian influenza-fowl pox vaccine;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML;
material entity;phCMV1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label phCMV1. This plasmid is 4200 base pairs long, has a CMV promoter, contains kanamycin and neomycin antibiotics resistance genes, and is manufactured by Genlantis.
material entity;Bovine Rhinotracheitis Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae- Pomona Bacterin;
material entity;YF-Vax Injectable Product;
material entity;AdCLD-CoV19;A SARS-CoV-2 replication-defective human adenovirus type 5/35 vector based vaccine expressing the S protein.
material entity;pCJ-3 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCJ-3. This plasmid has a CMV promoter and a kanamycin resistance gene.
material entity;Bovine Rhinotracheitis Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin;
material entity;influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML;
material entity;UB-612;A SARS-CoV-2 S1-RBD-protein based vaccine developed by Vaxxinity
material entity;pcDNA3.1/V5-His DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/V5-His. This plasmid has a CMV promoter.
material entity;Bovine Rhinotracheitis Vaccine-Leptospira Hardjo-Pomona Bacterin;
material entity;YF-VAX 0.5 ML Injection;
material entity;pSecTag2 C DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSecTag2 C. This plasmid is 5167 base pairs long, has a CMV promoter and ampicillin and zeocin resistance genes.
material entity;Bovine Rhinotracheitis Vaccine-Leptospira Pomona Bacterin;
material entity;YF-VAX Injection;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML;
material entity;CoVLP vaccine;A recombinant coronavirus-like particle SARS-CoV-2 vaccine developed by Medicago
material entity;Bovine Parainfluenza 3-Respiratory Syncytial Virus Vaccine;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML;
material entity;COVAXIN vaccine;BBV152 (also known as Covaxin) is an inactivated COVID-19 vaccine that is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research.
material entity;pSCA1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSCA1.
material entity;Bovine Rhinotracheitis Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid;
material entity;influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML;
material entity;SCB-2019;A SARS-CoV-2 trimeric S protein subunit vaccine.
material entity;Bovine Rhinotracheitis Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML;
material entity;Ad35.CS.01 malaria vaccine;A P. falciparum malaria vaccine that is formed by tull length CS-expressing replication-deficient recombinant human adenovirus 35.
material entity;E protein of SARS-CoV-2;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO];
material entity;0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO];
material entity;0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [H-B-Vax II];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B];
material entity;0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B];
material entity;0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk];
material entity;0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection [Hiberix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax];
material entity;0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection [Hiberix] by Glaxosmithkline;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution by Aventis;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution by Aventis;
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin;
material entity;YF-Vax Injectable Suspension;
material entity;pBC12/CMV/IL-2 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pBC12/CMV/IL-2.
material entity;bovine rhinotracheitis-parainfluenza 3 vaccine;
material entity;YF-Vax 4000 UNT/ML Injectable Suspension;
material entity;AKS-452;A SARS-CoV-2-RBD-Fc fusion protein designed to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein.
material entity;Giardiavax;
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Haemophilus Somnus Bacterin;
material entity;plant-based Newcastle disease virus vaccine;The plant-based Newcastle disease virus vaccine is a Newcastle disease virus vaccine that is developed by Dow AgroSciences LLC. It uses technology discovered at Washington University. It is the first plant-made animal vaccine approved for sale in the United States.
material entity;Coxsackievirus vaccine vector;a viral vaccine vector that uses a Coxsackievirus strain
material entity;Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract;
material entity;Canine Coronavirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract;
material entity;Oka varicella vaccine vector;a poxvirus vaccine vector that uses an attenuated Oka varicella virus strain
material entity;Nobivac Piro;
material entity;chicken Bursal Disease-Newcastle Disease-Reovirus Vaccine;
material entity;Equilis StrepE;
material entity;chicken bursal disease-reovirus vaccine;
material entity;chimpanzee adenovirus vaccine vector;an adenovirus vaccine vector that uses a chimpanzee adenovirus strain
material entity;Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine;
material entity;measles virus vaccine vector;a viral vaccine vector that uses a measles virus strain
material entity;Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-GrippotyphosaIcterohaemorrhagiae-Pomona Bacterial Extract;
material entity;Bovine Virus Diarrhea Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;pseudorabies virus strain Bartha vaccine vector;A herpesevirus vaccine vector that uses an established live-virus vaccine against Aujeszky's disease of swine, pseudorabies virus (PrV) strain Bartha (PrV-Ba), to serve as vector.
material entity;Bovine Virus Diarrhea Vaccine-Leptospira Pomona Bacterin;
material entity;porcine adenovirus 3 vaccine vector;an adenovirus vaccine vector that uses a porcine adenovirus 3 strain
material entity;Bursal Disease-Mareks Disease Vaccine;
material entity;poliovirus vaccine vector;a viral vaccine vector that uses a poliovirus strain
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Vaccine;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 20;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 50;
material entity;Herpes simplex virus vaccine 1 vector;A Herpes simplex virus vaccine vector that uses a virus type 1 strain
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract;
material entity;Mycobacterium smegmatis vaccine vector;a bacterial vaccine vector that uses an attenuated Mycobacterium smegmatis strain
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine;
material entity;Neospora caninum vaccine;
material entity;Canine Distemper-Adenovirus Type 2 Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract;
material entity;Lactobacillus gasseri vaccine vector;a bacterial vaccine vector that uses an attenuated Lactobacillus gasseri strain
material entity;Canine Distemper-Adenovirus Type 2 Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin;
material entity;herpesvirus of turkey vaccine vector;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Borrelia Burgdorferi Bacterin;
material entity;Newcastle disease virus vaccine vector;a viral vaccine vector that uses a NewCastle virus strain
material entity;Canine Coronavirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract;
material entity;Theileria parva vaccine;
material entity;Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin;
material entity;myxoma virus vaccine vector;a viral vaccine vector that uses a myxoma virus strain
material entity;Canine Coronavirus-Parvovirus Vaccine;
material entity;Maraba virus vaccine vector;a viral vaccine vector that uses a Maraba virus strain
material entity;Canine Distemper-Adenovirus Type 2 Vaccine;
material entity;Canine Coronavirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract;
material entity;Yersinia ruckeri vaccine;a bacterial vaccine against Yersinia ruckeri infection
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona-Mannheimia Haemolytica Bacterin;
material entity;Fluarix Quadrivalent 2016-2017 vaccine;
material entity;Streptococcus gordonii vaccine vector;a bacterial vaccine vector using a live attenuated Streptococcus gordonii vaccine vector.
material entity;Bursal Disease-Newcastle Disease-Bronchitis Vaccine;
material entity;Fluarix Quadrivalent 2015-2016 vaccine 0.5 ML Prefilled Syringe;
material entity;Bordetella pertussis BPZE vaccine vector;a bacterial vaccine vector using a live attenuated Bordetella pertussis BPZE as a vaccine vector.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Hardjo Bacterin;
material entity;Actinobacillus pleuropneumoniae HS93Tox vaccine vector;a bacterial vaccine vector using the HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae. This mutant lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica Toxoid;
material entity;Fluarix Quadrivalent 2016-2017 Injectable Product;
material entity;Salmonella typhimurium SL3261 vaccine vector;a bacterial vaccine vector using a live attenuated Salmonella enterica strain SL3261.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Fluarix Quadrivalent 2015-2016 Injectable Product;
material entity;Edwardsiella tarda EIB202 vaccine vector;a bacterial vaccine vector using a live attenuated Edwardsiella tarda strain EIB202
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus-Mannheimia Haemolytica Bacterin;
material entity;Fluarix Quadrivalent 2015-2016 vaccine;
material entity;Babesia bigemina vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Fluarix Quadrivalent 2015-2016 vaccine Prefilled Syringe;
material entity;parasite vaccine vector;a vaccine vector that uses a parasite as the vector.
material entity;chicken bursal disease-Newcastle disease vaccine;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2015-2016];
material entity;Fluvirin 2017-2018 vaccine Injectable Suspension;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Fluvirin 2017-2018 vaccine 0.5 ML Prefilled Syringe;
process;vaccine-induced mouse immune response;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus Bacterin;
material entity;Fluvirin 2017-2018 vaccine Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension;
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe;
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution;
material entity;Herpes simplex virus vaccine vector;a herpesvirus vaccine vector that uses a herpes simplex virus strain
material entity;Bovine Rotavirus-Coronavirus Vaccine-Escherichia Coli Bacterin;
material entity;simian adenovirus ChAd63 vaccine vector;an adenovirus vaccine vector that uses the simian adenovirus ChAd63 strain.
material entity;Bovine Virus Diarrhea Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin;
material entity;raccoon poxvirus vaccine vector;an orthopoxvirus vaccine vector that uses an attenuated Raccoon poxvirus strain
material entity;Bovine Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid;
material entity;Vaxsafe MS;
material entity;BoHV-4 vaccine vector;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Vaccine-Leptospira Pomona Bacterin;
material entity;canarypox vaccine vector;an Avipox virus vaccine vector that uses an attenuated canarypox virus strain
material entity;Bovine Rotavirus-Coronavirus Vaccine;
material entity;Vibrio cholerae vaccine vector;a bacterial vaccine vector that uses an attenuated Vibrio cholerae strain
material entity;Bovine Rotavirus-Coronavirus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid;
material entity;APMV-3 vaccine vector;a viral vaccine vector that uses an avian paramyxovirus strain
material entity;Bovine Rotavirus-Coronavirus Vaccine-Clostridium Perfringens Types C & D-Escherichia Coli Bacterin-Toxoid;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid;
material entity;fowlpox virus vaccine vector;an Avipox virus vaccine vector that uses a fowlpox virus as the vector
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus-Mannheimia Haemolytica-Pasteurella Multocida Vaccine;
material entity;L. monocytogenes LM1-2 vaccine vector;A Listeria monocytogenes vaccine vector that uses the highly attenuated LM1-2 strain
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Vaccine;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 2;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 20;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B] Box of 1;
material entity;RECOMBITEK rDistemper;
material entity;persons living with or providing care for infants aged <6 months;
material entity;health-care and emergency medical services personnel;
material entity;NYVAC vaccine vector;a vaccinia vaccine vector that uses the highly attenuated NYVAC as vector
material entity;pregnant women;
process;passive immunization by injecting pre-made immune element;passive immunization by injecting a recipient with pre-made antibody, antitoxin, epitope, etc.
material entity;Ovastim;A vaccine used to increase the fecundity in breeding ewes. Ovastim increases the number of multiple ovulations and therefore the number of multiple births.
material entity;vaccinee priority group;A population group that have priority for vaccination when a vaccine is first available.
material entity;Poulvac FluFend I AI H5N3 RG;
material entity;Salmonella typhi vaccine vector;a bacterial vaccine vector that uses a Salmonella typhi strain
material entity;recombinant homologous vector vaccine;a recombinant vector vaccine that uses a homologous vector, i.e., when the target species of the vaccine is a natural host for the vector.
material entity;Mycoplasma synoviae vaccine;a bacterial vaccine against Mycoplasma synoviae infection
material entity;recombinant heterologous vector vaccine;a recombinant vector vaccine that uses a homologous vector, i.e., when the target species of the vaccine is not one of the natural hosts for the vector.
material entity;AquaVac Vibrio;
material entity;duck enteritis virus vector;a viral vaccine vector that uses a duck enteritis virus strain
material entity;CMV vaccine vector;a herpesvirus vaccine vector that uses a CMV virus strain
material entity;Babesia canis vaccine;
material entity;E. coli vaccine vector;a bacterial vaccine vector that uses an E. coli strain
material entity;complex adenovirus vaccine vector;an adenovirus vaccine vector that uses a complex adenovirus as the vector strain.
material entity;human adenovirus vaccine vector;an adenovirus vaccine vector that uses a human adenovirus as the vector strain.
material entity;murine leukemia viral vector vaccine;a viral vaccine vector that uses a murine leukemia virus as the vaccine vector
generically dependent continuant;CDC recommendation of the use of Influenza A (h1N1) 2009 vaccine;
material entity;AcMNPV vector;an adenovirus vaccine vector that contains a deletion of the gp64 gene. As a result of the deletion, this vector is unable to propagate infection from cell to cell, and this defect results from both a severe reduction in the production of budded virions and the absence of GP64 on virions.
material entity;Giardia duodenalis vaccine;protozoan vaccine that is used to protect against Giardia intestinalis infection
material entity;baculovirus vaccine vector;a viral vaccine vector that uses a baculovirus as the vector
material entity;Chlamydophila abortus vaccine;a Chlamydia bacterial vaccine against C. abortus infection
material entity;Androstenedione;
material entity;adenovirus serotype 5 vaccine vector;an adenovirus vaccine vector that uses an Adenovirus serotype 5 strain.
quality;human age;
process;vaccine specific Th2 immune response indicated by IgG1 production;vaccine-induced T-helper 2 type immune response that is indicated by the presence of IgG1 production
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] by Glaxosmithkline;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Tripacel] Box of 5;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection Box of 5;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Boostrix] Box of 10;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 10;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Tripacel];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Boostrix];
generically dependent continuant;human age range at vaccination;
generically dependent continuant;age range at vaccination;
generically dependent continuant;human adult age range at vaccination;
generically dependent continuant;human child age range at vaccination;
quality;adolescence age;
quality;child age;
quality;senior age;
quality;adult age;
generically dependent continuant;human senior age range at vaccination;
material entity;influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen;
generically dependent continuant;human adolescence age range at vaccination;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] by GSK;
material entity;0.5 ML Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] by GSK;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetravac];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetravac] by Sanofi;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix];
material entity;Fluzone Quadrivalent 2013-2014 Formula Injectable Product;
generically dependent continuant;human age 12 to 23 months at vaccination;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML;
generically dependent continuant;human age 7 to 11 months at vaccination;
material entity;Fluzone Quadrivalent 2013-2014 Formula Influenza Virus Vaccine Prefilled Syringe;
material entity;influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone Quadrivalent 2013-2014 Formula];
generically dependent continuant;human age 2 to 3 years at vaccination;
material entity;influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML;
generically dependent continuant;human age 4 months at vaccination;
material entity;influenza B virus B/Maryland/15/2016 antigen;
generically dependent continuant;human age 1 to 2 months at vaccination;
material entity;influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML;
generically dependent continuant;human age 4 to 6 years at vaccination;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML;
generically dependent continuant;human age 11 to 12 years at vaccination;
material entity;COVID-19 vaccine;A coronavirus vaccine against the infection of SARS-CoV-2 (cause of COVID-19)
material entity;MERS-CoV S protein with alum and CpG adjuvant;
material entity;Influenza A virus (A/Indonesia/05/2005) antigen;
material entity;MERS-CoV S protein;
material entity;MERS-CoV protein;
material entity;influenza B virus B/Wisconsin/1/2010 antigen;
material entity;MERS vaccine;
material entity;Inactivated monovalent influenza A/H5N1 (3.75 mcg hemagglutinin [HA] A/Indonesia/05/2005) split-virus (SV) vaccine (Sanofi);Inactivated monovalent influenza A/H5N1 (3.75 mcg hemagglutinin [HA] A/Indonesia/05/2005) split-virus (SV) vaccine (Sanofi)
material entity;influenza A virus A/Victoria/361/2011 (H3N2) antigen;
material entity;PfSPZ Vaccine;A Plasmodium falciparum vaccine that is composed of aseptic, purified, live (metabolically active), radiation-attenuated, cryopreserved Plasmodium falciparum sporozite.
process;vaccine specific Th1 immune response indicated by IgG2a production;vaccine-induced T-helper 1 type immune response that is indicated by the presence of IgG2a production
process;vaccine specific IL-2 immune response;vaccine-induced T-helper 1 type immune response that is indicated by the presence of interleukin-2 production
process;vaccine specific interferon-γ immune response;vaccine-induced T-helper 1 type immune response that is indicated by the presence of Interferon-gamma production
process;vaccine specific interleukin-10 response;vaccine-induced T-helper 2 type immune response that is indicated by the presence of interleukin-10 production
process;vaccine specific interleukin-4 response;vaccine-induced T-helper 2 type immune response that is indicated by the presence of interleukin-4 production
material entity;PfSPZ-GA1;Sanaria(R) PfSPZ-GA1 consists of purified, aseptic, cryopreserved Pf sporozoites (NF54 strain) genetically attenuated by removal of the b9 and slarp genes to halt development in the early liver stages.
material entity;PfSPZ-CVac;The fully infectious PfSPZ are attenuated in vivo by concomitant administration of an anti-malarial drug (chloroquine). Chloroquine kills disease-associated blood stages but does not affect pre-erythrocytic (sporozoite or liver) stages, which are exposed to the host's immune system. Sporozoites-induced protection is mediated by immunity against pre-erythrocytic stages.
material entity;virus-like particle vaccine;A vaccine that uses virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines.
role;virus-like particle vaccine role;A vaccine role that inheres in a vaccine using virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines.
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.21);
material entity;Fluzone Quadrivalent 2016-2017 Formula 0.5 ML Injection;
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.23);
material entity;Fluzone Quadrivalent 2016-2017 Formula Injection;
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.24);
material entity;Fluzone Quadrivalent 2016-2017 vaccine Prefilled Syringe;
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.22);
material entity;Fluzone Quadrivalent 2016-2017 Injectable Suspension;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2016-2017];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection Box of 10 by Massbiologics;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension by Iaf Biovac;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension by Lederle Products;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection Box of 10;
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension;
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension Box of 5;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension Box of 5 by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im] by Lederle Products;
material entity;Porcine Rotavirus Modified Live Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 49C1.21);
material entity;Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.22);
material entity;Fluzone Quadrivalent 2017-2018 Injectable Product;
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.23);
material entity;Fluzone Quadrivalent 2016-2017 vaccine 0.25 ML Prefilled Syringe;
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.25);
material entity;Fluzone Quadrivalent 2016-2017 vaccine 0.1 ML Prefilled Syringe;
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.26);
material entity;Fluzone Quadrivalent 2017-2018 vaccine;
material entity;Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 49B1.21);
material entity;Fluzone Quadrivalent 2016-2017 vaccine 0.5 ML Prefilled Syringe;
material entity;Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.24);
material entity;Fluzone Quadrivalent 2017-2018 vaccine 0.5 ML Injection;
material entity;Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.22);
material entity;Fluzone Quadrivalent 2017-2018 vaccine Injection;
material entity;Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.23);
material entity;Fluzone Quadrivalent 2017-2018 vaccine Prefilled Syringe;
material entity;Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.24);
material entity;Fluzone Quadrivalent 2017-2018 vaccine Injectable Suspension;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2017-2018];
material entity;Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.23);
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2017-2018];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection by Massbiologics;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Bordetella Bronchiseptica-Clostridium Perfringens Type C-Erysipelothrix Rhusiopathiae-Escherichia Coli-Pasteurella Multocida Bacterin-Toxoid (USDA: 49T9.21);
material entity;Porcine Rotavirus Modified Live Virus Vaccine-Escherichia Coli Bacterin (USDA: 49K1.20);
material entity;Fluzone Quadrivalent 2017-2018 vaccine 0.25 ML Prefilled Syringe;
material entity;Porcine Circovirus Type 2, Killed Baculovirus Vector Vaccine- Mycoplasma Hyopneumoniae Bacterin (USDA: 49K5.R1);
material entity;Fluzone Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe;
material entity;Porcine Reproductive & Respiratory Syndrome-Circovirus Reproductive & Respiratory Form, Type 2, Modifed Live Virus,Killed Baculovirus Vector Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 49K9.R0);
material entity;Fluzone Quadrivalent 2018-2019 vaccine;
material entity;Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Escherichia Coli Bacterin (USDA: 49P1.20);
material entity;Fluzone Quadrivalent 2017-2018 vaccine 0.1 ML Prefilled Syringe;
material entity;Fluzone Quadrivalent 2013-2014 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe;
generically dependent continuant;human age 7 to 10 years at vaccination;
generically dependent continuant;human age 6 months at vaccination;
material entity;Fluzone Quadrivalent 2014-2015 Formula Injectable Product;
generically dependent continuant;human age 27 to 59 years at vaccination;
material entity;Fluzone Quadrivalent 2014-2015 Formula vaccine;
generically dependent continuant;human age 19 to 26 years at vaccination;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML / tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML / tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension by Statens Serum Institut;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection;
material entity;0.5 ML Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;0.5 ML Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution by Aventis;
material entity;0.5 ML Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension [Tripacel];
material entity;0.5 ML Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension;
material entity;0.5 ML Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension [Adacel];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2015-2016];
material entity;Fluzone Quadrivalent 2015-2016 Injectable Product;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2015-2016];
material entity;Fluzone Quadrivalent 2014-2015 Formula Prefilled Syringe;
material entity;influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Fluzone Quadrivalent 2014-2015 Formula];
generically dependent continuant;human age within one month at vaccination;A human child age range at vaccination with the range from the birth to one month after birth at when a vaccination is taken. HepB vaccination is sometimes taken within 12 hours after birth.
material entity;Fluzone Quadrivalent 2015-2016 vaccine;
material entity;Fluzone Quadrivalent 2014-2015 Formula 0.1 ML Prefilled Syringe;
material entity;Fluzone Quadrivalent 2015-2016 vaccine 0.5 ML Injection;
material entity;Fluzone Quadrivalent 2015-2016 Injection;
material entity;Fluzone Quadrivalent 2015-2016 vaccine Prefilled Syringe;
material entity;Fluzone Quadrivalent 2015-2016 vaccine Injectable Suspension;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im];
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 50;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] by Glaxosmithkline;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Booster];
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] by Glaxosmithkline;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Booster] Box of 5;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Intramuscular Solution [Recombivax] by Merck;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Vaccine];
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 5;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection Box of 10;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 25;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection Box of 10 by Massbiologics;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 3;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection by Massbiologics;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 50;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2016-2017];
material entity;Fluzone Quadrivalent 2016-2017 Injectable Product;
material entity;Fluzone Quadrivalent 2015-2016 vaccine 0.25 ML Prefilled Syringe;
material entity;Fluzone Quadrivalent 2015-2016 vaccine 0.1 ML Prefilled Syringe;
material entity;Fluzone Quadrivalent 2016-2017 vaccine;
material entity;Fluzone Quadrivalent 2015-2016 vaccine 0.5 ML Prefilled Syringe;
material entity;Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46E5.23);
material entity;Bacilli vaccine;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135;
material entity;Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46E5.24);
material entity;Firmicutes vaccine;
material entity;Menomune A/C/Y/W-135 Vaccine Injectable Solution;
material entity;Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46E5.25);
material entity;meningococcal group A polysaccharide;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J7.20);
material entity;Lactobacillales vaccine;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.1 MG/ML;
material entity;Enterobacterales vaccine;
material entity;meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.1 MG/ML [Menomune A/C/Y/W-135];
material entity;Canine Coronavirus Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46D5.27);
material entity;Alphaproteobacteria vaccine;
material entity;Adenovirus Type 7 Vaccine Live 32000 UNT;
material entity;Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46E5.20);
material entity;Spirochaetia vaccine;
material entity;Menomune A/C/Y/W-135 Vaccine 0.5 ML Injection;
material entity;Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46E5.21);
material entity;Enterobacteriaceae vaccine;
material entity;Menomune A/C/Y/W-135 Vaccine Injection;
material entity;Adenovirus Type 7 Vaccine Live 32000 UNT Delayed Release Oral Tablet;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [Hepasorbat];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 5 by Statens Serum Institut;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [Heptavax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 10 by Sanofi;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Suspension [Engerix B];
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [Gemvites];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10 by Statens Serum Institut;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [Gen Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 20 by Sanofi;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [H B Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 20 by Statens Serum Institut;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 5 by Sanofi;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 2 by Novartis;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [Bimmugen];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 1 by Novartis;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10 by Glaxosmithkline;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution [Fendrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10 by Novartis;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J7.22);
material entity;Prevnar 13 vaccine 0.5 ML Prefilled Syringe;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J8.20);
material entity;meningococcal group A polysaccharide 0.1 MG/ML;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J9.20);
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46J9.29);
material entity;PNEUMOVAX 23 vaccine Injectable Solution;
material entity;coronavirus vaccine;A vaccine against coronavirus infection
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live Virus, Live Canarypox Vector Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J9.R1);
material entity;PNEUMOVAX 23 0.5 ML Injection;
generically dependent continuant;intersex biological sex datum;A biological sex datum that represents the biological sex of an animal (including human) as being intersex.
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46L9.27);
material entity;PNEUMOVAX 23 vaccine 0.5 ML Prefilled Syringe;
material entity;2012-2013 seasonal trivalent inactivated influenza vaccine (A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Wisconsin/1/2010);2012-2013 trivalent seasonal inactivated influenza vaccine 2012-2013 Influenza A virus (A/California/7/2009 (H1N1)), Influenza A virus (A/Victoria/361/2011 (H3N2)), and Influenza B virus (B/Wisconsin/1/2010)
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46P9.27);
material entity;PNEUMOVAX 23 vaccine Prefilled Syringe;
material entity;Influenza A virus A/Perth/16/2009 (H3N2) antigen;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.21);
material entity;pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML;
material entity;Fluenz vaccine;Fluenz is a seasonal trivalent live attenuated influenza vaccine (LAIV) administered intranasally. The vaccine contained A/California/07/2009 (H1N1) pdm09-like strain, A/Victoria/361/2011 (H3N2)-like strain, and B/Massachusetts/2/2012-like strain.
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46J9.25);
material entity;pneumococcal capsular polysaccharide type 9V vaccine;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.26);
material entity;Pneumovax 23 Injection;
generically dependent continuant;female biological sex datum;A biological sex datum that represents the biological sex of an animal (including human) as being female.
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.27);
material entity;Pneumovax 23 Injectable Product;
material entity;quadrivalent seasonal inactivated influenza vaccine 2014;quadrivalent seasonal inactivated influenza vaccine 2014 consisting of Influenza A virus (A/California/7/2009(H1N1)), Influenza A virus (A/Texas/50/2012(H3N2)), Influenza B virus (B/Brisbane/60/2008), Influenza B virus (B/Massachusetts/02/2012)
material entity;CN54gp140 + GLA;
material entity;gH1-Qbeta vaccine;The gH1-Qbeta vaccine is a novel pandemic-influenza vaccine produced by covalently linking the globular head domain of haemagglutinin (gH1) from A/California/07/09 produced in E. coli to VLPs from the bacteriophage Qbeta
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [H B Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [HBvaxPRO];
material entity;Hepatitis B Surface Antigen Vaccine Injection [H-B-Vax II];
material entity;diphtheria toxoid vaccine, inactivated 0.2 LFU/ML Injectable Solution by Connaught;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Engerix B];
material entity;diphtheria toxoid vaccine, inactivated 50 LFU/ML Injectable Solution by Aventis;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Fendrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Gen Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Suspension [Engerix-B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 50 by Sanofi;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Suspension [Fendrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix] Box of 25 by Glaxosmithkline;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Suspension [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 10 by Sanofi;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Suspension [VACCIN GENHEVAC B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 20 by Sanofi;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 25 by Sanofi;
material entity;Encephalomyelitis-Influenza-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 46W5.21);
material entity;Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47A5.20);
material entity;Prevnar 13 Injectable Product;
material entity;Fowl Pox-Mycoplasma Gallisepticum Live Fowl Pox Vector Vaccine (USDA: 1D51.R0);
material entity;Yersiniaceae vaccine;A vaccine that is used against an infection by a pathogen under Yersiniaceae.
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.1 MG/ML;
material entity;Fowl Pox-Laryngotracheitis Live Fowl Pox Vector Vaccine (USDA: 1F31.R0);
material entity;Betaproteobacteria vaccine;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.01 MG/ML;
material entity;Newcastle-Bronchitis B1 Type, C2 Strain, Mass Type, Live Virus Vaccine (USDA: 1XB1.10);
material entity;Gammaproteobacteria vaccine;
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.01 MG/ML [MenHibrix];
material entity;Newcastle-Bronchitis B1 Type, C2 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1XC1.10);
material entity;Corynebacterium vaccine;A vaccine that is used against an infection by a pathogen under Corynebacterium.
material entity;MenHibrix Injectable Product;
material entity;MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y;
material entity;Proteobacteria vaccine;
material entity;meningococcal group C polysaccharide 0.1 MG/ML;
material entity;Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1B82.50);
material entity;influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML;
material entity;meningococcal group C polysaccharide 0.01 MG/ML;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [VACCIN GENHEVAC B];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [Fendrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 10 by Glaxosmithkline;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [Gen Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 20 by Glaxosmithkline;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [H-B-Vax II];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 25 by Glaxosmithkline;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 50 by Glaxosmithkline;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Gemvites];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [H B Vax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10 by Statens Serum Institut;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Hepasorbat];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20 by Statens Serum Institut;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Lt Grk];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5 by Statens Serum Institut;
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML Injectable Solution Box of 5;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Engerix B];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.22);
material entity;Bovine Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 40A5.20);
material entity;Varicellovirus vaccine;A vaccine that is used against an infection by a pathogen under Varicellovirus.
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML;
material entity;Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4629.20);
material entity;Bacillus vaccine;A vaccine that is used against an infection by a pathogen under Bacillus.
material entity;MENHIBRIX vaccine 0.5 ML Injection;
material entity;Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4629.27);
material entity;Orthopoxvirus vaccine;A vaccine that is used against an infection by a pathogen under Orthopoxvirus.
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.20);
material entity;Papillomaviridae vaccine;A vaccine that is used against an infection by a pathogen under Papillomaviridae.
material entity;HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.21);
material entity;Rubulavirus vaccine;A vaccine that is used against an infection by a pathogen under Rubulavirus.
material entity;Adenovirus Type 4 Vaccine Live 32000 UNT Delayed Release Oral Tablet;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.22);
material entity;Morbillivirus vaccine;A vaccine that is used against an infection by a pathogen under Morbillivirus.
material entity;Adenovirus Type 4 Vaccine Live Delayed Release Oral Tablet;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 4639.25);
material entity;Flaviviridae vaccine;A vaccine that is used against an infection by a pathogen under Flaviviridae.
material entity;Adenovirus Type 7 Vaccine Live Oral Product;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4639.27);
material entity;Lyssavirus vaccine;A vaccine that is used against an infection by a pathogen under Lyssavirus.
material entity;Adenovirus Type 4 Vaccine Live 32000 UNT;
material entity;Orthohepadnavirus vaccine;A vaccine that is used against an infection by a pathogen under Orthohepadnavirus.
material entity;HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142;
material entity;Menomune A/C/Y/W-135 Injectable Product;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.23);
material entity;Sedoreovirinae vaccine;A vaccine that is used against an infection by a pathogen under Sedoreovirinae.
material entity;Adenovirus Type 4 Vaccine Live Pill;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 4637.29);
material entity;Reoviridae vaccine;A vaccine that is used against an infection by a pathogen under Reoviridae.
material entity;Adenovirus Type 4 Vaccine Live Oral Product;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10 by Sanofi;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Intramuscular Solution [Recombivax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20 by Sanofi;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 10 by Novartis;
material entity;Haemophilus B Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine Injectable Solution [Procomvax];
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN Injectable Suspension [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 20 by Sanofi;
material entity;Hepatitis B Surface Antigen Vaccine 0.001 MG/ML;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 5 by Sanofi;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 10 by Sanofi;
material entity;Hepatitis B Surface Antigen Vaccine Intramuscular Solution;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 20 by Sanofi;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis] Box of 10 by Sanofi;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring] Box of 10 by Novartis;
material entity;Hepatitis B Surface Antigen Vaccine Intramuscular Solution [Recombivax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 10 by Sanofi;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4639.28);
material entity;Hepatovirus vaccine;A vaccine that is used against an infection by a pathogen under Hepatovirus.
material entity;Adenovirus Type 7 Vaccine Live Delayed Release Oral Tablet;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus, Live Canarypox Vector Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.R1);
material entity;Enterovirus vaccine;A vaccine that is used against an infection by a pathogen under Enterovirus.
material entity;Adenovirus Type 7 Vaccine Live Pill;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4659.20);
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46B9.21);
material entity;Rubivirus vaccine;A vaccine that is used against an infection by a pathogen under Rubivirus.
material entity;Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.26);
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen;
material entity;Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.27);
material entity;Fluzone 2018-2019 high-dose vaccine 0.5 ML Prefilled Syringe;
material entity;Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4867.20);
material entity;Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.00);
material entity;Fluzone 2018-2019 Injectable Product;
material entity;Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.01);
material entity;Fluzone 2018-2019 vaccine;
material entity;Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.21);
material entity;Fluzone 2018-2019 high-dose vaccine Prefilled Syringe;
material entity;Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.23);
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML [Fluzone 2018-2019];
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML [Fluzone 2017-2018];
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.24);
material entity;Fluzone 2017-2018 Injectable Product;
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.32);
material entity;Fluzone 2017-2018 high-dose vaccine 0.5 ML Prefilled Syringe;
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza-West Nile Virus Eastern & Western, Killed Virus, Killed Flavivirus Chimera Vaccine-Tetanus Toxoid (USDA: 4855.R2);
material entity;Fluzone 2017-2018 high-dose vaccine Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B];
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B];
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk];
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites];
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax];
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat];
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B];
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax];
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO];
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B];
material entity;Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.20);
material entity;Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.21);
material entity;Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.A1);
material entity;Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Mycoplasma Gallisepticum Bacterin (USDA: 48B5.10);
material entity;Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Mycoplasma Gallisepticum Bacterin (USDA: 48B6.10);
material entity;Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.01);
material entity;Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4867.21);
material entity;Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.23);
material entity;Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.24);
material entity;Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.A0);
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO];
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [H-B-Vax II];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix];
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin (USDA: 47K1.20);
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 20000 UNT/ML [ProQuad];
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin (USDA: 47L9.20);
material entity;Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML [Prevnar 13];
material entity;Canine Distemper-Hepatitis-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 47P9.22);
material entity;Fluzone Quadrivalent 2013-2014 Formula vaccine;
material entity;Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.20);
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone 2015-2016];
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47C5.20);
material entity;ProQuad vaccine Injection;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47C5.29);
material entity;ProQuad Injectable Product;
material entity;Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 47E5.20);
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML [Pneumovax 23];
material entity;Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 47E5.21);
material entity;ProQuad vaccine 0.5 ML Injection;
material entity;pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML;
material entity;Canine Parvovirus Modified Live Virus Vaccine-Leptospira Canicola Icterohaemorrhagiae Bacterin (USDA: 47B1.20);
material entity;Prevnar 13 vaccine Prefilled Syringe;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 10 by Novartis;
material entity;Haemophilus B Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine Injectable Solution;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1 by Boehringer Ingelheim;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1 by Novartis;
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10 by Novartis;
material entity;hepatitis B surface antigen vaccine Prefilled Syringe [Heptavax];
material entity;10 ML diphtheria toxoid vaccine, inactivated 0.5 UNT/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Hevac B];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1 by Boehringer Ingelheim;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Lt Grk];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1 by Novartis;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Intramuscular Solution;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 10 by Boehringer Ingelheim;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Hepasorbat];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10;
material entity;Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.23);
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.32);
material entity;Fluzone 2016-2017 High-Dose vaccine 0.5 ML Prefilled Syringe;
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.33);
material entity;Fluzone 2016-2017 High-Dose vaccine Prefilled Syringe;
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.22);
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.23);
material entity;Fluzone 2017-2018 vaccine;
material entity;Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.46);
material entity;Fluzone 2016-2017 vaccine;
material entity;Encephalomyelitis-Rhinopneumonitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4844.30);
material entity;Fluzone 2015-2016 vaccine Injectable Suspension;
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.23);
material entity;Fluzone 2016-2017 Injectable Product;
material entity;Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.24);
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML [Fluzone 2016-2017];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML [Fluzone 2015-2016];
material entity;Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.24);
material entity;Fluzone 2015-2016 High-Dose vaccine 0.5 ML Prefilled Syringe;
material entity;Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.45);
material entity;Fluzone 2015-2016 High-Dose vaccine Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis];
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] by Sanofi;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax];
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adacel];
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adacel] Box of 5;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 5;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 0.2 LFU/ML Injectable Solution Box of 5 by Aventis;
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML Injectable Solution Box of 5 by Aventis;
material entity;Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO];
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;Rabies Killed Virus Vaccine-Ehrlichia Risticii Bacterin (USDA: 4905.20);
material entity;Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.21);
material entity;Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.22);
material entity;Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.23);
material entity;Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus, Live Canarypox Vector Vaccine-Tetanus Toxoid (USDA: 48W9.R0);
material entity;Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D6.10);
material entity;Newcastle Disease-Bronchitis Mass & Ark Types, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D7.10);
material entity;Newcastle Disease-Bronchitis Mass & Ark Types, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D7.11);
material entity;Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.20);
material entity;Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.22);
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution;
material entity;HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25;
material entity;Trichomonas Foetus Vaccine, Killed Protozoa-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4990.00);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4993.20);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4993.21);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.20);
material entity;Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.01);
material entity;Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.20);
material entity;Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.22);
material entity;Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4989.00);
material entity;Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4906.20);
material entity;Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4960.00);
material entity;NYVAC-CSP (malaria);
material entity;2008-2009 trivalent influenza vaccine;
material entity;M. bovis DNA vaccine pCI-Ag85B;
material entity;rVEE-Ebola-NP;
material entity;APSV Wetvax;
material entity;Bacillus Calmette-Guérin Danish;
material entity;HDAd-sFsyn;
material entity;BDES-PfCSP (baculovirus dual expression system);
material entity;BL21(DE3)/pUTa-E + pET28a-FT;
material entity;LM1-2-E7;
material entity;Recombinant Aeromonas hydrophila vaccine (Aera);
material entity;2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008);2010-2011 trivalent seasonal inactivated influenza vaccine 2010 consisting of Influenza A virus (A/California/7/2009(H1N1)), Influenza A virus (A/Texas/50/2012(H3N2)), Influenza B virus (B/Brisbane/60/2008)
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 UNT/ML [Rotarix];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 UNT/ML;
material entity;Rotarix Oral Liquid Product;
material entity;Rotarix, Rotavirus, live attenuated (RV1) G1P[8] Oral Vaccine;
material entity;v2RVFH;
material entity;C-KCE (vBAC-C-KCE);
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain;
material entity;Biothrax 0.5 ML Injectable Suspension;
material entity;influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML;
material entity;Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML;
material entity;influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML;
material entity;Menveo Injectable Product;
material entity;influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.12 MG/ML;
material entity;Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML;
material entity;Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 20;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 50;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 25;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 50;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 2;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 20;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 25;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 5;
material entity;human influenza B virus vaccine;
material entity;Borreliella vaccine;A vaccine that is used against an infection by a pathogen under Borreliella.
material entity;Trumenba vaccine Prefilled Syringe;
material entity;influenza virus vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML;
material entity;MENVEO vaccine 0.5 ML Injection;
material entity;influenza virus vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain;
material entity;Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Menveo];
material entity;influenza virus vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain;
material entity;Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML [Trumenba];
material entity;influenza virus vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.09 MG/ML;
material entity;Trumenba Injectable Product;
material entity;influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML;
material entity;BEXSERO vaccine 0.5 ML Prefilled Syringe;
material entity;influenza B virus vaccine, B-Wisconsin-1-2010-like virus;
material entity;meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML [Bexsero];
material entity;influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.03 MG/ML;
material entity;smallpox vaccine live vaccinia virus 500000000 UNT/ML;
material entity;influenza virus vaccine, Inactivated B-Brisbane-60-2008;
material entity;smallpox vaccine live vaccinia virus;
material entity;human influenza B-like virus;
material entity;Bexsero Injectable Product;
material entity;Trumenba vaccine 0.5 ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [H-B-Vax II];
material entity;diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [HBvaxPRO];
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML [HBvaxPRO];
material entity;diphtheria toxoid vaccine, inactivated 0.2 LFU/ML Injectable Solution Box of 5;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML [Hevac B];
material entity;diphtheria toxoid vaccine, inactivated 0.5 UNT/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [Gen Vax];
material entity;diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [H B Vax];
material entity;diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Solution;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution;
material entity;hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution;
material entity;Hepatitis B Surface Antigen Vaccine 0.001 MG/ML [HBvaxPRO];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML [H B Vax];
material entity;10 ML diphtheria toxoid vaccine, inactivated 0.5 UNT/ML Injectable Solution;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 25;
material entity;influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML;
material entity;influenza B virus vaccine, B-Massachusetts-2-2012-like virus;
material entity;ACAM2000 smallpox (vaccinia) vaccine, live Injectable Solution;
material entity;influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.09 MG/ML;
material entity;ACAM2000 Injectable Product;
material entity;influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML;
material entity;meningococcal group C polysaccharide;
material entity;influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML;
material entity;smallpox vaccine live vaccinia virus 500000000 UNT/ML [ACAM2000];
material entity;Human-Bovine Reassortant Rotavirus Strain G4 Vaccine;
material entity;Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine;
material entity;Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 1000000 UNT/ML;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 2;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 5;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 20;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 20;
material entity;Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 1150000 UNT/ML;
material entity;Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 1100000 UNT/ML;
material entity;Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 1400000 UNT/ML;
material entity;Human-Bovine Reassortant Rotavirus Strain G3 Vaccine;
material entity;Human-Bovine Reassortant Rotavirus Strain G2 Vaccine;
material entity;Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 1100000 UNT/ML;
material entity;Human-Bovine Reassortant Rotavirus Strain G1 Vaccine;
material entity;human influenza A (H3N2)-like virus vaccine;
material entity;Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 1400000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 1000000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 1150000 UNT/ML [RotaTeq];
material entity;RotaTeq Oral Liquid Product;
material entity;influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus;
material entity;Quadracel Injectable Product;
material entity;human influenza A (H3N2) virus vaccine;
material entity;RotaTeq, Rotavirus, live pentavalent (RV5) Oral Vaccine;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 1;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 20;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 25;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 50;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix] Box of 25;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML;
material entity;Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus;
material entity;Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML;
material entity;influenza virus vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain;
material entity;Quadracel vaccine 0.5 ML Injection;
material entity;influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Quadracel];
material entity;influenza virus vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine;
material entity;influenza virus vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML;
material entity;Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.21);
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML;
material entity;rORFV-D1701-V-HAh5n (H5N1);
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.22);
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175;
material entity;MG1-hDCT Vaccine;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.23);
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injection;
material entity;rORFV-RHDV-VP60;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.25);
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injection;
material entity;rORFV-RabG;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Product;
material entity;rMVTT- HPV16-E6/E7;
material entity;rMVTT-SIV-gpe;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza Modified Live Virus Vaccine (USDA: 13C1.20);
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe;
material entity;rLSDV-RPV;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.20);
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML;
material entity;rLSDV-Rabies-gP;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 20;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 5;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 20;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 10;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.27);
material entity;Typhoid Vaccine Live Ty21a 2000000000 UNT;
material entity;rORFV-p40(Borna disease virus);
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.28);
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injection;
material entity;rORFV-CSFV-E2;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.29);
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus, Canarypox Vector Vaccine (USDA: 13D1.R1);
material entity;Canine Distemper-Parvovirus Modified Live Virus Vaccine (USDA: 13P1.20);
material entity;Typhoid Vaccine Live Ty21a 2000000000 UNT Delayed Release Oral Capsule;
material entity;NYVAC-JEV;
material entity;Canine Distemper-Parvovirus Modified Live Virus Vaccine (USDA: 13P1.27);
material entity;vaccine foreign to USA;This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine.
material entity;NYVAC-HIV-2;
material entity;Encephalomyelitis-Influenza-West Nile Virus Eastern & Western, Killed Virus Vaccine (USDA: 13W5.20);A horse Encephalomyelitis-Influenza-West Nile Virus vaccine that is inactivated and manufactured by Wyeth Pharmaceuticals Inc.
material entity;Typhoid Vaccine Live Ty21a Delayed Release Oral Capsule;
material entity;NYVAC-PRV- gII/ gp50;
material entity;Encephalomyelitis Eastern & Western, Killed Virus Vaccine (USDA: 1475.00);
material entity;Typhoid Vaccine Live Ty21a;
material entity;ALVAC-JEV;
material entity;meningococcal conjugate vaccine;Meningococcal conjugate vaccine, which contains four of the most common types of meningococcal bacteria (serogroups A, C, W, and Y), is used to prevent infection caused by meningococcal bacteria.
material entity;NYVAC- CDV-H/F;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.T0);
material entity;Fluzone Intradermal Trivalent;A trivalent influenza vaccine containing two strains of influenza A and one strain of influenza B for use in people 18 years to 64 years for use during the 2012-2013 season.
material entity;NYVAC-EHV-1- vP1014;
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus-Rabies Modified Live & Killed Virus Vaccine (USDA: 13G9.20);
material entity;Typhoid Vi Polysaccharide vaccine;
material entity;NYVAC-HIV-1;
material entity;Canine Distemper-Adenovirus Type 2-Parvovirus-Rabies Modified Live & Killed Virus Vaccine (USDA: 13H9.20);
material entity;Acel-Imune vaccine;A DTaP vaccine used to keep up protection (immunity) against diphtheria, tetanus (lockjaw) and pertussis (whooping cough) in children and adults who have been vaccinated for these diseases in the past.
material entity;ALVAC- CDV-H/F;
material entity;rORFV-PRV-gC/gD;
material entity;diphtheria toxoid vaccine, inactivated 0.5 UNT/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix] Box of 25;
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 20;
material entity;diphtheria toxoid vaccine, inactivated 0.2 LFU/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 2;
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 25;
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 50;
material entity;Canine Distemper-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14D7.20);
material entity;Typhoid Vaccine Live Ty21a Oral Product;
material entity;Canine Distemper-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14D9.27);
material entity;Typhoid Vaccine Live Ty21a Pill;
material entity;NYVAC-SIV;
material entity;Canine Parainfluenza-Bordetella Bronchiseptica Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 14M1.20);
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injection [PedvaxHIB];
material entity;rFPV-AI-H5A-IL6;
material entity;0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML Injection;
material entity;FP-IBDV-VP2;
material entity;0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML Injection [PedvaxHIB];
material entity;vFP89-HA (H5N1 HPAI virus);
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML;
material entity;rFPV-ILTV;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Product;
material entity;ALVAC-MV-HA/F;
material entity;ALVAC-FL- env/gag;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur];
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring];
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension;
material entity;Hepatitis B Surface Antigen Vaccine Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Suspension;
material entity;ALVAC-AI-H5;
material entity;Hepatitis B Surface Antigen Vaccine Injectable Product;
material entity;rFPV-H5AI-L2;
material entity;Mumps-Rubella Vaccine;
material entity;rMDV-IBDV-VP2;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Suspension;
material entity;rPFV-CSFV-E0;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML;
material entity;BV-GD-ORF2;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe;
material entity;Ac-CMV-S1 (infectious bronchitis virus);
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe;
material entity;HVT-ILT(FC-126 strain) vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe;
material entity;rSPV/H3-2A-H1;
material entity;rFPV-IBDV-VP 2.4.3;
material entity;Hepatitis B Surface Antigen Vaccine Injection;
material entity;rFP-RPV-H/F;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe;
material entity;rFPV-NDV-H/F;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 20;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 25;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 50;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection;
material entity;rMVA- AHS-VP2;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection;
material entity;rBCG-Ag85A/Ag85B;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML;
material entity;Typhoid Vaccine Live Ty21a 2000000000 UNT [Vivotif];
material entity;rMVTT-HA-QH (H5N1);
material entity;Marek's Disease-Tenosynovitis Serotypes 2 & 3, Live & Modified Live Virus Vaccine (USDA: 16T1.00);
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML;
material entity;Marek's Disease-Tenosynovitis Serotypes 2 & 3, Live Virus Vaccine (USDA: 16T1.03);
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.11);
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.12);
material entity;influenza B virus B/Brisbane/60/2008 antigen;
material entity;Fowl Laryngotracheitis-Marek's Disease Serotypes 2 & 3, Modified Live & Live Marek's Disease Vector Vaccine (USDA: 16J1.R2);
material entity;influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML;
material entity;Marek's Disease-Newcastle Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16N1.R0);
material entity;influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML;
material entity;Marek's Disease-Newcastle Disease Serotypes 1 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 16N1.R1);
material entity;influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML;
material entity;Marek's Disease-Newcastle Disease Serotypes 1 & 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 16N1.R2);
material entity;influenza A virus A/South Australia/55/2014 (H3N2) antigen;
material entity;influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen;
material entity;Fowl Pox-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 15E2.00);
material entity;influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML;
material entity;Fowl Laryngotracheitis-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16J1.R1);
material entity;influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] by Novartis;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension by Glaxosmithkline;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension by Sanofi;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring] by Novartis;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] by Sanofi;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] by Sanofi;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] by Sanofi;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension by Statens Serum Institut;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] by Glaxosmithkline;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis] by Sanofi;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1762.11);
material entity;influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1762.13);
material entity;influenza B virus B/Phuket/3073/2013 antigen;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1762.1H);
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.17);
material entity;influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.18);
material entity;Neisseriales vaccine;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.19);
material entity;influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1761.1A);
material entity;influenza B virus B/Utah/9/2014 antigen;
material entity;influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1761.13);
material entity;influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.14);
material entity;influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.15);
material entity;influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 20;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 25;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 50;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension by Statens Serum Institut;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] by Sanofi;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix] by Glaxosmithkline;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] by Sanofi;
material entity;Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.22);
material entity;diphtheria toxoid vaccine, inactivated 50 UNT/ML;
material entity;dVV-HA5(H5N1);
material entity;Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.25);
material entity;diphtheria toxoid vaccine, inactivated;
material entity;rS.C-APP-ApxIIA;
material entity;Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.29);
material entity;1 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Injection [Vaqta];
material entity;rBCG-SIVgag;
material entity;Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine (USDA: 14W5.22);
material entity;diphtheria toxoid vaccine, inactivated 25 UNT/ML;
material entity;rCPV-BTV-Cpox;
material entity;Canine Parainfluenza-Bordetella Bronchiseptica Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 14M1.22);
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML;
material entity;rPIV5-H3 (influenza virus);
material entity;Canine Coronavirus-Parvovirus Modified Live Virus Vaccine (USDA: 14R1.20);
material entity;Twinrix Injectable Product;
material entity;rAdV-SjTPI.opt;
material entity;Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.20);
material entity;diphtheria toxoid vaccine, inactivated 13.4 UNT/ML;
material entity;rS.C-APP-ApxI/ApxII;
material entity;Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.21);
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen;
material entity;rVEE-HA(H1N1);
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML;
material entity;VC-TetC/Tcf;
material entity;NYVAC-JEV- prM/E/ NS1;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 2;
material entity;diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20;
material entity;diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 50 LFU/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution;
material entity;Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine (USDA: 14W5.23);
material entity;Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus, Live Canarypox Vector Vaccine (USDA: 14W7.R0);
material entity;Hepatitis A Vaccine, Inactivated 50 UNT/ML [Vaqta];
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live Virus. Canarypox Vector Vaccine (USDA: 1591.R1);
material entity;Hepatitis A Vaccine, Inactivated Injection;
material entity;NILV-Py CSP;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.20);
material entity;Hepatitis A Vaccine, Inactivated Injection [Vaqta];
material entity;ChAd63 -PvTRAP;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.21);
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.25);
material entity;Hepatitis A Vaccine, Inactivated Injectable Product;
material entity;SAd-ME.TRAP;
material entity;Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.26);
material entity;1 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Prefilled Syringe [Vaqta];
material entity;NYVAC-Pf7;
material entity;Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.27);
material entity;Vaqta Injectable Product;
material entity;HVT-LT;
material entity;Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.2A);
material entity;Hepatitis A Vaccine, Inactivated Prefilled Syringe [Vaqta];
material entity;MVA-PvTRAP;
material entity;Equine Rhinopneumonitis-Influenza Modified Live & Killed Virus Vaccine (USDA: 1518.20);
material entity;Hepatitis A Vaccine, Inactivated;
material entity;Toxminus-PLD toxoid;
material entity;rBCG-S1PT;
material entity;0.5 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Injection [Vaqta];
material entity;rMVA-SIV-CD40L human immunodeficiency virus vaccine;
material entity;Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.24);
material entity;0.5 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Prefilled Syringe [Vaqta];
material entity;rBCGMSP1-15;
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 50;
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 20;
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 25;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 5;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 50;
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 25;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 20;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 25;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.29);
material entity;Newcastle-Bronchitis VG/GA Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 17V1.11);
material entity;Marek's Disease-Newcastle Disease Serotypes 2 & 3, Live Virus & Live Marek's Disease Vector Vaccine (USDA: 17H1.R1);
material entity;Marek's Disease-Newcastle Disease Serotypes 2 & 3, Live Virus & Live Marek's Disease Vector Vaccine (USDA: 17H1.R2);
material entity;Newcastle-Paramyxovirus Type 3, Killed Virus Vaccine (USDA: 17P5.10);
material entity;Newcastle-Bronchitis VG/GA Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 17V1.10);
material entity;Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types Vaccine (USDA: 17B1.17);
material entity;Newcastle Disease-Fowl Pox Live Fowl Pox Vector Vaccine (USDA: 17C1.R0);
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B];
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B];
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe;
material entity;Bursal Disease-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 1A88.R0);
material entity;Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1A88.R1);
material entity;Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1A88.R2);
material entity;Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine (USDA: 19H1.20);
material entity;Porcine Circovirus Type 1 - Type 2 Chimera, Killed Virus Vaccine (USDA: 19K5.R1);
material entity;Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1A82.50);
material entity;Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1775.11);
material entity;Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1776.10);
material entity;human influenza A (H1N1)-like virus vaccine;
material entity;Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.18);
material entity;influenza virus vaccine, Inactivated A-Christchurch-16-2010 NIB-74 (H1N1) (A-California-7-2009) strain;
material entity;Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.19);
material entity;human influenza virus vaccine;
material entity;Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.1A);
material entity;human influenza A (H1N1) virus vaccine;
material entity;Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1775.10);
material entity;influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus;
material entity;Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.11);
material entity;influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML;
material entity;Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.12);
material entity;influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML;
material entity;Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1771.14);
material entity;Spirochaetes vaccine;A vaccine that is used against an infection by a pathogen under Spirochaetes.
material entity;Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1771.17);
material entity;influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML;
material entity;influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML;
material entity;Leishmania protein;
material entity;Plasmodium yoelii protein;
material entity;Plasmodium berghei protein;
material entity;Plasmodium chabaudi protein;
material entity;Plasmodium falciparum protein;
material entity;Plasmodium knowlesi protein;
material entity;Plasmodium vivax protein;
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A2.1M);
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1791.19);
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 1791.1X);
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A1.1M);
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A1.1N);
material entity;Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1785.11);
material entity;Newcastle-Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1785.12);
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1791.14);
material entity;Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1791.15);
material entity;Newcastle-Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1785.10);
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe;
material entity;Neisseria meningitidis Recombinant Fusion Protein Fhbp Group B;
material entity;Giardia lamblia protein;
material entity;Neisseria meningitidis Group B Membrane vesicles External Omv;
material entity;CVD 103-HgR- REPEC;
material entity;rVCG- Chlamydia-cholera;
material entity;pRP-RSV-HSV-1-gB;
material entity;rVCG- MOMP/HSV-2-gD;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring];
material entity;diphtheria toxoid vaccine, inactivated 50 LFU/ML;
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML;
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 30 UNT;
material entity;diphtheria toxoid vaccine, inactivated 40 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated 5 LFU/ML;
material entity;FP-AI-H5(H5N1);
material entity;ALVAC-RV;
material entity;ALVAC-AHSV;
material entity;RSV-H7;
material entity;ALVAC-HIV-2;
material entity;ALVAC-BTV-VP2/VP5;
material entity;tetanus toxoid vaccine, inactivated 20 UNT/ML;
material entity;ALVAC-BTV-CP(VP2/VP5);
material entity;tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;ALVAC-WNV-prM/E;
material entity;tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;ALVAC-NiV-F;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe;
material entity;ALVAC-NiV-G;
material entity;ALVAC-AI-H5(H5N1);
material entity;diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac];
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix];
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel];
material entity;diphtheria toxoid vaccine, inactivated Injectable Solution [Dipht Toxoid Asid];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injection;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine;
material entity;ALVAC-P53 Vaccine;Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed
material entity;tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution;
material entity;ALVAC-WNV-PrM/E (dogs and cats);
material entity;tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension;
material entity;ALVAC-EIV (equine influenza virus H3N8);
material entity;tetanus toxoid vaccine, inactivated 4 UNT/ML;
material entity;ALVAC-RHDV (vCP309);
material entity;tetanus toxoid vaccine, inactivated 8 UNT/ML;
material entity;ALVAC-HIV-2- env/gag/pol;
material entity;Typhi strain Ty21a-LPS-Shigella;
material entity;rAdV-SFV-E2;
material entity;Myxoma-FCV;
material entity;SG33-VP2/5;
material entity;rvOka-HN (mumps virus);
material entity;Maraba virus MG1 Vaccine;
material entity;Ty21a-O-Ps (Shigella dysenteriae );
material entity;Typhi strain Ty21a-PA (Bacillus anthracis);
material entity;Poliovirus vector expressing model antigen H2-Kb-restricted CTL epitope;
material entity;SabRV-SIV;
material entity;rOka-gD2- HSV-2;
material entity;rMV- WNV;
material entity;rMV- SARS-CoV -S/Ssol;
material entity;rCMV-TT;
material entity;rCMV- EBOV;
material entity;CVB4/p24(73(3));
material entity;rMV-Ed-G;
material entity;rMeV- SCD;
material entity;rMCMV-TRP2;
material entity;rLAG- PA-DCpep;
material entity;pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML;
material entity;CAdVax-Filoviruses (Ebola );
material entity;pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML;
material entity;CAdVax-Den12/Den34;
material entity;Infanrix Tetra;A combination vaccine against diphtheria, tetanus, acellular pertussis, and inactivated poliomyelitis for individuals ages from 16 months to 13 years of age.
material entity;cAdVaxM(fus);
material entity;pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML;
material entity;CAdVa-Filoviruses (EbMarburg viruses);
material entity;E. coli-CPPs (Edwardsiella tarda);
material entity;pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML;
material entity;CAdVax-RVFV glycoprotein;
material entity;pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML;
material entity;CAdVax-ZEBOV/SEBOV;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe Box of 1;
material entity;meningococcal group A polysaccharide 2.5 MG / meningococcal group C polysaccharide 2.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 2.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 2.5 MG Injectable Solution;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Box of 10;
material entity;meningococcal group A polysaccharide 0.5 MG / meningococcal group C polysaccharide 0.5 MG Injectable Solution;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1;
material entity;meningococcal group A polysaccharide 0.5 MG / meningococcal group C polysaccharide 0.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.5 MG Injectable Solution;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 10;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix] Box of 1;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection [Meningitec] Box of 10;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] Box of 1;
material entity;Shingrix vaccine;
material entity;RB51-SRS2;
material entity;Menitorix vaccine;A vaccine that can be given to children after the age of 2 months up to 2 years to prevent infectious diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis group C (MenC) bacteria.
material entity;cAdVax-based bivalent ebola virus vaccine (Sudan and Zaire species);
material entity;pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML;
material entity;TDAP/IPV vaccine foreign to USA;A vaccine against tetanus, diphtheria, pertussis, and inactivated poliovirus manufactured outside of the U.S.
material entity;RB51-MIC3/GRA6/MIC1/SRS2;
material entity;pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML;
material entity;BacMam-sHAPQ;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML;
material entity;BV-H5/H7/H9;
material entity;pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML;
material entity;rBCG -Stx2B (Escherichia coli );
material entity;pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML;
material entity;rBCGpMV361-TgCyP;
material entity;pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML;
material entity;BV-RVG/RVG;
material entity;BPZE1- FHA (H1N1/PR8 influenza A virus);
material entity;pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML;
material entity;AcHERV-sH1N1-HA;
material entity;pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML;
material entity;BV-Dual-S1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Emra-Med;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Eurim-Pharm;
material entity;0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Gerke;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Aca Mueller;
material entity;0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by A+S Unicare;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection [Meningitec] Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 10;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Cc;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 10;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection Box of 10;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10;
material entity;0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Boostrix] by GSK;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1;
material entity;0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Bexsero] by GSK;
material entity;pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML;
material entity;VSV-DeltaG-H5 (H5N1);
material entity;pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML;
material entity;rDEV-us78HA;
material entity;pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML;
material entity;fp-IBD1;
material entity;vNDV-H5;
material entity;FPV-LT vaccine;
material entity;rDEV-re6 (H5);
material entity;vFP89-H5;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Box of 1;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection [Meningitec];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10;
material entity;0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Bexsero];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe;
material entity;0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Boostrix];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix];
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix];
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;Haemophilus B Conjugate Vaccine / meningococcal group C polysaccharide Injectable Solution;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG Injection;
material entity;L. T -HIV-1 Gag;
material entity;LT-BCG- Ag85B /Rv3425;
material entity;rFPV-IBDV-VP2;
material entity;A2-CPA-CPB(-CTE)-recombinant L. tarentolae;
material entity;L. T -PpSP15;
material entity;L1 protein, Human papillomavirus type 18 Vaccine;
material entity;rHVT-H5;
material entity;L1 protein, Human papillomavirus type 11 Vaccine;
material entity;HVT-ND;
material entity;L1 protein, Human papillomavirus type 31 Vaccine;
material entity;rSPV-MRP (Streptococcus suis);
material entity;L1 protein, Human papillomavirus type 16 Vaccine;
material entity;rHVT-H5 (clade 2.2 H5N1 HPAIV);
material entity;L1 protein, Human papillomavirus type 6 Vaccine;
material entity;rAd-GP (Ebola virus);
material entity;AdC68- rabies virus glycoprotein;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult] Box of 1 by Glaxosmithkline;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10;
material entity;Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric] Box of 1 by Glaxosmithkline;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB] Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10;
material entity;0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe Box of 1;
material entity;0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection;
material entity;0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Box of 10;
material entity;0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate];
material entity;pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML;
material entity;L1 protein, Human papillomavirus type 45 Vaccine;
material entity;HS93Tox-/pIG-T1K;
material entity;L1 protein, Human papillomavirus type 33 Vaccine;
material entity;rSPV-HA1 (Swine influenza virus H1N1);
material entity;L1 protein, Human papillomavirus type 58 Vaccine;
material entity;ALVAC-rabies;
material entity;L1 protein, Human papillomavirus type 52 Vaccine;
material entity;ALVAC-SIV/gp120;
material entity;Bovine Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4595.21);
material entity;Vivotif Oral Product;
material entity;M. S- H. pylori -opm26;
material entity;Bovine Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4595.25);
material entity;Typhoid Vaccine Live Ty21a 2000000000 UNT Delayed Release Oral Capsule [Vivotif];
material entity;HSVT[VP7/6/2];
material entity;Bovine Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4599.00);
material entity;meningococcal group B vaccine Prefilled Syringe [Bexsero];
material entity;Bovine Virus Diarrhea-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 12A5.20);
material entity;Vivotif Pill;
material entity;M.S-Delta-esx-3-IKEPLUS (M. tuberculosis);
material entity;Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Escherichia Coli Bacterin (USDA: 4585.20);
material entity;Vivotif vaccine;
material entity;rAPMV3-F (newcastle disease);
material entity;Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Escherichia Coli Bacterin (USDA: 4585.22);
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML;
material entity;rNDV-H6;
material entity;Bovine Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 45B5.21);
material entity;BoHV-4-A-IgK-VP2gD;
material entity;Bovine Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 4C95.20);
material entity;Typhoid Vaccine Live Ty21a Delayed Release Oral Capsule [Vivotif];
material entity;BoHV-4-A-gD(cp)gD(106)DeltaTK;
material entity;rNDV-ILTV-gD;
material entity;meningococcal group B vaccine Injectable Product;
material entity;rNDV-H5 ( HPAI H5N1 challenge in mule ducks);
material entity;Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Types C & D-Escherichia Coli Bacterin-Toxoid (USDA: 4575.20);
material entity;meningococcal group B vaccine Prefilled Syringe;
material entity;rNDV-H5;
material entity;Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML Injection;
material entity;hepatitis A virus / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Europharma;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection Box of 10 by Saudi;
material entity;hepatitis A virus / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Suspension [ViATIM];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Gerke;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection Box of 10;
material entity;Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Kohlpharma;
material entity;Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML [Vivaxim];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Orifarm Leverkus;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection by Saudi;
material entity;Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by A+S Unicare;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution [Ipol] Box of 10;
material entity;Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Abacus Medicine;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution [Ipol];
material entity;Hepatitis A Virus / Salmonella Typhi Inactivated Antigen Injection;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by ADL;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection;
material entity;Hepatitis A Virus / Salmonella Typhi Inactivated Antigen Injection [Vivaxim];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Cc;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution Box of 10;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Tisida;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution;
material entity;Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML [Vivaxim];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Veron;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML Injectable Suspension [Polio Sabin-S];
material entity;Mannheimia Haemolytica-Pasteurella Multocida Avirulent Live Culture Vaccine (USDA: 1861.01);
material entity;Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.14);
material entity;Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen;
material entity;PrV-PCV2-ORF2;
material entity;Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.40);
material entity;Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML;
material entity;PrV-HA (swine-origin H1N1);
material entity;Avian Encephalomyelitis-Fowl Pox-Laryngotracheitis Live Virus, Live Fowl Pox Vector Vaccine (USDA: 10S1.R0);
material entity;Avian Encephalomyelitis-Chicken Anemia Virus-Fowl Pox C155Live and Modified Live C212Virus Vaccine (USDA: 10T1.40)+C433;
material entity;Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML;
material entity;avian influenza-Fowl Pox H5 Subtype, Live Fowl Pox Vector Vaccine (USDA: 1061.R0);
material entity;Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle;
material entity;PAV3-HA (H5N1);
material entity;Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.10 );
material entity;Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML;
material entity;RCN-IRES-tPA-YpF1( Yersinia pestis);
material entity;Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.11);
material entity;Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen;
material entity;rAd-P97c;
material entity;Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.13);
material entity;Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML;
material entity;PAV3-HA (A/Hanoi/30408/2005 H5N1);
material entity;Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen;
material entity;RCN-HA (H5N1);
material entity;YF17D- HIV-1 p24;
material entity;Avian Encephalomyelitis-Fowl Pox-Mycoplasma Gallisepticum Live Fowl Pox Vector, Live Virus Vaccine (USDA:1D61.R0);
material entity;Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen;
material entity;RCN-rabies-G;
material entity;Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: );
material entity;Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML;
material entity;RCN-F1-V (Yersinia pestis F1 and V);
material entity;diphtheria toxoid vaccine, inactivated 60 LFU/ML [Tetravac];
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML [Infanrix];
material entity;diphtheria toxoid vaccine, inactivated 60 UNT/ML [Pediacel];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML [Repevax];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML [Revaxis];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML [Td-Impfstoff Merieux];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML [Td-Pur];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML [Boostrix];
material entity;Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML Injection [Vivaxim];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML [Covaxis];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML [Diphtherie-Adsorbat-Impfstoff Behring];
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Hardjo Bacterin (USDA: 4L49.20);
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;MVA-CHIKV;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica Toxoid (USDA: 4X49.20);
material entity;Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;rMVA-CCHF;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica Toxoid (USDA: 4X49.21);
material entity;Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;S. gordonii -M6-Sj-F1;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45B9.20);
process;live attenuated vaccine-induced down-regulated gene expression compared to infection with wild type pathogen;a vaccine-induced down-regulation gene expression that occurs in live attenuated vaccine and compared with the host system infected with live wild type virulent strain which is the parent strain of this live attenuated vaccine.
material entity;MVTT-HA-QH;
material entity;pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML;
material entity;rVSVDeltaG-ANDV-GPC;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.23);
material entity;pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML;
material entity;rVSV- SEBOV-GP and -VP40;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.24);
material entity;Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;rMVA-SIV-CD40L Simian immunodeficiency virus vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.26);
material entity;pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML;
material entity;rMVA-GnGc (Rift Valley fever virus);
material entity;rVSV-EBOV;An Ebola virus vaccine that uses a recombinant vesicular stomatitis virus (rVSV) vector expressing an Ebola filovirus glycoprotein
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Suspension [Havrix];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Axicorp;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Suspension [Hepatyrix];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Bb Farma;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] by Nuron Biotech;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe [Epaxal];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Solution [Hav Sorbat Ssw];
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Eurim-Pharm;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Solution [Vaqta];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by A+S Unicare;
material entity;0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Aca Mueller;
material entity;0.5 ML meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.1 MG/ML Injectable Solution;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Suspension [Hav Sorbat Ssw];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by ADL;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Veron;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 1;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by A+S Unicare;
material entity;0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 10;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Aca Mueller;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection Box of 10;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Solution;
material entity;0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Emra-Med;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate];
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45B9.21);
material entity;Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus-Mannheimia Haemolytica-Pasteurella Multocida Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 11A8.22);
material entity;Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;Streptococcus gordonii-TTFC;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 11A5.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.26);
material entity;Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;Schmidt-Ruppin Rous sarcoma virus-H7 (H7N7);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.30);
material entity;Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;SL3261 expressing streptococcal M protein;
material entity;Bovine Rotavirus-Coronavirus Modified Killed Virus Vaccine (USDA: 1935.20);
process;live attenuated vaccine-induced up-regulated gene expression compared to infection with wild type pathogen;A vaccine-induced up-regulation gene expression that occurs in live attenuated vaccine and compared with the host system infected with live wild type virulent strain which is the parent strain of this live attenuated vaccine.
material entity;RBD-rAAV-SARS-CoV prime/RBD-specific T cell peptide boost;
material entity;Bovine Rotavirus-Coronavirus Modified Live Virus Vaccine (USDA: 1931.20);
material entity;meningococcal group B vaccine;
material entity;RBD-rAAV-SARS-CoV;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.20);
material entity;Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;quadrivalent influenza vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.26);
material entity;Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;SL3261-L. donovani;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.30);
material entity;Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;SL3261- UreA and UreB;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.20);
material entity;Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;SL3261-P. aeruginosa serogroup O11 O antigen;
material entity;Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine;
material entity;SL3261-L. major;
material entity;S. gordonii-PT;
material entity;Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Prefilled Syringe [ViATIM];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Orifarm Leverkus;
material entity;Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML;
material entity;Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension [ViATIM];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Mevita;
material entity;0.5 ML poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution;
material entity;Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Intramuscular Solution;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Milinda Am;
material entity;meningococcal group A polysaccharide 2.5 MG / meningococcal group C polysaccharide 2.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 2.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 2.5 MG Injectable Solution by Aventis;
material entity;Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Intramuscular Solution [Vivaxim];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Mtk;
material entity;0.5 ML poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution [Poliovaccine Ssi] by Statens Serum Institut;
material entity;Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Prefilled Syringe;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Opti;
material entity;0.5 ML poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution [Poliovaccine Ssi];
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe [Havpur];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Gerke;
material entity;0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] Box of 1 by Glaxosmithkline;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe [Vaqta];
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by HVD;
material entity;0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 1 by Nuron Biotech;
material entity;Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Kohlpharma;
material entity;meningococcal group A polysaccharide 0.5 MG / meningococcal group C polysaccharide 0.5 MG Injectable Solution by Aventis;
material entity;Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Medicopharm;
material entity;meningococcal group A polysaccharide 0.5 MG / meningococcal group C polysaccharide 0.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.5 MG Injectable Solution by Sanofi;
material entity;0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB] Box of 1 by Sanofi;
material entity;1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Europharma;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] by Glaxosmithkline;
material entity;Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 4570.20);
material entity;Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 4570.22);
material entity;meningococcal group B vaccine 0.1 MG/ML;
material entity;Bursal Disease-Newcastle Disease-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 12H1.4M);
material entity;Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.10);
material entity;tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.11);
material entity;tetanus toxoid vaccine;A clostridium tetani vaccine that consists of formaldehyde inactivated tetanospasmin (aka tetanus toxoid).
material entity;Bursal Disease-Newcastle Disease Standard & Variant, Killed Virus Vaccine (USDA: 12G5.42);
material entity;tetanus toxoid vaccine, inactivated Injectable Product;
material entity;Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.43);
material entity;tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.E0);
material entity;TIV Dresden;A trivalent influenza vaccine contianing two A influenza strains and one B influenza strain.
material entity;Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.F0);
material entity;acellular pertussis vaccine, inactivated 96 UNT/ML;
material entity;Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.F1);
material entity;diphtheria toxoid vaccine, inactivated 30 UNT/ML;
material entity;Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.T0);
material entity;QIV Quebec;An inactivated quadrivalent influenza vaccine against 2 influenza A strains and 2 influenza B strains for infants 6 months up to 23 months, and if needed it can be administered to children 2 to 17 years old with compromised immune systems and those considered vulnerable and high risk.
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML;
material entity;Bursal Disease-Newcastle Disease-Bronchitis Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12D5.45);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.01);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.11);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Killed Virus Vaccine (USDA: 12M5.40);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12M5.41);
material entity;Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.43);
material entity;Bursal Disease-Newcastle Disease-Bronchitis Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12J5.61);
material entity;Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.62);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.00);
material entity;Bursal Disease-Newcastle Disease-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 12H1.67);
material entity;Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.40);
material entity;Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1288.4A);
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain Injection;
material entity;Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.50);
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injection [Stamaril];
material entity;Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.51);
material entity;Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1288.42);
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain Injectable Product;
material entity;Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.43);
material entity;Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML;
material entity;Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.44);
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain Injection [Stamaril];
material entity;Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.45);
material entity;Stamaril Injectable Product;
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain;
material entity;Bursal Disease-Marek's Disease Serotypes 1 & 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1281.R0);
material entity;Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen;
material entity;Bursal Disease-Marek's Disease Serotypes 1 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1281.R1);
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injection;
material entity;Bursal Disease-Marek's Disease Variant, Serotype 3, Live Virus Vaccine (USDA: 1282.50);
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Td-Impfstoff Merieux];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Td-Pur];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Infanrix];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Pediacel];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Repevax];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Revaxis];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Boostrix];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Covaxis];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Dipht Toxoid Asid];
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring];
material entity;Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.04);
material entity;Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.30);
material entity;Acellular Pertussis Vaccine;
material entity;Bursal Disease-Marek's Disease Standard & Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C8.44);
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML;
material entity;Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.01);
material entity;tetanus toxoid vaccine, inactivated 10 UNT/ML;
material entity;Bursal Disease-Reovirus Killed Virus Vaccine (USDA: 12D5.02);
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML;
material entity;Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.03);
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML;
material entity;Bursal Disease-Marek's Disease Variant Strain, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.52);
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML Injectable Suspension;
material entity;Bursal Disease-Marek's Disease Standard & Variant, Serotype 3, Live Virus Vaccine (USDA: 12C8.40);
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML;
material entity;Bursal Disease-Marek's Disease Standard & Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C8.42);
material entity;tetanus toxoid vaccine, inactivated;
material entity;Bursal Disease-Marek's Disease Standard & Variant, Serotype 3, Live Virus Vaccine (USDA: 12C8.43);
material entity;diphtheria toxoid vaccine, inactivated 5 UNT/ML;
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML Injection;
material entity;diphtheria toxoid vaccine, inactivated 30 LFU/ML;
material entity;diphtheria toxoid vaccine, inactivated 150 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated 20 UNT;
material entity;diphtheria toxoid vaccine, inactivated 0.2 LFU/ML;
material entity;diphtheria toxoid vaccine, inactivated 0.5 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated 10 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated 12.5 LFU/ML;
material entity;diphtheria toxoid vaccine, inactivated Injectable Suspension [Tetravac];
material entity;Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.41);
material entity;Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.E0);
material entity;Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Modified Live Virus & Avirulent Live Culture Vaccine (USDA: 12X1.20);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.90);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.91);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.E0);
material entity;Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.40);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12M5.42);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.43);
material entity;Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.50);
material entity;Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine (USDA: 13A1.20);
material entity;Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine (USDA: 13A1.27);
material entity;Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus, Canarypox Vector Vaccine (USDA: 1331.R1);
material entity;Canine Distemper-Adenovirus Type 2-Measles-Parainfluenza Modified Live Virus Vaccine (USDA: 1341.20);
material entity;Canine Distemper-Measles Modified Live Virus Vaccine (USDA: 1351.20);
material entity;Canine Distemper-Hepatitis-Parainfluenza Modified Live Virus Vaccine (USDA: 1381.21);
material entity;Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.20);
material entity;Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.25);
material entity;Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.27);
material entity;Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.30);
material entity;B. melitensis WR201 (16MΔpurEK);
material entity;E. ictaluri crp mutant vaccine;
material entity;Burkholderia pseudomallei aroC deletion mutant vaccine;
material entity;Burkholderia pseudomallei asd mutant vaccine;
material entity;Burkholderia pseudomallei purM mutant vaccine;
material entity;Burkholderia pseudomallei purN mutant vaccine;
material entity;arthritis vaccine;A vaccine that prevents or treats arthritis.
material entity;live attenuated B. abortus with deletion of znuA;
material entity;Edwardsiella tarda aroC mutant vaccine;
material entity;Equine arteritis virus vaccine;viral vaccine that is used to protect against Equine arteritis virus infection
material entity;Edwardsiella tarda aroC/slyA mutant vaccine;
material entity;Feline calicivirus vaccine;viral vaccine that is used to protect against Feline calicivirus infection
material entity;Transmissible gastroenteritis virus vaccine;viral vaccine that is used to protect against Transmissible gastroenteritis virus infection
material entity;Escherichia coli carAB mutant vaccine;
material entity;Bovine Parainfluenza 3 Virus vaccine;viral vaccine that is used to protect against Bovine Parainfluenza 3 Virus (BPIV-3) (Bovine parainfluenza virus 3) infection
material entity;autoimmune disease vaccine;A vaccine that prevents or treats an autoimmune disease.
material entity;Bovine Respiratory Syncytial Virus vaccine;viral vaccine that is used to protect against Bovine Respiratory Syncytial Virus infection
material entity;Escherichia coli ler mutant vaccine;
material entity;Feline immunodeficiency virus vaccine;viral vaccine that is used to protect against Feline immunodeficiency virus infection
material entity;Escherichia coli rfaL mutant vaccine;
material entity;Bovine viral diarrhea virus 1 vaccine;viral vaccine that is used to protect against Bovine viral diarrhea virus 1 infection
material entity;Edwardsiella tarda aroC/esrC mutant vaccine;
material entity;Infectious Bronchitis Virus vaccine;viral vaccine that is used to protect against Infectious Bronchitis Virus (IBV) infection
material entity;Edwardsiella tarda esrB mutant vaccine;
material entity;bovine coronavirus vaccine;viral vaccine that is used to protect against Bovine coronavirus infection
material entity;Feline infectious peritonitis virus vaccine;viral vaccine that is used to protect against Feline infectious peritonitis virus infection
material entity;Bordetella pertussis aroA mutant vaccine;
material entity;Bordetella pertussis dnt mutant vaccine;
material entity;Borrelia burgdorferi fla mutant vaccine;
material entity;Bordetella bronchiseptica bscN and cyaA double mutant vaccine;
material entity;Bordetella bronchiseptica dnt mutant vaccine;
material entity;Bordetella bronchiseptica aroA mutant vaccine (strain BBS18);
material entity;Bordetella bronchiseptica aroA/trpE mutant vaccine;
material entity;Brucella abortus pgk mutant vaccine;
material entity;Brucella abortus pgm mutant vaccine;
material entity;B. melitensis mucR mutant vaccine;
material entity;B. melitensis omp25 mutant vaccine;
material entity;B. melitensis omp31 mutant vaccine;
material entity;B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA;
material entity;diabetes vaccine;A vaccine that prevents or treats diabetes.
material entity;Brucella abortus exsA mutant vaccine;
material entity;Canary Pox Modified Live Virus Vaccine (USDA: 1623.10);
material entity;Pigeon Pox Live Virus Vaccine (USDA: 1881.10);
material entity;Pasteurella multocida aroA mutant vaccine;
material entity;Pigeon Pox Live Virus Vaccine (USDA: 1881.12);
material entity;Salmonella typhi aroA mutant vaccine;
material entity;Pigeon Pox Live Virus Vaccine (USDA: 1881.14);
material entity;Aro-deleted S. Typhi;
material entity;Hepatitis A virus gene;
material entity;Porcilis-PCV2;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen;
material entity;licensed pig vaccine;
material entity;Mink Distemper Modified Live Virus Vaccine (USDA: 1451.20);
material entity;Salmonella Typhimurium atpA mutant vaccine;
material entity;Mink Enteritis Vaccine;
material entity;Suvaxyn PCV2;
material entity;Quail Pox Live Virus Vaccine (USDA: 18E1.10);
material entity;CVD 908-htrA;
material entity;pHIS64 DNA vaccine plasmid;
material entity;Fox Encephalitis Killed Virus Vaccine (USDA: 1635.20);
role;vaccine in research role;A vaccine role that is not licensed or in clinical trial. instead, it has been experimently approved to induce protection or treatment effect in vivo in at least an experimental animal model.
material entity;Mink Distemper Modified Live Virus Vaccine (USDA: 1451.00);
material entity;Salmonella Typhimurium asd mutant vaccine;
disposition;vaccine contraindication;A vaccine contraindication is a contraindication that increases the risks of a vaccination.
material entity;Mink Distemper Modified Live Virus Vaccine (USDA: 1451.01);
material entity;Salmonella Typhimurium asd/rfc mutant vaccine;
material entity;Feline calicivirus Modified Live Virus Vaccine (USDA: 15C1.22);
material entity;Salmonella Typhimurium clpP mutant vaccine;
material entity;Feline immunodeficiency virus Killed Virus Vaccine (USDA: 15A5.21);
material entity;Feline immunodeficiency virus Killed Virus Vaccine (USDA: 15A5.23);
material entity;Feline Infectious Peritonitis Modified Live Virus Vaccine (USDA: 15A1.20);
disposition;hypersensitivity to chicken product;
material entity;pCI DNA vaccine plasmid;a DNA vaccine plasmid that uses the plasmid labeled pCI.
quality;vaccine organism inactivated;an organismal quality of a whole organism vaccine where the whole organism is inactivated/killed and lacks the capability of replication.
material entity;Salmonella Gallinarum cbiA/cobS mutant vaccine;
process;hemagglutination-inhibition assay;an immune response detection assay that detects specific antiviral antibodies in a test serum. The serum, usually a twofold dilution series, is mixed with a standard number, usually 4 to 8 HA units, of virus and incubated prior to the addition of a standard suspension of erythrocytes. The highest dilution of serum that inhibits hemagglutination is the HI titer of the serum. For example, influenza (AI) viruses agglutinate erythrocytes through the interaction of the virus surface glycoprotein, the hemagglutinin (HA), with receptors on the surface of the erythrocyte. Inhibition of the agglutination reaction by HA subtype-specific antisera is the basis of the hemagglutination-inhibition (HI) assay.
material entity;Feline calicivirus Killed Virus Vaccine (USDA: 15C5.21);
material entity;Salmonella Enteritidis guaBA/clpP mutant vaccine;
material entity;Feline Leukemia Live Canarypox Vector Vaccine (USDA: 1555.R3);
material entity;pCMV-1 DNA vaccine plasmid;
material entity;pCMV DNA vaccine plasmid;
material entity;pCI-neo DNA vaccine plasmid;
material entity;Feline Leukemia Killed Virus Vaccine (USDA: 1555.20);
material entity;Salmonella Typhimurium gyrA/cpxA/rpoB mutant vaccine;
material entity;Feline Leukemia Killed Virus Vaccine (USDA: 1555.21);
material entity;Salmonella Gallinarum cpxR/Ion mutant vaccine;
material entity;vaccine solvent;a vaccine component that is used to dissolve vaccine powder into liquid. The vaccine in a powder form has to be reconstituted by mixing vaccine powder with vaccine solvent before administered.
material entity;Feline Leukemia Killed Virus Vaccine (USDA: 1555.22);
material entity;Salmonella Typhimurium cya/crp mutant vaccine;
disposition;hypersensitivity to chicken egg;
material entity;Feline Leukemia Killed Virus Vaccine (USDA: 1555.R1);
material entity;Salmonella Gallinarum crp mutant vaccine;
material entity;Francisella tularensis capB mutant vaccine;
material entity;chicken anemia virus vaccine;viral vaccine that is used to protect against Chicken Anemia Virus infection
material entity;Francisella tularensis clpB mutant vaccine;
material entity;Porcine respiratory and reproductive syndrome virus vaccine;viral vaccine that is used to protect against Porcine respiratory and reproductive syndrome virus (Porcine reproductive and respiratory syndrome virus) infection
material entity;Francisella tularensis FTL0552 mutant vaccine;
material entity;Turkey hemorrhagic enteritis virus vaccine;viral vaccine that is used to protect against Turkey hemorrhagic enteritis virus (Turkey adenoirus 3) infection
material entity;Francisella tularensis IglB mutant vaccine;
material entity;Canarypox virus vaccine;viral vaccine that is used to protect against Canarypox virus infection
material entity;Psittacid herpesvirus 1 vaccine;viral vaccine that is used to protect against Psittacid herpesvirus 1 infection
material entity;Francisella tularensis purMCD mutant vaccine;
material entity;Mycobacterium bovis vaccine;A vaccine that protects against infection with Mycobacterium bovis
material entity;Riemerella anatipestifer vaccine;bacterial vaccine that is used to protect against Riemerella anatipestifer infection
material entity;Francisella tularensis FTT0918 mutant vaccine;
material entity;avian reovirus vaccine;viral vaccine that is used to protect against Avian Reovirus (Avian orthoreovirus) infection
material entity;Francisella tularensis galU mutant vaccine;
material entity;avian pneumovirus vaccine;viral vaccine that is used to protect against avian pneumovirus (avian metapneumovirus) infection
material entity;Francisella tularensis guaA mutant vaccine;
material entity;Bluetongue virus vaccine;viral vaccine that is used to protect against Bluetongue virus infection
material entity;Francisella tularensis guaB mutant vaccine;
material entity;Francisella tularensis purF mutant vaccine;
material entity;Infectious salmon anemia virus vaccine;viral vaccine that is used to protect against Infectious salmon anemia virus infection
material entity;Edwardsiella ictaluri vaccine;An Edwardsiella bacterial vaccine that is used to protect against Edwardsiella ictaluri infection
material entity;Streptococcus pyogenes vaccine;A Streptococcus vaccine against Streptococcus pyogenes infection.
material entity;avian encephalomyelitis virus vaccine;viral vaccine that is used to protect against Avian Encephalomyelitis Virus infection
material entity;Francisella tularensis sodC mutant vaccine;
material entity;avian paramyxovirus vaccine;viral vaccine that is used to protect against Avian Paramyxovirus infection
material entity;Neisseria meningitidis metH/siaD mutant vaccine;
material entity;Duck hepatitis virus 1 vaccine;viral vaccine that is used to protect against Duck hepatitis virus 1 (Duck hepatitis A virus) infection
material entity;Neisseria meningitidis rfaF/siaD mutant vaccine;
material entity;Mannheimia haemolytica vaccine;bacterial vaccine that is used to protect against Mannheimia haemolytica infection
material entity;Francisella tularensis wbtA mutant vaccine;
material entity;porcine circovirus 2 vaccine;viral vaccine that is used to protect against Porcine circovirus 2 infection
material entity;Francisella tularensis wbtI mutant vaccine;
material entity;Duck enteritis virus vaccine;viral vaccine that is used to protect against Duck enteritis virus (Anatid herpesvirus 1) infection
material entity;Mannheimia haemolytica aroA mutant vaccine;
material entity;canine parainfluenza virus vaccine;viral vaccine that is used to protect against Canine parainfluenza virus infection
material entity;Mycoplasma gallisepticum lpd mutant vaccine;
process;CFU reduction assay;CFU reduction assay is an assay that measures the reduction of the colony forming units of infected pathogens in vaccine-vaccinated animals compared to nonvaccinated animals.
material entity;Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.22);
process;preparation of vaccine using heat inactivation;A vaccine prepraration process that is performed by heat inactivation of virulent pathogen.
material entity;Brucella Abortus Strain 19, Live Culture Vaccine (USDA: 1251.01);
disposition;hypersensitity to gelatin;
material entity;Brucella Abortus Strain 19, Live Culture, Reduced Dose Vaccine (USDA: 1251.02);
material entity;Brucella Abortus Strain RB-51, Live Culture Vaccine (USDA: 1261.00);
quality;edible;A quality of edibility that inheres in a bearer by virtue of the bearer being suitable for oral ingestion as food, drug, or vaccine.
material entity;Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.22);
quality;edibility;A physical quality inhering in a bearer by virtue of the bearer being fit to be eaten.
material entity;Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.25);
disposition;hypersensitity to arginine;
material entity;Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.00);
process;assay of CFU reduction in spleen;assay of CFU reduction in spleen is a CFU reduction assay that is measured using the extracted spleen as the tissue for isolation of infected pathogens.
material entity;Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.20);
process;vaccine-induced antiviral neutralizing antibody response;
disposition;history of asthma;
quality;vaccine efficacy;Vaccine efficacy is an efficacy of a vaccine in induction of protective immune response in vivo or protection against infection of a virulent pathogen. Specifically, vaccine efficacy (VE) is the percentage reduction in disease incidence attributable to vaccination, calculated by means of the following equation: VE(%) = (U - V)/U x 100 where U = the incidence in unvaccinated people and V = the incidence in vaccinated people. Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71.
material entity;Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1841.00);
material entity;Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1841.20);
material entity;pECK DNA vaccine plasmid;
material entity;Avian Encephalomyelitis Killed Virus Vaccine (USDA: 1015.I0);
material entity;pDRVISV1.0 DNA vaccine plasmid;
material entity;Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.10);
material entity;pgp.LAMP-1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pgp.LAMP-1. This plasmid has a CMV promoter and contains the human lysosomal-associated membrane protein-1 signal sequence.
material entity;Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.11);
material entity;pcREV DNA vaccine plasmid;
material entity;Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.12);
material entity;pET-28a DNA vaccine plasmid;
material entity;Salmonella Choleraesuis Avirulent Live Culture Vaccine (USDA: 19A1.01);
material entity;pET21a DNA vaccine plasmid;
material entity;Salmonella Dublin Live Culture Vaccine (USDA: 19D1.R0);
disposition;usage of bronchodilator;
material entity;Trichomonas Foetus Killed Protozoa Vaccine (USDA: 1859.00);
material entity;pES DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pES. This plasmid has a CMV promoter and contains a kanamycin resistance gene.
material entity;Wart Killed Virus Vaccine (USDA: 1985.50);
material entity;Salmonella Choleraesuis Avirulent Live Culture Vaccine (USDA: 19A1.00);
material entity;pGEX-3X DNA vaccine plasmid;
material entity;pGA DNA vaccine plasmid;
material entity;avian influenza H10N9 Subtype, Killed Virus Vaccine (USDA: 1057.H0);
material entity;pCMVI.UBF3/2 DNA vaccine plasmid;
material entity;Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.20);
material entity;Salmonella Typhi galE mutant vaccine;
material entity;Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.21);
material entity;Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.23);
material entity;Salmonella Typhimurium guaBA/clpP mutant vaccine;
material entity;Feline Rhinotracheitis Modified Live Virus Vaccine (USDA: 16A1.22);
disposition;hypersensitivity to antibiotic;
material entity;pCMV-LacZ DNA vaccine plasmid;
material entity;pCMV-int DNA vaccine plasmid;
material entity;Feline Panleukopenia Killed Virus Vaccine (USDA: 1565.20);
material entity;Salmonella enterica fliC/guaB mutant vaccine;
material entity;pCMV-3FUB DNA vaccine plasmid;
material entity;Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.00);
material entity;Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine;
material entity;vaccine powder;a vaccine component that contains the solid form of all vaccine components. A vaccine can be reconstituted by mixing vaccine powder with vaccine solvent.
disposition;reaction to previous vaccination;
disposition;hypersensitivity to polymyxin;
disposition;hypersensitivity to neomycin;
material entity;Edwardsiella ictaluri Avirulent Live Culture Vaccine (USDA: 1531.00);
material entity;Anthrax Spore live culture Vaccine (USDA: 1011.00);
material entity;Bovine Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1095.20);
process;bacterial vaccine preparation;A vaccine preparation that results in the generation of a bacterial vaccine
material entity;Bovine Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1095.21);
material entity;pCMVLuc DNA vaccine plasmid;
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.20);
material entity;pCMV-LIC DNA vaccine plasmid;
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.21);
material entity;Salmonella Typhimurium IppA/IppB/msbB;
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.22);
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.B0);
material entity;Salmonella Typhimurium IppB/msbB mutant vaccine;
disposition;life-threatening reaction to previous influenza vaccination;
material entity;pCR3.1 DNA vaccine plasmid;
material entity;Bovine Respiratory Syncytial Virus Vaccine Modified Live Virus (USDA: 1091.20);
disposition;life-threatening reaction to previous vaccination;
material entity;Bovine Rhinotracheitis Killed Virus Vaccine (USDA: 1105.20);
material entity;Salmonella Typhimurium hfq mutant vaccine;
material entity;pCR3 DNA vaccine plasmid;
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.00);
material entity;Salmonella Typhimurium htrA mutant vaccine;
process;allergy vaccine preparation;A vaccine preparation that results in the generation of a Allergy vaccine
process;cancer vaccine preparation;A vaccine preparation that results in the generation of a Cancer vaccine
process;vaccine-induced down-regulated gene expression;
material entity;vaccine dominant epitope;
disposition;hypersensitivity to gentamicin;
material entity;pCR4-TOPO DNA vaccine plasmid;
material entity;Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.00);
material entity;Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.20);
material entity;Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.21);
material entity;bacterial vaccine;A vaccine that targets against a bacterial disease.
material entity;infectious bursal disease virus vaccine;viral vaccine that is used to protect against Infectious Bursal Disease Virus (IBDV) infection
material entity;Mycobacterium tuberculosis gene;
material entity;Eastern Equine Encephalitis Virus vaccine;viral vaccine that is used to protect against Eastern Equine Encephalitis Virus infection
process;vaccine-induced gene up-regulation controlling intracellular bacterial replication;
material entity;VEE Virus vaccine;viral vaccine that is used to protect against VEE Virus (Venezuelan equine encephalitis virus) infection
quality;vaccine organism avirulent;a virulence of vaccine organism that shows an avirulent pheontype of the organism as the major component of a vaccine. The avirulence means that an vaccine organism is not virulent and does not cause pathogenic phenotype in a host organism.
material entity;Shigella gene;
material entity;Mink enteritis virus vaccine;viral vaccine that is used to protect against Mink enteritis virus infection
material entity;Salmonella gene;
material entity;Porcine parvovirus vaccine;viral vaccine that is used to protect against Porcine parvovirus infection
material entity;pcDNA3.1V5HisTOPO/TA DNA vaccine plasmid;
material entity;Porcine rotavirus vaccine;viral vaccine that is used to protect against Porcine rotavirus infection
material entity;bacterial vaccine vector;a vaccine vector that uses a live bacterium as the vector
material entity;Equine rotavirus vaccine;viral vaccine that is used to protect against Equine rotavirus infection
material entity;canine adenovirus Type 2 vaccine;viral vaccine that is used to protect against Canine Adenovirus Type 2 (Canine adenovirus 2) infection
material entity;Bovine papillomavirus vaccine;viral vaccine that is used to protect against Bovine papillomavirus infection
material entity;avian polyomavirus vaccine;viral vaccine that is used to protect against Avian Polyomavirus infection
material entity;Escherichia coli gene;
material entity;influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur);
process;vaccine-induced T cell differentiation;
material entity;pCEP4 DNA vaccine plasmid;
material entity;Leishmania gene;
quality;vaccine organism live attenuated;a virulence of vaccine organism that shows an attenuated pheontype of the organism as the major component of a vaccine.
material entity;vaccine component;a processed material that is output of the vaccine preparation and part of a vaccine.
process;inactivated vaccine preparation;A vaccine preparation that results in the generation of a inactivated vaccine
material entity;cancer vaccine;Vaccine that prevents or treats cancer.
material entity;Plasmodium falciparum gene;
material entity;Plasmodium gene;
material entity;protozoan gene;
material entity;Leishmania amazonensis vaccine;A vaccine that protects against Leishmania amazonensis.
material entity;Leishmania infantum vaccine;A vaccine that protects against Leishmania infantum.
material entity;cholera toxin vaccine adjuvant;A microbial derivative vaccine adjuvant consisting of cholera toxin (CT) from Vibrio cholerae.
material entity;sei whale vaccine;
material entity;incomplete Freund's adjuvant;A Freund's emulsified oil adjuvant that does not contain the mycobacterial components.
material entity;sheep vaccine;
material entity;salmoninae vaccine;vaccine that used for immunizing salmoninae (tourts, salmons & chars )
role;agglutinating antibody role;
material entity;turkey vaccine;
role;vaccine adjuvant role;an adjuvant role that inheres in a vaccine component which is added as part of a vaccine and induces enhanced adaptive immune response to the vaccine antigen.
material entity;gray wolf vaccine;
material entity;Corynebacterium-derived P40 vaccine adjuvant;A microbial derivative vaccine adjuvant that is the P40 particulate fraction isolated from Corynebacterium.
material entity;horse vaccine;
role;recombinant vaccine vector role;a vaccine component role that inheres in a recombinant vaccine vector as a vaccine component. The combination of a recombinant vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombinant vector vaccine.
material entity;parrot vaccine;
material entity;alphavirus vaccine vector;a viral vaccine vector that uses an alphavirus as the vector.
material entity;pig vaccine;
material entity;catfish vaccine;
role;antibody role;
generically dependent continuant;vaccine target specification;The objective that intends to produce vaccine via the vaccine preparation process.
material entity;sodC from B. abortus strain 2308;A Brucella abortus gene that has the name sodC and comes from strain 2308.
material entity;Equid herpesvirus 1 vaccine;viral vaccine that is used to protect against Equid herpesvirus 1 infection
process;preparation of toxoid vaccine;A vaccine preparation that results in the generation of a toxoid vaccine
material entity;Feline herpesvirus 1 vaccine;viral vaccine that is used to protect against Feline herpesvirus 1 (Felid herpesvirus 1) infection
material entity;Francisella tularensis vaccine;a bacterial vaccine against an infection with F. tularensis.
material entity;Gallid herpesvirus 1 vaccine;viral vaccine that is used to protect against Gallid herpesvirus 1 infection
quality;immunized;an organismal quality that indicates an organism (e.g., human) is immunized against a disease.
material entity;canine adenovirus type 1 vaccine;viral vaccine that is used to protect against Canine adenovirus type 1 (Canine adenovirus 1) infection
material entity;pcDNA3.1 DNA vaccine plasmid;
material entity;bovine herpesvirus 1 vaccine;viral vaccine that is used to protect against Bovine herpesvirus 1 infection
material entity;HIV gene;
material entity;Borna disease virus vaccine;A viral vaccine that protects against infection with Borna disease virus
material entity;viral gene;
material entity;Caprine herpesvirus 1 vaccine;A viral vaccine that protects against infection with Caprine herpesvirus 1
material entity;USA licensed vaccine;A vaccine licensed in the USA
material entity;African horse sickness virus vaccine;A viral vaccine that protects against infection with African horse sickness virus
material entity;Pigeonpox virus vaccine;viral vaccine that is used to protect against Pigeonpox virus infection
generically dependent continuant;antibody titer;A titer of antibody that shows how much antibody an organism has produced that recognizes a particular epitope, expressed as the greatest dilution ratio (or its reciprocal) that still gives a positive result. ELISA is a common means of determining antibody titers.
process;preparation of live attenuated vaccine by serial passages in vitro;A live attenuated vaccine prepraration process that is performed by serial passages in vitro for pathogen attenuation.
material entity;Clostridium botulinum vaccine;A vaccine that protects against Clostridium botulinum .
material entity;Western equine encephalomyelitis virus vaccine;A vaccine that protects against Western equine encephalomyelitis virus.
material entity;Haemophilus influenzae vaccine;A vaccine that protects against Haemophilus influenzae.
material entity;Yersinia enterocolitica vaccine;A vaccine that protects against Yersinia enterocolitica.
material entity;canine parvovirus vaccine;A vaccine that protects against Canine parvovirus.
material entity;SARS vaccine;A vaccine that protects against SARS-CoV.
material entity;Trypanosoma brucei vaccine;A vaccine that protects against Trypanosoma brucei.
material entity;Helicobacter pylori vaccine;A vaccine that protects against Helicobacter pylori.
material entity;Campylobacter jejuni vaccine;A Campylobacter vaccine that protects against Campylobacter jejuni.
material entity;Tick-borne Encephalitis Virus (TBEV) vaccine;A vaccine that protects against Tick-borne Encephalitis Virus (TBEV).
material entity;muramyl dipeptide vaccine adjuvant;A synthetic vaccine adjuvant formulated to correspond to a component found in a water-soluble extract of cell walls of mycobacteria used in complete Freund's adjuvant (CFA).
material entity;RNA vaccine;A vaccine that uses RNA(s) derived from a pathogen organism.
material entity;Influenza virus gene;
material entity;Ebola virus gene;
generically dependent continuant;colony forming unit;A titer measurement of viable bacterial or fungal numbers. Unlike in direct microscopic counts where all cells, dead and living, are counted, CFU measures viable cells. By convenience the results are given as CFU/mL (colony-forming units per milliliter) for water, and CFU/g (colony-forming units per gram) for soil or other porous material.
material entity;Dengue virus gene;
material entity;Japanese encephalitis virus gene;
process;vaccine-induced antibacterial agglutination antibody response;
material entity;lipopolysaccharide vaccine adjuvant;A microbial derivative vaccine adjuvant made from bacterial lipopolysaccharide (LPS) of gram-negative bacteria.
process;vaccine-induced cell activation;
material entity;Infectious Hematopoietic Necrosis Virus vaccine;A vaccine that protects against Infectious Hematopoietic Necrosis Virus.
material entity;Rift Valley Fever virus vaccine;A vaccine that protects against Rift Valley Fever virus.
material entity;Marburg Virus vaccine;A vaccine that protects against Marburg Virus.
material entity;Nipah virus vaccine;A vaccine that protects against Nipah virus.
material entity;Hantavirus vaccine;A vaccine that protects against Hantavirus.
material entity;Herpes simplex virus type 1 and 2 vaccine;A vaccine that protects against Herpes simplex virus type 1 and 2.
material entity;bovine leukemia virus vaccine;A vaccine that protects against Bovine Leukemia virus.
material entity;Marek's disease virus vaccine;A vaccine that protects against Marek's disease virus.
material entity;Cryptosporidium parvum vaccine;A vaccine that protects against Cryptosporidium parvum.
material entity;chickenpox virus gene;
process;preparation of recombinant vector vaccine;A vaccine preparation that results in the generation of a recombinant vector vaccine
material entity;conjugate vaccine;Conjugate vaccine is vaccine that conjugates/links antigens to the molecules that form the outer coat of disease-causing bacteria to promote an immune response.
material entity;Rubella virus gene;
material entity;squalene vacccine adjuvant;An emulsion vaccine adjuvant that contains an organic polymer with some antigenic epitopes which might be shared with other organic polymers acting as immunostimulators.
role;FDA licensed vaccine role;a USA licensed vaccine role that inheres ina vaccine approven to be by the US FDA to be used for humans in the USA.
material entity;Bordetella pertussis component vaccine adjuvant;A microbial derivitive vaccine adjuvant that contains components from killed Bordetella pertussis. The killed B. pertussis has a strong adjuvant effect on the diphtheria and tetanus toxoids in the DPT vaccines.
material entity;Montanide 103 vaccine adjuvant;A Montanide vaccine adjuvant that is Montanide 103.
material entity;arlacel A vaccine adjuvant;A synthetic vaccine adjuvant that is an emulsifier called Arlacel A.
material entity;Chlamydia muridarum vaccine;A Chlamydia vaccine that protects against Chlamydia muridarum.
material entity;Lassa Fever Virus vaccine;A vaccine that protects against Lassa Fever Virus.
material entity;Chlamydophila psittaci vaccine;A Chlamydia bacterial vaccine against Chlamydophila psittaci infection
material entity;Burkholderia pseudomallei vaccine;A vaccine that protects against Burkholderia pseudomallei.
material entity;canine distemper virus vaccine;A vaccine that protects against Canine distemper virus.
material entity;Coccidioides vaccine;A vaccine that protects against Coccidioides spp.
material entity;Chlamydophila pneumoniae vaccine;A Chlamydia vaccine that protects against Chlamydophila pneumoniae.
material entity;Hendra virus vaccine;A vaccine that protects against Hendra virus.
material entity;Entamoeba histolytica vaccine;A vaccine that protects against Entamoeba histolytica.
material entity;UL23 from Feline herpesvirus 1;
material entity;ORF-A from Feline immunodeficiency virus;
material entity;E2 gene from Classical swine fever virus;
material entity;gE from Equid herpesvirus;
material entity;gI from Equid herpesvirus;
process;TK from Equid herpesvirus;A thymidine kinase-deficient mutant (PR1) is attenuated in mice and induced significant protection from challenge with wild type EHV-1 5 weeks after vaccination. In foals, PR1 also showed attenuation. however, the mutant induced only partial protection from challenge with EHV-1
material entity;US8 from Bovine herpesvirus 1;
material entity;glycoprotein G from Bovine Respiratory Syncytial Virus;
material entity;E(rns) from Classical swine fever virus;
material entity;E1 from Classical swine fever virus;
material entity;vif from Feline immunodeficiency virus;
material entity;HBVgp3 X protein from Hepatitis B virus;
material entity;7b from Feline infectious peritonitis virus;
material entity;UL0 from Gallid herpesvirus 1;
material entity;UL23 from Gallid herpesvirus 1;
material entity;UL47 from Gallid herpesvirus 1;
material entity;3a from Feline infectious peritonitis virus;
material entity;3b from Feline infectious peritonitis virus;
material entity;3c from Feline infectious peritonitis virus;
material entity;7a from Feline infectious peritonitis virus;
material entity;US3 from Pseudorabies virus;
material entity;Borrelia burgdorferi gene;A bacterial gene that is from Borrelia burgdorferi.
material entity;glycoprotein G from Rabies virus;
material entity;Burkholderia pseudomallei gene;A bacterial gene that is from Burkholderia pseudomallei.
material entity;P protein from Rabies virus;
material entity;Edwardsiella ictaluri gene;A bacterial gene that is from Edwardsiella ictaluri.
material entity;E from SARS-CoV;
material entity;Neisseria meningitidis gene;A bacterial gene that is from Neisseria meningitidis.
material entity;C protein from West Nile virus;
material entity;Pasteurella multocida gene;A bacterial gene that is from Pasteurella multocida.
material entity;E1 from Western equine encephalomyelitis virus;
material entity;Salmonella Typhi gene;A bacterial gene that is from Salmonella Typhi.
material entity;Edwardsiella tarda gene;A bacterial gene that is from Edwardsiella tarda.
material entity;nef from Simian Immunodeficiency Virus;
material entity;Francisella tularensis gene;A bacterial gene that is from Francisella tularensis.
material entity;C protein from Tick-borne Encephalitis Virus;
material entity;Mannheimia haemolytica gene;A bacterial gene that is from Mannheimia haemolytica.
material entity;E1 glycoprotein from VEE Virus;
material entity;Mycoplasma gallisepticum gene;A bacterial gene that is from Mycoplasma gallisepticum.
material entity;PE2 from VEE Virus;
material entity;Salmonella Gallinarum gene;A bacterial gene that is from Salmonella Gallinarum.
material entity;E2 gene from Western equine encephalomyelitis virus;
material entity;Salmonella Typhimurium gene;A bacterial gene that is from Salmonella Typhimurium.
material entity;Salmonella Enteritidis gene;A bacterial gene that is from Salmonella Enteritidis.
material entity;PE2 from Western equine encephalomyelitis virus;
material entity;Vibrio cholerae gene;A bacterial gene that is from Vibrio cholerae.
material entity;Yersinia ruckeri gene;A bacterial gene that is from Yersinia ruckeri.
material entity;py36 from Plasmodium yoelii;
material entity;Bovine Respiratory Syncytial Virus gene;A viral gene that is from Bovine Respiratory Syncytial Virus.
material entity;Bovine herpesvirus 1 gene;A viral gene that is from Bovine herpesvirus 1.
material entity;cen1 from Leishmania donovani;
material entity;Yersinia enterocolitica gene;A bacterial gene that is from Yersinia enterocolitica.
material entity;HSP70 II from Leishmania infantum;
material entity;Yersinia pestis gene;A bacterial gene that is from Yersinia pestis.
material entity;fabB/fabF from Plasmodium falciparum;
material entity;Yersinia pseudotuberculosis gene;A bacterial gene that is from Yersinia pseudotuberculosis.
material entity;p36p from Plasmodium berghei;
material entity;gD from Herpes simplex virus type 1 and 2;
material entity;gH from Herpes simplex virus type 1 and 2;
material entity;G protein from Human metapneumovirus;
material entity;M2-2 from Human metapneumovirus;
material entity;M2-2 from Human Respiratory Syncytial Virus;
material entity;NV from Infectious Hematopoietic Necrosis Virus;
material entity;iCP0 from Herpes simplex virus type 1 and 2;
material entity;TK from Herpes simplex virus type 1 and 2;
material entity;UL29 from Herpes simplex virus type 1 and 2;
material entity;US8 from Herpes simplex virus type 1 and 2;
material entity;M2 from Influenza virus;
material entity;Brucella melitensis gene;A Brucella gene that is from B. melitensis.
material entity;NS1 from Influenza virus;
material entity;Brucella suis gene;A Brucella gene that is from B. suis.
material entity;GP5 protein from Porcine respiratory and reproductive syndrome virus;
material entity;Aeromonas hydrophila gene;A bacterial gene that is from Aeromonas hydrophila.
material entity;gp63 from Pseudorabies virus;
material entity;Bordetella bronchiseptica gene;A bacterial gene that is from Bordetella bronchiseptica.
material entity;UL23 from Pseudorabies virus;
material entity;Aeromonas salmonicida gene;A bacterial gene that is from Aeromonas salmonicida.
material entity;UL50 from Pseudorabies virus;
material entity;Bordetella pertussis gene;A bacterial gene that is from Bordetella pertussis.
material entity;Bacillus anthracis gene;A bacterial gene that is from Bacillus anthracis.
material entity;glycoprotein E from Pseudorabies virus;
material entity;Listeria monocytogenes gene;A bacterial gene that is from Listeria monocytogenes.
material entity;glycoprotein G from Pseudorabies virus;
material entity;Mycobacterium avium gene;A bacterial gene that is from Mycobacterium avium.
material entity;glycoprotein M from Pseudorabies virus;
material entity;Staphylococcus aureus gene;A bacterial gene that is from Staphylococcus aureus.
material entity;gp50 from Pseudorabies virus;
material entity;YF-Vax vaccine;
material entity;Toxoplasma gondii gene;A protozoan gene that is from Toxoplasma gondii.
material entity;Mycobacterium tuberculosis mce-2/mce-3 mutant vaccine;
material entity;Vivotif (USA);
material entity;Human herpesvirus 2 gene;A viral gene that is from Human herpesvirus 2.
material entity;chikungunya virus vaccine;A viral vaccine that protects against infection with Chikungunya virus
material entity;rinderpest virus vaccine;A viral vaccine that protects against infection with Rinderpest virus
material entity;Mycobacterium tuberculosis panCD mutant vaccine;
material entity;Erysipelothrix rhusiopathiae vaccine;bacterial vaccine that is used to protect against Erysipelothrix rhusiopathiae infection
material entity;Mycobacterium tuberculosis RD1/panCD mutant vaccine;RD1 and panCD mutants in Mycobacterium tuberculosis were attenuated and provided protection in CD4-deficient mice against an aerosol challenge with virulent M. tuberculosis
material entity;licensed turkey vaccine;
material entity;Mycobacterium tuberculosis drrC mutant vaccine;
material entity;Zostavax vaccine;
material entity;Leishmania donovani gene;A protozoan gene that is from Leishmania donovani.
material entity;Mycobacterium tuberculosis fadD26 mutant vaccine;
material entity;yellow fever virus vaccine;A viral vaccine that protects against infection with Yellow fever virus.
material entity;Plasmodium berghei gene;A Plasmodium gene that is from Plasmodium berghei.
material entity;Mycobacterium tuberculosis leuD mutant vaccine;
material entity;Yellow fever 17D vaccine vector;a viral vaccine vector that uses Yellow fever vaccine strain 17D as the vector.
material entity;Plasmodium yoelii gene;A Plasmodium gene that is from Plasmodium yoelii.
material entity;Mycobacterium tuberculosis lysA/secA2 mutant vaccine;
continuant;vaccination frequency;Vaccination frequency is a qualitative term that represents how many times vaccination has occurred.
material entity;aluminum phosphate vaccine adjuvant;An aluminum vaccine adjuvant that is aluminum phosphate.
material entity;aluminum hydroxide vaccine adjuvant;An aluminum vaccine adjuvant that contains aluminum hydroxide.
material entity;live attenuated vaccine organism;a vaccine organism that is live and attenuated
material entity;Trichomonas foetus vaccine;protozoan vaccine that is used to protect against Tritrichomonas suis infection
material entity;Streptococcus suis vaccine;a bacterial vaccine against Streptococcus suis infection
material entity;Corynebacterium pseudotuberculosis vaccine;a diphtheria vaccine against infection with Corynebacterium pseudotuberculosis
material entity;Eimeria spp. vaccine;protozoan vaccine that is used to protect against Eimeria spp. (Eimeria) infection
material entity;pcDNA3 DNA vaccine plasmid;
material entity;carnivora vaccine;vaccine that used for immunizing carnivora.
material entity;Mycobacterium tuberculosis sigE mutant vaccine;
material entity;calcium phosphate vaccine adjuvant;A mineral salt vaccine adjuvant composed of calcium phosphate.
material entity;cat vaccine;vaccine that used for immunizing cat (felis catus)
material entity;Mycobacterium tuberculosis trpD mutant vaccine;
material entity;pcDNA I/Amp DNA vaccine plasmid;
material entity;cattle vaccine;
material entity;Staphylococcus aureus aroA mutant vaccine;
material entity;dog vaccine;
material entity;Streptococcus equi vicK mutant vaccine;
material entity;adenovirus vaccine vector;a viral vaccine vector that uses an adenovirus as the vector.
material entity;Orf Virus vaccine;viral vaccine that is used to protect against Orf Virus infection
material entity;Mycobacterium tuberculosis proC mutant vaccine;
process;vaccine-induced adaptive immune response;
material entity;bird vaccine;Vaccine that used for immunizing birds.
material entity;Trichinella spiralis vaccine;A protozoan vaccine against Trichinella spiralis infection
process;vaccine-induced T cell proliferation;
material entity;fish vaccine;vaccine that used for immunizing fishes
material entity;atherosclerosis vaccine;A vaccine that prevents or treats atherosclerosis disease.
material entity;Freund's emulsified oil adjuvant;An emulsion vaccine adjuvant that consists of a water-in-oil emulsion of aqueous antigen in paraffin (mineral) oil of low specific gravity and low viscosity. It is named after Jules T. Freund (1890-1960), Hungarian-born American immunologist. It is a water in oil emulsion.
material entity;Fowlpox virus vaccine;viral vaccine that is used to protect against Fowlpox virus infection
material entity;complete Freund's adjuvant;A Freund's emulsified oil adjuvant that contains inactivated and dried mycobacteria, usually Mycobacterium tuberculosis (the pathogenic agent of tuberculosis).
role;combination vaccine role;A vaccine role that indicates the vaccine being a combination vaccine.
material entity;chicken vaccine;
material entity;Aeromonas hydrophila aroA mutant vaccine;
material entity;duck vaccine;
material entity;Equid herpesvirus gene;A viral gene that is from Equid herpesvirus 1.
material entity;mic2 from Toxoplasma gondii;
material entity;Feline herpesvirus 1 gene;A viral gene that is from Feline herpesvirus 1.
material entity;OMPDC from Toxoplasma gondii;
material entity;Feline immunodeficiency virus gene;A viral gene that is from Feline immunodeficiency virus.
material entity;Feline infectious peritonitis virus gene;A viral gene that is from Feline infectious peritonitis virus.
material entity;UP from Toxoplasma gondii;
material entity;TICE BCG;
material entity;TENIVAC vaccine;
process;vaccine-induced T-helper 2 type immune response;
material entity;py52 from Plasmodium yoelii;
process;vaccine-induced T-helper 1 type immune response;
material entity;Classical swine fever virus gene;A viral gene that is from Classical swine fever virus.
material entity;UIS3 from Plasmodium yoelii;
process;T cell vaccine antigen processing and presentation;
material entity;Human Respiratory Syncytial Virus gene;A viral gene that is from Human Respiratory Syncytial Virus.
process;vaccine-induced T cell mediated immunity;
material entity;vaccine T cell epitope;
material entity;TYPHIM VI vaccine;Typhim Vi, Typhoid Vi Polysaccharide Vaccine, for intramuscular use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain.
material entity;Gallid herpesvirus 1 gene;A viral gene that is from Gallid herpesvirus 1.
material entity;Actinobacillus pleuropneumoniae apxIA mutant vaccine;
material entity;Hepatitis B virus gene;A viral gene that is from Hepatitis B virus.
material entity;Actinobacillus pleuropneumoniae ApxIC mutant vaccine;
material entity;Tetanus Toxoid Adsorbed by Aventis Pasteur Inc;
material entity;Human herpesvirus 1 gene;A viral gene that is from Human herpesvirus 1.
material entity;Actinobacillus pleuropneumoniae ureC and apxIIA double mutant deletion vaccine;
material entity;Brucella abortus vaccine;
material entity;Human metapneumovirus gene;A viral gene that is from Human metapneumovirus.
material entity;Actinobacillus pleuropneumoniae apxIIC and apxIVA double deletion mutant vaccine;
material entity;E. coli O157:H7 intimin vaccine;
material entity;Pseudorabies virus gene;A viral gene that is from Pseudorabies virus.
material entity;Rabies virus gene;A viral gene that is from Rabies virus.
material entity;SARS-CoV gene;A viral gene that is from SARS-CoV.
material entity;Bacillus anthracis mntA deletion mutant vaccine;
material entity;Simian Immunodeficiency Virus gene;A viral gene that is from Simian Immunodeficiency Virus.
material entity;Listeria monocytogenes actA mutant vaccine;
material entity;pCAGGST7 DNA vaccine plasmid;
material entity;Twinrix vaccine;
material entity;Tripedia vaccine;
material entity;Infectious Hematopoietic Necrosis Virus gene;A viral gene that is from Infectious Hematopoietic Necrosis Virus.
material entity;Actinobacillus pleuropneumoniae apxIIIB and apxIIID double mutant vaccine;
material entity;Tetanus and Diphtheria Toxoids Adsorbed by MA Biologic Lab;
material entity;Porcine respiratory and reproductive syndrome virus gene;A viral gene that is from Porcine respiratory and reproductive syndrome virus.
material entity;microbial derivative vaccine adjuvant;A vaccine adjuvant that contains microbial derived material.
material entity;pCdm7 DNA vaccine plasmid;
material entity;pCBINT DNA vaccine plasmid;
process;vaccine-induced T cell activation;
material entity;Tick-borne Encephalitis Virus gene;A viral gene that is from Tick-borne Encephalitis Virus.
material entity;Listeria monocytogenes actA/plcB mutant vaccine;
material entity;VEE Virus gene;A viral gene that is from VEE Virus.
material entity;West Nile virus gene;A viral gene that is from West Nile virus.
material entity;Mycobacterium avium relA mutant vaccine;
material entity;Varivax vaccine;
material entity;Western equine encephalomyelitis virus gene;A viral gene that is from Western equine encephalomyelitis virus.
material entity;FluMist;
quality;vaccinated;an organismal quality that indicates an organism (e.g., human) is vaccinated with a vaccine.
material entity;FluLaval;
quality;unvaccinated;an organismal quality that indicates an organism (e.g., human) is unvaccinated with any vaccine.
material entity;pBHT DNA vaccine plasmid;
quality;vaccinated with a licensed vaccine;a vaccinated quality that indicates an organism is vaccinated with a licensed vaccine.
material entity;Escherichia coli vaccine;A bacterial vaccine that prevents against Escherichia coli infection.
quality;unvaccinated with a licensed vaccine;a unvaccinated quality that indicates an organism has not been vaccinated with a licensed vaccine.
material entity;virmugen;A gene that once deleted, would make an attenuated microbe that can be used as a live attenuated vaccine against virulent pathogen.
quality;unimmunized;an organismal quality that indicates an organism (e.g., human) is not yet immunized against a disease.
material entity;Fluzone;
quality;immunized by vaccination with a licensed vaccine;an organismal quality that indicates an organism (e.g., human) is immunized against a disease through vaccination with a licensed vaccine.
material entity;Fluvirin;
material entity;vaccinee;an organism that is vaccinated with a vaccine
material entity;Fluarix vaccine;
material entity;Streptococcus agalactiae vaccine;A Streptococcus vaccine against Streptococcus agalactiae infection.
material entity;formalin-killed vaccine;an inactivation vaccine that is prepared by formalin inactivation.
process;preparation of vaccine using H2O2 inactivation;A vaccine prepraration process that is performed by H2O2 inactivation of virulent pathogen.
material entity;pBC12/CMV DNA vaccine plasmid;
material entity;Gardasil vaccine;
generically dependent continuant;vaccine related journal article;A jourmal article that mentions a vaccine, which was retrieved from PubMed and annotated using VO-SciMinner.
material entity;T. cruzi DNA vaccine encoding G2;A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi G2 protein.
material entity;IPOL vaccine;IPOL, Poliovirus Vaccine Inactivated is a sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). IPOL vaccine is a highly purified, inactivated poliovirus vaccine with enhanced potency.
material entity;T. cruzi DNA vaccine encoding G4;A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi G4 protein.
material entity;Neisseria meningitidis vaccine;A bacterial vaccine that prevents Neisseria meningitidis infection.
material entity;T. cruzi DNA vaccine encoding TSA-1;A T. cruzi DNA vaccine that uses a DNA plasmid expressing T. cruzi TSA-1 protein.
material entity;Havrix vaccine;
material entity;unvaccinated organism;an organism that is unvaccinated with a vaccine
material entity;Actinobacillus pleuropneumoniae gene;A bacterial gene from Actinobacillus pleuropneumoniae.
material entity;Trypanosoma cruzi vaccine;A vaccine that protects against Trypanosoma cruzi.
material entity;T. cruzi DNA vaccine encoding CRP-10;A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi CRP-10 protein.
material entity;B16 Vaccine adjuvanted by Loxoribine;
material entity;immunized organism;an organism that is immunized for a disease
material entity;rabbit hemorrhagic disease virus vaccine;A viral vaccine that protects against infection with Rabbit hemorrhagic disease virus
material entity;Balb/c mouse;
material entity;HIV based lentivirus vaccine vector;a lentivirus vaccine vector that uses a HIV strain as the vector
material entity;Brucella abortus vaccine strain 19;A live attenuated Brucella abortus vaccine that is licensed and used in many countries.
material entity;combination vaccine adjuvant;A vaccine adjuvant that is composed of differnt compounds under more than one category.
material entity;aroA from Yersinia enterocolitica;
material entity;Brucella abortus vaccine RB51;Brucella abortus vaccine RB51 is a Brucella abortus vaccine that is licensed in the USA since 1992.
material entity;emulsion vaccine adjuvant;
material entity;htrA from Yersinia enterocolitica;
material entity;Brucella abortus strain RB51 vaccine vector;A bacterial vaccine vector that uses B. abortus vaccine strain RB51 as the vector.
material entity;particulate antigen delivery system vaccine adjuvant;A vaccine adjuvant that serves as a particulate antigen delivery system.
material entity;ompR from Yersinia enterocolitica;
material entity;synthetic vaccine adjuvant;A vaccine adjuvant that contains synthetic material.
material entity;sodA from Yersinia enterocolitica;
material entity;pCMV4 DNA vaccine plasmid;
material entity;Sendai Proteoliposomes, Sendai-containing Lipid Matrices;A liposome-based vaccine adjuvant that includes the glycoproteins of Sendai virus.
material entity;Brucella vaccine;A vaccine that protects against Brucella that causes brucellosis in animals and humans.
material entity;threonyl muramyl dipeptide (TMDP) vaccine adjuvant;A synthetic vaccine adjuvant that is threonyl muramyl dipeptide (TMDP).
material entity;virG from Shigella;
material entity;pVAX1 DNA vaccine plasmid;
material entity;ty particles vaccine adjuvant;A microbial derivative vaccine adjuvant made of virus like particles (VLPS) containing the yeast retrotransposon Ty which has the amino acids 1-381 of the pI protein encoded.
material entity;cytokine vaccine adjuvant;A vaccine adjuvant that contains active cytokine compound.
material entity;hemA from Vibrio cholerae;
material entity;senB from Shigella;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20;
material entity;Daptacel vaccine;
material entity;Comvax vaccine;
material entity;pAp031 DNA vaccine plasmid;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 25;
material entity;tensoactive compound vaccine adjuvant;A vaccine adjuvant that includes tensioactive material. Tensioactive materials, surfactants or active surface agents are chemical substances with a polar-non polar structure. These substances have a tendency to locate themselves at the surface creating an adsorbed monomolecular layer on the interface.
material entity;guaA from Yersinia pestis;
material entity;carbohydrate vaccine adjuvant;A vaccine adjuvant that is primarily composed of carbohydrates.
material entity;Diphtheria and Tetanus Toxoids Adsorbed USP by Sanofi Pasteur Inc;
material entity;Crimean-Congo Haemorrhagic Fever vaccine;A viral vaccine that protects against infection with CCHF virus
material entity;yopH from Yersinia pestis;
material entity;DNA vaccine;A vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing the whole of parts of genes encoding one or more vaccine antigen proteins.
material entity;Caprine herpesvirus type 1 vaccine;A viral vaccine that protects against infection with Caprine herpesvirus type 1 virus
material entity;phoP from Yersinia pseudotuberculosis;
material entity;MenHibrix vaccine;A vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age.
material entity;heat-killed vaccine;an inactivation vaccine that is prepared by heat inactivation.
material entity;aroA from Yersinia ruckeri;
material entity;Decavac vaccine;
material entity;irradiation-inactivated vaccine;an inactivation vaccine that is prepared by irradiation inactivation.
material entity;UL23 from Bovine herpesvirus 1;
material entity;adenovirus vaccine;A viral vaccine that protects against infection of an adenovirus.
role;virmugen role;a role that is inherenced in a gene that can be mutated in a virulent pathogen, leading to an attenuated strain serving as a live attenuated vaccine strain.
material entity;nlpD from Yersinia pestis;
material entity;ETEC vaccine ACAM2010;ACAM2007 is a vaccine candidate expressing CFA/II.
material entity;allergy vaccine;a vaccine that targets for allergy.
material entity;pcm from Yersinia pestis;
material entity;Dryvax vaccine;a vaccinia virus vaccine that is a freeze-dried calf lymph smallpox vaccine, specifically, Dryvax is a live-virus preparation of vaccinia prepared from calf lymph.
material entity;Clostridium perfringens vaccine;bacterial vaccine that is used to protect against Clostridium perfringens infection
material entity;smpB from Yersinia pestis;
generically dependent continuant;human immunization objective;
material entity;ssrA from Yersinia pestis;
material entity;guaB from Yersinia pestis;
material entity;IFN-gamma vaccine adjuvant;A cytokine vaccine adjuvant that includes IFN-gamma.
material entity;ipxM from Yersinia pestis;
material entity;pBacPAK9 DNA vaccine plasmid;
process;vaccine persistence assay;An assay that measures the persistent survival of live vaccine in a host in vivo.
material entity;H2O2-killed vaccine;an inactivation vaccine that is prepared by H2O2 inactivation.
material entity;Pneumovax 23 vaccine;
material entity;Plasmodium falciparum vaccine;a malaria vaccine that protects against malaria caused by Plasmodium falciparum.
material entity;pBudCE4.1 DNA vaccine plasmid;
material entity;Plague Vaccine by Greer Laboratories Inc;
material entity;Poliovax;
material entity;pBK-SFV DNA vaccine plasmid;
material entity;Pentacel vaccine;
material entity;PedvaxHIB vaccine;PedvaxHIB is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Haemophilus influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an outer membrane protein complex (OMPC) of the B11 strain of Neisseria meningitidis serogroup B.
material entity;Pediarix vaccine;
material entity;influenza A (H1N1) 2009 Monovalent Vaccine (Novartis);
material entity;Pcaggs DNA vaccine plasmid;
material entity;SIV based lentivirus vaccine vector;a lentivirus vaccine vector that uses a SIV strain as the vector
material entity;RotaTeq vaccine;
material entity;Adenovirus Type 4 and Type 7 Vaccine, Live, Oral;
material entity;ProQuad vaccine;A Measles-Mumps-Rubella-Vericella vaccine that is live and manufactured by Merck & Co, Inc.
material entity;Prevnar vaccine;
material entity;Rabies Vaccine Adsorbed by BioPort Corp;
material entity;RabAvert vaccine;RabAvert Rabies Vaccine is a sterile, freeze-dried vaccine obtained by growing the fixed-virus strain Flury Low Egg Passage (LEP) in primary cultures of chicken fibroblasts.
material entity;mineral salt vaccine adjuvant;A vaccine adjuvant that is formed as a mineral salt.
material entity;Fluzone Intradermal Quadrivalent;
material entity;JE-Vax vaccine;JE-VAX is a sterile, lyophilized vaccine for subcutaneous use, prepared by inoculating mice intracerebrally with Japanese encephalitis (JE) virus, "Nakayama-NIH" strain.
material entity;vaccine containing DNA vaccine for priming and Ad vector vaccine for boosting;a prime-boost vaccine with a DNA vaccine priming that contains a Ad vector vaccine for boosting
material entity;influenza virus vaccine H5N1 (Sanofi Pasteur Inc);
material entity;fusion conjugate protein vaccine;a conjugate vaccine that conjugate more than one open reading frames of protective antigens or conjugate a protective antigen to a carrier protein.
material entity;Infanrix vaccine;
material entity;Imovax Rabies (USA);The Imovax(R) 9 Rabies Vaccine is a sterile, stable, freeze-dried 10 suspension of rabies virus prepared from strain PM-1503-3M.
material entity;T. cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2;A T. cruzi vaccine that uses Sendai virus vector to express T. cruzi amastigote surface protein-2.
material entity;M-M-R II vaccine;A Measles-Mumps-Rubella vaccine that is live attenuated and manufactured by Merck & Co, Inc.
material entity;cocktail vaccine;a vaccine that contains two or more individual vaccines.
material entity;Listeria monocytogenes vaccine vector;a bacterial vaccine vector that uses L. moncytogenes as the vector.
material entity;cocktail vaccine containing subunit vaccine and inactivated whole organism vaccine;a cocktail vaccine that contains both subunit vaccine and inactivated whole organism vaccines.
material entity;Kinrix vaccine;
material entity;vaccine containing DNA vaccine for priming and subunit vaccine for boosting;a prime-boost vaccine with DNA vaccine priming that contains a subunit vaccine for boosting
material entity;T. cruzi DNA vaccine pGFP-TSA1;A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi TSA-1 protein.
material entity;T. cruzi PAR1 protein vaccine;A T. cruzi subunit vaccine that uses T. cruzi PAR1 protein as protective antigen.
material entity;T. cruzi PAR2 protein vaccine;A T. cruzi subunit vaccine that uses T. cruzi PAR2 protein as protective antigen.
material entity;T. cruzi vaccine using attenuated Salmonella expressing T. cruzi Cruzipain;A T. cruzi vaccine that uses attenuated Salmonella to express T. cruzi Cruzipain protein.
material entity;Mycobacterium tuberculosis vaccine;A Mycobacterium vaccine that protects against Mycobacterium tuberculosis.
material entity;pBISIA DNA vaccine plasmid;
material entity;pBI/tTA DNA vaccine plasmid;
material entity;Mumpsvax vaccine;
material entity;Fluzone High-dose;an influenza vaccine that is similar to Fluzone but has high dose.
material entity;Mycobax;
material entity;Meruvax II vaccine;
material entity;Menomune A C Y W135;
material entity;Menactra vaccine;Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
material entity;M-M-Vax;A Measles-Mumps vaccine that is manufactured by Merck and used for human.
material entity;FLUAD 2015-2016 vaccine 0.5 ML Prefilled Syringe;
material entity;FLUAD 2015-2016 vaccine Prefilled Syringe;
material entity;influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML;
material entity;influenza B virus B/Brisbane/9/2014 antigen;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML [FLUAD 2015-2016];
material entity;FLUAD 2015-2016 Injectable Product;
material entity;Fluad 2016-2017 vaccine;
material entity;FLUAD 2015-2016 vaccine;
material entity;Fluad 2018-2019 vaccine;
material entity;Fluad 2017-2018 vaccine;
material entity;Fluad 2016-2017 Injectable Product;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Fluad 2018-2019];
material entity;Fluad 2017-2018 vaccine Prefilled Syringe;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluad 2017-2018];
material entity;Fluad 2018-2019 Injectable Product;
material entity;Fluad 2017-2018 vaccine 0.5 ML Prefilled Syringe;
material entity;Fluad 2016-2017 vaccine Prefilled Syringe;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluad 2016-2017];
material entity;Fluad 2017-2018 Injectable Product;
material entity;Fluad 2016-2017 vaccine 0.5 ML Prefilled Syringe;
material entity;influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML;
material entity;Flublok Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe;
material entity;influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML;
material entity;Flublok Quadrivalent 2018-2019 Injectable Product;
material entity;Flublok Quadrivalent 2018-2019 vaccine;
material entity;Flublok Quadrivalent 2018-2019 vaccine Prefilled Syringe;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2018-2019];
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2017-2018];
material entity;Flublok Quadrivalent 2017-2018 vaccine Prefilled Syringe;
material entity;Flublok Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe;
material entity;Ixiaro Injectable Product;
material entity;cbiA from Salmonella Gallinarum;
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML;
material entity;clpP from Salmonella Enteritidis;
material entity;Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) Prefilled Syringe;
material entity;clpP from Salmonella Typhimurium;
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML [Ixiaro];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 20;
material entity;cpxR from Salmonella Gallinarum;
material entity;pneumococcal capsular polysaccharide type 10A vaccine;
material entity;crp from Salmonella Typhimurium;
material entity;Infanrix Injectable Product;
material entity;crp from Salmonella Gallinarum;
material entity;vibrio cholerae CVD 103-HGR strain live antigen;
material entity;0.5 ML Ixiaro 0.012 MG/ML Prefilled Syringe;
material entity;cobS from Salmonella Gallinarum;
material entity;Vaxchora Oral Product;
material entity;cpxA from Salmonella Typhimurium;
material entity;vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML;
material entity;cya from Salmonella Typhimurium;
material entity;Vaxchora Oral Suspension;
material entity;Loxoribine vaccine adjuvant;A synthetic vaccine adjuvant that includes loxoribine which is a guanosine analog derivatized at position N7 and C8, and activates TLR-7.
material entity;fliC from Salmonella Enteritidis;
material entity;ChAd63-KH vaccine;replication defective simian adenoviral vector expressing KH, a self-cleaving polyprotein comprising L. donovani KMP-11 and HASPB
material entity;MF59 vaccine adjuvant;An emulsion vaccine adjuvant consisting of an oil (squalene)-in-water nano emulsion.
material entity;fliD from Salmonella Typhimurium;
material entity;vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML [Vaxchora];
material entity;MTP-PE Liposomes vaccine adjuvant;A liposome-based vaccine adjuvant that consists of liposomes containing the synthetic lipophilic analog of muramyl dipeptide, muramyl tripeptide phosphatidylethanolamine (MTP-PE).
material entity;galE from Salmonella Typhi;
material entity;Vaxchora 1,200,000,000 UNT per 100 ML Oral Suspension;
material entity;Neisseria meningitidis vaccine antigen;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 250;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 100;
material entity;non-ionic surfactant vesicles vaccine adjuvant;A synthetic vaccine adjuvant consisting of multi-lamellar vesicles comprising a mixture of non-ionic surfactant (e.g., 1-monopalmitoyl-rac-glycerol), cholesterol and dicetyl phosphate used as a primary vaccine adjuvant for entrapped antigen.
material entity;PMMA vaccine adjuvant;A synthetic vaccine adjuvant made from the emulsion polymerization of methyl methacrylate.
material entity;guaB from Salmonella Enteritidis;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML;
material entity;protein cochleates vaccine adjuvant;A synthetic vaccine adjuvant synthesized from stable protein phospholipid-calcium precipitates.
material entity;Murametide vaccine adjuvant;A synthetic vaccine adjuvant made of murametide that has adjuvant activity similar to MDP.
material entity;guaA from Salmonella Enteritidis;
material entity;HEPLISAV-B Prefilled Syringe;
material entity;Murapalmitine vaccine adjuvant;A synthetic vaccine adjuvant called murapalmitine.
material entity;guaA from Salmonella Typhimurium;
material entity;Heplisav-B Injectable Product;
material entity;D-Murapalmitine vaccine adjuvant;A synthetic vaccine adjuvant that includes an MDP analog called D-Murapalmitine.
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [Heplisav-B];
material entity;NAGO vaccine adjuvant;A synthetic vaccine adjuvant that is composed of neuraminidase-galactose oxidase (NAGO) a mixture of mixture of the two enzymes-neuraminidase and galactose oxidase.
material entity;guaB from Salmonella Typhimurium;
material entity;HEPLISAV-B 20 MCG per 0.5 ML Prefilled Syringe;
material entity;Fluad 2018-2019 vaccine 0.5 ML Prefilled Syringe;
material entity;purF from Francisella tularensis;
material entity;Fluad 2018-2019 vaccine Prefilled Syringe;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 1;
material entity;rfaF from Neisseria meningitidis;
material entity;wbtI from Francisella tularensis;
material entity;GARDASIL 0.5 ML Prefilled Syringe;
material entity;aroA from Mannheimia haemolytica;
material entity;GARDASIL Prefilled Syringe;
material entity;lpd from Mycoplasma gallisepticum;
material entity;L1 protein, Human papillomavirus type 6 Vaccine 0.04 MG/ML;
material entity;metH from Neisseria meningitidis;
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.08 MG/ML;
material entity;purM from Francisella tularensis;
material entity;L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.04 MG/ML [Gardasil];
material entity;sodB from Francisella tularensis;
material entity;Gardasil Injectable Product;
material entity;sodC from Francisella tularensis;
material entity;GARDASIL 0.5 ML Injection;
material entity;wbtA from Francisella tularensis;
material entity;GARDASIL Injection;
material entity;Human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine;
material entity;siaD from Neisseria meningitidis;
material entity;Human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML;
material entity;Human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 2;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 20;
material entity;aroD from Salmonella Typhi;
material entity;Japanese encephalitis virus vaccine, inactivated;
material entity;asd from Salmonella Typhimurium;
material entity;CERVARIX 0.5 ML Prefilled Syringe;
material entity;atpA from Salmonella Typhimurium;
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated;
material entity;aroA from Pasteurella multocida;
material entity;Cervarix Injectable Product;
material entity;aroA from Salmonella Typhi;
material entity;Human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML;
material entity;aroC from Salmonella Typhi;
material entity;CERVARIX Prefilled Syringe;
material entity;Human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / Human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML [Cervarix];
material entity;part of pathogen organism in vaccine;A pathogen component in vaccine that contains only a part of the pathogen organism instead of the whole organism.
material entity;poly(I:C) vaccine adjuvant;A synthetic vaccine adjuvant containing Poly(I:C), a synthetic double stranded analog of RNA.
material entity;trxA from Salmonella Typhimurium;
material entity;Boostrix Injectable Product;
material entity;ISCOMATRIX vaccine adjuvant;A particulate antigen delivery system vaccine adjuvant that is a vaccine adjuvant comprising cholesterol, phospholipid and saponin but without antigen.
material entity;wecA from Salmonella Typhimurium;
material entity;INFANRIX vaccine 0.5 ML Prefilled Syringe;
material entity;Abisco-100 vaccine adjuvant;A saponin vaccine adjuvant that is made from highly purified saponins.
material entity;znuA from Salmonella Typhimurium;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Boostrix];
material entity;albumin-heparin microparticles vaccine adjuvant;A particulate antigen delivery system vaccine adjuvant that is albumin-heparin microparticles vaccine adjuvant that is prepared from albumin and heparin stabilized by cross-linking reaction with EDC.
material entity;znuB from Salmonella Typhimurium;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Boostrix];
material entity;ActHIB vaccine;
material entity;INFANRIX vaccine Injection;
material entity;ACAM2000 vaccine;
material entity;spoT from Salmonella Gallinarum;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Infanrix];
process;vaccination;A process of administering a vaccine in vivo to a recipient (e.g., human) with the intent to invoke a protective or therapeutic adaptive immune response.
material entity;AF03 vaccine adjuvant;An emulsion vaccine adjuvant containing 2.5% squalene.
material entity;surA from Salmonella Typhimurium;
material entity;INFANRIX vaccine Prefilled Syringe;
material entity;vaccine;Material entity that is manufactured to realize the vaccine function.
material entity;Flagellin vaccine adjuvant;A microbial derivative vaccine adjuvant composed of flagellin from gram-negative bacteria.
material entity;tolA from Salmonella Typhimurium;
material entity;INFANRIX vaccine 0.5 ML Injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 250;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3;
process;vaccine-induced lymphocyte activation;
material entity;Attenuvax vaccine;
material entity;Afluria vaccine;
material entity;Adacel vaccine;
material entity;AS-2 vaccine adjuvant;A combination vaccine adjuvant and is based on the combination of Monophosphoryl Lipid A(MPL), QS21 (a purified fraction of Saponin extracted from Quillarja Saponaria), and a proprietary oil in water emulsion.
material entity;znuC from Salmonella Typhimurium;
material entity;BOOSTRIX vaccine 0.5 ML Injection;
material entity;B7-2 vaccine adjuvant;A cytokine vaccine adjuvant that includes B7-2.
material entity;aroA from Shigella;
material entity;BOOSTRIX vaccine Injection;
material entity;Bupivacaine vaccine adjuvant;A synthetic vaccine adjuvant that is a local anaesthetic drug belonging to the amino amide group, and is used as a vaccine adjuvant in DNA vaccines.
process;vaccine-induced B cell antigen processing and presentation;
material entity;cationic liposome-DNA complex JVRS-100 vaccin adjuvant;A liposome-based vaccine adjuvant that is composed of virus sized liposomes that contain a DNA plasmid.
material entity;vaccine B cell epitope;
material entity;immunoliposomes containing antibodies to costimulatory molecules;A liposome-based vaccine adjuvant which is prepared from dehydration-rehydration vesicles (DRVs).
material entity;envZ from Shigella;
process;vaccine-induced B cell cytokine production;
material entity;LTK72 vaccine adjuvant;An E. coli LT toxin derived vaccine adjuvant that is a mutant form of heat-labile Escherichia coli enterotoxin (LT) that contains a substitution Ala -> Arg in position 72 of the A subunit.
material entity;icsA/virG from Shigella;
material entity;MPL-SE vaccine adjuvant;A microbial derivative vaccine adjuvant containing MPL and squalene.
material entity;formaldehyde vaccine preservative;a vaccine preservative that contains formaldehyde.
material entity;msbB2 from Shigella;
material entity;Boostrix vaccine;
material entity;Biothrax vaccine;
material entity;DHEA vaccine adjuvant;A synthetic vaccine adjuvant that is DHEA, which is relatively stable and can be directly incorporated into vaccine formulations.
material entity;Bacillus anthracis vaccine;A vaccine that protects against Bacillus anthrax that causes anthrax.
material entity;DL-PGL (Polyester poly (DL-lactide-co-glycolide)) vaccine adjuvant;A synthetic vaccine adjuvant that is PLGA, which has been used in the controlled delivery of peptide drugs.
material entity;aroD from Shigella;
process;vaccine-induced B cell mediated immunity;
material entity;IL-15 vaccine adjuvant;A cytokine vaccine adjuvant that uses the adjuvant effect of cytokine IL-15.
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1;
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1;
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk] Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1;
material entity;pVAX DNA vaccine plasmid;
material entity;Brucella abortus DNA vaccine pcDNA-SOD;A Brucella abortus vaccine that expresses Cu/Zn SOD with DNA plasmid pcDNA.
material entity;killed vaccine;whole organism vaccine that uses killed pathogen organism as its component.
material entity;non-toxic mutant E112K of Cholera Toxin mCT-E112K vaccine adjuvant;A microbial derived vaccine adjuvant made of E112K mC, a mutated CT created by substituting a single amino acid in the ADP-ribosyltransferase active centre, glutamate to lysine at position 112.
material entity;senA from Shigella;
material entity;cholera toxin derived vaccine adjuvant;A microbial derivative vaccine adjuvant that is derived from cholera toxin.
material entity;SAF-1 vaccine adjuvant;A combination vaccine adjuvant that is composed of threonyl-MDP (0.05-1%) in an emulsion vehicle [5% squalane, 2.5% Pluronic(R) L121, 0.2% Polysorbate 80 and phosphate buffered saline (pH 7.4)].
material entity;QS-21 vaccine adjuvant;A saponin vaccine adjuvant that is composed of extracts from the bark of the Quillaja saponaria Molina tree. Specifically, it is an acylated 3, 28-bisdesmodic triterpene glycosides (1,3) or "saponin" with a molecular formula of C92O46H148 and molecular weight of 1990 Da. QS-21 is one of the active fractions of the bark of Chilean tree, Quillaja saponaria, purified using a reverse-phase chromatography (RP-HPLC).
material entity;gyrA from Salmonella Typhimurium;
material entity;Pentacel vaccine 0.5 ML Injection;
material entity;Rehydragel HPA vaccine adjuvant;An aluminum vaccine adjuvant that is a synthetic oxyhydroxide of aluminum (aluminum hydroxide) prepared by acid-base precipitation.
material entity;hfq from Salmonella Typhimurium;
material entity;Pentacel vaccine Injection;
material entity;Rehydragel LV vaccine adjuvant;An aluminum hydroxide vaccine adjuvant that is a low visosity aluminum hydroxide gel.
material entity;htrA from Salmonella Typhimurium;
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Kinrix];
material entity;Sclavo peptide vaccine adjuvant;A cytokine vaccine adjuvant that contains the 163-171 peptide of IL-1β.
material entity;lon from Salmonella Gallinarum;
material entity;Kinrix Injectable Product;
material entity;acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Pentacel];
material entity;Pentacel Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 250;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 100;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 1;
material entity;CRL1005 vaccine adjuvant;A synthetic vaccine adjuvant that is a copolymer (CRL1005), based on a 12 kDa polyoxypropylene (POP) core with 5% POE.
material entity;nanoemulsion vaccine adjuvant;An emulsion vaccine adjuvant and is made from non-toxic lipid droplets a few hundred nanometers in diameter and made from surfactants approved for human consumption and common food substances that are 'Generally Recognized as Safe' (GRAS) by the FDA.
material entity;Specol vaccine adjuvant;An emulsion vaccine adjuvant that is a water-in-oil emulsion that is used as an adjuvant and has immunostimulating properties similar to Freund's complete adjuvant (FCA).
material entity;lppA from Salmonella Typhimurium;
material entity;KINRIX vaccine Prefilled Syringe;
material entity;SPT (Antigen Formulation);An emulsion vaccine adjuvant that is an emulsion of squalane (5%), Tween 80( 0.2%), Pluronic L121( 1.25%), phosphate-buffered saline pH 7.4, and antigen.
material entity;lppB from Salmonella Typhimurium;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Kinrix];
material entity;stearyl tyrosine vaccine adjuvant;A synthetic vaccine adjuvant stearyl tyrosine is considered an "organic equivelant" of aluminum hydroxide.
material entity;KINRIX vaccine Injection;
material entity;Theramide vaccine adjuvant;A synthetic vaccine adjuvant called Theramide that is composed of N-acetylglucosaminyl-N-acetylinuramyl-L-Ala-D-isoGlu-L-Ala-dipalmitoxy propylamide (DTP-DPP).
material entity;msbB from Salmonella Typhimurium;
material entity;KINRIX vaccine 0.5 ML Prefilled Syringe;
material entity;LTR192G vaccine adjuvant;An E. coli LT toxin derived vaccine adjuvant that is a mutant form of E.coli heat-labile toxin.
material entity;ompR from Salmonella Typhimurium;
material entity;Adacel Injectable Product;
material entity;E. coli heat-labile toxin vaccine adjuvant;A microbial derivative vaccine adjuvant containing E. coli heat-labile toxin.
material entity;phoP from Salmonella Typhi;
material entity;DAPTACEL vaccine 0.5 ML Injection;
material entity;amorphous aluminum hydroxyphosphate sulfate adjuvant;An aluminum vaccine adjuvant that is a a proprietary aluminum hydroxyphosphate sulfate formulation that is both physically and functionally distinct from traditional aluminum phosphate and aluminum hydroxide adjuvants.
material entity;poxA from Salmonella Typhimurium;
material entity;Adacel Prefilled Syringe;
material entity;Matrix-S vaccine adjuvant;
material entity;relA from Salmonella Gallinarum;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Adacel];
material entity;KINRIX vaccine 0.5 ML Injection;
material entity;nmpC from Salmonella Typhimurium;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Daptacel];
material entity;AS03 vaccine adjuvant;An emusion vaccine adjuvant that contains alpha-tocopherol and squalene, two biodegradable polyprenyls, in an oil-in-water emulsion.
material entity;nuoG from Salmonella Gallinarum;
material entity;Daptacel Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 100;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 100;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 250;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1;
material entity;resiquimod vaccine adjuvant;A synthetic vaccine adjuvant, resiquimod is a chemical analog of imiquimod.
material entity;Brucella abortus subunit vaccine using Bfr;
material entity;rfc from Salmonella Typhimurium;
material entity;Adacel Injection;
material entity;Brucella abortus subunit vaccine using Omp16;
material entity;rpoB from Salmonella Typhimurium;
material entity;Adacel 0.5 ML Prefilled Syringe;
material entity;B. melitensis DNA vaccine encoding Bp26 and Tf;
material entity;rpoS from Salmonella Typhimurium;
material entity;imiquimod vaccine adjuvant;A synthetic vaccine adjuvant contiaing imiquimod a imidazoquinoline.
material entity;ruvB from Salmonella Typhimurium;
material entity;Adacel 0.5 ML Injection;
material entity;polysaccharide subunit vaccine;a subunit vaccine that uses polysaccharide as protective antigen
material entity;carA from Escherichia coli;
material entity;polysaccharide of pathogen organism as vaccine component;
material entity;carB from Escherichia coli;
generically dependent continuant;prevention of disorder objective;The specification of an objective to prevent a disorder.
material entity;ler from Escherichia coli;
generically dependent continuant;amelioration of disorder objective;The specification of an objective to ameliorate a disorder.
material entity;rfaL from Escherichia coli;
material entity;LTK63 vaccine mutant;An E. coli LT toxin derived vaccine adjuvant that is a mutant form of LT containing a Ser-Lys substitution in position 63 which has been shown to be totally devoid of toxicity stable to protease treatment and able to act as mucosal adjuvant.
material entity;toxoid;is a bacterial toxin (usually an exotoxin) whose toxicity has been weakened or suppressed either by chemical (formalin) or heat treatment, while other properties, typically immunogenicity, are maintained.
material entity;esrB from Edwardsiella tarda;
material entity;capsular polysaccharide subunit vaccine;
material entity;esrC from Edwardsiella tarda;
material entity;capsular polysaccharide of pathogen organism as vaccine component;
material entity;slyA from Edwardsiella tarda;
material entity;aroC from Edwardsiella tarda;
material entity;monophosphoryl lipid A vaccine adjuvant;A microbial derivative vaccine adjuvant derived from the lipopolysaccharide (LPS) of Salmonella minnesota R595.
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 1;
material entity;killed Corynebacterium parvum vaccine adjuvant;A microbial derivative vaccine adjuvant derived from heat-killed Corynebacterium parvum.
material entity;VSA-3 vaccine adjuvant;An emulsion vaccine adjuvant which is an emulsion plus DDA.
material entity;iglB from Francisella tularensis;
material entity;saponin vaccine adjuvant;A tensoactive compound vaccine adjuvant that is derived from saponin, a compound that is an immunostimulator found in the plant P. senega.
material entity;iglC from Francisella tularensis;
material entity;Montanide ISA 720 vaccine adjuvant;A Montanide vaccine adjuvant that is formulated as water-in-oil emulsions and induces high antibody titers in several animal species. It is a vaccine adjuvant composed of metabolizable oil and a surfactant system designed to make a water-in-oil emulsion. It has been used since 1992 in more than 50 clinical trials related to therapeutic vaccines against various diseases such as cancer and malaria.
material entity;purC/purD from Francisella tularensis;
material entity;Montanide incomplete Seppic adjuvant;A Montanide vaccine adjuvant that is a mineral oil adjuvant.
material entity;cationic liposomal vaccine adjuvant DDA:TDB;A liposome-based vaccine adjuvant that have a positive surface charge.
material entity;FTT0918 from Francisella tularensis;
material entity;QuilA vaccine adjuvant;A tenosactive compound vaccine adjuvant that contains purified extract from the bark of the South American tree Quillaja saponaria Molina.
material entity;galU from Francisella tularensis;
material entity;AS02 vaccine adjuvant;A combination vaccine adjuvant comprised of monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion.
material entity;guaA from Francisella tularensis;
material entity;AS04 vaccine adjuvant;A combination vaccine adjuvant that is a combination of 50 ug of the immunoenhancer MPL (3-O-desacyl-4′-monophosphoryl lipid A) with 500 ug of aluminium salt.
material entity;guaB from Francisella tularensis;
material entity;capB from Francisella tularensis;
material entity;Titermax Gold vaccine adjuvant;An emulsion vaccine adjuvant which is a water-in-oil adjuvant with CRL-8300 (a block copolymer), squalene, and sorbitan monooleate.
material entity;clpB from Francisella tularensis;
material entity;DDA vaccine adjuvant;A synthetic vaccine adjuvant that is dimethyldioctadecylammonium bromide (DDA), a lipophilic quaternary ammonium salt known as a good adjuvant when co-administered systemically or nasally with an antigen.
material entity;FTL0552 from Francisella tularensis;
process;viral vaccine preparation;A vaccine preparation that results in the generation of a viral vaccine
material entity;manB from B. melitensis;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML [Flublok 2017-2018];
process;protozoan vaccine preparation;A vaccine preparation that results in the generation of a protozoan vaccine
material entity;mucR from B. melitensis;
material entity;Flublok 2017-2018 Injectable Product;
process;fungal vaccine preparation;A vaccine preparation that results in the generation of a fungal vaccine
material entity;omp25 from B. melitensis;
material entity;Flublok Quadrivalent 2017-2018 vaccine;
material entity;trivalent influenza vaccine;
material entity;omp31 from B. melitensis;
material entity;Flublok 2017-2018 vaccine 0.5 ML Injection;
material entity;asp24 from B. abortus;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML [Flublok 2016-2017];
material entity;Treponema pallidum vaccine;a bacterial vaccine against Treponema pallidum infection
material entity;bp26 from B. melitensis;
material entity;Flublok 2016-2017 Injectable Product;
material entity;Leishmania major vaccine;A vaccine that protects against Leishmania major.
material entity;exsA from B. abortus;
material entity;Flublok 2017-2018 vaccine;
material entity;protective antigen;
material entity;manA from B. melitensis;
material entity;Flublok 2016-2017 vaccine 0.5 ML Injection;
material entity;Flublok 2016-2017 vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10;
material entity;CpG DNA vaccine adjuvant;A microbial derivative vaccine adjuvant compsed of CpG DNA.
material entity;pgk from B. abortus;
material entity;Ribi vaccine adjuvant;An emulsion vaccine adjuvant that is a stable oil-in-water emulsion.
material entity;pgm from B. abortus;
material entity;Flublok Quadrivalent 2017-2018 Injectable Product;
material entity;RC529 vaccine adjuvant;A synthetic vaccine adjuvant named RC529 that is a lipid A mimetic.
material entity;Prevnar 13 vaccine;
material entity;aroC from Burkholderia pseudomallei;
material entity;Synflorix vaccine;SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and invasive disease caused by these serotypes (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia).
material entity;asd from Burkholderia pseudomallei;
material entity;Menveo vaccine;
material entity;purM from Burkholderia pseudomallei;
material entity;Arepanrix H1N1;
material entity;purN from Burkholderia pseudomallei;
material entity;aluminum potassium sulfate adjuvant;An aluminum vaccine adjuvant that is aluminum potassium sulfate (AlK(SO4)2).
material entity;purK from B. melitensis;
material entity;Alhydrogel vaccine adjuvant;An aluminum hydroxide vaccine adjuvant that is a gel that is made by precipitation of aluminum hydroxide Al(OH)3 under alkaline conditions.
material entity;virB2 from B. abortus;
material entity;cholera toxin B subunit vaccine adjuvant;A cholera toxin derived vaccine adjuvant made of the B subunit of the cholera toxin from Vibrio cholerae.
material entity;vjbR from B. melitensis;
material entity;znuA from Brucella spp.;
material entity;purE from B. melitensis;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 50;
material entity;Intanza vaccine;
material entity;crp from Edwardsiella ictaluri;
material entity;RC529-AF vaccine adjuvant;An aqueous formula of the synthetic vaccine adjuvant RC529.
material entity;interleukin-7 vaccine adjuvant;A cytokine vaccine adjuvant that includes IL-7.
material entity;GMDP vaccine adjuvant;A synthetic vaccine adjuvant containing GMDP, a higly effective primary adjuvant.
material entity;recombinant hIFN-gamma/Interferon-g vaccine adjuvant;An IFN-gamma vaccine adjuvant that is composed of recombinant hIFN-gamma.
material entity;interleukin-1b vaccine adjuvant;A cytokine vaccine adjuvant that includes IL-1b.
material entity;interleukin-2 vaccine adjuvant;A cytokine vaccine adjuvant that includes IL-2.
material entity;DOC/Alum Complex vaccine adjuvant;A mineral salt vaccine adjuvant that is composed of Deoxycholic acid sodium salt (DOC) complexed with aluminum hydroxide.
material entity;gamma Inulin vaccine adjuvant;A carbohydrate adjuvant that is a highly specific activator of the alternative pathway of complement in vitro and in vivo, and is composed of linear (unbranched) b-D-(2-1) polyfructofuranosyl-a-D-glucose.
material entity;Gerbu vaccine adjuvant;A combination vaccine adjuvant that is comprised of a mixture of GMDP, DDA, and Zinc L-proline salt complex (ZnPro8).
material entity;GM-CSF vaccine adjuvant;A cytokine vaccine adjuvant that includes GM-CSF.
material entity;cholera toxin A1-subunit-ProteinA D-fragment fusion protein;A microbial derivative vaccine adjuvant composed of the CTA1-DD fusion protein.
process;viral vaccine immunization;
process;cancer vaccine immunization;
process;parasite vaccine immunization;
material entity;Polygen vaccine adjuvant;A synthetic vaccine adjuvant with the tradename Polygen.
role;vaccine recipient role;Role that inheres in an organism that is the target of a vaccine administration (vaccination process).
role;immunization target role;A role that represents a target (i.e., some disorder) of immunization.
process;bacterial vaccine immunization;
material entity;Montanide ISA51 vaccine adjuvant;A Montanide vaccine adjuvant that is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion.
material entity;Montanide vaccine adjuvant;An emulsion vaccine adjuvant developed by Montanide.
material entity;EtxB vaccine adjuvant;An E. coli LT toxin derived vaccine adjuvant composed of the B subunit of E. coli heat-labile toxin.
material entity;Avridine vaccine adjuvant;A synthetic vaccine adjuvant that is N, N-dioctadecyl-N', N'-bis(2-hydroxyethyl) propanediamine (Avridine).
material entity;calcium phosphate gel vaccine adjuvant;A calcium phosphate vaccine adjuvant that is a gel prepared by precipitating soluable calcium and phosphate salts.
role;immunization target role of fungal pathogen;
material entity;Algal Glucan vaccine adjuvant;A carbohydrate vaccine adjuvant, which enhances both humoral and cell-mediated immunity to oligopeptides in experimental animal models.
material entity;Algammulin vaccine adjuvant;A combination vaccine adjuvant that suspension of 1-2um ovoids of immune stimulant gamma inulin (g-IN) in which alum is embedded as a carrier for protein or other anionic antigens.
material entity;BAY R1005 vaccine adjuvant;A synthetic vaccine adjuvant that is Bay R1005 (N-(2-Deoxy-2-L-leucylamino beta-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate ).
role;immunization target role of pathogen;
role;immunization target role of bacterial pathogen;
role;immunization target role of viral pathogen;
role;immunization target role of parasite pathogen;
material entity;FluMist Quadrivalent, 2015-2016 Formula Nasal Spray;
material entity;Flumist Quadrivalent 2017-2018 vaccine;
material entity;influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML;
material entity;influenza A virus A/Bolivia/559/2013 (H1N1) antigen;
material entity;Flumist Quadrivalent 2016-2017 vaccine;
material entity;FluMist 2015-2016 vaccine;
material entity;Varicella zoster virus glycoprotein E;
material entity;0.5 ML Shingrix 0.1 MG/ML Injection;
material entity;Varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML;
material entity;Varicella zoster virus glycoprotein E, recombinant;
material entity;Havrix Injection;
material entity;Listeria monocytogenes vaccine;A vaccine that protects against Listeria monocytogenes.
material entity;Havrix, Hepatitis A Vaccine (Inactivated), (Adult Dose) 1 ML Prefilled Syringe;
material entity;Mycobacterium avium vaccine;A vaccine that protects against Mycobacterium avium.
material entity;Havrix, Hepatitis A Vaccine (Inactivated), (Pediatric Dose) 0.5 ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 250;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 3;
material entity;Edwardsiella tarda vaccine;An Edwardsiella bacterial vaccine that protects against Edwardsiella tarda.
material entity;PEDIARIX Injectable Product;
material entity;Salmonella typhimurium vaccine;A bacterial vaccine that protects against infections by Salmonella typhimurium species.
material entity;poliovirus vaccine inactivated, type 3 (Saukett);
material entity;Salmonella gallinarum vaccine;A bacterial vaccine that protects against infections by Salmonella enterica subsp. enterica serovar Gallinarum.
material entity;Salmonella enteritidis vaccine;A bacterial vaccine that protects against infections by Salmonella enterica subsp. enterica serovar Enteritidis.
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [PEDIARIX];
material entity;Staphylococcus aureus vaccine;A bacterial vaccine that protects against infection with Staphylococcus aureus.
material entity;poliovirus vaccine inactivated;
material entity;Streptococcus gene;A bacterial gene that is from Streptococcus.
material entity;Havrix Prefilled Syringe;
material entity;Streptococcus equi gene;A bacterial gene that is from Streptococcus equi.
material entity;poliovirus vaccine inactivated, type 2 (MEF-1);
material entity;Aeromonas hydrophila vaccine;An Aeromonas vaccine that protects against Aeromonas hydrophila.
material entity;poliovirus vaccine inactivated, type 1 (Mahoney);
material entity;PEDIARIX vaccine 0.5 ML Prefilled Syringe;
material entity;Yersinia pseudotuberculosis vaccine;A bacterial vaccine that protects against infections by Yersinia pseudotuberculosis.
material entity;PEDIARIX vaccine Prefilled Syringe;
material entity;human metapneumovirus vaccine;A viral vaccine that protects against infection of human metapneumovirus.
material entity;poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML;
material entity;Human respiratory syncytial virus vaccine;A viral vaccine that protects against infection of Human respiratory syncytial virus.
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by GSK;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] by Glaxosmithkline;
material entity;0.5 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by Organon;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] by Glaxosmithkline;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by Merck;
material entity;apxIC from Actinobacillus pleuropneumoniae;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain;
material entity;apxIIA from Actinobacillus pleuropneumoniae;
material entity;IPOL vaccine Injectable Solution;
material entity;apxIIC from Actinobacillus pleuropneumoniae;
material entity;Plasmodium berghei vaccine;a malaria vaccine that protects against malaria caused by Plasmodium berghei.
material entity;Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine;
material entity;Plasmodium yoelii vaccine;a malaria vaccine that protects against malaria caused by Plasmodium yoelii.
material entity;poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML;
material entity;Leishmania infantum gene;A protozoan gene that is from Leishmania infantum.
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML [Ipol];
material entity;apxIA from Actinobacillus pleuropneumoniae;
material entity;Ipol Injectable Product;
material entity;influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML [Flumist 2015-2016];
material entity;influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML;
material entity;FluMist Quadrivalent, 2017-2018 Formula Nasal Spray;
material entity;influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [Flumist Quadrivalent 2017-2018];
material entity;influenza A virus A/Slovenia/2903/2015 (H1N1) antigen;
material entity;influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML;
material entity;influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML;
material entity;influenza A virus A/New Caledonia/71/2014 (H3N2) antigen;
material entity;FluMist Quadrivalent, 2016-2017 Formula Nasal Spray;
material entity;influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML [Flumist Quadrivalent 2016-2017];
material entity;influenza B virus B/Colorado/06/2017 antigen;
material entity;Flumist Quadrivalent 2018-2019 vaccine;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 100;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 100;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 250;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML [Havrix];
material entity;Havrix Injectable Product;
material entity;Havrix adult vaccine 1440 UNT in 1 ML Injection;
material entity;Havrix pediatric/adolescent vaccine 720 UNT in 0.5 ML Injection;
material entity;influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [Flumist Quadrivalent 2018-2019];
material entity;influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML;
material entity;influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML;
material entity;FluMist Quadrivalent, 2018-2019 Formula Nasal Spray;
material entity;African swine fever virus vaccine;viral vaccine that is used to protect against African swine fever virus infection
material entity;RD1 from Mycobacterium tuberculosis;
material entity;Flublok 2012-2013 Formula vaccine;
material entity;secA2 from Mycobacterium tuberculosis;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML / Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [COMVAX];
material entity;Foot-and-mouth disease virus vaccine;A viral vaccine that protects against infection with Foot-and-mouth disease virus.
material entity;Reticuloendotheliosis virus vaccine;A viral vaccine that protects against infection with Reticuloendotheliosis virus
material entity;Flublok 2012-2013 Formula Influenza Virus Vaccine Injectable Solution;
material entity;inactivated bacterial vaccine;a bacterial vaccine that uses inactivated bacterial organism.
material entity;sigE from Mycobacterium tuberculosis;
material entity;Flublok 2012-2013 Formula Injectable Product;
material entity;Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML;
material entity;phoP from Mycobacterium tuberculosis;
material entity;COMVAX Injection 0.5 ML Injection;
material entity;lipopolysaccharide subunit vaccine;a subunit vaccien that uses LPS as protective antigen
material entity;proC from Mycobacterium tuberculosis;
material entity;COMVAX Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO] by Sanofi;
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10 by Glaxosmithkline;
material entity;1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25 by Glaxosmithkline;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] by Merck;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] by Merck;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] by MSD;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] by Glaxosmithkline;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] by Waymade;
material entity;Vaxstrate;an anti-reproductive vaccine for cattle. The vaccine is based on the established principle that antibodies to the hypothalamic releasing hormone, gonadotrophin releasing hormone (GnRH) block the action of GnRH on pituitary secretion of luteinizing hormone and follicle stimulating hormone, leading to gonadal atrophy in mammals. The vaccine comprises an immunogenic GnRH:ovalbumin conjugate formulated in a novel double adjuvant system and is administered in a two-dose treatment regimen.
material entity;trpD from Mycobacterium tuberculosis;
material entity;Flublok 2013-2014 Formula vaccine;
material entity;Lymphocytic choriomeningitis mammarenavirus vaccine;A viral vaccine that protects against infection with Lymphocytic choriomeningitis mammarenavirus
material entity;aroA from Staphylococcus aureus;
material entity;Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML [Flublok 2012-2013 Formula];
material entity;live attenuated bacterial vaccine;a bacterial vaccine that is live and attenuated
material entity;vicK from Streptococcus equi;
material entity;veterinary vaccine;Veterinary vaccine is a vaccine that is used for animals (excluding humans), for example, pet, domestic, wildlife, and livestock animals.
material entity;aroA from Aeromonas hydrophila;
material entity;Flublok 2013-2014 Formula Injectable Product;
material entity;Newcastle disease virus vaccine;A viral vaccine that protects aganist Newcastle disease virus infection.
material entity;bscN from Bordetella bronchiseptica;
material entity;Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Flublok 2014-2015 Formula];
material entity;Brucella melitensis subunit vaccine;
material entity;cyaA from Bordetella bronchiseptica;
material entity;Flublok 2014-2015 Formula Influenza Virus Vaccine Injectable Solution;
material entity;Viral hemorrhagic septicemia virus vaccine;A viral vaccine that protects against infection with Viral hemorrhagic septicemia virus
material entity;dnt from Bordetella bronchiseptica;
material entity;Flublok 2015-2016 Injectable Product;
material entity;Brucella abortus DNA vaccine;
material entity;trpE from Bordetella bronchiseptica;
material entity;Flublok 2015-2016 vaccine;
material entity;Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Flublok 2013-2014 Formula];
material entity;aroA from Aeromonas salmonicida;
material entity;Flublok 2013-2014 Formula Influenza Virus Vaccine Injectable Solution;
material entity;live attenuated viral vaccine;a viral vaccine that is live attenuated
material entity;aroA from Bordetella bronchiseptica;
material entity;Flublok 2014-2015 Formula Injectable Product;
material entity;Brucella abortus subunit vaccine;a B. abortus vaccine that uses subunit antigen
material entity;Flublok 2014-2015 Formula vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 25;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 25;
material entity;Brucella melitensis DNA vaccine;
material entity;aroA from Bordetella pertussis;
material entity;Flublok 2015-2016 vaccine 0.5 ML Injection;
material entity;Human betaherpesvirus 5 vaccine;A viral vaccine that protects against infection with Human herpesvirus 5.
material entity;dnt from Bordetella pertussis;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok 2015-2016];
material entity;Coxsackievirus vaccine;A viral vaccine that protects against infection with Coxsackievirus
material entity;fla from Borrelia burgdorferi;
material entity;Schistosoma japonicum vaccine;A protozoan vaccine that protects against infection with Schistosoma japonicum
material entity;Typhim Vi Injectable Solution;
material entity;apxIIIB from Actinobacillus pleuropneumoniae;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML [Typhim VI];
material entity;apxIIID from Actinobacillus pleuropneumoniae;
material entity;Typhim Vi 0.5 ML Prefilled Syringe;
material entity;apxIVA from Actinobacillus pleuropneumoniae;
material entity;Typhim VI Prefilled Syringe;
material entity;Typhim VI Injectable Product;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by Merck;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10 by Glaxosmithkline;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25 by Glaxosmithkline;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Glaxosmithkline;
material entity;0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 50 by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] by GSK;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] by Glaxosmithkline;
material entity;plcB from Listeria monocytogenes;
material entity;relA from Mycobacterium avium;
material entity;Imovax Injectable Product;
material entity;ureC from Actinobacillus pleuropneumoniae;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML;
material entity;mntA from Bacillus anthracis;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML;
material entity;actA from Listeria monocytogenes;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated;
material entity;Leishmune;
material entity;fadD26 from Mycobacterium tuberculosis;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML;
material entity;Enterisol Ileitis;
material entity;leuD from Mycobacterium tuberculosis;
material entity;rabies virus vaccine flury-lep strain;
generically dependent continuant;challenge dose (unit: CFU);A challenge dose that is represented with the unit of colony forming units (CFU).
material entity;lysA from Mycobacterium tuberculosis;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML [RabAvert];
generically dependent continuant;vaccination-challenge interval in days;A measurement datum that represents a length of days as the interval between a vaccination and a challenge in a specific vaccine protection study.
material entity;mce-2 from Mycobacterium tuberculosis;
material entity;RabAvert Injectable Product;
material entity;1 ML Imovax 2.5 UNT/ML Injection;
material entity;drrC from Mycobacterium tuberculosis;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML [Imovax];
material entity;1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Waymade;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] by Glaxosmithkline;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] by Waymade;
material entity;1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by GSK;
material entity;1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by Organon;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] by Sanofi;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] by Glaxosmithkline;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] by Waymade;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by MSD;
material entity;B. abortus BLS-L7/L12;B. abortus BLS-L7/L12 is a B. abortus subunit vaccine using L7/L12 that is made as a recombinant BLS-L7/L12 fusion protein vaccine.
process;vaccine protection efficacy measurement;vaccine protection efficacy measurement is an assay that measures the protection efficayc of a vaccine.
generically dependent continuant;CFU per spleen;A colony forming unit (CFU) from the sample of mouse spleen.
material entity;mce-3 from Mycobacterium tuberculosis;
material entity;Hiberix Injectable Product;
generically dependent continuant;CFU reduction per spleen;A reduction of colony forming unit that was measured with the unit of colony forming units (CFU) from the sample of mouse spleen.
material entity;panC from Mycobacterium tuberculosis;
material entity;1 ML RabAvert 2.5 UNT/ML Injection;
generically dependent continuant;vaccine protection efficacy datum;A measurement datum that represents a type of vaccine protection efficacy as an outcome of a vaccine protection study. The result can be represented as a digit, for example, 0 = no protection, and 1 = protection (determined by a p-value cutoff).
material entity;HIBERIX vaccine 0.5 ML Injection;
material entity;Chlamydia trachomatis vaccine;A Chlamydia bacterial vaccine against Chlamydia trachomatis infection
material entity;panD from Mycobacterium tuberculosis;
material entity;Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML [Hiberix];
material entity;live attenuated Brucella abortus vaccine;live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella abortus infection.
material entity;Parvovirus-Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Leptospira CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Shingrix Injectable Product;
material entity;live attenuated Brucella melitensis vaccine;live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella melitensis infection.
material entity;Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus-Rabies Virus Vaccine;
material entity;Flucelvax Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe;
material entity;live attenuated Brucella suis vaccine;live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella suis infection.
material entity;Porcine Circovirus Vaccine- Mycoplasma Hyopneumoniae Bactin;
material entity;Shingrix vaccine 0.5 ML Injection;
material entity;Eimeria tenella vaccine;
material entity;Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Bordetella Bronchiseptica-Clostridium Perfringens Type C-Erysipelothrix Rhusiopathiae-Escherichia Coli-Pasteurella Multocida Bacterin-Toxoid;
material entity;Varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML [Shingrix];
material entity;Actinobacillus pleuropneumoniae vaccine;a bacterial vaccine against A. pleuropneumoniae infection
material entity;Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2017-2018];
material entity;replicating adenovirus accine vector;an adenovirus vaccine vector that is able to replicate.
material entity;Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Flucelvax Quadrivalent 2017-2018 Injectable Product;
process;assay of CFU reduction in liver;assay of CFU reduction in liver is a CFU reduction assay that is measured using the extracted liver as the tissue for isolation of infected pathogens.
material entity;Porcine Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae vaccine;
material entity;Flucelvax Quadrivalent 2017-2018 vaccine Prefilled Syringe;
process;assay of CFU reduction in lung;assay of CFU reduction in lung is a CFU reduction assay that is measured using the extracted lung as the tissue for isolation of infected pathogens.
material entity;Parvovirus-Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Flucelvax Quadrivalent 2017-2018 Injectable Suspension;
material entity;Flucelvax Quadrivalent 2017-2018 vaccine;
material entity;Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 2;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1;
material entity;Ovilis Toxovax;
material entity;Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid;
quality;vaccine organism viability;vaccine viability is a viability of a vaccine organism.
quality;vaccine organism live;vaccine being viable is a vaccine viability that indicates a vaccine uses live organism.
material entity;Rabies Vaccine-Ehrlichia Risticii Bacterin;
material entity;Orthopoxvirus vaccine vector;a poxvirus vaccine vector that uses an orthopox virus as the vector
material entity;Swine Influenza Vaccine;
material entity;IL-12 vacince adjuvant;A cytokine vaccine adjuvant that contains IL-12.
material entity;Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae Bacterin;
quality;no vaccine protection;
material entity;Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin;
material entity;fungal vaccine vector;a recombinant vaccine vector that uses a fungus as the vaccine vector
material entity;Porcine Reproductive & Respiratory Syndrome-Circovirus Vaccine-Mycoplasma Hyopneumoniae Bacterin;
material entity;Leishmania donovani vaccine;
material entity;Porcine Reproductive & Respiratory Syndrome-Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
material entity;Avipox virus vaccine vector;a poxvirus vaccine vector that uses an avipox virus as the vector
material entity;Porcine Rotavirus Vaccine-Escherichia Coli Bacterin;
material entity;Brucella DNA vaccine encoding chimera BLSOmp31;
material entity;Porcine Rotavirus-Transmissible Gastroenteritis Vaccine;
material entity;Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Escherichia Coli Bacterin;
material entity;West Nile-Innovator DNA;
material entity;Porcine Rotavirus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 20;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 3;
quality;significant vaccine protection;
material entity;bovine parainfluenza virus vaccine vector;a viral vaccine vector that uses a bovine parainfluenza virus strain as vector
material entity;Fowl Pox-Laryngotracheitis Vaccine;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2018-2019];
material entity;CoxAbic;
material entity;Fowl Pox-Mareks Disease Vaccine;
material entity;Flulaval Quadrivalent 2018-2019 Injectable Product;
material entity;Bordetella avium vaccine;a Bordetella bacterial vaccine against infection of B. avium
material entity;Fowl Pox-Mycoplasma Gallisepticum Vaccine;
material entity;Flulaval Quadrivalent 2018-2019 vaccine Prefilled Syringe;
material entity;capripoxvirus vaccine vector;a poxvirus vaccine vector that uses an attenuated capripoxvirus strain as the vaccine vector
material entity;Mannheimia Haemolytica-Pasteurella Multocida Vaccine;
material entity;Flulaval Quadrivalent 2018-2019 vaccine Injectable Suspension;
material entity;Flulaval Quadrivalent 2017-2018 vaccine Prefilled Syringe;
material entity;Feline Rhinotracheitis-Calicivirus Vaccine;
material entity;FluLaval Quadrivalent 2017-2018 vaccine Injectable Suspension;
material entity;Fecundin;a fertility vaccine that enhance fertility in sheep.
material entity;Fowl Laryngotracheitis-Mareks Disease Vaccine;
material entity;Flulaval Quadrivalent 2018-2019 vaccine;
material entity;lumpy skin disease virus vaccine vector;A poxvirus vaccine vector that uses an attenuated lumpy skin disease virus as the vector.
material entity;Infectious Salmon Anemia Virus Vaccine-Aeromonas Salmonicida-Vibrio Anguillarum-Ordalii-Salmonicida Bacterin;
material entity;Flulaval Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1;
process;survival of live vaccine inside host;survival of live vaccine inside host is a processual entity that represents the survival of a live vaccine inside its host. The time of the survival is often important for the success of the live vaccine.
material entity;Mareks Disease-Newcastle Disease Vaccine;
material entity;Flucelvax 2015-2016 vaccine;
process;persistence of vaccine induced immune response;persistence of vaccine induced immune response is a processual entity that indicates the persistence of an immune reponse induced by a vaccine in a vaccinated host.
material entity;chicken Mareks disease-tenosynovitis vaccine;
material entity;Flulaval Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe;
material entity;Corynebacterium pseudotuberculosis vaccine vector;a bacterial vaccine vector that uses a Corynebacterium pseudotuberculosis strain as the vaccine vector
material entity;Mink Distemper-Enteritis Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid;
material entity;RECOMBITEK Canine Parvo;
material entity;Newcastle-Bronchitis Vaccine-Mycoplasma Gallisepticum Bacterin;
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2016-2017];
material entity;VEE vaccine vector;a viral vaccine vector that uses a Venezuelan equine encephalitis virus strain as the vaccine vector
material entity;Hirame rhabdovirus vaccine;A viral vaccine that protects against infection with Hirame rhabdovirus
material entity;Flucelvax Quadrivalent 2016-2017 Injectable Product;
material entity;Eimeria maxima vaccine;
material entity;Newcastle Disease-Fowl Pox Vaccine;
material entity;Flucelvax Quadrivalent 2016-2017 0.5 ML Prefilled Syringe;
material entity;Agriflu;
material entity;Newcastle-Bronchitis Vaccine;
material entity;Flucelvax Quadrivalent 2016-2017 Prefilled Syringe;
material entity;Mink Distemper-Enteritis Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid;
material entity;Flucelvax 2015-2016 vaccine Prefilled Syringe;
material entity;Bovilis Neoguard;
material entity;Mink Enteritis Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid;
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax 2015-2016];
material entity;rhabdovirus-based vaccine vector;a viral vaccine vector that uses a rhabdovirus-based viral strain as the vaccine vector
material entity;Mink Enteritis Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid;
material entity;Flucelvax Quadrivalent 2016-2017 vaccine;
material entity;Saccharomyces cerevisiae vaccine vector;a recombinant vaccine vector that uses Saccharomyces cerevisiae as the vaccine vector
material entity;Newcastle Disease-Bronchitis Vaccine-Salmonella Enteritidis Bacterin;
material entity;Flucelvax 2015-2016 vaccine 0.5 ML Prefilled Syringe;
material entity;Flucelvax 2015-2016 Injectable Product;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 10;
material entity;live attenuated Brucella vaccine;live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella infection.
material entity;Newcastle-Paramyxovirus Vaccine;
material entity;ALVAC vaccine vector;a canarypox vaccine vector that uses an attenuated canarypox virus strain ALVAC. The ALVAC vector is a canarypox virus clone obtained after four rounds of plaque purification of a strain from a vaccine for canaries.
material entity;bovine parainfluenza 3 vaccine-Leptospira Pomona vaccine;
material entity;influenza B virus B/Hong Kong/259/2010 antigen;
material entity;non-replicating adenovirus accine vector;an adenovirus vaccine vector that is not able to replicate.
material entity;live attenuated influenza vaccine;live attenuated influenza vaccine is a live attenuated vaccine that protects against influenza viral infection.
material entity;B. abortus L7/L12 fused to MBP;B. abortus L7/L12 fused to MBP is a B. abortus subunit vaccine using L7/L12 that uses recombinant L7/L12 fused on maltose binding protein MBP.
material entity;inactivated influenza vaccine;inactivated influenza vaccine is an inactivated viral vaccine that targets at influenza viral infections.
material entity;Livacox;
material entity;vaccine strain;a vaccine organism that is a specific strain
material entity;B. melitensis Rev. 1 with bp26 and omp31 deletions;B. melitensis bp26 and omp31 deletion vaccine is a Brucella melitensis vaccine that has double deletions of bp26 and omp31.
material entity;pCIOmp31;pCIOmp31 is a B. melitensis DNA vaccine expressing Omp31 that uses the pCI plasmid.
material entity;pTargeTomp31;pTargeTomp31 is a B. melitensis DNA vaccine expressing Omp31 that uses the pTargeT mammalian expression system vector (Promega, USA).
generically dependent continuant;vaccine viability datum;A measurement datum that represents vaccine viability. 0 = live. 1 = irradiated. 2 = killed.
material entity;Inovocox;
generically dependent continuant;vaccine investigation data set;A data set that represents a set of data for a list of variables (e.g., vaccination dose) for the data analysis of an vaccine investigation study.
process;intramuscular vaccination;a vaccination that occurs in the intramuscular route.
generically dependent continuant;vaccine strain datum;A measurement datum that represents a vaccine strain. Different strains can be represented using distinct digital numbers.
material entity;Vaxsafe MG;
role;vaccine strain role;a vaccine role that is borne by an organism strain serving as a vaccine
material entity;GonaCon;
process;vaccine protection ANOVA;
process;laboratory test;
material entity;avian pathogenic E. coli vaccine;a vaccine against avian pathogenic Escherichia coli (APEC) infection, a major problem for the poultry industry in the world.
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract;
material entity;E. coli O157 vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Pomona Bacterin;
material entity;Porcilis APP;
material entity;Bovine Respiratory Syncytial Virus Virus Vaccine-Haemophilus somnus Bacterin;
material entity;PUREVAX Ferret Distemper;PUREVAX Ferret Distemper is a lyophilized ferret vaccine of a recombinant canarypox vector expressing the HA and F glycoproteins of canine distemper virus.
material entity;enterotoxigenic E. coli vaccine;An E. coli vaccine against enterotoxigenic E. coli infections
material entity;horse Encephalomyelitis-Influenza-West Nile Virus vaccine;A horse vaccine that protects against EEE, VEE, WEE, influenza virius infection, and West Nile virus infection.
material entity;Androvax;
material entity;Mink Distemper-Enteritis Vaccine;
material entity;B. abortus HSA-L7/L12;B. abortus L7/L12 is a B. abortus subunit vaccine using L7/L12 that is formed by recombinant Human Serum Albumin (HAS)-L7/L12 fusion protein.
material entity;porcine parvovirus-erysipelothrix rhusiopathiae vaccine;
material entity;Shiga toxin-producing E. coli vaccine;An E. coli vaccine against Shiga toxin-producing E. coli (STEC) infections
material entity;Bovine Virus Diarrhea-Respiratory Syncytial Virus Vaccine;
material entity;Swine Influenza Vaccine-Mycoplasma Hyopneumoniae Bacterin;
quality;enhanced significant protection;
material entity;Trichomonas Foetus-Campylobacter Fetus-Leptospira vaccine;
material entity;Piscirickettsia salmonis vaccine;bacterial vaccine that is used to protect against Piscirickettsia salmonis infection
material entity;Canine Distemper-Coronavirus-Parvovirus Vaccine;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 250;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 3;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 50;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10;
material entity;Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 100;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 25;
material entity;Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 3;
material entity;KLH-s-FimH1-25 with CFA and then IFA;
material entity;E. coli FimH with CFA and then IFA;an E. coli subunit vaccine that uses E. coli FimH adhesin protein as teh antigen, and uses the complete Freund's adjuvant (CFA) in the first vaccination and the incomplete Freund's adjuvant (IFA) in the boost vaccination.
material entity;influenza A (H1N1) 2009 Monovalent Vaccine (IDB);
material entity;E. coli DNA vaccine;E. coli DNA vaccine is a DNA vaccine that protects against an E. coli infection.
generically dependent continuant;pathogen challenge protocol;pathogen challenge protocol is a protocol that is used for a pathogen challenge process.
material entity;influenza vaccine (whole virion, inactivated);
generically dependent continuant;reduction of colony forming unit;A titer measurement of viable bacterial or fungal numbers. It equals to a reduction of a CFU count from another CFU count. This term is often used as a measurement of a vaccine protection study.
material entity;influenza vaccine (split virion, inactivated);
process;intraperitoneal pathogen challenge;intraperitoneal pathogen challenge is a pathogen challenge process that occurs in the intraperitoneal site of a host.
material entity;influenza vaccine (surface antigens, inactivated);
process;intraperitoneal vaccination;a vaccination process that occurs in the intraperitoneal route
material entity;influenza vaccine (inactivated, adjuvanted);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Haemophilus somnus-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin;
generically dependent continuant;vaccination dose specification;
material entity;Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Modified Live Virus & Avirulent Live Culture Vaccine (USDA: 12X1.21);
generically dependent continuant;challenge dose specification;
material entity;Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46L9.20);
generically dependent continuant;specification of vaccination-challenge interval;specification of time interval after vaccination for challenge is a plan specification that specifies the time interval after vacciation for challenge
material entity;Fowl Laryngotracheitis-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16J1.R3);
generically dependent continuant;vaccination dose (unit: CFU);A vaccination dose that is used with the unit of colony forming units (CFU).
generically dependent continuant;animal age at vaccination in days;An age range at vaccination that represents the animal age (unit: day) at the time of vaccination.
generically dependent continuant;pathogen strain for challenge datum;A measurement datum that represents a specific pathogen strain used for animal challenge study. Different pathogen strains can be represented using discretized digitals.
generically dependent continuant;pathogen challenge datum;A measurement datum that represents a specific pathogen used for animal challenge study. Different pathogens can be represented using discretized digitals.
generically dependent continuant;mutated gene in vaccine strain datum;A measurement datum that represents a specific mutated gene from a vaccine strain. The mutated can be represented by a described digit.
generically dependent continuant;vaccination mouse strain datum;A measurement datum that represents a specific mouse strain used for vaccination. Different strains can be represented using discretized digitals. For example, 0 = BALB/c. 1 = CD1. 2 = mixed/outbred. 3 = C57BL/6. 4 = OF1. 5 = 129/Sv. 6 = Swiss albino.
generically dependent continuant;biological sex datum;A measurement datum that represents the biological sex of an animal. The result can be represented using a discretized digit, for example, 0 = female. 1 = male.
generically dependent continuant;vaccination route datum;A measurement datum that represents a specific route (e.g., i.p.) used for vaccination. Different routes can be represented using discretized digitals. 0 = IP. 1 = PO. 2 = SC. 3 = IM. 4 = IN. 6 = IG. 7 = IV. 8 = ID.
generically dependent continuant;vaccine adjuvant usage datum;A measurement datum that indicates the usage of a vaccine adjuvant. Different digital numbers can be used to represent different adjuvants.
generically dependent continuant;vaccine protective antigen datum;A measurement datum that represents a specific protective antigen used in a vaccine. The antigen can be represented by a described digit.
material entity;viral vaccine;A vaccine that targets against a viral disease.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Mannheimia Haemolytica Bacterin (USDA: 44A5.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.00);
material entity;Edwardsiella vaccine;A bacterial vaccine that is used to protect against Edwardsiella bacterial infection
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4439.00);
material entity;Yersinia vaccine;A bacterial vaccine that protects against Yersinia bacterial infection.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4439.20);
material entity;vaccinia virus vector;an orthopoxvirus vaccine vector that uses vaccinia virus as the vector
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4479.00);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4509.00);
material entity;delta ureC hly+ rBCG;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.30);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4560.24);
material entity;Mycoplasma vaccine;a bacterial vaccine against Mycoplasma bacterial infection
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4560.25);
material entity;BCG mutant secreting listeriolysin;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Haemophilus somnus-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4489.30);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.20);
material entity;E. coli live attenuated vaccine;
role;vaccine antigen role;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1185.20);
generically dependent continuant;male biological sex datum;A biological sex datum that represents the biological sex of an animal (including human) as being male.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.25);
quality;vaccine organism virulent;a virulence of vaccine that shows a virulent pheontype of the organism as the major component of a vaccine. The virulent phenotype means that an vaccine organism is virulent and is able to cause a pathogenic phenotype in a host organism.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.26);
material entity;Haemophilus parasuis vaccine;bacterial vaccine that is used to protect against Haemophilus parasuis infection
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.28);
material entity;viral vaccine vector;a vaccine vector that uses a virus as the vector.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.30);
role;vaccine component role;A role that inheres in a material entity that becomes an ingredient of a vaccine.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.21);
role;animal model of vaccine research;Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.22);
role;vaccine role;Role that inheres in a prepared material entity that is designed to induce protection or treatment for a disease or infection.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.23);
material entity;Nontypeable H. influenzae protein P6 with cholera toxin;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.24);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4359.00);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Hardjo-Pomona Bacterin (USDA: 4399.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.00);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.23);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.26);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4141.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4339.00);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.22);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.25);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.26);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.27);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.00);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.22);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.24);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.21);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Killed Virus Vaccine (USDA: 1175.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4435.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.22);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.25);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.00);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.21);
material entity;influenza virus vaccine;A viral vaccine that protects against infection with influenza virus.
material entity;combination vaccine;Combination vaccine is a vaccine that induces protection against multiple infectious diseases or several different serotypes of the same organism. The anitgens contained in combination vaccines are either formulated together by the manufacturer or physically mixed by a health care provider just prior to administration. Both approaches require licensure. Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1624.
material entity;Clostridium tetani vaccine;a Clostridium vaccine that protects against infection with Clostridium tetani that causes tenanus.
material entity;Hepatitis A virus vaccine;A viral vaccine that protects against infection with Hepatitis A virus.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.20);
material entity;licensed fish vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.22);
material entity;Hepatitis B virus vaccine;A viral vaccine that protects against infection with Hepatitis B virus.
material entity;licensed cattle vaccine;a vaccine with license that is used for cattle.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.30);
material entity;licensed dog vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B9.21);
material entity;Yersinia pestis vaccine;A bacteria vaccine that prevents against Yersinia pestis infection that causes plague.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B9.22);
material entity;licensed goat vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44F9.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.30);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.22);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.23);
material entity;licensed ferret vaccine;
material entity;licensed cat vaccine;
material entity;Smallpox virus vaccine;A viral vaccine that protects against infection with Smallpox virus.
material entity;Rabies virus vaccine;A viral vaccine that protects against infection with Rabies virus.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.25);
material entity;MOMP from C. psittaci 6BC;
material entity;E2 from Western equine encephalomyelitis virus;
material entity;HA from Influenza A virus (A/equine/Kentucky/1/1981(H3N8));
material entity;FliC;
material entity;CP23;
material entity;CP15/60;
material entity;E1;
material entity;6K;
material entity;T. cruzi PAR2;
material entity;T. cruzi PAR1;
material entity;licensed bird vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.24);
material entity;Mumps virus vaccine;A viral vaccine that protects against infection with Mumps virus.
material entity;licensed deer vaccine;
material entity;Measles virus vaccine;A viral vaccine that protects against infection with Measles virus.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.25);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.20);
material entity;HIBTITER vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.21);
material entity;Rotavirus vaccine;A viral vaccine that protects against infection with Rotavirus.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.23);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1185.22);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44M5.20);
material entity;Pasteurella multocida vaccine;bacterial vaccine that is used to protect against Pasteurella multocida infection
material entity;B. anthracis recombinant vaccine using PA domain 4;
role;subunit vaccine role;A vaccine role that indicates the vaccine being a subunit vaccine.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C5.20);
role;DNA vaccine role;A vaccine role that indicates the vaccine being a DNA vaccine.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C7.20);
role;vaccine protective antigen role;a vaccine antigen role that inheres in a vaccine antigen which is capable of inducing protective immunity.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44D5.20);
role;laboratory animal model of vaccine research;Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research in the laboratory.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D7.20);
material entity;E. coli subunit vaccine;An E. coli vaccine that uses subunit antigen type.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44M5.22);
material entity;H. influenzae Type b capsular polysaccharide vaccine;A vaccine used to prevent infection by Haemophilus influenzae type b (Hib) bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the disease.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B5.20);
process;survival assessment;Survival assessment is an assay that measures the occurence of death events in one or more organisms that are monitored over time.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B6.20);
role;conjugate vaccine role;A vaccine role that indicates the vaccine being a conjugate vaccine.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B6.21);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D7.22);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica Bacterin (USDA: 4477.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.20);
role;vaccine in clinical trial role;A vaccine in clinical trial role is a regulation-assigned role that inheres in a vaccine that is currently in clinical trial.
role;licensed vaccine role;A licensed vaccine role is a regulation-assigned role that indicates that a vaccine obtains official approval for commercial production and selling on the market.
material entity;licensed human vaccine;a licensed vaccine with license for human use.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona-Mannheimia Haemolytica Bacterin (USDA: 4475.20);
process;intravenous vaccination;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.20);
material entity;B. melitensis Rev. 1 with P39 deletion;A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the p39 gene deletion.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.21);
process;vaccine-induced humoral immune response;Vaccine induced immue response mediated hrough a body fluid
material entity;Clostridium vaccine;A bacterial vaccine that protects against infection with Clostridium spp.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.21);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.22);
material entity;Flavobacterium columnare vaccine;bacterial vaccine that is used to protect against Flavobacterium columnare infection
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4466.20);
role;recombinant vector vaccine role;A vaccine role that indicates the vaccine being a recombinant vector vaccine.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4466.21);
material entity;S. flexneri 2a LPS vaccine complexed with N. meningitidis proteosomes;
material entity;Shigella dysenteriae vaccine;
material entity;Shigella flexneri vaccine;
role;recombinant bacterial vector vaccine role;a recombinant vector vaccine role that inheres in a bacterium that carries a vaccine antigen for development of a particular vaccine
process;vaccine transportation;A processual entity of transporting vaccine from one place to another place.
process;vaccine regulation;A processual entity that regulates vaccine-related processes, such as vaccine trial, vaccine license application.
material entity;Crptosporidium parvum CpP2;A CpP2 protein that is part of Crptosporidium parvum
material entity;NAP;
material entity;Crptosporidium parvum Cp23;A Cp23 protein that is part of Crptosporidium parvum
material entity;TSA from Trypanosoma brucei;
material entity;Eimeria maxima gam56;A gam56 protein that is part of Eimeria maxima
material entity;UreB;
material entity;Eimeria acervulina 3-1E;A 3-1E protein that is part of Eimeria acervulina
material entity;Hsp60;
material entity;Giardia duodenalis a1-giardin;A a1-giardin protein that is part of Giardia duodenalis
material entity;Catalase;
material entity;GEL1.00;
material entity;Crptosporidium parvum Cp21;A Cp21 protein that is part of Crptosporidium parvum
material entity;Pra;
material entity;Crptosporidium parvum Cp12;A Cp12 protein that is part of Crptosporidium parvum
material entity;MAPP15;
material entity;Crptosporidium parvum CP60;A CP60 protein that is part of Crptosporidium parvum
material entity;URE;
material entity;Crptosporidium parvum Cp15;A Cp15 protein that is part of Crptosporidium parvum
material entity;Pmp1;
role;peptide vaccine role;A subunit vaccine role that indicates the vaccine being a peptide vaccine.
material entity;Leishmania donovani Gp63;A Gp63 protein that is part of Leishmania donovani
material entity;5CVMB;
material entity;Leishmania donovani FML;A FML protein that is part of Leishmania donovani
material entity;L. amazonensis DNA vaccine encoding WD protein;
material entity;Leishmania donovani KH;A KH protein that is part of Leishmania donovani
material entity;DeltaFTT0918;
material entity;Leishmania donovani HASPB1;A HASPB1 protein that is part of Leishmania donovani
material entity;Leishmania donovani LdyGCS;A LdyGCS protein that is part of Leishmania donovani
material entity;Rop2;
material entity;VacA;
material entity;Giardia lamblia a1-giardin;A a1-giardin protein that is part of Giardia lamblia
material entity;Giardia lamblia CWP2;A CWP2 protein that is part of Giardia lamblia
material entity;OmpU;
material entity;Giardia lamblia alpha-enolase;A alpha-enolase protein that is part of Giardia lamblia
material entity;Japanese encephalitis virus DNA vaccine encoding PrM;
material entity;Leishmania donovani Beta-tubulin;A Beta-tubulin protein that is part of Leishmania donovani
material entity;TcrP;
material entity;Leishmania donovani Acen1;A Acen1 protein that is part of Leishmania donovani
material entity;GLURP;
material entity;ProHIBiT vaccine;
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.23);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.24);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.21);
material entity;Poliovirus vaccine;A viral vaccine that protects against infection with Poliovirus.
material entity;SC602;A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin).
material entity;Haemophilus influenzae serotype b vaccine;A vaccine that protects against Haemophilus influenzae type b infection.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.20);
material entity;Haemophilus vaccine;A bacterial vaccine that protects against infection with Haemophilus.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.21);
material entity;PrM from Dengue Virus;
material entity;M protein;
material entity;G glycoprotein from Nipah virus;
material entity;F fusion protein from Nipah virus;
material entity;RVFVsSgp2 N protein;
material entity;SpaP;
material entity;RVFVsMgp1 M protein;
material entity;E protein from Dengue virus;
material entity;NS1 from Dengue virus;
material entity;G glycoprotein from Hendra virus;
material entity;CVD 1208S;
material entity;human papillomavirus vaccine;a vaccine against human papillomavirus infection
material entity;CVD 1208;
material entity;Japanese encephalitis virus vaccine;A viral vaccine that protects against infection with Japanese encephalitis virus.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.22);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.25);
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.00);
material entity;Varicella-zoster virus vaccine;a Herpesvirus vaccine that is used against Varicella-zoster virus infection.
material entity;Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.01);
material entity;Salmonella typhi vaccine;A Salmonella vaccine against typhoid fever (or called typoid), caused by Salmonella enterica enterica, serovar Typhi.
material entity;EcSf2a-2;A Shigella flexneri vaccine that is an aro-D mutant derivative of EcSf2a-1.
material entity;Streptococcus pneumoniae vaccine;a Streptococcal vaccine that is used against S. pneumoniae infection, which causes pneumococcal diseases.
material entity;Recombinant SFL124-27 expressing S. dysenteriae type 1 O antigen;
material entity;Shigella Sfl 124 vaccine;
material entity;heat-killed virulent Shigella flexneri 2a;
material entity;CEL-170/4;
material entity;PLB;
material entity;SREHP;
material entity;PEP1;
material entity;AMN1;
material entity;ELI-Ag1;
material entity;GEh29;
material entity;Gal/GalNAc lectin;
material entity;S protein of SARS-CoV;
material entity;LcrV;
material entity;Shigella sonnei vaccine;
material entity;Shigella sonnei virG mutant vaccine;A stable attenuated Shigella sonnei strain with virG mutation. PMID:9712824.
material entity;S. flexneri 2a strain CVD 1207;A live attenuated Shigella flexneri 2a vaccine with specific deletion mutations in virG, sen, set, and guaBA.
material entity;S. dysenteriae 1 strain WRSd1;
material entity;Plasmodium falciparum PfSSP2;A PfSSP2 protein that is part of Plasmodium falciparum
material entity;Plasmodium falciparum PfCelTOS;A PfCelTOS protein that is part of Plasmodium falciparum
material entity;Bovine leukemia virus DNA vaccine encoding Tax;
material entity;Plasmodium falciparum EBA-175 RII;A EBA-175 RII protein that is part of Plasmodium falciparum
material entity;Cancer DNA Vaccine pLXSHDmB7-2 encoding Cd86;
material entity;Plasmodium falciparum ABRA;A ABRA protein that is part of Plasmodium falciparum|An ABRA protein that is part of Plasmodium falciparum
material entity;Phleum pratense Allergy Phl p 12 Subunit Vaccine;
material entity;Plasmodium falciparum MSP1;A MSP1 protein that is part of Plasmodium falciparum
material entity;Cancer VEGFA protein vaccine;
material entity;Plasmodium falciparum Hsp90;A Hsp90 protein that is part of Plasmodium falciparum
material entity;cancer Retroviral vector vaccine encoding Cd40lg;
material entity;Plasmodium falciparum MSP2;A MSP2 protein that is part of Plasmodium falciparum
material entity;B. pertussis BrkA protein vaccine;
material entity;Plasmodium falciparum RESA;A RESA protein that is part of Plasmodium falciparum
material entity;Bovine leukemia virus DNA vaccine encoding Env;
material entity;Plasmodium falciparum Pf ribosomal protein P0;A Pf ribosomal protein P0 protein that is part of Plasmodium falciparum
material entity;B. bovis GST-12D3;
material entity;Plasmodium falciparum MSP4;A MSP4 protein that is part of Plasmodium falciparum
material entity;Cancer EPCAM protein vaccine;
material entity;Plasmodium knowlesi SSP2;A PkSSP2 protein that is part of Plasmodium knowlesi|A SSP2 protein that is part of Plasmodium knowlesi
material entity;Plasmodium falciparum Pfs230;A Pfs230 protein that is part of Plasmodium falciparum
material entity;A. pleuropneumoniae ApxIa and ApxIIa protein vaccine;
material entity;Plasmodium falciparum Pfen;A Pfen protein that is part of Plasmodium falciparum
material entity;A. pleuropneumoniae HS93C-Ampr;
material entity;Plasmodium falciparum Pfs48;A Pfs48 protein that is part of Plasmodium falciparum
material entity;Bovine herpesvirus 1 DNA vaccine AdCMVgC;
material entity;Plasmodium falciparum Pfs25;A Pfs25 protein that is part of Plasmodium falciparum
material entity;Bovine herpesvirus 1 GPI protein vaccine;
material entity;Plasmodium falciparum TRAP;A TRAP protein that is part of Plasmodium falciparum
material entity;Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein;
material entity;Plasmodium falciparum RH5;A RH5 protein that is part of Plasmodium falciparum
material entity;Rickettsia DNA Vaccine encoding OmpB Protein boosted with Recombinant OmpB;
material entity;Plasmodium knowlesi PkCSP;A PkCSP protein that is part of Plasmodium knowlesi
material entity;A. salmonicida live-attenuated vaccine encoding AroA;
material entity;Plasmodium falciparum Pfs45;A Pfs45 protein that is part of Plasmodium falciparum
material entity;NP-VRP;An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus NP protein.
material entity;B. abortus DNA vaccine encoding RplL and Omp16;
material entity;Bovine herpesvirus 1 DNA vaccine AdCMVgD;
material entity;Plasmodium falciparum LSA1;A LSA1 protein that is part of Plasmodium falciparum
material entity;Leishmania major P36;A P36 protein that is part of Leishmania major
material entity;B. pertussis CyaA protein vaccine;
material entity;Leishmania major LIPO-A;A LIPO-A protein that is part of Leishmania major
material entity;Leishmania major LeIF;A LeIF protein that is part of Leishmania major
material entity;B. pertussis Cpn60 protein vaccine;
material entity;Leishmania major PEPCK;A PEPCK protein that is part of Leishmania major
material entity;L. infantum HASPB1 protein vaccine;
material entity;Japanese encephalitis virus DNA vaccine pUJENS5;
material entity;Leishmania donovani P1;A P1 protein that is part of Leishmania donovani
material entity;Leishmania donovani NH36;A NH36 protein that is part of Leishmania donovani
material entity;L. infantum H1 protein vaccine;
material entity;Leishmania infantum HSP70 II;A HSP70 II protein that is part of Leishmania infantum
material entity;L. amazonensis M2 protein vaccine;
material entity;Leishmania infantum A2;A A2 protein that is part of Leishmania infantum
material entity;A. pleuropneumoniae ApxIA protein vaccine;
material entity;Leishmania major LmSTI1;A LmSTI1 protein that is part of Leishmania major
material entity;Japanese encephalitis virus DNA vaccine encoding E protein;
material entity;Leishmania major KMP-11;A KMP-11 protein that is part of Leishmania major
material entity;L. amazonensis DNA vaccine encoding GP46;
material entity;Neospora caninum SAG1;A SAG1 protein that is part of Neospora caninum
material entity;Cancer recombinant vector vaccine encoding H-2Kb;
material entity;Plasmodium berghei P36p;A P36p protein that is part of Plasmodium berghei
material entity;cancer DNA vaccine encoding TEM8;An xenogenic DNA vaccine encoding human TEM8 carried by attenuated Salmonella typhimurium to help reduce tumor growth and suppress angiogenesis in the tumors.
material entity;Neospora caninum MIC3;A MIC3 protein that is part of Neospora caninum
material entity;C. parvum DNA vaccine encoding CP23;
material entity;Cancer Her-2/neu Protein Subunit Vaccine;
material entity;Neospora caninum GRA6;A GRA6 protein that is part of Neospora caninum
material entity;V. cholerae CTB DNA Vaccine;
material entity;Neospora caninum GRA2;A GRA2 protein that is part of Neospora caninum
material entity;B. pertussis PTx protein vaccine;
material entity;Neospora caninum MIC10;A MIC10 protein that is part of Neospora caninum
material entity;Cancer Subunit NY-ESO-1 Protein Vaccine;
material entity;Neospora caninum SRS2;A SRS2 protein that is part of Neospora caninum
material entity;Cancer DNA Vaccine encoding Endoglin Boosted with Recombinant Endoglin Protein;
material entity;Neospora caninum PDI;A PDI protein that is part of Neospora caninum
material entity;Cancer DNA Vaccine MIDGE/hNIS encoding hNIS protein;
material entity;Neospora caninum p24;A p24 protein that is part of Neospora caninum
material entity;Cancer DNA Vaccine pSURV encoding Survivin;
material entity;T. cruzi TSA-1;
material entity;T. cruzi CRP-10;
material entity;T. cruzi TS;
material entity;CP cysteine proteinase;
material entity;T. cruzi G4;
material entity;T. cruzi G2;
material entity;Gp46;
material entity;T. cruzi Cruzipain;
material entity;WD;
material entity;M2;
material entity;LmSTI1;
material entity;Cpa;
material entity;TcpF;
material entity;TSA from Leishmania major;
material entity;Gp63;
material entity;PSA-2;
material entity;SP;
material entity;H2B;
material entity;CtxB;
material entity;TcpA;
material entity;H1;
material entity;HASPB1;
material entity;LIPO-A;
material entity;P36/LACK;
material entity;T. cruzi amastigote surface protein-2;
material entity;Tox;
material entity;P4 from Leishmania amazonensis;
material entity;Cpb;
material entity;SMT;
material entity;SW3.1;
material entity;Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.00);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 43S5.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid (USDA: 43T5.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4335.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4336.30);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine (USDA: 1155.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine (USDA: 1155.30);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4145.20);
material entity;Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4145.21);
material entity;Bovine Rhinotracheitis-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 11B5.20);
material entity;Afluria Quadrivalent;
material entity;Arthrobacter Live Culture Vaccine (USDA: 1K11.00);
material entity;West Nile Virus Killed Virus Vaccine (USDA: 1995.22);
material entity;West Nile Virus Live Canarypox Vector Vaccine (USDA: 1991.R0);
material entity;West Nile Virus Live Flavivirus Chimera Vaccine (USDA: 1991.R1);
material entity;Bluetongue Modified Live Virus Vaccine (USDA: 1061.00);
material entity;swine influenza pH1N1, killed virus vaccine (USDA: 19A5.2P);
material entity;Transmissible Gastroenteritis Modified Live Virus Vaccine (USDA: 1961.20);
material entity;West Nile Virus Killed Virus Vaccine (USDA: 1995.20);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.23);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.24);
material entity;Hemorrhagic Enteritis Live Virus Vaccine (USDA: 17E1.20);
material entity;Porcine Circovirus Type 2, Killed Baculovirus Vector Vaccine (USDA: 19K5.R0);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.12);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.22);
material entity;Bordetella Avium Avirulent Live Culture Vaccine (USDA: 1021.01);
material entity;Escherichia coli avirulent live culture vaccine (USDA: 1551.02);
material entity;Escherichia coli avirulent live culture vaccine (USDA: 15R1.00);
material entity;Escherichia coli live culture vaccine (USDA: 1551.R0);
material entity;Pseudorabies Modified Live Virus Vaccine (USDA: 1891.20);
material entity;Pseudorabies Modified Live Virus Vaccine (USDA: 1891.22);
material entity;Pseudorabies Modified Live Virus Vaccine (USDA: 1891.R2);
material entity;Pseudorabies Modified Live Virus Vaccine (USDA: 1891.R4);
material entity;Porcine Reproductive & Respiratory Syndrome Reproductive Form, Modified Live Virus Vaccine (USDA: 19Q1.20);
material entity;Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine (USDA: 19S1.20);
material entity;Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine (USDA: 19S1.21);
material entity;Porcine Rotavirus Modified Live Virus Vaccine (USDA: 19E1.20);
material entity;Porcine Reproductive & Respiratory Syndrome Reproductive & Respiratory Form, Modified Live Virus Vaccine (USDA: 19T1.21);
material entity;Porcine Reproductive & Respiratory Syndrome Reproductive Form, Killed Virus Vaccine (USDA: 19S5.20);
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live & Killed Virus, Modified Live Chlamydia Vaccine (USDA: 1559.2B);
material entity;Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.20);
material entity;Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.21);
material entity;B. anthracis DNA vaccine encoding PA83 and LF;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.22);
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.23);
quality;smooth phenotype;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.24);
material entity;DAAV using PA and PGA;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 16D5.20);
material entity;M. tuberculosis arabinomannan-protein conjugate;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 16D5.23);
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 16D9.20);
material entity;rPA with adjuvant Nanoemulsion;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.20);
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D8.20);
material entity;Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D8.21);
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 16E5.20);
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 16E5.23);
site;subcutaneous route;A route of administration that is loacted in the hypodermis (subcutaneous tissue) region.
material entity;Ag85B and ESAT-6 fusion protein;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Modified Live & Killed Virus, Modified Live Chlamydia Vaccine (USDA: 1619.20);
material entity;recombinant S. typhimurium secreting M. tuberculosis ESAT-6;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Modified Live Virus and Chlamydia, Canarypox Vector Vaccine (USDA: 1619.R1);
material entity;subunit vaccine;A vaccine that is composed of a purified protein(s) or other antigenic determinant(s) from a disease-causing organism. A subunit vaccine does not include the whole organism of a pathogen, so the subunits have less risk of causing adverse reactions.
material entity;vaccine subdominant epitope;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Killed Chlamydia Vaccine (USDA: 16E6.20);
material entity;equine EEV, VEV and WEV encephalomyelitis-influenza vaccine-tetanus toxoid;
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E1.20);
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E1.24);
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E8.20);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.26);
material entity;nontypeable H. influenzae P5 peptide MVF/H3 vaccine;
material entity;Diphtheria toxoid vaccine;a diphtheria vaccine that uses diphtheria toxoid
material entity;Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 49A5.20);
material entity;licensed sheep vaccine;
material entity;Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 4949.31);
material entity;Inactivated ETEC expressing CFA/I and CFA/II;
material entity;Mink Distemper-Enteritis Modified Live Virus & Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4929.20);
material entity;E. coli vaccine using verocytotoxin toxoid;
material entity;Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4955.20);
process;infection disorder prevention;infection disorder prevention is a process that prevents a disorder that is the physical basis of an infectious disease.
material entity;Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4955.21);
material entity;Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.29);
material entity;vaccine organism;an organism that is used as part of a vaccine
material entity;Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine (USDA: 1679.31);
material entity;EHEC O157 subunit vaccine using his-tagged N-terminal intimin;
material entity;Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid (USDA: 4929.31);
role;whole organism vaccine role;a vaccine role that indicates the vaccine being a whole organism vaccine.
material entity;Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 4949.20);
material entity;Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 49A5.21);
material entity;Feline Immunodeficiency-Leukemia Virus Killed Virus Vaccine (USDA: 15D5.R0);
material entity;nontypeable H. influenzae rTbpB vaccine;
material entity;human ACPP;
material entity;typhoid-paratyphoid vaccine;a Salmonella vaccine against both typhoid caused by S. typhi and paratyphoid caused by S. paratyphi.
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 15B9.21);
material entity;Quail pox vaccine;a Pox vaccine for Quail pox
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.20);
material entity;Pox vaccine;a viral vaccine against a disease caused by a virus belong to Poxviridae.
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.23);
material entity;ETEC vaccine ACAM2007;
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live & Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.2C);
material entity;B. anthracis DNA vaccine encoding PA63;
material entity;Feline Leukemia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1A69.20);
material entity;ETEC vaccine ACAM2017;
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 15B5.20);
material entity;human protein;a protein from human
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 15B5.21);
quality;rough phenotype;
material entity;Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 15B9.20);
material entity;toxoid vaccine;A vaccine containing a toxoid, used to protect against toxins produced by certain bacteria. A toxoid (also called inactivated toxin) is a processed toxin that has been treated by chemical means, heat, or irradiation and is no longer capable of causing disease.
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4179.00);
material entity;toxin;A toxin is a poisonous substance produced within living cells or organisms. man-made substances created by artificial processes are thus excluded.
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4209.00);
material entity;Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.00);
material entity;Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.20);
material entity;rBCG-Ag85A[Tokyo];
material entity;M. tuberculosis secA2 mutant;
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.31);
material entity;bacterial and viral combination vaccine;a combination vaccine that is used against both bacterial and viral infections.
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 4139.20);
function;therapeutic vaccine function;A vaccine function realized the process of vaccination and leading to induction of an adaptive immune response to treat an existing specific disorder.
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4129.00);
material entity;Fbp;
material entity;CS from P. berghei str. ANKA;
material entity;Fnz;
material entity;Sfs;
material entity;P. falciparum CSP;
material entity;CS from P. yoelii str. 17XNL;
material entity;MSP1 from P. yoelii str. 17XNL;
material entity;collagen binding, ancillary pilus subunit Cne;
material entity;SERA-5;
material entity;binding protein Eag;
process;vaccine-induced up-regulated gene expression;
material entity;Campylobacter vaccine;A vaccine that protects against Campylobacter bacterial infectioni.
material entity;DNA vaccine Rv1806-1807;
material entity;Vibrio vaccine;a bacterial vaccine against Vibrio infection
material entity;Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.21);
material entity;Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.22);
material entity;Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.23);
generically dependent continuant;vaccination protocol;vaccination protocol is the protocol of a vaccination procedure.
material entity;AAV vaccine vector;a viral vaccine vector that uses an AAV virus as the vector.
material entity;thimerosal vaccine preservative;vaccine preservative that has thimerosal as part.
material entity;vaccine candidate;vaccine candidate is a processed material that is designed to prevent or ameliorate a disorder in a target organism by modulating adaptive immune responses in that organism by administrating the vaccine.
site;route of administration;A path that is located in gross anatomical part of an organism (e.g., human) and is used for administering a vaccine, a drug, fluid, poison, or other substance into the body.
material entity;Chlamydia vaccine;A vaccine that protects against Chlamydia bacterial infection.
material entity;VP4 from Bovine rotavirus;
material entity;HEP17;
material entity;MSP1 from P. berghei;
material entity;VP7 from Bovine rotavirus;
material entity;EMP1;
material entity;MSP3;
material entity;PF10 0155 enolase;
material entity;AMA-1 from P. berghei;
material entity;MSP8;
material entity;VP6 from Murine rotavirus;
material entity;Haemophilus somnus vaccine;bacterial vaccine that is used to protect against Haemophilus somnus infection
material entity;H1N1 influenza vaccine;H1N1 Influenza vaccine is an Influenza virus vaccine that is used to vaccinate against H1N1 Influenza subtype vaccine.
material entity;peptide vaccine;A subunit vaccine that uses small peptide(s) as immunoepitopes.
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Modified Live Virus, Canarypox Vector Vaccine (USDA: 16T9.R0);
material entity;Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.20);
material entity;Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.21);
material entity;Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.22);
material entity;attenuated M. bovis strain WAg539;
material entity;equine EEV, VEV and WEV encephalomyelitis-rhinopneumonitis-influenza vaccine-tetanus toxoid;
material entity;equine EEV, VEE & WEV encephalomyelitis-tetanus toxoid;
one-dimensional temporal region;time of survival of live vaccine inside host;time of survival of live vaccine inside host is a temporal interval during which a live vaccine survives inside a host organism. This entity is related to the process survival of live vaccine inside host.
material entity;Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Modified Live & Killed Virus Vaccine (USDA: 16T9.20);
material entity;Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid (USDA: 4109.20);
material entity;vaccinee population;a population group that are vaccinated with a specific vaccine
material entity;human vaccinee population;a population of human beings who are vaccinated.
material entity;human vaccinee;a vaccinee that is a human being
material entity;Bovine Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1161.00);
material entity;Bovine Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1161.20);
quality;bacterial phenotype;
material entity;Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45H5.20);
material entity;human vaccinee population at age 2-17 years old;
material entity;Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45H5.21);
material entity;therapeutic vaccine;A vaccine that is used for treatment for a disease.
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Hardjo-Pomona Bacterin (USDA: 4069.20);
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4089.00);
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4089.20);
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Killed Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin (USDA: 4265.00);
material entity;human vaccinee at age 2-17 years old;
material entity;attenuated M. bovis strain WAg520;
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4019.00);
material entity;Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4059.00);
material entity;NcDG2;
material entity;Gnd;
material entity;CbpA;
material entity;PspA;
material entity;HN hemagglutinin-neuraminidase;
material entity;PiaA;
material entity;F fusion protein from Newcastle disease virus;
material entity;GltX;
material entity;NcDG1;
material entity;NcMIC1;
material entity;recombinant nontypeable H. influenzae protein P6 with AdDP;
material entity;attenuated M. bovis strain WAg522;
material entity;multivalent vaccine;a vaccine that is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms.
generically dependent continuant;titer;A titer (or titre) is a measure of concentration. Titer testing employs serial dilution to obtain approximate quantitative information from an analytical procedure that inherently only evaluates as positive or negative. The titer corresponds to the highest dilution factor that still yields a positive reading. for example, positive readings in the first 8 serial twofold dilutions translate into a titer of 1:256.
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.00);
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.20);
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.21);
material entity;adamantylamide dipeptide vaccine adjuvant;A synthetic vaccine adjuvant, adamantylamide dipeptide (AdDP) is the desmuramyl analog of MDP.
material entity;Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.24);
material entity;VP6 from Bovine rotavirus;
material entity;NS1 (non-structural protein 1);
material entity;E (envelope glycoprotein);
material entity;SAG1 from Sarcocystis neurona;
material entity;GIII;
material entity;GI;
material entity;VP7 from Murine rotavirus;
material entity;VP6 from Rotavirus A;
material entity;VP2 from Rotavirus;
material entity;VP4 from Murine rotavirus;
material entity;TviB;
material entity;Gag from HIV 1;
material entity;NP from Influenza A virus (A/nt/60/1968(H3N2));
material entity;Nef;
material entity;Tat;
material entity;E1 glycoprotein;
material entity;DnaJ;
material entity;E2 envelope protein;
material entity;HslU;
material entity;LACK;
material entity;nontypeable H. influenzae gene hel (encoding P4);
process;vaccine license application;A vaccine regulatory process that is for vaccine producer to apply for vaccine license.
material entity;H. influenzae gene;
material entity;vaccine adjuvant;A vaccine component that is chemical substance added to vaccine and enhance and direct immune response to protective antigen. Many of vaccine adjuvants cause a range of serious side-effects.
material entity;Bordetella vaccine;a bacterial vaccine against infection of Bordetella bacterial infection
material entity;multivalent vaccine against bacterial and viral diseases;a multivalent vaccine that is designed to immunize against at least one bacterial disease and one viral disease.
generically dependent continuant;immunization objective;immunization objective is the specification of an objective to achieve immunization.
process;immune response detection assay;An assay that is used to detect the immune response of a host to vaccination of a vaccine.
material entity;GB;
material entity;UL44 from Pseudorabies virus;
material entity;MSP4/5;
material entity;AMA-1 from P. chabaudi;
material entity;MSP1 from P. vivax;
material entity;Glycoprotein;
material entity;OmpA;
material entity;OmpB;
material entity;RABVgp1 nucleoprotein N;
material entity;Kbeta;
material entity;Aeromonas vaccine;A bacterial vaccine that is used to protect against Aeromonas bacterial infection
material entity;M. tuberculosis phoP mutant SO2;
process;vaccine specific T cell mediated cytotoxicity;
process;vaccine specific T cell cytokine production;
material entity;Mycobacterium vaccine;A bacterial vaccine that protects against Mycobacterium bacterial infection.
process;vaccine protection assay;An assay that is used to detect if a vaccine protects a host against infection of virulent pathogen after vaccine immunization.
material entity;whole organism vaccine;A vaccine that uses whole organism as its component
process;vaccine clinical trial;A processual entity by which a vaccine is tested clinically for safety and effectiveness. Clinical trials are conducted in phases. Classically, clinical trials unfold in three phases in order to gather data and information about a vaccine and its performance. This will form the basis of a dossier submitted to regulatory authorities by way of an application for licensure. After a vaccine is licensed and is being used by large numbers of people, a Phase IV study may or may not be taken for vaccine clinical evaluation.
generically dependent continuant;vaccine dose;A dose of vaccine specified by the vaccine manufacturer, distributor, or a regulatory agent.
material entity;GII;
material entity;ORF67;
material entity;Gp50;
process;vaccine preparation;vaccine preparation is a manufacturing process to produce a vaccine.
material entity;Hsp90;
material entity;IE180;
material entity;US6 from Pseudorabies virus;
material entity;TBEVgp1 polyprotein;
material entity;ORF68;
material entity;ORF2;
material entity;VP4 from Poliovirus;
material entity;recombinant vaccine vector;
material entity;Apa;
material entity;Mpt63;
material entity;Mtb72F;
material entity;MIC3;
material entity;PrM from West Nile virus;
material entity;E protein from West Nile virus;
material entity;TM-1;
material entity;HN;
material entity;FbpB from M. tuberculosis;
material entity;M matrix protein;
material entity;ExbB;
material entity;Spag-1;
material entity;NspA from N. meningitidis;
material entity;LctP;
material entity;TA17050 merozoite-piroplasm surface antigen Tams1;
material entity;NcMAG1;
material entity;TBP2;
material entity;P67;
material entity;P1 from Neisseria meningitidis;
material entity;LpdA;
material entity;ORFF;
material entity;A2;
material entity;F1-ATPase;
material entity;LASVsSgp1 nucleoprotein;
material entity;GRP-78;
material entity;KMP-11;
material entity;MspC;
material entity;Beta-tubulin;
material entity;Hsp70;
material entity;PreM;
material entity;MDV040;
material entity;MDV095;
material entity;L. donovani HASPB1;
material entity;NP from Lake Victoria marburgvirus;
material entity;N nucleocapsid protein;
material entity;P phosphoprotein;
material entity;H hemagglutinin protein;
material entity;F fusion protein from Measles virus;
material entity;BT1;
material entity;NH;
material entity;PsrP;
material entity;MIC10;
material entity;NcSRS2;
material entity;NcSAG1;
material entity;SrtA;
material entity;PsaA;
material entity;ClpP;
material entity;LplA;
material entity;NcPDI;
material entity;Ply;
material entity;Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.18);
material entity;Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 17A2.10);
material entity;Newcastle Disease B1 Type, C2 Strain, Live VirusVaccine (USDA: 17B1.10);
material entity;Mycoplasma Gallisepticum Live Culture Vaccine (USDA: 1751.01);
material entity;Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.10);
material entity;Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.12);
material entity;Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.14);
material entity;Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 16G1.00);
material entity;Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 16L1.07);
material entity;Mycoplasma Gallisepticum Live Culture Vaccine (USDA: 1751.00);
material entity;Tenosynovitis Live Virus Vaccine (USDA: 1951.10);
material entity;Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.01);
material entity;prime-boost vaccine;A vaccine that contains one vaccine for priming and at least one other vaccine for boosting.
material entity;licensed horse vaccine;
material entity;Brucella abortus RB51WboA;
material entity;Tenosynovitis Modified Live Virus Vaccine (USDA: 1952.01);
material entity;porin-S-LPS from B. abortus strain 2308;
material entity;Duck Virus Enteritis Modified Live Virus Vaccine (USDA: 1461.10);
material entity;AIDSVAX;
material entity;Duck Virus Hepatitis Modified Live Virus Vaccine (USDA: 14B1.10);
material entity;prime-boost vaccine with DNA vaccine priming;A prime-boost vaccine that contains one DNA vaccine for priming and at least one other vaccine for boosting.
material entity;Riemerella Anatipestifer Avirulent Live Culture Vaccine (USDA: 1811.00);
process;organ or tissue specific immune response to vaccine;
material entity;Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.02);
material entity;recombinant O. anthropi 49237SOD;
material entity;Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.03);
material entity;AIDSVAX B/E;
material entity;Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.04);
material entity;AIDSVAX B/B;The AIDSVAX that is bicovalent vaccine including two kinds of gp120 protein: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 (MN and GNE8 are strain names).
material entity;Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.11);
material entity;Flavobacterium Columnare Avirulent Live Culture Vaccine (USDA: 17F1.00);
material entity;Bordetella Bronchiseptica Avirulent Live Culture Vaccine (USDA: 1081.00);
material entity;Bordetella Bronchiseptica Avirulent Live Culture Vaccine (USDA: 1081.01);
material entity;B. melitensis Bp26 and Tf protein vaccine;
material entity;Pandemrix vaccine;Pandemrix is an influenza vaccine for influenza pandemics, such as the H1N1 2009 flu pandemic colloquially called the swine flu. The vaccine was developed by GlaxoSmithKline and patented in September 2006.
role;vaccine additive role;A role inheres in a material entity, that has been added into a vaccine's formulation by the manufacture for a specific purpose. For example: adjuvant to enhance the effect of immunogen, perservatives, stablizers and those materials added for affecting PH and isotonicity.
material entity;Canine Parainfluenza Modified Live Virus Vaccine (USDA: 1421.21);
material entity;Panvax;Panvax is an H1N1 unadjuvanted monovalent vaccine.
material entity;Distemper Live Canarypox Vector Vaccine (USDA: 1471.R0);
material entity;recombinant chimera BLSOmp31;
material entity;Distemper Modified Live Virus Vaccine (USDA: 1471.10);
material entity;B. melitensis P39 recombinant protein vaccine;A Brucella subunit vaccine that uses recombinant Brucella melitensis 16M P39, a putative periplasmic binding protein.
material entity;Varicella-zoster virus live vaccine;a Varicella-zoster virus vaccine that is live attenuated.
material entity;Canine Coronavirus Killed Virus Vaccine (USDA: 14P5.20);
material entity;Menactra injection 0.5mL vial;
material entity;Canine Coronavirus Killed Virus Vaccine (USDA: 14P5.21);
material entity;protozoan vaccine;A vaccine that protects against some protozoan disease.
material entity;Canine Coronavirus Modified Live Virus Vaccine (USDA: 14P1.20);
site;intravenous route;A route of administration that is located in the vein
material entity;canine influenza H3N8, killed virus vaccine (USDA: 15K5.20);
material entity;Newcastle Disease Killed Virus Vaccine (USDA: 1705.13);
material entity;Newcastle Disease Killed Virus Vaccine (USDA: 1705.15);
material entity;Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.16);
material entity;Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.17);
material entity;Newcastle Disease Killed Virus Vaccine (USDA: 1705.10);
material entity;Newcastle Disease Killed Virus Vaccine (USDA: 1705.11);
material entity;Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.0A);
material entity;Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.10);
material entity;Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.11);
material entity;Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.15);
material entity;Newcastle Disease VG/GA Strain, Live Virus Vaccine (USDA: 1701.10);
material entity;Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.02);
material entity;Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.04);
material entity;Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.05);
material entity;Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.00);
material entity;Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.01);
material entity;Newcastle Disease VG/GA Strain, Live Virus Vaccine (USDA: 17A2.V1);
material entity;Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.01);
material entity;Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.02);
material entity;Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.03);
process;vaccine approval process;vaccine approval process is a processual entity that involves approval of a vaccine.
material entity;equine influenza killed virus vaccine (USDA: 1505.24);
material entity;equine influenza killed virus vaccine (USDA: 1505.25);
material entity;equine influenza killed virus vaccine (USDA: 1505.28);
material entity;equine influenza live canarypox vector vaccine (USDA: 1501.R0);
process;vaccine licensing;vaccine licensing is a vaccine approval process that involves in licensing a vaccine.
generically dependent continuant;vaccine effectiveness rate;A measurement datum that measues the vaccine effectiveness. It is assessed with respect to prevention of the disease against which the vaccine is given. One simple method to estimate vaccine effectiveness is to use routine data on notifications of disease cases in vaccinated and unvaccinatted children and to compare the porportion of cases vaccinated with the vaccine covervage among the same age group in the general population. If p is the proportion vaccinated in the population and c is the proportion of cases reported to be vaccinated, then VE = (p-c)/p(1-c) x 100%.
process;CFU measurement assay;CFU measurement assay is an assay that measures the colony forming unit (CFU) of a bacterium in a specific location (e.g., spleen of a mouse).
material entity;equine influenza killed virus vaccine (USDA: 1505.20);
role;vaccine candidate role;Role of a material entity in an investigation, which has not been experimentally or clinically verified to induce a protection or treatment in vivo in a recipient organism.
material entity;equine influenza killed virus vaccine (USDA: 1505.21);
material entity;Salmonella paratyphi vaccine;a Salmonella vaccine against infection with S. paratyphi, which causes paratyphoid fevers. Paratyphoid fevers are a group of enteric illnesses caused by serotypic strains of the Salmonella genus of bacteria, S. Paratyphi.
material entity;poxvirus vaccine vector;a viral vaccine vector that uses an poxvirus as the vector.
material entity;licensed chicken vaccine;
material entity;equine influenza modified live virus vaccine (USDA: 1501.10);
material entity;equine influenza modified live virus vaccine (USDA: 1501.20);
material entity;Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.20);
material entity;Moraxella Bovis Bacterin Piliguard Pinkeye-1 Trivalent;
material entity;Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.21);
material entity;Parainfluenza 3 virus vaccine;A viral vaccine that protects against infection with Parainfluenza 3 virus.
material entity;Equine Rotavirus Killed Virus Vaccine (USDA: 1E15.20);
material entity;NPAP Brucella vaccine;
material entity;Streptococcus Equi Live Culture Vaccine (USDA: 1831.00);
material entity;Avian Polyomavirus Killed Virus Vaccine (USDA: 1A15.00);
material entity;Chlamydia Psittaci Killed Chlamydia Vaccine (USDA: 1585.20);
material entity;prophylactic vaccine;a vaccine that is used for prevention against a disease.
material entity;APEC vaccine using GST-Iss fusion protein;
material entity;Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.22);
generically dependent continuant;prime boost regimen;
material entity;Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.24);
function;preventive vaccine function;A vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to prevent a specific disorder.
material entity;Equine Rhinopneumonitis Modified Live Virus Vaccine (USDA: 1521.20);
material entity;HPV L2;
material entity;HPV E6;
material entity;US8;
material entity;HPV E7;
material entity;HPV L1;
material entity;G glycoprotein from Infectious Hematopoietic Necrosis Virus;
material entity;US4;
material entity;UL44 from Herpes simplex virus type 1 and 2;
material entity;ICP27 from Herpes simplex virus type 2;
material entity;ICP27 from Herpes simplex virus type 1;
material entity;E. coli O157:H7 subunit vaccine expressing Esps and Tir;
material entity;E. coli LB-T vaccine;
role;protective antigen role;An antigen that stimulates protective immunity when used in vivo.
quality;protection efficacy;Protection efficacy is an efficiency that is associated with protection by a biological product (e.g., vaccine) against a disease.
material entity;Chlamydia Psittaci Modified Live Chlamydia Vaccine (USDA: 1581.20);
material entity;Pacheco's Disease Killed Virus Vaccine (USDA: 18C5.00);
material entity;Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.00);
material entity;Giardia Lamblia Killed Protozoa Vaccine (USDA: 18G5.00);
material entity;Neospora Caninum Killed Protozoa Vaccine (USDA: 1N11.00);
material entity;Parvovirus Killed Virus Vaccine (USDA: 18P5.20);
material entity;Parvovirus Killed Virus Vaccine (USDA: 18P5.21);
material entity;melanoma vaccine;A cancer vaccine that is used against melanoma, a malignant tumor of melanocytes.
material entity;Brucella abortus pcDNA-BLS;
material entity;pathogen organism component in vaccine;a vaccine component that originates from an organism such as a pathogen or a modified organism.
material entity;p60;
material entity;NucA;
material entity;Sip;
material entity;Rib;
material entity;DnaK from Mycobacterium tuberculosis;
material entity;MPT83;
material entity;OmpP1;
material entity;PstS1;
material entity;TmpB;
material entity;Tp92;
one-dimensional temporal region;period of persistence of vaccine induced immune response;period of persistence of vaccine induced immune response is a temporal interval during which a vaccine-induced immune response continuously exists. This term is related to the process 'persistence of vaccine induced immune response'.
material entity;Parvovirus Modified Live Virus Vaccine (USDA: 18M1.25);
material entity;Staphylococcus toxoid vaccine;
material entity;Parvovirus Modified Live Virus Vaccine (USDA: 18M1.29);
material entity;polyvalent pneumococcal vaccine;a pneumococcal vaccine that is formed using polyvalent polysaccharides
material entity;escheriosome-mediated delivery of B. abortus L7/L12;
material entity;Parvovirus Modified Live Virus Vaccine (USDA: 18M1.20);
process;phase 3 vaccine trial;A vaccine clinical trial that takes the trial to a large-scale safety and efficacy study in a relevant patient population, usually in excess of 3,000.
material entity;Parvovirus Modified Live Virus Vaccine (USDA: 18M1.21);
process;phase 2 vaccine trial;A vaccine clinical trial that studies vaccine efficacy with a target population (numbering 50-100). Different dosage levels will also be explored at this stage to determine the optimum dose.
material entity;Parvovirus Modified Live Virus Vaccine (USDA: 18M1.22);
process;phase 1 vaccine trial;A vaccine clinical trial that investigates the safety profile of a vaccine in a small group (10-50) of healthy volunteers.
material entity;Parvovirus Modified Live Virus Vaccine (USDA: 18M1.23);
material entity;Rabies Killed Virus Vaccine (USDA: 1905.21);
material entity;Rabies Killed Virus Vaccine (USDA: 1905.22);
material entity;Rabies Killed Virus Vaccine (USDA: 1905.23);
material entity;Rabies Killed Virus Vaccine (USDA: 1905.24);
material entity;vaccinia virus vaccine;a Smallpox virus vaccine that uses vaccinia virus
material entity;nontypeable H. influenzae Hap protein vaccine;A subunit nontypeable H. influenzae vaccine that uses Hap protein.
material entity;rLm/iglC;Seven F. tularensis proteins including IglC (rLm/iglC) were expressed in recombinant L. monocytogenes (rLm) vaccines. These 7 F. tularensis proteins are: AcpA, Bfr, DnaK, GroEL, IglC, Pld and KatG from SchuS4 strain.
process;phase 4 vaccine trial;The final stage of vaccine clinical evaluation. Phase IV occurs after a vaccine or therapy is licensed and is being used by large numbers of people. These studies are not always required or completed.
material entity;Rabies Killed Virus Vaccine (USDA: 1905.20);
material entity;Moraxella bovis vaccine;a bacterial vaccine against Moraxella bovis infection. Moraxella bovis is a Gram-negative, aerobic, oxidase-positive diplococcus that is implicated in infectious bovine keratoconjunctivitis, an eye disease of cattle, also colloquially known as Pink Eye.
material entity;equine influenza killed virus vaccine (USDA: 1505.10);
material entity;B. melitensis DNA vaccine encoding Omp31 boosted with Omp31;
material entity;DNA vaccine plasmid vector;a vaccine component that is composed of a plasmid and used in the generation of a DNA vaccine.
material entity;Mixed Bacterial Vaccine;Mixed Bacterial Vaccine (MBV, Coley's Toxins) is a historical, vaguely defined preparation of heat-inactivated Streptococcus pyogenes and Serratia marcescens used as non-specific immunotherapy in the treatment of cancer.
material entity;Rabies Live Canarypox Vector Vaccine (USDA: 1901.R1);
material entity;Rabies Live Canarypox Vector Vaccine (USDA: 1901.R6);
role;USDA licensed vaccine role;a USA licensed vaccine role that indicates the vaccine is for veterinary uses.
material entity;Rabies Live Vaccinia Vector Vaccine (USDA: 1901.R0);
material entity;Moraxella bovis bacterin vaccine;a Moraxella bovis vaccine that is prepared using a bacterial bacterin.
material entity;Equine Arteritis Modified Live Virus Vaccine (USDA: 1531.20);
material entity;recombinant vector vaccine;A vaccine that uses a modified virus or bacterium as the vector to deliver vaccine antigen(s) to the cells of the host body.
material entity;protein subunit vaccine;A subunit vaccine that is made using a part of whole organism as subunit for vaccine development.
process;preparation of recombinant protein vaccine;A vaccine preparation process that uses recombinant molecular technology to prepare recombinant protein.
material entity;E. coli subunit vaccine using IroN;
material entity;E. coli subunit vaccine using FyuA;
material entity;typhoid live oral vaccine;a S. typhi vaccine that is live and orally administerred
material entity;chicken ovalbumin egg protein allergen;A chicken egg protein allergen where the protein allergen is ovalbumin, the main protein found in egg write, making up 60-65% of the total protein.
material entity;E. coli subunit vaccine using CO393;
material entity;HA from Influenza A virus (A/chicken/Guangdong/02/2007(H9N2));
material entity;NP from Influenza A virus (A/chicken/Hubei/489/2004(H5N1));
material entity;HA from Influenza A virus (A/Viet Nam/1203/2004(H5N1));
material entity;nontypeable H. influenzae LOS-TT conjugate vaccine;
material entity;HA from Influenza A virus (A/Indonesia/CDC594/2006(H5N1));
material entity;HA from Influenza A virus (A/Hawaii/01/1991(H3N2));
material entity;HA from Influenza A virus (A/Indonesia/CDC669/2006(H5N1));
material entity;NA from Influenza A virus (A/chicken/Henan/12/2004(H5N1));
material entity;M1 from Influenza A virus (A/chicken/Henan/12/2004(H5N1));
material entity;HA from Influenza A virus (A/chicken/Henan/12/2004(H5N1));
material entity;NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1));
process;induction of adaptive immune response to antigen;induction of adaptive immune response to antigen is an active immunization process that results in induction of adaptive immune response to some antigens, for example, in a vaccine.
process;vaccine immunization;An immunization that is induced by a vaccine via vaccination process.
process;natural active immunization;natural active immunization is an active immunization that occur naturally when a person or animal comes in contact with antigens includeing microbes.
process;passive immunization;An immunization where pre-synthesized elements of the immune system are transferred to an organism so that the body does not need to produce these elements itself.
function;preventive infectious disease vaccine function;
process;modification of adaptive immune response to antigen;modification of adaptive immune response to antigen is an active immunization process that results in modification of an adaptive immune response to some antigens, for example, in a therapeutic vaccine.
process;disorder treatment;disorder treatment is a processual entity that leads to treat a disorder that is the physical basis of a disease.
process;disorder prevention;disorder prevention is a processual entity that prevents a disorder that is the physical basis of a disease.
material entity;NS3;
material entity;NS5;
process;active immunization;An immunization that involves the introduction of foreign molecules into a recipient body, in a way which causes the recipient to actively induce adaptive immunity against the immunization target.
process;immunization;A process that results in an adaptive immune response to one or more antigens.
material entity;HA from Influenza A virus (A/chicken/Indonesia/7/2003(H5N1));
material entity;HA from Influenza A virus (A/Hatay/2004/(H5N1));
material entity;HA from Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1));
material entity;HA from Influenza A virus (A/turkey/Ireland/1378/1983(H5N8));
material entity;PrM from Japanese encephalitis virus;
material entity;NS1 from Japanese encephalitis virus;
material entity;HA from Influenza A virus (A/whooper swan/Mongolia/3/05(H5N1));
material entity;Envelope protein;
material entity;Haemophilus Parasuis Avirulent Live Culture Vaccine (USDA: 19J1.00);
material entity;avian influenza vaccine;An influenza vaccine for avian use
material entity;Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.00);
material entity;equine influenza vaccine;an influenza virus vaccine against equine influenza viral infection
material entity;Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.01);
material entity;Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.02);
material entity;soybean-expressed E. coli LTB vaccine;
material entity;Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.01);
material entity;Staphylococcus aureus bacterin vaccine;a S. aureus vaccine that uses bacterin as the protective antigen.
material entity;Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.02);
material entity;protein of pathogen organism as vaccine component;
material entity;Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.03);
material entity;Coxiella burnetii vaccine;a bacterial vaccine against infection with Coxiella burnetii which causes Q fever
material entity;Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.04);
material entity;HA from Influenza B virus (Strain B/England/222/82);
material entity;HA from Influenza A virus (A/duck/Badung-Bali/05/2005(H5N1));
material entity;HA from Influenza A virus (A/Aichi/2/1968(H3N2)), (X31);
material entity;HA from Influenza A virus (A/chicken/Italy/13474/99(H7N1));
material entity;M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1));
material entity;NP from Influenza B virus;
material entity;HA from Influenza A virus (A/WSN/1933(H1N1));
material entity;HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1));
material entity;NP from Influenza A virus H3N2;
material entity;HA from Equine influenza virus H3N8;
material entity;autogenous bacterin vaccine;a bacterial vaccine that uses bacterin from a bacterial strain isolated from a herd with a purpose to generate hard-specific vaccine.
material entity;Mycoplasma gallisepticum bacterin vaccine;a Mycoplasma gallisepticum vaccine that uses bacterin as the protective antigen
material entity;Staphylococcus aureus phage lysate vaccine;a S. aureus vaccine that uses the bacterial phage lysate as the protective antigen.
material entity;Porcine Circovirus Type 2, Killed Virus Vaccine (USDA: 19K5.20);
material entity;Porcine Reproductive & Respiratory Syndrome Reproductive & Respiratory Form, Modified Live Virus Vaccine (USDA: 19T1.20);
material entity;non-typeable H. influenzae rLP4/rLP6 and Moraxella catarrhalis UspA2 protein vaccine;
material entity;nontypeable Haemophilus influenzae;Nontypeable Haemophilus influenzae (NTHi) is a nonencapsulated Haemophilus influenzae (a gram-negative bacterium). It is the cause of a number of human respiratory tract diseases, such as otitis media, sinusitis, bronchitis, and pneumonia.
material entity;nontypeable H. influenzae vaccine;
material entity;autogenous poulty bacterin vaccine;an autogenous bacterin vaccine that is prepared for poultry use.
material entity;human Rabies vaccine;a Rabies virus vaccine against Rabies in human
material entity;animal Rabies vaccine;a Rabies virus vaccine against Rabies in animal
material entity;killed nontypeable H. influenzae whole-cell vaccine;
material entity;HA from Influenza B virus (B/Ibaraki/2/85);
material entity;NA from Influenza B virus (B/Ibaraki/2/85);
material entity;HA from Influenza A virus (A/Yamagata/120/1986(H1N1));
material entity;HA from Influenza A virus (A/Fukuoka/C29/85(H3N2));
material entity;HA from Influenza A virus (A/Hong Kong/1/68(H3N2));
material entity;HA from Influenza A virus (A/environment/Hong Kong/156/1997(H5N1));
material entity;HA from Influenza A virus (A/Solomon Islands/3/2006(H1N1));
material entity;HA from Influenza A virus (A/Goose/Guangdong/1/96(H5N1));
material entity;NP from Influenza A virus (A/Puerto Rico/8/34(H1N1));
material entity;NA from Influenza A virus (A/Aichi/2/1968(H3N2));
material entity;nontypeable H. influenzae cell membrane vaccine (CM-Hi);
material entity;E. coli vaccine using intimin polypeptide;
material entity;VP2 from Canine parvovirus;
material entity;OspB;
material entity;VP1 from Canine parvovirus;
material entity;OspC;
material entity;CDVgp6 haemagglutinin protein H;
material entity;phpA-79;
material entity;CDVgp5;
material entity;OspA;
material entity;Pomp90A;
material entity;CNA;
material entity;CAB049 putative penicillin-binding protein;
material entity;DnaX;
material entity;DbpA;
material entity;GatC;
material entity;Hly;
material entity;Tax;
material entity;LSA-3;
material entity;Env/Rex/Tax;
material entity;eba-175;
material entity;TbpA;
material entity;TA4;
material entity;FbaA;
material entity;3-1E;
material entity;Emm1;
material entity;MIC2;
material entity;SfbI;
material entity;Rho;
material entity;FBP54;
material entity;Gag;
material entity;GX3262;
material entity;Sib35;
material entity;Env;
material entity;GlpQ;
material entity;CAB613 putative peptidase;
material entity;FnbA;
material entity;Gam82;
material entity;BPS;
material entity;ClfA;
material entity;OmlA;
material entity;MecA;
material entity;Brucella abortus DNA vaccine encoding L7/L12 and P39;
material entity;IL-15 plasmid vaccine adjuvant;
process;vaccine-induced, adjuvant boosted T cell interferon-gramm production;a vaccine-induced T cell interferon-gramm production that results from the addition of a vaccine adjuvant
process;pharyngeal mucosal vaccination;
material entity;Feline panleukopenia virus vaccine;viral vaccine that is used to protect against Feline panleukopenia virus infection
material entity;E. coli LT toxin derived vaccine adjuvant;A microbial derivative vaccine adjuvant that is derived from E. coli heat labile toxin LT.
process;mucosal immune response to vaccine;
material entity;attenuated Brucella abortus with deletion of znuA;
material entity;PtxC;
material entity;KatG;
material entity;PtxE;
process;sublingual vaccination;
process;subtenon vaccination;
material entity;PtxD;
material entity;AY243312;
material entity;Prn;
material entity;Ag85B from M. tuberculosis H37Rv;
material entity;FhaB;
material entity;PcrV;
material entity;CyaA;
material entity;OprI;
material entity;BrkA;
material entity;MPT64;
material entity;PtxB;
material entity;ESAT-6;
material entity;PtxA;
material entity;znuA;
material entity;Cpn60;
material entity;FbpD;
material entity;OprF;
material entity;licensed rabbit vaccine;
material entity;inactivated vaccine organism;
material entity;Bordetella bronchiseptica vaccine;a Bordetella bacterial vaccine that is used to protect against Bordetella bronchiseptica infection
material entity;Pseudomonas aeruginosa vaccine;bacterial vaccine that is used to protect against Pseudomonas aeruginosa infection
process;vaccine-induced T cell interferon-gramm production boosted by IL-15 vaccine adjuvant;A vaccine-induced adjuvant boosted T cell interferon-gramm production that results from the addition of a IL-15 vaccine adjuvant
material entity;microencapsulated B. melitensis mutant vaccine;A live attenuated Brucella melitensis vaccine that is composed of live Brucella melitensis attenuated mutant vjbR::Tn5 (BMEII1116) delivered using a microsphere delivery system.
role;neutralizing antibody role;
material entity;FspA2;
material entity;Campylobacter fetus vaccine;a Campylobacter bacterial vaccine that is used to protect against Campylobacter fetus infection
material entity;Leptospira spp. vaccine;bacterial vaccine that is used to protect against Leptospira spp. infection
material entity;UL44 from Bovine herpesvirus 1;
material entity;PPE14;
material entity;CadF;
material entity;Gap;
material entity;US6 from Bovine herpesvirus 1;
material entity;PPE31;
material entity;US7;
material entity;HBHA;
material entity;FspA1;
material entity;HspB from Helicobacter pylori;
material entity;FlaC;
material entity;GltA;
material entity;Peb1A;
material entity;HtrA;
material entity;FlaA from C. jejuni 81-176;
material entity;HspA;
material entity;PstS3;
material entity;UL49 from Bovine herpesvirus 1;
material entity;PE20;
material entity;US5;
material entity;UL27 from Herpes simplex virus type 1;
material entity;US6 from Herpes simplex virus type 1 and 2;
material entity;UL27 from Herpes simplex virus type 2;
material entity;M Segment;
material entity;HTNVsSgp1;
material entity;PreS2 middle surface protein;
material entity;HBVgp2 pre-S1/pre-S2/S;
material entity;ANDVsSgp1;
material entity;Hepatitis B surface antigen;
material entity;TUL4;
material entity;SodB from F. tularensis SCHU S4;
material entity;WbtI;
material entity;GroEL from Francisella tularensis;
material entity;FopA;
material entity;LpnA;
material entity;IglC1;
material entity;IglC2;
material entity;FopB;
material entity;IglB;
material entity;SNVsSgp1;
material entity;PUUVsSgp1;
material entity;Gc;
material entity;G1;
material entity;N protein [Topografov virus];
material entity;CWP2;
material entity;D15;
material entity;OmpP2;
material entity;Hpd;
material entity;OmpP5;
material entity;Salmonella Typhimurium rpoS mutant vaccine;
material entity;Salmonella Typhimurium ruvB mutant vaccine;
material entity;Salmonella Typhimurium ompR mutant vaccine;
material entity;Salmonella Typhi phoP mutant vaccine;
material entity;Salmonella Typhimurium poxA mutant vaccine;
material entity;Salmonella Gallinarum relA/spoT mutant vaccine;
material entity;Salmonella Typhimurium ompD/nmpC mutant vaccine;
material entity;Salmonella Gallinarum nuoG mutant vaccine;
material entity;Salmonella Typhimurium trxA mutant vaccine;
material entity;Salmonella Typhimurium wecA mutant vaccine;
material entity;Salmonella Typhimurium znuABC mutant vaccine;
material entity;Salmonella Typhimurium surA mutant vaccine;
material entity;Salmonella Typhimurium tolA mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.11);
material entity;Yersinia pestis IpxM mutant vaccine;
material entity;Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1235.15);
material entity;Bronchitis Conn Type, Live Virus Vaccine (USDA: 1231.15);
material entity;Yersinia pestis yopH mutant vaccine;
material entity;Bronchitis Delaware Type, Modified Live Virus Vaccine (USDA: 1231.1D);
material entity;Yersinia pseudotuberculosis phoP mutant vaccine;
material entity;Bronchitis Georgia Type, Live Virus Vaccine (USDA: 1231.1J);
material entity;Yersinia ruckeri aroA mutant vaccine;
material entity;Bronchitis Georgia Type, Live Virus Vaccine (USDA: 1231.1L);
material entity;Bovine herpesvirus 1 UL23 mutant vaccine;
material entity;Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.1M);
material entity;Yersinia pestis nlpD mutant vaccine;
material entity;Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.20);
material entity;Yersinia pestis pcm mutant vaccine;
material entity;Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.21);
material entity;Yersinia pestis smpB/ssrA mutant vaccine;
material entity;Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.22);
material entity;Bovine herpesvirus 1 US8 (gE) mutant vaccine;
material entity;Bronchitis Mass & Ark Types, Live Virus Vaccine (USDA: 1231.13);
material entity;Bovine respiratory syncytial virus glycoprotein G mutant vaccine;
material entity;Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA: 1231.14);
material entity;Classical swine fever virus E(rns) mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.1A);
material entity;Equid herpesvirus TK mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.1F);
material entity;Feline herpesvirus 1 UL23 mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1232.10);
material entity;Feline immunodeficiency virus ORF-A mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1232.15);
material entity;Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA: 1231.1G);
material entity;Classical swine fever virus E1 mutant vaccine;
material entity;Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA:1231.1N);
material entity;Classical swine fever virus E2 mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.12);
material entity;Equid herpesvirus gE mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.18);
material entity;Equid herpesvirus gI mutant vaccine;
material entity;Shigella sonnei virG/senA/senB mutant vaccine;
material entity;Shigella flexneri envZ mutant vaccine;
material entity;Brucella ovis vaccine;a Brucella vaccine against infection wtih B. ovis
material entity;Shigella sonnei virG/senA/senB/msbB2 mutant vaccine;
material entity;S. flexneri 2a strain CVD 1203;
material entity;S. flexneri strain Sfl 124;
material entity;Shigella flexneri aroD mutant vaccine;
material entity;Avian Reovirus Killed Virus Vaccine (USDA: 1045.02);
material entity;Yersinia pestis guaBA mutant vaccine;
material entity;Avian Reovirus Killed Virus Vaccine (USDA: 1045.30);
material entity;Avian Paramyxovirus Type 3, Killed Virus Vaccine (USDA: 10C5.10);
material entity;Yersinia enterocolitica aroA mutant vaccine;
material entity;Avian Pneumovirus Modified Live Virus Vaccine (USDA: 1A31.20);
material entity;Yersinia enterocolitica htrA mutant vaccine;
material entity;Avian Reovirus Killed Virus Vaccine (USDA: 1045.00);
material entity;Yersinia enterocolitica ompR mutant vaccine;
material entity;Avian Reovirus Killed Virus Vaccine (USDA: 1045.01);
material entity;Yersinia enterocolitica sodA mutant vaccine;
material entity;avian influenza H5N2 Subtype, Killed Virus Vaccine (USDA: 10F5.10);
material entity;avian influenza H5N3 Subtype, Killed Virus Vaccine (USDA: 1057.R3);
material entity;avian influenza H9N2 Subtype, Killed Virus Vaccine (USDA: 1057.H9);
material entity;Avian Paramyxovirus Type 1, Killed Virus Vaccine (USDA: 10C5.11);
material entity;Vibrio cholerae hemA mutant vaccine;
material entity;Bursal Disease Modified Live VirusVaccine (USDA: 1271.15);
material entity;Porcine respiratory and reproductive syndrome virus GP5 protein mutant vaccine;
material entity;Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.01);
material entity;Pseudorabies virus glycoprotein E/G/UL23 mutant vaccine;
material entity;Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.40);
material entity;Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.41);
material entity;Psuedorabies virus glycoprotein M mutant vaccine;
material entity;Brucella abortus conjugate vaccine using L7/L12;
material entity;pTR600 DNA vaccine plasmid;
material entity;Brucella abortus DNA vaccine encoding BCSP31, SOD and L7/L12;
material entity;influenza virus CTA1-3M2e-DD protein vaccine;
material entity;pTHamp DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1272.00);
material entity;influenza virus NS1 mutant vaccine;
material entity;pUC19 DNA vaccine plasmid;
material entity;Bursal Disease Variant, Live Virus Vaccine (USDA: 12L1.00);
material entity;pUC18 DNA vaccine plasmid;
material entity;B. melitensis DNA vaccine encoding Omp31;
material entity;pTVG4 DNA vaccine plasmid;
material entity;Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.4A);
material entity;Pseudorabies virus gp50/gp63 mutant vaccine;
material entity;Bursal Disease Standard & Variant, Live Virus Vaccine (USDA: 12B1.00);
material entity;Mycoplasma hyopneumoniae vaccine;bacterial vaccine that protect against Mycoplasma hyopneumoniae infection
material entity;Bursal Disease Standard & Variant, Live Virus Vaccine (USDA: 12B1.01);
material entity;pV1J DNA vaccine plasmid;
material entity;Bursal Disease Variant, Killed Virus Vaccine (USDA: 12A5.00);
material entity;Pseudorabies virus UL50 mutant vaccine;
quality;inedible;A quality of edibility that inheres in a bearer by virtue of the bearer being not suitable for oral ingestion.
material entity;Chicken Anemia Virus Modified Live Virus Vaccine (USDA: 10A1.10);
material entity;SARS-CoV E gene mutant vaccine;
material entity;Coccidiosis Live Oocysts Vaccine (USDA: 1431.50);
material entity;Simian Immunodeficiency Virus nef mutant vaccine;
material entity;Coccidiosis Live Oocysts Vaccine (USDA: 1431.51);
material entity;ick-borne Encephalitis Virus C protein mutant vaccine;
material entity;Coccidiosis Live Oocysts Vaccine (USDA: 1431.56);
material entity;VEE Virus PE2/E1 mutant vaccine;
material entity;pVR1012 DNA vaccine plasmid;
material entity;Protozoa;Protozoa are a diverse group of unicellular eukaryotic organisms,[1] many of which are motile. Originally, protozoa had been defined as unicellular protists with animal-like behavior, e.g., movement. Protozoa were regarded as the partner group of protists to protophyta, which have plant-like behaviour, e.g., photosynthesis.(http://en.wikipedia.org/wiki/Protozoa)
material entity;Pseudorabies virus US3 mutant vaccine;
process;tertiary vaccination;tertiary vaccination is a vaccination that is performed at the third time in a row.
material entity;Chicken Anemia Virus Live Virus Vaccine (USDA: 10A1.00);
material entity;Rabies virus glycoprotein G mutant vaccine;
material entity;pVCL(pCXN2-mVIN) DNA vaccine plasmid;
material entity;Chicken Anemia Virus Live Virus Vaccine (USDA: 10A1.01);
material entity;Rabies virus P protein mutant vaccine;
material entity;B. melitensis bp26 deletion vaccine;A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the bp26 deletion. It has similar vaccine efficacy to Rev. 1. Its advantage compared to Rev. 1 is that this feature of bp26 deletion promotes diagnosis. PMID:17070627.
material entity;pWRG1644 DNA vaccine plasmid;
material entity;pVR1012x/s DNA vaccine plasmid;
site;vaccine injection site;A vaccination site that is used for injection of a vaccine.
material entity;Coccidiosis Live Oocysts Vaccine (USDA: 1431.57);
material entity;Coccidiosis Live Oocysts Vaccine (USDA: 1431.58);
material entity;West Nile virus C protein mutant vaccine;
material entity;Coccidiosis Live Oocysts Vaccine (USDA: 1431.59);
material entity;F. tularensis vaccine FSC043;A spontaneous mutant of the SCHU S4 strain that protects against virulent F. tularensis infection.
material entity;Coccidiosis Live Oocysts Vaccine (USDA: 1431.5C);
material entity;Feline immunodeficiency virus vif mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1233.10);
material entity;Feline infectiour peritonitis virus 3abc mutant vaccine;
material entity;Bronchitis Mass Type, Live Virus Vaccine (USDA: 1235.10);
material entity;Bursal Disease Killed Virus Vaccine (USDA: 1275.00);
material entity;pRc/CMV DNA vaccine plasmid;
material entity;B. melitensis strain VTRM1;
material entity;pRSV DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.02);
material entity;Gallid herpesvirus 1 UL47 mutant vaccine;
material entity;pRK DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.04);
material entity;Hepatitis B virus X protein mutant vaccine;
material entity;Brucella suis strain VTRS1;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.0A);
material entity;pRc/CMV2 DNA vaccine plasmid;
process;vaccine-induced antibody mediated immune response;
material entity;Bursal Disease Killed Virus Vaccine (USDA: 1275.02);
material entity;Feline infectious peritonitis virus 7ab mutant vaccine;
material entity;F. tularensis vaccine LVS LPS;
material entity;Bursal Disease Killed Virus Vaccine (USDA: 1275.20);
material entity;KKF24;KKF24 is a recombinant strain of Francisella novicida U112 with iglC mutation (F. novicida delta-iglC::ermC). PMID:14680699.
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.00);
material entity;Gallid herpesvirus 1 UL0 mutant vaccine;
material entity;pRSV0 DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.01);
material entity;Gallid herpesvirus 1 UL23 mutant vaccine;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.10);
material entity;Herpes simplex virus 1 gH mutant vaccine;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.11);
material entity;Herpes simplex virus 2 ICP0 mutant vaccine;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.12);
material entity;Herpes simplex virus 1 TK mutant vaccine;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.13);
material entity;Herpes simplex virus 1 UL29 mutant vaccine;
material entity;B. melitensis LPS-GBOMP noncovalent complex vaccine;
material entity;B. melitensis lipopolysaccharide vaccine;
material entity;vaccine emulsifier;a vaccine additive that stabilizes the vaccine emulsification manufacturing process and makes emulsion of the vaccine easier.
material entity;Herpes simplex virus 1 gD mutant vaccine;
material entity;pSG5 DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.40);
material entity;Infectious Hematopoietic Necrosis Virus NV mutant vaccine;
material entity;inactivated vaccine;A whole organism vaccine that uses an inativated pathogen organism as its component.
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.41);
material entity;pSG2 DNA vaccine plasmid;
material entity;pSC65 DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.16);
material entity;pTH DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.17);
material entity;human metapneumovirus G protein mutant vaccine;
material entity;pTARGET DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.18);
material entity;human metapneumovirus M2-2 mutant vaccine;
material entity;Psin DNA vaccine plasmid;
material entity;Bursal Disease Live Virus Vaccine (USDA: 1271.19);
material entity;Human Respiratory Syncytial Virus M2-2 mutant vaccine;
material entity;licensed vaccine;A vaccine that is licensed for commercial use.
material entity;Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16L1.08);
material entity;USA licensed human vaccine;a licensed human vaccine that is licensed in the USA.
material entity;Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.00);
process;vaccine-induced leukocyte activation;
material entity;Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.01);
material entity;pcDNA1.1/Amp DNA vaccine plasmid;
material entity;Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.02);
material entity;live attenuated vaccine;A vaccine that is made from microbes that have been attenuated (weakened) in the laboratory so that they can't cause disease.
material entity;Marek's Disease Serotypes 1 & 2 & 3, Live Virus Vaccine (USDA: 16L1.01);
material entity;liposome-based vaccine adjuvant;A particulate antigen delivery system vaccine adjuvant that contains particles made up of concentric lipid membranes containing phospholipids and other lipids in a bilayer configuration separated by aqueous compartments. It is a relatively stable but non-covalently-bound complex of saponin adjuvant Quil-A, cholesterol and amphipathic antigen in a molar ratio of approximately 1:1:1. The spectrum of viral capsid antigens and non-viral amphipathic antigens of relevance for human vaccination, incorporated into ISCOMs, comprises influenza, measles, rabies, gp340 from EB-virus, gp120 from HIV, Plasmodium falciparum and Trypanosoma cruzi.
material entity;Marek's Disease Serotypes 1 & 3, Live Herpesvirus Chimera Vaccine (USDA: 1631.R0);
material entity;lipopolysaccharide of pathogen organism as vaccine component;
material entity;Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16G1.02);
material entity;pRK7 DNA vaccine plasmid;
material entity;Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16L1.02);
material entity;P145;
material entity;ApxIA;
material entity;pYV0055;
material entity;Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 16L1.06);
material entity;Caf1 from Y. pestis;
material entity;LolA;
material entity;YerA;
material entity;Psn;
material entity;YopH from Y. pestis CO92;
material entity;YPO0420;
material entity;HpmB;
material entity;live vaccine organism;a vaccine organism that is live
material entity;Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.05);
material entity;divalent DNA B. abortus vaccine using L7/L12 and Omp16;
material entity;Brucella recombinant DnaK protein vaccine;
material entity;profertility vaccine;A vaccine that is used to improve conception.
process;quaternary vaccination;quaternary vaccination is a vaccination that is performed at the fourth time in a row.
site;intravaginal route;
site;sublingual route;An oral route of administration that is underneath the tongue.
site;subtenon route;A route of administration that is through the membrane covering the muscles and nerves at the back of the eyeball
process;preparation of gene mutant vaccine;A live attenuated vaccine prepraration process that is performed by mutation of a gene(s) from a virulent pathogen.
material entity;PagA from B. anthracis;
material entity;12D3;
material entity;Treponema pallidum protein;
material entity;21B4;
material entity;YopH from Y. pestis strain: CO92, biovar: Orientalis;
material entity;live virulent vaccine;
material entity;CP;
material entity;APP7 1016;
material entity;ApxIIA;
material entity;AsaP1;
material entity;Streptococcus agalactiae protein;
material entity;RAP-1;
material entity;Streptococcus pyogenes protein;
material entity;AroA;
material entity;Staphylococcus aureus protein;
process;intravaginal vaccination;
site;intranasal route;A rounte of administration that located in nose.
material entity;Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.11);
site;intramuscular route;A route of administration that inject the material(such as vaccines, allergens) directly into a muscle.
material entity;Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.13);
material entity;Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.14);
material entity;Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.15);
material entity;B. melitensis WR201;
site;intraperitoneal route;A route of administration that located in the peritoneum.
material entity;Coccidiosis Live Oocysts, Chicken Isolates Vaccine (USDA: 1431.55);
site;intranasal route by spray;
material entity;Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.01);
site;intranasal route by drop;
material entity;Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.02);
material entity;influenza A (H1N1) 2009 Monovalent vaccine (MedImmune LLC);
material entity;influenza A (H1N1) 2009 Monovalent vaccine (CSL Limited);
material entity;Brucella abortus bacA mutant;
material entity;pWRG7077 DNA vaccine plasmid;
material entity;Fowl Pox Live Virus Vaccine (USDA: 1621.00);
material entity;Fowl Pox Live Virus Vaccine (USDA: 1621.10);
material entity;Fowl Pox Live Virus Vaccine (USDA: 1621.11);
material entity;Megan Egg;Megan Egg is a Salmonella vaccine that that consists of a double gene-deleted S. enterica serovar Typhimurium strain and is formulated fro immunization of pullets. Megan Egg contains the same Megan Vac1 organism but Megan Vac1 is used for younger birds (broilers).
material entity;Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.04);
material entity;Adjumer vaccine adjuvant;A synthetic vaccine adjuvant that is PCPP salt.
material entity;Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.09);
material entity;Marek's Disease Serotype 2, Live Virus Vaccine (USDA: 1631.00);
material entity;Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.00);
material entity;pME18100 DNA vaccine plasmid;
material entity;Fowl Pox Live Virus Vaccine (USDA: 1621.13);
material entity;pzz DNA vaccine plasmid;
material entity;Fowl Pox Live Virus Vaccine (USDA: 1621.14);
material entity;B. ovis microparticle subunit vaccine;
material entity;Fowl Pox Live Virus Vaccine (USDA: 1622.00);
material entity;pWRM DNA vaccine plasmid;
material entity;Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.00);
material entity;YPO0612;
material entity;HtpG;
material entity;YapF;
material entity;Irp7;
material entity;YdeN;
material entity;SAG1 from Toxoplasma gondii;
material entity;YopO;
material entity;YPMT1.84 (F1 capsule antigen);
material entity;YscF from Y. pestis KIM 10;
material entity;YopD from Y. pestis KIM 10;
material entity;lentivirus vaccine vector;a viral vaccine vector that uses a lentivirus as the vector.
material entity;Brucella recombinant SurA protein vaccine;
material entity;pVIVO2 DNA vaccine plasmid;
material entity;Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.01);
material entity;Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.06);
process;vaccine-induced host gene response;
material entity;pND DNA vaccine plasmid;
material entity;pMASIA DNA vaccine plasmid;
material entity;herpesvirus vaccine vector;a viral vaccine vector that uses a herpesvirus as the vector.
process;host response to vaccine adjuvant;a process that specifies host response to a vaccine adjuvant.
process;vaccine-induced host response;a processual entity that specifies host response to a vaccine.
process;vaccine-induced host immune response;Any immune system process that functions in the calibrated response of the host to a vaccine.
material entity;pMAMneoBlue DNA vaccine plasmid;
material entity;pMV60 DNA vaccine plasmid;
material entity;pNL3-gal DNA vaccine plasmid;
material entity;human immunodeficiency virus vaccine;A viral vaccine that protects against infection with human immunodeficiency virus that causes AIDS.
material entity;pNGVL DNA vaccine plasmid;
material entity;company;A legal organization that represents an association of people with a specific objective.
material entity;pN4a-gal DNA vaccine plasmid;
material entity;pND2 DNA vaccine plasmid;
process;host response to vaccine vaccine vector;a process that specifies host response to a vaccine vector.
process;host response to vaccine antigen;a process that specifies host response to a vaccine antigen.
process;host response to vaccine component;a processual entity that specifies host response to a vaccine component.
material entity;avian influenza H7N2 Subtype, Killed Virus Vaccine (USDA: 10F5.12);
material entity;sodB(Ft);sodBFt is a live vaccine strain mutant of Francisella tularensis with reduced Fe-superoxide dismutase gene expression. Ref: PMID:18692537.
material entity;avian influenza H7N3 Subtype, Killed Virus Vaccine (USDA: 1057.H7);
material entity;pIRES DNA vaccine plasmid;
material entity;avian influenza H7N3 Subtype, Killed Virus Vaccine (USDA: 10F5.13);
disposition;usage of steroid;
material entity;avian influenza H1N1 Subtype, Killed Virus Vaccine (USDA: 1057.H1);
material entity;avian influenza H4N6 Subtype, Killed Virus Vaccine (USDA: 1057.H4);
material entity;fungal vaccine;A vaccine that targets against a fungus infection.
material entity;avian influenza H5N2 Subtype, Killed Virus Vaccine (USDA: 1057.H5);
disposition;fungal disease;
material entity;avian influenza H5N9 Subtype, Killed Virus Vaccine (USDA: 1057.14);
material entity;avian influenza H6N8 Subtype, Killed Virus Vaccine (USDA: 1057.H6);
material entity;avian influenza H2N2 Subtype, Killed Virus Vaccine (USDA: 1057.H2);
material entity;avian influenza H3N4 Subtype, Killed Virus Vaccine (USDA: 1057.H3);
process;vaccine-induced follicular dendritic cell activation;
material entity;pJW24 DNA vaccine plasmid;
material entity;pING DNA vaccine plasmid;
process;vaccine-induced T cell interferon-gamma production;
material entity;pIRES2 DsRed2 DNA vaccine plasmid;
material entity;pK3 DNA vaccine plasmid;
function;vaccine function;To induce or modify protective or therapeutic immune response against a disease.
material entity;pK0 DNA vaccine plasmid;
material entity;pJW4303 DNA vaccine plasmid;
material entity;F. tularensis vaccine LVS;A live attenuated Francisella tularensis vaccine. It is available in American Type Culture Collection with ATCC ID: 29684.
material entity;human influenza virus vaccine 2011-2012;
material entity;human influenza virus vaccine 2014-2015;
material entity;human influenza virus vaccine 2012-2013;
material entity;licensed human influenza virus vaccine;
material entity;human influenza virus vaccine 2013-2014;
material entity;influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2021-2022];
material entity;influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2022-2023];
material entity;licensed human papillomavirus vaccine;human papillomavirus vaccine with license for human use.
material entity;licensed human poliovirus vaccine;Poliovirus vaccine with license for human use.
material entity;licensed human neisseria meningitidis vaccine;Neisseria meningitidis vaccine with license for human use.
material entity;licensed human orynebacterium diphtheriae vaccine;Corynebacterium diphtheriae vaccine with license for human use.
material entity;licensed human rabies virus vaccine;Rabies virus vaccine with license for human use.
material entity;licensed human rotavirus vaccine;Rotavirus vaccine with license for human use.
material entity;licensed human mumps virus vaccine;Mumps virus vaccine with license for human use.
material entity;licensed human mycobacterium tuberculosis vaccine;Mycobacterium tuberculosis vaccine with license for human use.
material entity;licensed human Japanese encephalitis virus vaccine;Japanese encephalitis virus vaccine with license for human use.
material entity;licensed human measles virus vaccine;Measles virus vaccine with license for human use.
material entity;influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2022-2023];
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2022-2023];
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2022-2023];
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2022-2023];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2022-2023];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;seasonal licensed human influenza virus vaccine;
material entity;licensed human vibrio cholerae vaccine;Vibrio cholerae vaccine with license for human use.
material entity;licensed human yellow fever virus vaccine;yellow fever virus vaccine with license for human use.
material entity;licensed human rubella virus vaccine;Rubella virus vaccine with license for human use.
material entity;licensed human streptococcus pneumoniae vaccine;Streptococcus pneumoniae vaccine with license for human use.
material entity;licensed human tick-borne encephalitis virus vaccine;Tick-borne Encephalitis Virus (TBEV) vaccine with license for human use.
material entity;licensed human salmonella typhi vaccine;Salmonella typhi vaccine with license for human use.
material entity;licensed human smallpox virus vaccine;Smallpox virus vaccine with license for human use.
material entity;human influenza virus vaccine 2020-2021;
material entity;human influenza virus vaccine 2021;
material entity;human influenza virus vaccine 2016;
material entity;human influenza virus vaccine 2021-2022;
material entity;human influenza virus vaccine 2022-2023;
material entity;human influenza virus vaccine 2023;
material entity;human influenza virus vaccine 2010-2011;
material entity;human influenza virus vaccine 2015-2016;
material entity;human influenza virus vaccine 2019-2020;
material entity;human influenza virus vaccine 2020;
material entity;licensed human bordetella pertussis vaccine;Bordetella pertussis vaccine with license for human use.
material entity;licensed human clostridium tetani vaccine;Clostridium tetani vaccine with license for human use.
material entity;human influenza virus vaccine 2017-2018;
material entity;licensed human bacillus anthracis vaccine;Bacillus anthracis vaccine with license for human use.
material entity;licensed human hepatitis B virus vaccine;Hepatitis B virus vaccine with license for human use.
material entity;licensed human haemophilus influenzae serotype b vaccine;Haemophilus influenzae serotype b vaccine with license for human use.
material entity;licensed human hepatitis A virus vaccine;Hepatitis A virus vaccine with license for human use.
material entity;human influenza virus vaccine 2018-2019;
material entity;human influenza virus vaccine 2016-2017;
material entity;human influenza virus vaccine 2022;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe;
material entity;influenza virus vaccine 2016-2017 (trivalent - California/Hong Kong/Brisbane) 0.5 ML Prefilled Syringe;
material entity;influenza virus vaccine 2022-2023 (quadrivalent - Austria/Darwin/Phuket/Victoria) Prefilled Syringe;
material entity;influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Victoria/Austria/Phuket) Prefilled Syringe;
material entity;influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Wisconsin/Austria/Phuket) Prefilled Syringe;
material entity;L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Prefilled Syringe [Gardasil];
material entity;L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Prefilled Syringe;
material entity;L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Prefilled Syringe [Gardasil 9];
material entity;L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Injection [Gardasil 9];
material entity;L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Injection;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2021-2022];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2021-2022];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2021-2022];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2021-2022];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2020-2021];
material entity;influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2020-2021];
material entity;SARS Coronavirus 2 XBB.1.5;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2020-2021];
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021 Southern Hemisphere];
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2021-2022];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022-2023];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2020-2021];
material entity;influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2020-2021];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2020-2021];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2020-2021];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection;
material entity;0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Injection;
material entity;0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe [Comirnaty 2023-2024];
material entity;0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Injection [Comirnaty 2023-2024];
material entity;0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML ;
material entity;0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Injection;
material entity;0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe;
material entity;0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Injection [Spikevax 2023-2024];
material entity;0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe [Spikevax 2023-2024];
material entity;0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML;
material entity;0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe;
material entity;Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML Injection [Menveo];
material entity;Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML Injection;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Quadracel];
material entity;zoster vaccine, live;A varicella-zoster virus live vaccine designed to prevent shingles (herpes zoster).
material entity;varicella virus vaccine;A varicella-zoster virus vaccine, also known as the chickenpox vaccine, that protects against the varicella-zoster virus (VZV) causes chickenpox.
material entity;DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine (non-US);A DTP-Haemophilus influenzae type b conjugate and hepatitis B vaccine that is used outside USA.
material entity;0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.0333 MG/ML Injection;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.01 MG/ML Injectable Suspension;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML Injection;
material entity;0.25 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Injection;
material entity;L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Prefilled Syringe;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML / varicella-zoster virus vaccine live (Oka-Merck) strain 20000 UNT/ML Injection [ProQuad];
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML / varicella-zoster virus vaccine live (Oka-Merck) strain 20000 UNT/ML Injection;
material entity;meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Prefilled Syringe [Bexsero];
material entity;meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Prefilled Syringe;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Prefilled Syringe [Menactra];
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Injection [Menactra];
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Injection;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Prefilled Syringe;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML Injection [Menquadfi];
material entity;Fluzone Quadrivalent 2022-2023 Northern Hemisphere vaccine Injection;
material entity;Fluzone Quadrivalent 2022-2023 Northern Hemisphere vaccine Prefilled Syringe;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022-2023];
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2019-2020];
material entity;influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2021-2022];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Kinrix];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [Infanrix];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Infanrix];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Vaxelis];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Quadracel];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Quadracel];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Vaxelis];
material entity;killed infectious bursal disease Virus vaccine;
material entity;live attenuated infectious bursal disease virus vaccine;
material entity;recombinant vaccine vector E. coli vaccine;An E. coli vaccine that uses a recombinant vaccine vector to express an E. coli antigen(s)
material entity;rBCG-Stx2B;
material entity;pBLUESCRIPT DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pBLUESCRIPT.
material entity;nkCMVint DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label nkCMVint.
material entity;recombinant E. coli mutant vaccine;An E. coli vaccine that uses a live mutant by knocking out one gene(s) from a wild type E. coli.
material entity;E. coli toxoid vaccine;an E. coli vaccine that uses toxoid antigen
material entity;potato expressed E. coli LB-T vaccine;
material entity;E. coli Tir protein Vaccine;
material entity;LHRH;
material entity;enterohemorrhagic E. coli vaccine;An E. coli vaccine against enterohemorrhagic E. coli infections
material entity;Flublok;
material entity;Bovilis IBR Marker;
material entity;E. coli Shiga toxin 2B vaccine;
material entity;inactivated E. coli vaccine;
material entity;uropathogenic E. coli vaccine;An E. coli vaccine against uropathogenic E. coli infections
material entity;extraintestinal pathogenic E. coli vaccine;An E. coli vaccine against extraintestinal pathogenic E. coli infections
material entity;Streptococcus equi vaccine;a bacterial vaccine against S. equi infection
material entity;Mycoplasma gallisepticum vaccine;a bacterial vaccine against Mycoplasma gallisepticum infection
material entity;V. cholerae and E. coli vaccine;
material entity;Measles-Rubella vaccine;A Measles virus vaccine that is also used against Rubella virus infection.
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine;A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, Hepatitis B, and Haemophilus influenzae type b.
material entity;PreveNile;
material entity;yeast protein cell culture residual in vaccine;a cell culture residual in vaccine that is yeast protein.
material entity;Apex-IHN;
material entity;Diphtheria-Tetanus-Pertussis-Haemophilus b vaccine;
material entity;Diphtheria-Tetanus-Poliovirus vaccine;
material entity;Salmonella typhi-Hepatitis A vaccine;
process;host survival to pathogen challenge after vaccination;
material entity;Brucella abortus conjugate vaccine;a B. abortus vaccine that uses a conjugate vaccine format
material entity;Brucella abortus recombinant vector vaccine;a B. abortus vaccine that uses a recombinant vector.
material entity;Herpes simplex virus type 1 vaccine;A vaccine that protects against Herpes simplex virus type 1.
material entity;Bayovac CSF E2;
material entity;Dhori virus vaccine;
site;pharyngeal mucosal route;Pharyngeal mucosal route is an oral route of administration.
material entity;Intervet avian influenza virus vaccine;
material entity;hepatitis A virus strain CR 326F antigen, inactivated vaccine;
material entity;Varicella zoster virus glycoprotein E vaccine;
material entity;Haemophilus capsular oligosaccharide vaccine;
material entity;influenza A virus (H5N1) antigen vaccine;
material entity;influenza A virus A/Victoria/361/2011 (H3N2) antigen vaccine;
material entity;hepatitis B virus subtype ADW2 HBsAg surface protein antigen vaccine;
material entity;Varicella zoster virus glycoprotein E, recombinant vaccine;
material entity;Bordetella Pertussis Filamentous Haemagglutinin Antigen vaccine;
material entity;Bordetella Pertussis Fimbriae Serotype 2 And 3 Antigen vaccine;
material entity;Neisseria meningitidis Recombinant Fusion Protein Fhbp Group B vaccine;
material entity;AFLURIA QUADRIVALENT SOUTHERN HEMISPHERE vaccine;
material entity;AFLURIA SOUTHERN HEMISPHERE vaccine;
material entity;ABRYSVO (STN 125768) vaccine;
material entity;ABRYSVO (STN 125769) vaccine;
material entity;AREXVY vaccine;
material entity;AUDENZ vaccine;
material entity;tumor-specific antigen;Antigen that is only expressed by tumor cells.
material entity;tumor-associated antigen;Antigen that is overexpressed by tumor cells.
site;intratumoral route;A route of administration that inject the material (such as vaccines, allergens) directly into a tumor.
site;intralesional route;A route of administration that inject the material (such as vaccines, allergens) directly into a lesion or into the skin.
material entity;Flucelvax;
material entity;Porcilis Pesti;
material entity;FluMist Quadrivalent vaccine;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen vaccine;
material entity;Fluarix Quadrivalent;
material entity;influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen vaccine;
material entity;influenza B virus B/Brisbane/60/2008 antigen vaccine;
material entity;influenza B virus antigen vaccine;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen vaccine;
material entity;influenza A virus A/Bolivia/559/2013 (H1N1) antigen vaccine;
material entity;influenza B virus B/Brisbane/9/2014 antigen vaccine;
material entity;influenza B virus B/Phuket/3073/2013 antigen vaccine;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen vaccine;
material entity;influenza B virus B/Utah/9/2014 antigen vaccine;
material entity;Theileria parva vaccine by local veterinary institutes;
material entity;Tetanus Toxoid (for Boost use Only) by Sanofi Pasteur Inc;a tetanus vaccine manusfactured by Sanofi Pasteur Inc. that is only for booster use (not recommended for primary immunization)
material entity;fowl pox vaccine;a viral vaccine that is used to protect against fowl pox virus infection
material entity;bovine rhinotracheitis vaccine;
material entity;pDONR221 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pDONR221. The plasmid length is 4762.
material entity;pCN3 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCN3. The plasmid promoter is CMV.
material entity;V1R DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label V1R.
material entity;Toxoplasma gondii vaccine;
material entity;bovine parainfluenza 3 vaccine;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen vaccine;
material entity;influenza A virus A/Slovenia/2903/2015 (H1N1) antigen vaccine;
material entity;vibrio cholerae CVD 103-HGR strain live antigen vaccine;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen vaccine;
material entity;influenza B virus B/Colorado/06/2017 antigen vaccine;
material entity;Neisseria meningitidis Group B Membrane vesicles External Omv vaccine;
material entity;influenza B virus B/Maryland/15/2016 antigen vaccine;
material entity;influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen vaccine;
material entity;influenza B virus B/Hong Kong/259/2010 antigen vaccine;
material entity;influenza A virus A/New Caledonia/71/2014 (H3N2) antigen vaccine;
material entity;pVCL1012 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pVCL1012. The promoter is HCMV and the manufacturer is Vical Inc.
material entity;pVAC1 3.0 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pVAC1 3.0. The manufacturer is Invitrogen.
material entity;SpayVac;A contraceptive vaccine that has proven highly effective in deer and can be used to control populations.
material entity;pSin-CMV-Vac DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSin-CMV-Vac. The promoter is CMV.
material entity;pGACAG DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pGACAG. The promoter is CAG and the antibiotics resistance gene is kanamycin.
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU [Varilrix];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU Injection;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU Injection [Varilrix];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injectable Solution;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML [Zostavax];
material entity;Fluzone Quadrivalent 2022-2023 formula vaccine;
material entity;(Squeezable Tube Presentation) - ROTARIX vaccine;
material entity;Fluzone High-Dose Quadrivalent Southern Hemisphere vaccine;
material entity;TICOVAC vaccine;
material entity;VAXELIS vaccine;
material entity;TDVAX (NDC 14362-0111) vaccine;
material entity;Zostavax (Frozen) vaccine;
material entity;Zostavax (Refrigerator Stable) vaccine;
material entity;Varivax (Frozen) vaccine;
material entity;Varivax (Refrigerator) vaccine;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 19400 PFU Injection [Zostavax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML [Varilrix];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix];
material entity;Pentacel - (inactivated poliovirus component grown in Vero cells) vaccine;
material entity;(Refrigerated) - ProQuad vaccine;
material entity;TDVAX (NDC 13533) vaccine;
material entity;Pentacel MRC-5 vaccine;
material entity;Frozen Formulation - Recombinant Human Albumin (RHA) - ProQuad vaccine;
material entity;M-M-R II vaccine - patient;Patient information for M-M-R II vaccine
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 1;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 10;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution Box of 1;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution Box of 10;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 PFU Injection [Varivax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT [Varivax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT Injectable Solution;
material entity;Frozen Formulation - Human SerumAlbumin (HSA) - ProQuad vaccine;
material entity;IXCHIQ vaccine;
material entity;Fluzone High-Dose Quadrivalent vaccine;
material entity;Fluzone Intradermal vaccine;
material entity;Influenza A (H1N1) 2009 Monovalent Vaccine (ID Biomedical Corporation of Quebec);
material entity;CAPVAXIVE vaccine;
material entity;ERVEBO vaccine;
material entity;FLUAD QUADRIVALENT vaccine;
material entity;CYFENDUS vaccine;
material entity;DENGVAXIA vaccine;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT Injection;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT Injection [Varivax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT Injection [Varivax] by Merck;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 19400 PFU;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 19400 PFU [Zostavax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 19400 PFU Injection;
material entity;Refrigerator-Stable Formulation - ProQuad vaccine;
material entity;SPIKEVAX vaccine;
material entity;PREVNAR 20 vaccine;
material entity;Proquad (Frozen) vaccine;
material entity;Influenza Virus Vaccine, H5N1 (for National Stockpile);
material entity;JYNNEOS vaccine;
material entity;PENBRAYA vaccine;
material entity;PREHEVBRIO vaccine;
material entity;MRESVIA vaccine;
material entity;MenQuadfi vaccine;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Varilrix];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Varivax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Zostavax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Suspension;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Suspension [Zostavax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [Varilrix];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Prefilled Syringe;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Prefilled Syringe [Zostavax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe Box of 1;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML [Varilrix];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1;
role;vaccine multivalent role;A vaccine that is designed to immunize against multiple antigen or multiple strain of a pathogen.
generically dependent continuant;flu season;A period typically associated with a higher incidence of influenza virus infections, characterized by the increased circulation of flu viruses in a population.
role;vaccine monovalent role;A vaccine that is designed to immunize against a single antigen or single strain of a pathogen.
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution Box of 1;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution Box of 10;
material entity;Quadracel (inactivated poliovirus component grown in MRC-5 cells) vaccine;
material entity;Quadracel (inactivated poliovirus component grown in Vero cells) vaccine;
material entity;human albumin cell culture residual in vaccine;a cell culture residual in vaccine that is human albumin.
material entity;human serum cell culture residual in vaccine;a cell culture residual in vaccine that is human serum.
material entity;Raboral;
material entity;polysorbate 20 vaccine stabilizer;a vaccine stabilizer that is a polysorbate 20. It encourages the suspension of one liquid in another and has mild toxicity.
material entity;monosodium glutamate stabliizer;a vaccine stablizer that is based on monosodium glutamate.
material entity;RECOMBITEK Corona MLV;
material entity;glutaraldehyde vaccine additive;
material entity;Babesia bovis vaccine;
material entity;bovine albumin cell culture residual in vaccine;a cell culture residual in vaccine that is bovine albumin.
material entity;bovine serum cell culture residual in vaccine;a cell culture residual in vaccine that is bovine serum.
material entity;sucrose albumin cell culture residual in vaccine;a cell culture residual in vaccine that is sucrose albumin.
material entity;xanthan gum vaccine ajuvant;A synthetic vaccine adjuvant that is derived from Xanthomonas campestris, has a pentasaccharide repeating unit structure, and its terminus contains a mannose moiety which acts as a toll-like receptor 2 agonist.
material entity;yeast extract cell culture residual in vaccine;a cell culture residual in vaccine that is from yeast extract.
material entity;E. coli CS3 in PLGA microspheres;
material entity;sorbitol vaccine stabilizer;a vaccine stabilizer that is specifically made by sorbitol.
material entity;Sarcocystis neurona vaccine;
material entity;Suvaxyn Aujeszky;A vaccine that is made of a TK-negative (TK -) and gI/gE-negative (gI/gE -) pseudorabies virus (PRV) mutant to protect pigs against Aujeszky's disease. Aujeszky's disease is also known as pseudorabies. It is a disease primarily of pigs and is caused by porcine herpesvirus 1. This disease is characterized by respiratory, reproductive and nervous signs.
material entity;polysorbate 80 vaccine emulsifier;a vaccine emulsifier that uses polysorbate 80, also known as polyoxyethylene sorbitan monooleate or Tween(TM) 80.
material entity;vaccine residual protein from cell culture;a cell culture residual in vaccine that is residual protein from cell culture.
material entity;canine coronavirus vaccine;
material entity;Theileria annulata vaccine;
material entity;Eimeria vaccine;
material entity;surface antigens from the zona pellucida;
generically dependent continuant;challenge dose;A dose of a virulent pathogen used for a vaccine challenge process.
material entity;PROTEQ-FLU (European Union);
process;secondary vaccination;Secondary vaccination is a vaccination that is performed immediately after the primary or the first vaccination.
material entity;vaccine antigen;the vaccine component that is used as antigen to produce an immune responce protect against the specific pathogen or disease.
material entity;gelatin vaccine allergen;
material entity;protamine sulfate vaccine allergen;
material entity;polymyxin B vaccine allergen;
material entity;EURIFEL FeLV;
process;passive immunization using natural maternal antibody;passive immunization that Immunity is transferred from mother to fetus through placental transfer of IgG or colostral transfer of IgA.
material entity;chicken egg protein allergen;chicken egg protein allergen is a vaccine allergen that is composed of chicken egg protein.
material entity;latex vaccine allergen;
material entity;vaccine allergen;vaccine allergen is a material entity that is capable of stimulating a type-I hypersensitivity reaction in atopic individuals who has been vaccinated with a vaccine.
material entity;recombinant Yersinia rV10 vaccine;A Y. pestis vaccine that uses the recombinant V10 (rV10), a variant (lacking residues 271 to 300) of Yersinia pestis LcrV. PMID:16861680.
material entity;Improvac;A vaccine that stimulates the pig's own immune system to produce specific antibodies against GnRF. This temporarily inhibits testes function and thus stops the production and accumulation of boar taint-causing compounds.
material entity;VSV vector expressing Y. pestis lcrV;
material entity;Plague vaccine USP;A formalin-inactivated preparation that was manufactured by Cutter Biologicals (a division of Miles Laboratories, Inc.). It is now available only from Greer Laboratories, Inc. The killed or inactivated plague vaccine is prepared from Y. pestis organisms grown in artificial media and then inactivated in formaldehyde.
material entity;AquaVac ERM;
material entity;Feline leukemia virus vaccine;
material entity;Art Vax;
material entity;vaccine additive;a vaccine component that is added to the immunogen by the vaccine manufacturer for a specific purpose. Additives include adjuvants, preservatives and stablizers, as well as materials that are added to affect pH and isotonicity.
material entity;Classical swine fever virus vaccine VAC-E2;
material entity;vaccine preservative;vaccine preservative is an vaccine additive that is added to a vaccine formulation to prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during use. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73.
material entity;Classical swine fever virus E1 protein vaccine;
material entity;C. parvum DNA vaccine encoding CP15/60;
material entity;Y. enterocolititica Subunit V Antigen Protein Vaccine;
material entity;Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1);
material entity;Japanese encephalitis virus DNA vaccine pUJENS3;
material entity;WEEV Subunit E2 Protein Vaccine;
material entity;Cancer Subunit GV1001 Protein Vaccine;
material entity;C. botulinum FHc protein vaccine;
material entity;WEEV DNA Vaccine encoding 6K-E1 Protein;
material entity;cell culture residual in vaccine;a vaccine residual that is generatead from cell culture for vaccine preparation. Examples include: antibiotics, sensitizing substances, bacterial and cellular residuals, and adventitious agents.
process;vaccine-induced immune correlate of protection;
process;serologic correlate of protection;Serological correlate of protection is an immune correlate of protection that is reflected by serologic antibody levels.
process;cell mediated immune correlate of protection;A cell mediated immune correlate of protection is an immune correlate of protection that is reflected by a cell mediated immune response.
material entity;Periovac;
material entity;vaccine stabilizer;a vaccine additive that helps to protect the vaccine from adverse conditions such as the freeze-drying process (for those vaccines that are freeze-dried) or heat.
material entity;vaccine residual;a vaccine component that remains from the vaccine manufacturing process.
material entity;inactivation residual in vaccine;a vaccine residual that is used to inactivate bacteria and viruses or to detoxify bacterial toxins. For example, formaldehyde is a frequently used inactivation agent in vaccine preparation.
material entity;AdsecV;
material entity;Yersinia EV76;A Yersinia pestis vaccine that is a pigmentation negative mutant of Y. pestis derived from a fully virulent strain.
material entity;Y. pestis F1 protein vaccine;A Yersinia pestis subunit vaccine that uses Y. pestis F1 protein as antigen.
material entity;Vibrio anguillarum vaccine;a bacterial vaccine against V. anguillarum infection
material entity;MVA expressing HIV Gag, Pol and Env proteins;A recombinant modified vaccinia Ankara (MVA) expressing HIV Gag, Pol, and Env proteins. PMID:16472543.
material entity;DNA and poxvirus priming-boosting SIV vaccine;A SIV vaccine that is composed of a DNA vaccine and a poxvirus vector expressing the same SIV antigens. PMID:15258286.
material entity;Brucella abortus S19 with P39 deletion;A B. abortus vaccine that is recombinant B. abortus strain 19 vaccine with the p39 gene deletion.
material entity;Aeromonas salmonicida vaccine;An Aeromonas bacterial vaccine that is used to protect against Aeromonas salmonicida infection
material entity;Gag-VRPs;A cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140). PMID:12120997.
material entity;Ovilis Enzovax;
material entity;Trovac AI H5;
material entity;recombinant Y. pestis YopD protein vaccine;
material entity;Epm vaccine;
material entity;Y. pestis YscF subunit vaccine;A Y. pestis subunit vaccine that uses Y. pestis YscF protein as antigen. PMID:15978133.
material entity;microencapsulated Caf1 and LcrV vaccine;
material entity;rF1 + rV vaccine;A Y. pestis subunit vaccine that uses recombinant F1 and V antigens. PMID:312163.
material entity;Recombinant Y. pestis V antigen vaccine;A Y. pestis subunit vaccine that uses recombinant Y. pestis V antigen. PMID:7622205.
material entity;modified Y. pestis with TLR4-stimulating LPS;
material entity;Yersinia PAV;A Yersinia pestis subunit vaccine that contains staphylococcal protein A-V antigen fusion peptide (PAV). PMID:7622225.
material entity;Equity;Equity Oestrus Control Vaccine for Horses is prepared from an analogue of gonadotropin releasing factor (GnRF) linked to a carrier protein. It has an adjuvant that enhances the level and duration of the immune response to GnRF with minimal injection site reactivity. It is used as an aid in the control of oestrus and oestrus-related behaviour in fillies and mares not intended for breeding.
material entity;single-dose Vaxigrip;
material entity;multi-dose Vaxigrip;
material entity;aluminum vaccine adjuvant;A mineral salt vaccine adjuvant that is composed of some aluminum compound.
material entity;pCLF4;pCLF4 is a Bacillus anthracis vaccine that contains the N-terminal region (amino acids [aa] 10-254) of Bacillus anthracis LF cloned into the pCI expression plasmid.
material entity;meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine;
material entity;Measles Virus Vaccine VVN;
material entity;meningococcal B vaccine, fully recombinant;
material entity;Measles Virus Vaccine VVP;
material entity;meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P);
material entity;C. muridarum DNA vaccine encoding TC0439;
material entity;meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O);
material entity;C. muridarum DNA vaccine encoding TC0512;
material entity;poliovirus vaccine, unspecified formulation;
material entity;L. donovani ORFF Protein Subunit Vaccine;
material entity;Oral Polio Vaccine, Unspecified formulation;
material entity;meningococcal B vaccine, recombinant, OMV, adjuvanted;
material entity;Measles Virus Vaccine VVM;
material entity;pneumococcal polysaccharide vaccine, 23 valent;
material entity;B. pseudomallei DNA vaccine encoding Flagellin Protein;
material entity;Japanese Encephalitis vaccine for intramuscular administration;
material entity;influenza virus NP protein vaccine (influenza A virus (A/nt/60/1968(H3N2)));
material entity;meningococcal polysaccharide vaccine (MPSV4);
material entity;L. donovani gp63 Protein Subunit Vaccine;
material entity;L. donovani DNA vaccine encoding KMP-11;
material entity;PleuroStar APP;
role;vaccine preservative role;a role inhers in a vaccine component that when added into a vccine formmulation, it can prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during administrating process or the manufacturing process.
site;oral route;A route of administration that located in the mouth
site;intradermal route;A route of administration that inject the material(such as vaccines, allergens) into the skin itself.
material entity;phenol vaccine preservative;
material entity;phenoxy ethanol vaccine preservative;
material entity;Respiratory syncytial virus (RSV) vaccine, unspecified;
material entity;S. equi Subunit CNE Protein Vaccine;
material entity;Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified;
material entity;human rabies vaccine from Chicken fibroblast culture;
material entity;S. equi Subunit EAG, FNZ and SFS Protein Vaccine;
material entity;Respiratory syncytial virus (RSV), unspecified;
material entity;C. jejuni DNA vaccine pcDNA3.1(+)-cadF;
material entity;pneumococcal vaccine, unspecified formulation;
material entity;rotavirus, live, pentavalent vaccine;
material entity;F. tularensis DNA vaccine pTUL4-15;
material entity;rotavirus, live, monovalent vaccine;
material entity;P. berghei CS protein subunit vaccine;
material entity;pneumococcal conjugate vaccine, 13 valent;
material entity;L. donovani DNA Vaccine encoding NH36 Protein;
material entity;rabies vaccine, for intramuscular injection RETIRED CODE;
material entity;Sin Nombre virus DNA vaccine encoding SNVsSgp1 (NP);
material entity;influenza virus DNA vaccine encoding NA from influenza B virus (B/Ibaraki/2/85);
material entity;pneumococcal conjugate vaccine, 7 valent;
material entity;influenza virus DNA vaccine encoding NA from influenza A virus (A/chicken/Henan/12/2004(H5N1));
quality;age at vaccination;Age at vaccination is the age of an experiment animal at the time of vaccination.
material entity;Theileria annulata vaccine by local veterinary institutes;
quality;vaccine effectiveness;Vaccine effectiveness is an effectiveness associated with a vaccine.
material entity;C. abortus DNA vaccine encoding DnaX;
site;Canada;Canada is a country that exists in north America.
material entity;H. pylori catalase protein vaccine;
material entity;H. pylori NAP protein vaccine;
material entity;C. botulinum DNA vaccine pSCARSBHc;
material entity;Dobrava-Belgrade virus S nucleocapsid protein vaccine;
material entity;T. annulata Subunit SPAG-1 Protein Vaccine;
material entity;C. abortus DNA vaccine encoding DnaK;
material entity;M. gallisepticum TM-1 Protein Subunit Vaccine;
material entity;Japanese encephalitis virus vaccine BV-G-E;
material entity;Cancer Subunit DC (Tat-CEA) vaccine;
material entity;Influvac;Influvac is an Influenza virus vaccine that is manufactured by Solvay Pharma.
material entity;Vaxigrip;Vaxigrip is an Influenza virus vaccine that is manufactured by 'Sanofi Pasteur Limited.
material entity;Pirodog;
role;Canada licensed vaccine role;a licensed status that occurs in Canada.
material entity;Porphyromonas gulae vaccine;a bacterial vaccine against Porphyromonas gulae infection
material entity;Fluviral S/F;
material entity;Babesia bigemina vaccine by local veterinary institutes;
material entity;Purevax Feline Rabies;
material entity;Babesia bovis vaccine by local veterinary institutes;
material entity;PGA/ME;
material entity;C. muridarum DNA vaccine encoding TC0767/768;
material entity;T. gondii DNA Vaccine encoding SAG1 Protein;
material entity;C. muridarum DNA vaccine encoding TC0757;
material entity;T. gondii DNA vaccine pcDNA3-MIC3;
material entity;infleunza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1));
material entity;influenza virus DNA vaccine encoding NP from influenza A virus (A/chicken/Hubei/489/2004(H5N1));
material entity;C. abortus DNA vaccine encoding CAB049;
material entity;C. abortus DNA vaccine encoding CAB613;
material entity;C. abortus DNA vaccine encoding GatA/GatB;
material entity;T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine;
material entity;RECOMBITEKEquine WNV;
material entity;Porphyromonas denticanis;
material entity;Anthrax Spore Vaccine;Anthrax Spore Vaccine is a B. anthracis vaccine that is prepared with a relatively nonpathogenic, noncapsulated variant strain of B. anthracis, originally developed at the Onderstepoort Laboratory, Pretoria, South Africa. Further work was conducted in England, India and in many other countries. Vaccine Strain is Sterne 34F2. The vaccine is a suspension of viable Bacillus anthracis spores in saponin.
material entity;pSecTag-PA83;
material entity;pCMV/ER-PA83;
generically dependent continuant;pathogen strain variable;A variable representing the lineage of pathogen strain (incljuding presence or absence of virulence factors)
generically dependent continuant;pathogen attenuation variable;A variable representing the presence of an attenuation process (killed microbe) on a pathogen challenge
generically dependent continuant;assay platform variable;A variable representing the assay platform used (Nanopore,) etc.
generically dependent continuant;pathogen variable;A variable representing the species or type of the pathogen
generically dependent continuant;host adverse event variable;A variable representing the presence of host adverse events from the vaccination process.
generically dependent continuant;assay mesurement variable;A variable representing the measurement used for an assay
generically dependent continuant;assay analysis tool version variable;A variable representing the programs used to analyze an assay
generically dependent continuant;assay sample source variable;A variable representing the tissue or source of sample used for an assay.
generically dependent continuant;assay sample endpoint variable;A variable representing the timepoint a biological sample was taken after vaccination
generically dependent continuant;assay type variable;A variable representing the assay type (ELISA, microarray) etc.
generically dependent continuant;vaccine preservative variable;A variable representing the vaccine preservative
generically dependent continuant;vaccine adjuvant variable;A variable representing the vaccine adjuvant (silver) etc.
generically dependent continuant;vaccine vector variable;A variable representing the vaccine vector (DNA plasmid, viral vector) etc.
generically dependent continuant;vaccination route variable;A variable representing the vaccination route etc.
generically dependent continuant;vaccination dose variable;A variable representing dose representing the vaccination
generically dependent continuant;host vaccination frequency variable;A variable representing the host vaccination frequency etc.
generically dependent continuant;vaccine target variable;A variable representing the vaccine target (pathogen, disease) etc.
generically dependent continuant;vaccine antigen variable;A variable representing the vaccine antigen (SARS-CoV-2 protein, whole organism) etc.
generically dependent continuant;vaccination frequency variable;A variable represting the number of occurences a vaccination was administered
generically dependent continuant;vaccination interval variable;A variable representing the interval between multiple vaccinations.
material entity;yellow fever vaccine live;
material entity;Bovine herpesvirus 1 DNA vaccine pRSV-gC;
material entity;yellow fever vaccine live - alternative formulation for vaccine shortage;
material entity;Ixiaro vaccine;
material entity;zoster vaccine, unspecified formulation;
material entity;Rabies vaccine rVac-N;
material entity;cholera, WC-rBS;
material entity;Vivotif L;
material entity;yellow fever vaccine, unspecified formulation;
material entity;Cervarix vaccine;
generically dependent continuant;reserved cvx code for not using;An information content entity that specifies the CVX code that will not be used to avoid confusion with code 999.
material entity;G. duodenalis DNA vaccine encoding CWP2;
material entity;typhoid Vi capsular polysaccharide vaccine;
material entity;Rabies DNA Vaccine encoding Rabies virus Glycoprotein;
material entity;zoster vaccine recombinant;
material entity;Bovine herpesvirus 1 DNA vaccine tgD-VP22;
material entity;tetanus toxoid, adsorbed;
material entity;H. influenzae D15 protein vaccine;
material entity;Td(adult) unspecified formulation;
material entity;Newcastle Disease Virus HN Glycoprotein Subunit Vaccine;
generically dependent continuant;challenge-killing interval variable;A variable representing the interval between the pathogen challenge start and end
generically dependent continuant;challenge admistration route;A variable representing the administration route of the pathogen challenge
generically dependent continuant;vaccination-challenge interval variable;A variable representing the interval between vaccination and pathogen challenge
generically dependent continuant;intevention interval variable;A variable representing the interval between the vaccination and pathogen challenge start
generically dependent continuant;sacrifice process variable;A variable representing the planned process used for the sacrifice
process;tuberculin skin test. old tuberculin, multipuncture device;
material entity;Andes virus vaccine using adenovirus viral vector expressing ANDV NP;
process;tuberculin skin test. unspecified formulation;
material entity;N. caninum NcMAG1 Protein Subunit Vaccine;
generically dependent continuant;host lineage variable;A variable representing the lineage (breed, ethnicity) of the animal host
material entity;N. caninum NcDG2 Protein Subunit Vaccine;
process;tuberculin skin test. purified protein derivative solution, intradermal;
material entity;H. influenzae Omp26 protein vaccine;
process;tuberculin skin test. purified protein derivative, multipuncture device;
material entity;N. caninum NcMIC1 Protein Subunit Vaccine;
generically dependent continuant;vaccine preservative datum;A measurment datum that records the vaccine preservative of a vaccine.
process;vaccine challenge survival assay;An assay that measures the survival rate of organisms exposed to a pathogen.
generically dependent continuant;vaccine target datum;A measurment datum that records the intended target of a vaccine.
generically dependent continuant;vaccine vector datum;A measurment datum that records the vaccine vector of a vaccine.
generically dependent continuant;study design variable;A directive information entity that is part of a study design. It can be eithor independent variables whose values are selected to determine its relationship to an observed phenomenon (the dependent variable) or dependent variables that are studied and expected to change when the independent variable varies.
material entity;meningococcal group A polysaccharide vaccine;
process;pathogen gut adhesion assay;An assay that measures the gut adhesion of a pathogen within an organism.
process;viral neutralization titer assay;An assay that measures the titer of antibodies that neturalize a pathogen within an organism.
generically dependent continuant;vaccination frequency datum;A measurment datum that records the number of occurences the host was vaccinated as part of the vaccination process.
generically dependent continuant;vaccination interval datum;A measurment datum that records the interval between vaccinations of a host.
material entity;Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen vaccine;
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen vaccine;
material entity;Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen vaccine;
material entity;Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen vaccine;
material entity;influenza A virus (H3N2) antigen vaccine;
material entity;Influenza A virus (H1N1) antigen vaccine;
material entity;influenza A virus A/South Australia/55/2014 (H3N2) antigen vaccine;
material entity;Bacillus anthracis strain V770-NP1-R antigen vaccine;
material entity;Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen vaccine;
material entity;meningococcal group C polysaccharide vaccine;
generically dependent continuant;host comorbidity datum;A measurment datum that records the quality of the host to have a comorbidity.
generically dependent continuant;host pathogen exposure datum;A measurment datum that records the presence of a prior infection or immune memory to a pathogen.
generically dependent continuant;host response to vaccine study design;A vaccine study design that is about the host response to a vaccine.
generically dependent continuant;vaccine challenge study design;A vaccine study design that is about the vaccine challenge to a host.
generically dependent continuant;vaccine study design variable;A study design variable that is used in a vaccine study.
generically dependent continuant;vaccine study design;A study design that is about a vaccine study.
generically dependent continuant;host age datum;A measurment datum that records the age of thost.
generically dependent continuant;host pregnancy datum;A measurement datum that records to involvement of the host of the pregnancy process.
generically dependent continuant;host disease state datum;A measurement datum that records the presence of a disease process in a host during the implementation of a vaccine study.
generically dependent continuant;host sex datum;A biological sex datum that records the biological sex of the target of a vaccine.
generically dependent continuant;pathogen attenuation datum;A measurment datum that records the utilization of an attenaution process on a pathogen.
generically dependent continuant;host adverse event to vaccine datum;A measurment datum that records the presence or abasence of adverse event in a host in response of some vaccine.
generically dependent continuant;assay mesurement datum;A measurment datum that records the measurement of an assay.
generically dependent continuant;challenge admistration route datum;A measurment datum that records the route of a pathogen challenge occurs in.
generically dependent continuant;sacrifice process datum;A measurment datum that records the method of sacrifice (i.e. killing).
generically dependent continuant;assay analysis tool version datum;A measurment datum that records the version of an analysis tool (software) used for an assay.
generically dependent continuant;assay platform datum;A measurment datum that records the type of platform used for an assay.
generically dependent continuant;assay measurement sample interval;A measurment datum that records the time point between the start of a first intervention in a planned process and the measurment of a sample.
generically dependent continuant;assay type datum;A measurment datum that records the type of assay used.
generically dependent continuant;challenge-killing interval datum;A measurment datum that records the interval between the vaccine challenge and the sacrifice of the organism during a vaccine challenge.
material entity;influenza, recombinant, trivalent, injectable, preservative free;
material entity;influenza, split virus, quadrivalent, injectable, contains preservative;
material entity;influenza, split virus, quadrivalent, injectable, preservative free;
material entity;influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative free;
material entity;influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative free;
material entity;influenza A monovalent (H5N1), adjuvanted, National stockpile 2013;
material entity;influenza, adjuvanted, inactivated, trivalent, injectable, preservative free;
material entity;seasonal influenza, intradermal, preservative free;
material entity;influenza, live, quadrivalent, intranasal;
material entity;influenza, split virus, trivalent, injectable, contains preservative;
material entity;Influenza, adjuvanted, inactivated, quadrivalent, injectable, preservative free;
material entity;influenza, seasonal, Southern Hemisphere, high-dose, quadrivalent, 0.7mL dose, preservative free;
material entity;influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, no preservative;
material entity;influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservative;
material entity;influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservative;
material entity;Japanese Encephalitis vaccine SC;
material entity;influenza, high-dose, split virus, quadrivalent, injectable, preservative free;
material entity;influenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative free;
material entity;influenza, recombinant, quadrivalent, injectable, preservative free;
material entity;influenza, Southern Hemisphere, unspecified formulation;
generically dependent continuant;vaccination coverage;A measure datum that measures the coverage of vaccination in a specific area during a specific time period.
quality;effective;
quality;ineffective;
role;toxoid vaccine role;A vaccine role that indicates the vaccine being a toxoid vaccine.
process;rapid vaccination;A vaccination process that is implemented fast.
process;vaccine storage at room temperature;a vaccine storage that is execuated at room temperature. Room temperature is also referred to as ambient temperature. Room temperature denotes a certain temperature within enclosed space at which humans are accustomed. Room temperature is usually indicated by general human comfort, with the common range of 10 degree C (50 degree F) to 28 degree C (82.4 degree F).
process;vaccine storage in refrigerator;vaccine storage that is executed in refrigerator, usually 0-10^C.
process;vaccine storage in freezer;vaccine storage that is executed in freezer under 0^C.
quality;effectiveness;Effectiveness is physical quality that represents the capability of a single physical entity (e.g., vaccine) producing an effect (e.g, protection against a disease).
process;vaccine storage;a storage process that is specifically for vaccine.
continuant;biweekly;
material entity;DNA vaccine expressing multiple HIV epitopes;A HIV vaccine that is composed of a DNA vaccine expressing conserved, multiple HIV epitopes. PMID:16359234.
material entity;recombinant HIV gp120 with adjuvant NanoEmulsion;A HIV vaccine that is made of recombinant HIV gp120 protein adjuvanted with the adjuvant NanoEmulsion. PMID:18260780.
role;USA licensed vaccine role;a licensed vaccine role that indicates the vaccine occurs in USA.
material entity;USA licensed cattle vaccine;A cattle vaccine with license that is used in USA.
generically dependent continuant;vaccination dose;A dose of vaccine that is used in a vaccination. Vaccination dose may be and may be not the same as the vaccine dose.
continuant;monthly;
material entity;pSCAR DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSCAR . CMV promotor is used.
material entity;vaccine epitope;
role;RNA vaccine role;A vaccine role that indicates the vaccine being a RNA vaccine.
material entity;Herpes simplex virus vaccine;
material entity;cytomegalovirus vaccine;
material entity;Dengue virus vaccine;A viral vaccine that protects against infection with Dengue virus.
material entity;Ebola virus vaccine;A viral vaccine that protects against infection with Ebola virus.
material entity;Herpesvirus vaccine;A viral vaccine that protects against infection with Herpesvirus.
material entity;Brucella abortus strain RB51SOD;
material entity;Brucella suis vaccine;a Brucella vaccine against infection wtih B. suis
material entity;Brucella suis strain 2;An orally administrable brucellosis vaccine that was was developed in China. It is effective for oral vaccination of sheep, goats, cattle and pigs.
material entity;Brucella abortus strain 45/20;
material entity;Marek disease vaccine;
material entity;Shigella ribosome-based Vaccine (SRB);
material entity;Corynebacterium diphtheriae vaccine;A bacterial vaccine that protects against infection with Corynebacterium diphtheriae that causes Diphtheria.
material entity;Measles-Mumps vaccine;A Measles virus vaccine that also protects against infection with Mumps virus.
material entity;Measles-Mumps-Rubella-Varicella vaccine;A Measles-Mumps-Rubella vaccine that also protects against Varicella.
material entity;Diphtheria-Tetanus-Pertussis vaccine;
material entity;Measles-Mumps-Rubella vaccine;A Measles-Mumps vaccine that also protects against infection with Rubella virus.
material entity;Diphtheria-Tetanus vaccine;A Corynebacterium diphtheriae vaccine that also protect against infection with Clostridium tetani.
material entity;CVD 1204(pGA1-CS2);
material entity;CVD 1204(pGA1-CS3);
process;vaccine trial regulation;A vaccine regulation process for vaccine clinical trials.
process;primary vaccination;A vaccination process that occurs at the first time to a host organization in a specified period.
process;boost vaccination;A vaccination process that occurs after the primer vaccination with a purpose to boost host immune response to vaccine antigen.
material entity;Brucella melitensis vaccine;
role;recombinant viral vector vaccine role;a recombinant vector vaccine role that inheres in a virus that carries a vaccine antigen for development of a particular vaccine
material entity;antibiotics vaccine residual;a vaccine residual that is from antibiotics used during the manufacture process.
process;vaccine specific antibody test;
process;subunit vaccine preparation;A vaccine preparation that results in the generation of a subunit vaccine
process;live attenuated vaccine preparation;A vaccine preparation that results in the generation of a live attenuated vaccine
process;preparation of RNA vaccine;A vaccine preparation that results in the generation of a RNA vaccine
disposition;vaccine allergen disposition;
material entity;Canada licensed human vaccine;a licensed human vaccine that is licensed in Canada
process;preparation of DNA vaccine;A vaccine preparation that results in the generation of a DNA vaccine
process;preparation of conjugate vaccine;A vaccine preparation that results in the generation of a conjugate vaccine
material entity;B. melitensis strain Rev. 1;
material entity;inactivated viral vaccine;a viral vaccine that is inactivated
material entity;Alzheimer vaccine;A vaccine that prevents or treats Alzheimer disease.
material entity;malaria vaccine;Plasmodium vaccine is a vaccine that prevents against Plasmodium species causing malaria. It is made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
material entity;Leishmania vaccine;a protozoan vaccine that prevents against infection with Leishmania.
material entity;Vibrio cholerae vaccine;A bacterial vaccine that prevents infection with Vibrio cholera.
material entity;E. histolytica CEL-170/4 protein vaccine;
material entity;P. falciparum Subunit SE36 Protein Vaccine;
material entity;M. tuberculosis Mtb72F protein subunit vaccine;
material entity;B. pertussis DNA vaccine encoding TcfA;
material entity;P. falciparum Pfen Protein Subunit Vaccine;
material entity;Mumps HN Protein Subunit Vaccine;
material entity;E. histolytica SREHP protein vaccine;
material entity;E. coli C3389 protein vaccine;
material entity;M. tuberculosis DNA Vaccine encoding Ag85B Protein;
material entity;Hepatitis B virus DNA vaccine encoding HBVgp2 pre-S1/pre-S2/S;
material entity;Salmonella vaccine;A bacterial vaccine that protects against infections by various Salmonella species.
material entity;Shigella vaccine;A bacterial vaccine that protects against infections with Shigella species.
material entity;Lyme disease vaccine;A vaccine that prevents Lyme disease caused by Borrelia burgdorferi.
material entity;Bordetella pertussis vaccine;A bacterial vaccine that prevents against Bordetella pertussis infection that causes pertussis or whooping cough.
material entity;Pseudomonas vaccine;A bacterial vaccine that protects against infection with Pseudomonas.
material entity;Rickettsial vaccine;A bacterial vaccine that protects against diseases caused by various species of Rickettsia. Typhus is any of several similar diseases caused by Rickettsia bacteria. So Rickettsial vaccine is also called typhus vaccine.
material entity;BCG vaccine;BCG Vaccine is a Mycobacterium tuberculosis vaccine that is a live attenuated strain of Mycobacterium bovis (Bacillus Calmette Guerin. BCG).
material entity;Streptococcal vaccine;A bacterial vaccine that prevents streptococcal infections.
material entity;MSP3-LSP with aluminium hydroxide;
material entity;P. falciparum RTS,S/AS02A;RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen.
material entity;Staphylococcal vaccine;A bacterial vaccine that protects against infection with Staphylococcus.
material entity;C. pneumoniae DNA vaccine encoding Ssb;
material entity;C. psittaci DNA vaccine pcDNA1/MOMP;
material entity;Herpes simplex virus type 1 DNA vaccine encoding GE;
material entity;C. pneumoniae DNA vaccine encoding PknD;
material entity;C. abortus DNA vaccine encoding OmlA;
material entity;Classical swine fever virus vaccine VAC-E0;
material entity;C. abortus DNA vaccine encoding GatC;
material entity;Herpes simplex virus type 1 DNA vaccine encoding GD;
material entity;Measles Virus vaccine VEE/SIN-H+F;
material entity;Herpes simplex virus type 2 vaccine using phage displaying GG protein;
material entity;P. falciparum MSP1 from transgenic mice with Freund's adjuvant;
material entity;P. vivax PVS25 with Montanide ISA-720;
material entity;P. falciparum FMP1/AS02A;A recombinant E. coli-expressed protein based upon the apical membrane antigen-1 (AMA-1) of the 3D7 clone formulated with the AS02A adjuvant. PMID:17442466.
material entity;P. falciparum ABRA protein vaccine;
material entity;P. falciparum vaccine Combination B;A malaria vaccine that comprises recombinant Plasmodium falciparum (P. falciparum) blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant Montanide ISA 720.
material entity;Haemophilus influenzae serotype b;
material entity;Haemophilus b and Hepatitis B vaccine;a viral vaccine against Hepatitis B virus and at the same time against bacterial H. influenzae serotype b.
material entity;DNA and MVA encoding ME-TRAP;A vaccine that contains DNA and modified vaccinia virus Ankara (MVA) encoding thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP). This vaccine is used with a prime-boost regime by DNA priming and MVA boosting.
material entity;Papillomavirus vaccine;A viral vaccine that protects against infection with Papillomavirus.
material entity;Parainfluenza virus vaccine;A viral vaccine that protects against infection with Parainfluenza virus.
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus vaccine;A vaccine that protects against diphtheria, tetanus, pertussis, and poliovirus.
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine;A vaccine used to prevent infections of diphtheria, tetanus (lockjaw), pertussis (whooping cough), hepatitis B, and poliovirus.
material entity;Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine;A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, and Haemophilus influenzae type b.
material entity;Hepatitis A&B vaccine;
material entity;Pseudorabies virus vaccine;A viral vaccine that protects against infection with Pseudorabies virus.
material entity;Simian immunodeficiency virus vaccine;A viral vaccine that prevents against infection with Simian immunodeficiency virus.
material entity;Hendra virus G protein vaccine;
material entity;West Nile virus vaccine;A viral vaccine that protects against West Nile virus infection.
material entity;Topografov virus N protein vaccine;
material entity;Hepatitis B virus DNA vaccine pVAX-PS;
material entity;Sin Nombre virus DNA vaccine encoding G1;
material entity;Seoul virus vaccine rCAV-2-Gc;
material entity;NIpah Virus G and F Proteins Subunit Vaccine;
material entity;Herpes simplex virus type 1 DNA vaccine encoding GC;
material entity;Herpes simplex virus type 2 DNA vaccine encoding ICP27;
material entity;Herpes simplex virus type 2 DNA vaccine encoding GB;
material entity;Puumala virus PUUVsSgp1 (NP) protein vaccine;
material entity;ISCOM vaccine adjuvant;A particulate antigen delivery system vaccine adjuvant that consists of an assembly of antigens in multimeric form and presents an antigen to induce specific immunologic responses. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. MeSH term: D20.215.894.860.449.
material entity;Plasmodium vivax vaccine;
material entity;contraceptive vaccine;A vaccine that is used to prevent conception.
material entity;Respiratory syncytial virus vaccine;A viral vaccine that prevents infection with Respiratory syncytial virus.
material entity;marker vaccine;A vaccine that is used in conjunction with diagnostic tests to differentiate vaccinated animals from carrier animals. It can be a subunit or a gene-deleted vaccine.
material entity;edible vaccine;A vaccine that is edible and derived from an edible plant. The transgenic plant is used as recombinant protein production system. The edible plant tissue functions as an oral vaccine.
material entity;acellular vaccine;A subunit vaccine that is produced by using only the antigenic part of the disease causing organism. It often requires a "booster" every few years to maintain their effectiveness.
material entity;Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine.;
material entity;C. muridarum PmpG-1 protein vaccine;
material entity;influenza, live, intranasal, quadrivalent;
material entity;Canine distemper virus DNA vaccine encoding HA;
material entity;Staphylococcus bacteriophage lysate;
material entity;C. muridarum PmpE/F-2 protein vaccine;
generically dependent continuant;host species variable;A variable representing the species of the host used for a study.
material entity;Dengue Subunit E Protein Vaccine;
generically dependent continuant;host disease state variable;A variable representing the host's participation in a disease state (i.e. healthy, or diabetic).
material entity;E. histolytica Eh29 protein vaccine;
material entity;Toxoplasma gondii SAG5B;A SAG5B protein that is part of Toxoplasma gondii
material entity;E. histolytica Gal/GalNAc lectin protein vaccine;
material entity;Toxoplasma gondii TgNTPase-II;A TgNTPase-II protein that is part of Toxoplasma gondii
material entity;Dengue DNA Vaccine encoding NS1 Protein;
material entity;Toxoplasma gondii TgPF;A TgPF protein that is part of Toxoplasma gondii
material entity;Dengue Vaccine using Vaccinia Virus expressing M Protein;
material entity;Toxoplasma gondii SAG5C;A SAG5C protein that is part of Toxoplasma gondii
material entity;Dengue Vaccine using Vaccinia Virus expressing prM Protein;
material entity;Toxoplasma gondii TgADF;A TgADF protein that is part of Toxoplasma gondii
material entity;C. muridarum MOMP protein vaccine;
material entity;Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months;
material entity;E. tenella DNA vaccine proIE;
material entity;SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose;
material entity;Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free;
material entity;E. maxima Gam82 protein vaccine;
material entity;Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months;
material entity;S. flexneri Invaplex 50 Subunit Vaccine;
generically dependent continuant;host sex variable;A variable representing the biological sex of the host
material entity;C. posadasii DNA Vaccine encoding PRA protein;a Coccidioides vaccine that contains C. posadasii DNA vaccine encoding PRA protein
generically dependent continuant;host age variable;A variable representing the age of the host
material entity;Canine parvovirus DNA vaccine pGT36VP1;
material entity;C. posadasii subunit PMP1 protein vaccine;a Coccidioides vaccine that contains C. posadasii PMP1 protein
generically dependent continuant;host comorbidity variable;A variable representing host quality's that leads to a wore outcome to vaccination or pathogen disease state.
material entity;Ebola virus DNA vaccine encoding ZEBOV GP and SEBOV GP;
material entity;Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free;
material entity;S. flexneri Invaplex 24 Subunit Vaccine;
generically dependent continuant;host pregnancy variable;A variable representing the presence of another developing organism in an animal host
material entity;C. immitis subunit URE protein vaccine;a Coccidioides vaccine that contains C. immitis subunit URE protein
material entity;influenza, seasonal vaccine, quadrivalent, adjuvanted, 0.5mL dose, preservative free;
material entity;Canine parvovirus CPMV-PARVO1 protein vaccine;
material entity;VRP expressing VP30;An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP30 protein.
material entity;VRP expressing VP35;An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP35 protein.
material entity;VRP expressing VP40;An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP40 protein.
material entity;DNA vaccine expressing sGP;A DNA vaccine that encodes for a secreted form of Ebola virus GP protein.
material entity;GP-VRP;
material entity;VRP expressing VP24;An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP24 protein.
material entity;Toxoplasma gondii MIC13;A MIC13 protein that is part of Toxoplasma gondii
material entity;B. pseudomallei Subunit LolC Protein Vaccine;
material entity;Toxoplasma gondii MIC4;A MIC4 protein that is part of Toxoplasma gondii
material entity;C. muridarum RplF protein vaccine;
material entity;Toxoplasma gondii MIC1;A MIC1 protein that is part of Toxoplasma gondii
material entity;C. pneumoniae DNA vaccine encoding FabD;
material entity;Toxoplasma gondii MIC11;A MIC11 protein that is part of Toxoplasma gondii
material entity;C. pneumoniae LcrE protein vaccine;
material entity;Toxoplasma gondii PGAM2;A PGAM2 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii MIC6;A MIC6 protein that is part of Toxoplasma gondii
material entity;B. pseudomallei Subunit PotF Protein Vaccine;
material entity;Toxoplasma gondii MIC8;A MIC8 protein that is part of Toxoplasma gondii
material entity;P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine;
material entity;Toxoplasma gondii hsp70;A hsp70 protein that is part of Toxoplasma gondii
material entity;C. pneumoniae CopN protein vaccine;
material entity;Toxoplasma gondii ISP3;A ISP3 protein that is part of Toxoplasma gondii
material entity;prostate cancer DNA vaccine encoding prostatic acid phosphatase (PAP);
material entity;C. abortus DNA vaccine encoding MOMP;
material entity;Toxoplasma gondii GRA8;A GRA8 protein that is part of Toxoplasma gondii
material entity;C. abortus DNA vaccine Pomp90A;
material entity;DNA and adenoviral vector Ad5 expressing SIV gag protein;A vaccine combination that includes a DNA vaccine and a recombinant adenovirus Ad5 expressing the same codon-optimized SIV gag gene. The DNA vaccine is used for priming, and the Ad5 vaccine is used for boosting. PMID:11797011.
material entity;adenoviral vector Ad5 expressing SIV gag protein;A recombinant adenovirus (Ad5) expressing the codon-optimized SIV gag gene. PMID:11797011.
material entity;DNA and Ad5/35 vector expressing HIV gp160 protein;A vaccine combination that includes a DNA vaccine and a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) that express the same codon-optimized SIV gag gene. The DNA vaccine is used for priming, and the Ad5/35 vaccine is used for boosting. PMID:16079886.
material entity;Brucella abortus gene;A Brucella gene that is from B. abortus.
material entity;wboA from B. abortus strain 2308;A Brucella abortus gene that has the name wboA and comes from strain 2308.
material entity;mouse Ifng;
material entity;human ifng;
material entity;Brucella gene;
material entity;human gene;
material entity;mouse gene;
material entity;Toxoplasma gondii ROP8;A ROP8 protein that is part of Toxoplasma gondii
material entity;F. tularensis DNA vaccine rLm/iglC;
material entity;E. tenella vaccine rBCG pMV361-Rho;
material entity;Toxoplasma gondii PLP1;A PLP1 protein that is part of Toxoplasma gondii
material entity;E. coli IutA protein vaccine;
material entity;Toxoplasma gondii ROP38;A ROP38 protein that is part of Toxoplasma gondii
material entity;F. tularensis GroEL protein vaccine;
material entity;Toxoplasma gondii ROP2;A ROP2 protein that is part of Toxoplasma gondii
material entity;E. tenella DNA vaccine pcDNA-TA4-IL-2;
material entity;Toxoplasma gondii SAG2;A SAG2 protein that is part of Toxoplasma gondii
material entity;P. falciparum MSP3 Protein Subunit Vaccine;
material entity;Toxoplasma gondii ROP17;A ROP17 protein that is part of Toxoplasma gondii
material entity;E. coli Hma protein vaccine;
material entity;E. coli IreA protein vaccine;
material entity;Toxoplasma gondii RACK1;A RACK1 protein that is part of Toxoplasma gondii
material entity;Lassa Virus Nucleoprotein Subunit Vaccine;
material entity;Toxoplasma gondii ROP16;A ROP16 protein that is part of Toxoplasma gondii
material entity;E. coli C4424 protein vaccine;
material entity;cattle gene;
material entity;Ifng from cattle;
material entity;hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule;
material entity;diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV);
material entity;T. parva Subunit p67 Protein Vaccine;
material entity;non-US diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV);
material entity;C. jejuni FlaC protein vaccine;
material entity;diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated;
material entity;T. brucei Subunit p15 Protein Vaccine;
material entity;historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine.;
material entity;C. jejuni MBP-FlaA protein vaccine;
material entity;Haemophilus influenzae type b vaccine, PRP-T conjugate;
material entity;B. pertussis FhaB and 69 kDa OMP protein vaccine;
material entity;Haemophilus influenzae type b vaccine, PRP-OMP conjugate;
material entity;H. influenzae Hap protein vaccine;
material entity;Haemophilus influenzae type b conjugate and Hepatitis B vaccine;
material entity;Haemophilus influenzae type b vaccine, HbOC conjugate;
material entity;C. posadasii subunit GEL1 protein vaccine;a Coccidioides vaccine that contains C. posadasii subunit GEL1 protein
material entity;diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens;
material entity;T. brucei DNA Vaccine encoding TSA protein;
material entity;human papilloma virus vaccine, bivalent;
material entity;human papillomavirus 9-valent vaccine;
material entity;hepatitis B vaccine (recombinant), CpG adjuvanted;
material entity;human papilloma virus vaccine, quadrivalent;
material entity;influenza, high-dose, split virus, trivalent, injectable, preservative free;
material entity;influenza, split virus, trivalent, injectable, preservative free;
material entity;influenza, live, trivalent, intranasal;
material entity;influenza virus vaccine, H5N1, A/Vietnam/1203/2004 (national stockpile);
material entity;hepatitis A and hepatitis B vaccine, pediatric/adolescent (non-US);
material entity;hepatitis B vaccine, pediatric or pediatric/adolescent dosage;
generically dependent continuant;no vaccine administered;An information content entity that specify no vaccine adminstered.
material entity;Chikungunya, live attenuated vaccine, 0.5 mL, preservative free;
material entity;M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting;
material entity;Anthrax vaccine, adsorbed, adjuvanted, post-exposure prophylaxis;
material entity;H. pylori VacA protein vaccine;
material entity;SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose;
material entity;E. tenella DNA vaccine rBCG pMV261-Rho;
material entity;SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose;
material entity;Vaxxitek HVT+IBD;
material entity;E. tenella GX3262 protein vaccine;
material entity;SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose;
material entity;E. tenella DNA vaccine EtMIC2;
generically dependent continuant;host pathogen exposure variable;A variable representing the prior immungenic memory a host has against a specific pathogen
material entity;Theileria annulata vaccine by Local veterinary institutes;
material entity;Meningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative free;
material entity;H. pylori DNA vaccine encoding UreB;
material entity;SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose;
material entity;Newcastle disease virus vaccine by Dow AgroSciences;
material entity;SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose;
material entity;Theileria parva vaccine by Centre for Ticks and Tickborne Disease, Malawi;
material entity;diphtheria and tetanus toxoids, adsorbed for pediatric use;
material entity;Canine distemper virus DNA vaccine encoding F and HA;
material entity;tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid);
material entity;SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK;
generically dependent continuant;record of unknown vaccine or immune globulin;A record of missing knowledge indicating that vaccine or immune globulin is unknown.
material entity;PCV2 DNA Vaccine encoding ORF2 Protein;
material entity;Td Polio Adsorbed;A multivalent vaccine against tetanus, diphtheria, and poliomyelitis.
material entity;Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis;
material entity;C. jejuni FspA2 protein vaccine;
material entity;Diphtheria, Tetanus, Poliomyelitis adsorbed;
material entity;C. jejuni DNA vaccine pcDNA3.1(+)-peblA;
material entity;hepatitis B vaccine, adult dosage;
material entity;C. jejuni FspA1 protein vaccine;
material entity;hepatitis B vaccine, dialysis patient dosage;
material entity;SARS Subunit Spike Protein Vaccine;
material entity;Human papillomavirus DNA vaccine pNGVL4a-E6/opt;
material entity;Toxoplasma gondii CDPK6;A CDPK6 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii ROP18;A ROP18 protein that is part of Toxoplasma gondii
material entity;Trypanosoma cruzi TSSA;A TSSA protein that is part of Trypanosoma cruzi
material entity;Toxoplasma gondii CDPK1;A CDPK1 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii CST2;A CST2 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii CyP;A CyP protein that is part of Toxoplasma gondii
material entity;Trypanosoma cruzi TSA-1;A TSA-1 protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi TsF;A TsF protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi TCTS-154;A TCTS-154 protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi Trans-salidase;A Trans-salidase protein that is part of Trypanosoma cruzi
material entity;Toxoplasma gondii GRA41;A GRA41 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii GRA6;A GRA6 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii GRA23;A GRA23 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii GRA25;A GRA25 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii GRA7;A GRA7 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii GRA17;A GRA17 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii GRA24;A GRA24 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii GRA1;A GRA1 protein that is part of Toxoplasma gondii
material entity;Toxoplasma gondii GRA16;A GRA16 protein that is part of Toxoplasma gondii
material entity;Plasmodium vivax PvDBPII;A DBPII protein that is part of Plasmodium vivax|A PvDBPII protein that is part of Plasmodium vivax
material entity;Human papillomavirus E7 protein vaccine;
material entity;Plasmodium vivax TRAP;A TRAP protein that is part of Plasmodium vivax
material entity;P. falciparum Hsp90 Protein Subunit Vaccine;
material entity;Plasmodium vivax CelTOS;A CelTOS protein that is part of Plasmodium vivax|A PvCelTOS protein that is part of Plasmodium vivax
material entity;Marek's Disease Virus Vaccine rFPV/gB1;
material entity;Plasmodium vivax CS;A CS protein that is part of Plasmodium vivax|A PvCS protein that is part of Plasmodium vivax
material entity;Marburg Virus Nucleoprotein Vaccine;
material entity;Plasmodium yoelii SSP2;A SSP2 protein that is part of Plasmodium yoelii
material entity;Rift Valley Fever Virus DNA Vaccine encoding N Protein;
material entity;Trypanosoma cruzi ASP-1;A ASP-1 protein that is part of Trypanosoma cruzi
material entity;Plasmodium yoelii HEP17;A HEP17 protein that is part of Plasmodium yoelii
material entity;Human papillomavirus L2 protein vaccine;
material entity;Plasmodium yoelii HSP60;A HSP60 protein that is part of Plasmodium yoelii
material entity;IHNV DNA vaccine pIHNw-G;
material entity;Plasmodium knowlesi PkAMA1;A PkAMA1 protein that is part of Plasmodium knowlesi
material entity;B. pertussis DNA vaccine encoding Prn;
material entity;Plasmodium knowlesi PkMSP1p42;A PkMSP1 protein that is part of Plasmodium knowlesi|A PkMSP1p42 protein that is part of Plasmodium knowlesi
material entity;Marek's Disease Virus Vaccine rFPV/gI;
material entity;Trypanosoma cruzi Tc24;A Tc24 protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi Tc80;A Tc80 protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi PFR Ag;A PFR Ag protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi rTcENO from H8;A rTcENO from H8 protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi TcTASV-C;A TcTASV-C protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi TcENO;A TcENO protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi TcSSP4;A TcSSP4 protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi G1;A G1 protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi PAR3;A PAR3 protein that is part of Trypanosoma cruzi
material entity;Trypanosoma cruzi CRP;A CRP protein that is part of Trypanosoma cruzi
material entity;Alpha-type-1 Polarized Dendritic Cell Vaccine;A mature polarized dendritic cell with potent immunostimulating activity. Treating dendritic cells (DCs) with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma) produces mature but not exhausted alpha type-1 polarized DCs (alphaDC1) that are capable of: 1) high responsiveness to other lymphoid chemokines, and 2) producing high level of interleukin-12p70 (IL-12p70). Therefore, alphaDC1 has a much more significant capability of inducing helper T cell (CD4+ T-cell) responses in comparison with the ""gold standard"" DCs. When pulsed with specific tumor associated antigens (TAAs), alphaDC1 is able to induce a potent cytotoxic T lymphocyte (CTL) response against TAAs. as a result it can be used as a cancer vaccine.
material entity;Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cell Vaccine;A cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with the marine sponge glycolipid alpha-galactosylceramide (alpha-GalCer) with potential immunostimulatory and antimetastatic activities. Upon administration, alpha-galactosylceramide-pulsed autologous dendritic cells may result in the activation and proliferation of a subset of endogenous natural killer T (NKT) cells, B cells, and CD4+ and CD8+ T cells, and the production of interferon-gamma and interleukin-12. these cascade events may result in a T helper-1 cell-biased proinflammatory antitumor immune response. The NKT cell ligand alpha-GalCer was originally isolated from the marine sponge Agelas mauritianusis.
material entity;Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with four alpha-fetoprotein (AFP) peptides, with potential immunostimulatory and antineoplastic activities. Upon administration, AFP peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against AFP-expressing cancer cells, resulting in tumor cell lysis. AFP is overexpressed in a variety of cancer cells.
material entity;Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine;An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes.
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.0075 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.0075 MG/ML Injectable Suspension;
material entity;Alpha Fetoprotein Adenoviral Vector Vaccine;A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis.
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.015 MG/ML;
material entity;Allogenic Glioma Cancer Vaccine;A vaccine composed of killed glioma cancer cells from another patient for use in immunotherapy
material entity;TC0757 hypothetical protein;
material entity;Allogeneic Tumor Cell Vaccine;A vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient to stimulate cytotoxic immune responses to a similar tumor cell type. The cells found in this type of whole-cell vaccine express many cell-surface tumor-associated antigens. This vaccine is frequently administered with an adjuvant immunostimulant.
material entity;TC0439 adherence factor;
material entity;Allogeneic Renal Cell Carcinoma Vaccine MGN1601;A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.
material entity;CopN;
material entity;Allogeneic Multipotent Adult Progenitor Cells Vaccine;A biologic product that consists of undifferentiated stem cells, obtained from adult bone marrow or other non-embryonic tissue sources, that are expanded in vitro and deposited in master cell banks for ""off-the-shelf"" use, with potential hematopoiesis-inducing and immunomodulating activities. Allogeneic multipotent adult progenitor cells (MAPCs) are non-immunogenic due to the lack of major histocompatibility (MHC) molecule expression, and so elicit no immune response upon administration. In vivo, bone marrow-derived adult stem cells are capable of maturing into a broad range of cell types and may help restore the immune system by producing multiple therapeutic molecules in response to inflammation and tissue damage.
material entity;TC0512 outer membrane protein, putative;
material entity;Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a mixture of lysates from five allogeneic mesothelioma tumor cell lines, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic mesothelioma tumor cell lysates. Upon re-administration of the allogeneic mesothelioma tumor lysate-pulsed autologous DC vaccine, the immune system is exposed to an undefined amount of mesothelioma-associated antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against mesothelioma tumor cells and leads to tumor cell lysis
material entity;TC0767 hypothetical protein;
material entity;TC0768 hypothetical protein;
material entity;0.5 ML influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2022-2023];
material entity;0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;DnaK from Chlamydophila abortus;
material entity;0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;LcrE;
material entity;0.5 ML influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Prefilled Syringe;
material entity;GatB;
material entity;0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Omp1;
material entity;0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2021-2022];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.015 MG/ML Injectable Suspension;
material entity;0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.025 MG/ML;
material entity;0.5 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2021-2022];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.025 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.025 MG/ML Injectable Suspension;
material entity;0.5 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.05 MG/ML Injectable Suspension;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML Injectable Suspension;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML [Comirnaty];
material entity;ALVAC(2) Melanoma Multi-antigen Vaccine;A therapeutic cancer vaccine, based on a replication-defective recombinant canarypox virus (ALVAC) encoding multiple melanoma antigens, with potential immunostimulatory and antineoplastic activities. Vaccination with ALVAC(2) melanoma multi-antigen therapeutic vaccine may stimulate the host immune system to mount an immune response against antigen-expressing melanoma cells, resulting in inhibition of tumor growth and/or metastasis.
material entity;a2/4-1bbl melanoma vaccine;A cancer vaccine used to treat patients with malignant melanoma. It is made of a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation, with an immune response to residual tumor in the body. It will be used in combination with intravenous low dose cyclophosphamide, 300 mg/m2.
material entity;ALVAC-MART-1 Vaccine;A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine. a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation
material entity;ALVAC-hB7.1 Vaccine;A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient.
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.05 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5) 0.05 MG/ML Injectable Suspension;
material entity;ALVAC-ESO-1 Vaccine;A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC-ESO-1 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-1-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells.
material entity;E2 from Classical swine fever virus;
material entity;ALVAC-CEA Vaccine;A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types.
material entity;E0;
material entity;ALVAC-CEA B7.1 Vaccine;A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It causes infected cells to temporarily display CEA and activates the immune system to attack the tumor cells.
material entity;FabD;
material entity;ALVAC-CEA (VCP248) Vaccine;A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against CEA-positive tumor cells, thereby decreasing tumor growth. (NCI04)
material entity;Ssb;
material entity;ALVAC-B7-CEA Vaccine;A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-B7-CEA expresses carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cells, and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28, to augment the host immune response. This agent has been shown to stimulate a host immune response against tumor cells that express CEA. (NCI04)
material entity;ALVAC Vaccine;A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate. Thus, it produces a self-limiting infection which does not produce symptoms or harm the host. When carrying foreign genes it will cause transient expression of protein.
material entity;Gp55;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.0075 MG/ML;
material entity;MOMP;
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;PmpE/F-2;
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;PknD;
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2022-2023];
material entity;PmpG-1;
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;RplF;
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.1 MG/ML;
material entity;0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2022-2023];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.1 MG/ML Injectable Suspension;
material entity;0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2022-2023];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML;
material entity;0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2022-2023];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML [Spikevax];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension;
material entity;0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2022-2023];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension [Spikevax];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5) 0.025 MG/ML;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5) 0.05 MG/ML;
material entity;Allogeneic Cellular Vaccine 1650-G;A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.
material entity;Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine;An allogeneic whole cell vaccine, derived from irradiated allogenic tumor cells manipulated to express human B7.1 (CD80 antigen) and human leukocyte antigen (HLA) A1, with potential antitumor activity. Vaccination with allogeneic B7.1/HLA-A1 transfected tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor cell proliferation.
material entity;Allogeneic AML Antigen-expressing Dendritic Cell Vaccine;A cancer vaccine consisting of allogeneic, immortalized dendritic precursor cells derived from a patient with acute myelogenous leukemia (AML), with potential immunostimulatory and antineoplastic activities. Upon ex vivo stimulation and expansion of the precursor cells into mature, fully functional dendritic cells (DCs) and subsequent administration, the allogeneic AML antigen-expressing DC vaccine may elicit a potent cytotoxic T-cell (CTL) and antibody response against AML antigen-expressing cells, resulting in tumor cell death.
material entity;Algenpantucel-L Vaccine;A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft. murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells.
material entity;AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine;A cancer vaccine containing the three frame shift peptides (FSP) AIM2(-1), HT001(-1) and TAF1B(-1), with potential immunomodulating activity. Upon administration, the AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine may induce an immune response against microsatellite instability (MSI) colorectal cancer-associated antigens. Frame shift mutations of AIM2 (absent in melanoma 2, an interferon-inducible protein), HT001 (asteroid homolog 1 or ASTE1, with an unknown function) and TAF1B (TATA box-binding protein-associated RNA polymerase I B, a transcription factor) are seen in MSI-positive colorectal cancers and may be associated with malignant transformation, tumor progression and the presence of tumor-infiltrating lymphocytes. These FSPs all have one-base deletions.
material entity;Ag NY-ESO-1 Vaccine;A cancer vaccine made of a recombinant NY-ESO-1 protein with a TLR7 agonist
material entity;AFP Gene Hepatocellular Carcinoma Vaccine;A cancer vaccine composed of naked plasmid DNA of the gene for the tumor-associated antigen alpha-fetoprotein (AFP), a macromolecule that acts as a specific immunologic target for hepatocellular carcinoma. This agent exerts an antitumor effect by inducing cytotoxic T-lymphocytes to attack AFP-expressing tumor cells.
material entity;AE37 Peptide/GM-CSF Vaccine;A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.
material entity;VP35 from Zaire ebolavirus;
material entity;AdRTVP-1-Transduced Prostate Cancer Cell-Based Vaccine;A cell-based vaccine comprised of prostate cancer cells transduced with an adenoviral vector encoding human RTVP-1 (AdRTVP-1), with potential antineoplastic and immunostimulating activities. RTVP-1, also referred to as glioma pathogenesis-related protein 1 (GLIP1), is down-regulated in prostate tumors. Regulated by tumor suppressor p53, the expression of RTVP-1 functions as a tumor suppressor, and is abundant in normal human prostate epithelial cells as well as in differentiated macrophages. Administration of this vaccine leads to an induction of apoptosis through the expression of RTVP-1 and results in a reduction in cellular proliferation in prostate cancer cells. In addition, this cancer-cell based vaccine may induce a cytotoxic T lymphocyte (CTL) response against prostate specific tumor associated antigens, resulting in an immune-mediated prostate cancer cell death. Furthermore, RTVP-1 stimulates CTL and natural killer (NK) cell activities.
material entity;Tbp2;
material entity;Adenovirus-PSA Prostate Cancer Vaccine;A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer.
material entity;VP30 from Reston ebolavirus;
material entity;VP35 from Reston ebolavirus;
material entity;VP40 from Zaire ebolavirus;
material entity;LASVsSgp2 glycoprotein;
material entity;VP24 from Zaire ebolavirus;
material entity;VP30 from Zaire ebolavirus;
material entity;VP24 from Reston ebolavirus;
material entity;VP40 from Reston ebolavirus;
material entity;Allogeneic Melanoma Vaccine AGI-101H;A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells.
material entity;Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307;A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI.
material entity;Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine;A cancer vaccine, containing human-specific large multivalent immunogens (LMIs) isolated from the membrane fraction of cells from a breast cancer cell line, with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen breast cancer vaccine may stimulate a cytotoxic T lymphocyte (CTL) immune response against tumor cells that express the breast cancer cell-specific LMIs.
material entity;Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo;An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line.
material entity;Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo;An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line.
material entity;Allogeneic GM-CSF-Secreting Breast Cancer Vaccine;An allogenic vaccine consisting of irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene. Upon vaccination, the genetically modified cells secrete GM-CSF, thereby potentiating a tumor-specific T cell response against breast cancer cell-asociated antigens.A vaccine that is being studied as a way to help the body's immune system kill breast cancer cells. To make the vaccine, the GM-CSF gene is put into breast cancer cells in the laboratory. The cells are then treated with radiation to stop them from growing and injected into the same or a different patient. The GM-CSF protein made by the changed breast cancer cells may help the immune system kill breast cancer cells in the body.
material entity;Allogeneic GM-CSF-Based Myeloma Cell Vaccine;An allogeneic tumor cell vaccine containing myeloma cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, allogeneic GM-CSF-based myeloma cellular vaccine secretes GM-CSF, which may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against myeloma cancer cell-associated antigens.
material entity;LcrV from Y. pestis KIM 10;
material entity;Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from an allogeneic glioblastoma (GBM) stem-like cell line, with potential immunostimulatory and antineoplastic activities. Upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to GBM stem cell antigens, which may result in cytotoxic T lymphocyte (CTL) and antibody responses against GBM cells. This leads to GBM cell lysis. GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.
material entity;V antigen;
material entity;Allogeneic Dendritic Cell-Myeloma Idiotype Vaccine;A cell-based vaccine composed of allogeneic dendritic cells pulsed ex-vivo with an autologous myeloma idiotype with potential antineoplastic activity. Upon administration, allogeneic dendritic cell-myeloma idiotype vaccine may stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against myeloma cells, resulting in cell lysis.
material entity;Lef from B. anthracis str. Ames Ancestor;
material entity;Allogeneic Dendritic Cell Vaccine COMBIG-DC;A cancer vaccine consisting of allogeneic, immortalized dendritic cells (DCs) loaded with tumor specific antigens and activated, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration of the allogeneic dendritic cell vaccine COMBIG-DC, these activated DCs attract natural killer (NK) cells, induce an anti-inflammatory response leading to the induction of NK-cell-mediated tumor cell death. Upon release of tumor associated antigens (TAAs) from the lysed tumor cells, these antigens are taken up by antigen presenting cells which activate the immune system to elicit a potent cytotoxic T-cell (CTL) response against the TAAs, resulting in the death of TAAs-expressing tumor cells.
material entity;LcrV from y. pestis CO92;
material entity;GatA;
material entity;Pla;
material entity;YopD from Y. pestis CO92;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Injection;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe;
material entity;L1R from Monkeypox virus Zaire-96-I-16;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;PagA from B. anthracis str. Ames Ancestor;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Caf1 from Y. pestis biovar Microtus str. 91001;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [FluLaval Quadrivalent 2015-2016];
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016 Southern Hemisphere];
material entity;0.5 ML influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Prefilled Syringe [Prevnar];
material entity;Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML;
material entity;Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML;
material entity;Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML;
material entity;Autologous CD40L-expressing B-CLL Vaccine;A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced with an adenoviral vector encoding the gene for the human CD40 ligand (CD40L. TRAP. CD154), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD40L-expressing B-CLL vaccine expresses the co-stimulatory molecule CD40L, which binds to its cognate receptor, CD40, on antigen presenting cells (APC). This induces apoptosis, stimulates maturation and proliferation of APCs, and facilitates a cytotoxic T-lymphocyte (CTL) response against tumor cells. CD40L is a type II membrane protein that binds to CD40, which is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily.
material entity;Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML;
material entity;Autologous CD133-Positive BTSC mRNA-Pulsed Autologous Dendritic Cell Vaccine;A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with CD133-positive autologous brain tumor stem cells (BTSCs) -derived mRNA with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against the CD133-positive BTSCs from which the autologous tumor mRNA is derived. CD133, a tumor-associated antigen (TAA) and neural stem cell marker, has been found on a specific subset of glioblastoma multiforme (GBM) stem cells. its presence has been correlated with resistance to conventional chemotherapy and radiotherapy.
material entity;Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes Vaccine;Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein.
material entity;Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes Vaccine;Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues 154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas.
material entity;Autologous Ad-CD154-Transduced CLL B Cells Vaccine;An autologous tumor cell vaccine containing chronic lymphocytic leukemia (CLL) B cells transduced with an adenoviral vector carrying chimeric CD154 (ad-CD154) with potential antineoplastic activity. Administration of autologous ad-CD154 transduced CLL B cells may result in increases in the numbers of leukemia-specific CD4+ T cells and high serum-levels of IL-12 and IFN-gamma. Due to ligation of CD154 to CD40 on CLL cells, this agent may induce CLL cells to express the proapoptotic molecule BID and death receptors CD95 (Fas) and DR5, rendering CLL B cells first resistant and then sensitive to Fas-mediated apoptosis. In addition, autologous ad-CD154 transduced CLL B cells may induce MHC class I-dependent cytotoxic T lymphocyte (CTL) responses against autologous leukemia cells. CD154 is a type II membrane glycoprotein and ligand for CD40. both molecules are important in cognate co-stimulatory cell-cell interactions.
material entity;AUT-OV-ALVAC-hB7.1 Vaccine;A vaccine comprised of autologous epithelial ovarian cells infected with ALVAC-hB7.1
material entity;adenovirus-transfected autologous dc vaccine plus cik cells;A cancer vaccine that uses adenovirus MUC1 and Survivin transfected autologous dendritic cells combined with cytokine-induced killer cells in cancer patients with Extensive-Stage Small- Cell Lung Cancer.
material entity;Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells Vaccine;A cell based cancer vaccine composed of mature polarized dendritic cells (DCs) and pulsed with apoptotic autologous tumor cells that has potential immunostimulating and antineoplatic activities. Dendritic cells (DCs) were treated with interleukin-1beta, tumor necrosis factor alpha, interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (p-I:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with apoptotic autologous tumor cells. Upon administration, these DCs are able to induce a potent cytotoxic T lymphocyte (CTL) response against tumor associated antigens (TAAs), resulting in tumor cell lysis and inhibition of tumor cell growth. Apoptotic tumor cells contain an array of TAAs
material entity;APC8015F vaccine;A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.
material entity;Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells Vaccine;An autologous tumor cell vaccine containing CD34+ hematopoietic progenitor cell (HPC)-derived Langerhans-type dendritic cells (LCs) electroporated with mRNA encoding the full-length cancer-testis antigens, CT7 and melanoma-associated antigen 3 (MAGE-A3), and the self-differentiation tumor antigen, Wilms tumor 1 (WT1) with potential immunomodulating and antineoplastic activity. The autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cells are prepared by drawing a blood sample containing the CD34+ HPCs from a cancer patient. The CD34+ HPCs are treated with a combination of cytokines which specifically support LC development, and the LC population is enriched and expanded ex vivo. The cultured LCs are allowed to mature for one day and then electroporated separately with CT7, MAGE-A3 or WT1 mRNA before final maturation. Upon intradermal administration into the patient, the mature LCs may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against cancer cells expressing CT7, MAGE-A3 and WT1 tumor antigens. This may result in the immune-mediated inhibition of tumor cell proliferation, leading to tumor cell death. CT7 and MAGE-A3 are tumor-specific proteins overexpressed in a number of cancers but not in healthy tissues other than testis and placenta. WT1 is a transcription factor important in development and cancer pathogenesis, which is overexpressed in a variety of cancers, including multiple myeloma, leukemia, ovarian cancer, malignant mesothelioma, neural tumors and renal carcinoma.
material entity;Autologous Colorectal Tumor Antigen-pulsed Dendritic Cell Vaccine;A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with tumor cell lysates from a colorectal cancer patient containing tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous colorectal tumor antigen-pulsed DC vaccine exposes the immune system to colorectal tumor cell antigens, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the colorectal cancer cells. This leads to cancer cell lysis. The tumor cell lysate contains a range of antigens that are essential for the neoplastic growth and survival of the cancer cells.
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection;
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML;
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML;
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 0.048 MG/ML;
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 0.5 ML;
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Suspension [Dryvax];
material entity;Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Injectable Suspension;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Prevnar];
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Prefilled Syringe;
material entity;Autologous Dendritic Cell-Tumor Fusion Vaccine;A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous tumor cells with potential immunostimulatory and antineoplastic activities. Autologous dendritic cell-tumor fusion vaccine is generated in vitro by mixing DCs and irradiated tumor cells harvested from individual patients and treating them with polyethylene glycol (PEG) to produce DC-tumor cell fusion hybrid cells. Upon administration, autologous dendritic cell-tumor fusion vaccine may elicit antitumor humoral and cellular immune responses.
material entity;Autologous Dendritic Cell-based Immunotherapeutic AV0113 Vaccine;A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of autologous DC-based immunotherapeutic AV0113, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes.
material entity;Autologous Dendritic Cell-Autologous Tumor mRNA-Human CD40L Vaccine;cancer vaccine consisting of autologous dendritic cells transfected with autologous tumor mRNA and the human CD40 ligand (CD40L) gene with immunostimulatory and antitumor activities. Vaccination with autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine may elicit a cytotoxic T cell response against tumor cells from which the autologous tumor mRNA was derived. When expressed by dendritic cells, tumor antigens and the co-stimulatory molecule CD40L, which binds to CD40 receptors on antigen presenting cells (APC), facilitate both humoral and cellular immune responses against tumor cells.
material entity;Autologous Dendritic Cell-Allogeneic Melanoma Tumor Cell Lysate Vaccine;A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis.
material entity;Autologous Dendritic Cell-Adenovirus P53 Vaccine;An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth.
material entity;Autologous Dendritic Cell-Adenovirus CCL21 Vaccine;A cancer vaccine comprised of autologous dendritic cells (DCs) that have been transduced ex vivo with an adenoviral vector containing the CCL21 gene with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, autologous dendritic cell-adenovirus CCL21 vaccine expresses the chemokine CCL21, which may induce an antitumoral cytotoxic immune response in the tumor microenvironment. CCL21 [chemokine (C-C motif) ligand 21] has been shown to attract antigen presenting cells (APCs), like leukocytes and DCs, and natural killer (NK) cells and their T-cell effectors to induce a cytotoxic immune response.
material entity;Autologous Dendritic Cell Vaccine ACT2001;A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis.
material entity;autologous dendritic cell vaccine (DCV);
material entity;Autologous EBV-Transformed B Lymphoblastoid-Tumor Fusion Cell Vaccine;A cell-based vaccine composed of autologous tumor cells with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis.
material entity;Autologous Dinitrophenyl-Modified Ovarian Cancer Vaccine;A cancer vaccine consisting of autologous ovarian cancer cell peptide antigens conjugated to the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of autologous dinitrophenyl-modified ovarian cancer vaccine may induce a cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens.
material entity;Autologous Dinitrophenyl Vaccine;A vaccine consisting of autologous cancer cells modified with the hapten, Dinitrophenyl. The treatment program consists of multiple intradermal injections of irradiated DNP-modified autologous tumor cells mixed with bacillus Calmette-Guerin.
material entity;0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Prefilled Syringe [Prevnar];
material entity;0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML;
material entity;0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Injectable Suspension;
material entity;0.5 ML influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2018-2019];
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML [Prevnar];
material entity;0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Injectable Suspension [Prevnar];
material entity;0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain 100000000 UNT/ML;
material entity;Anti-CTLA4 MoAb RNA-transfected Autologous Dendritic Cell Vaccine;An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4). expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain 100000000 UNT/ML [Dryvax];
material entity;Anti-CEA TCR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes;Autologous human peripheral blood lymphocytes (PBLs), transduced with a retroviral vector encoding both the alpha and beta chains of a T cell receptor (TCR) specific for the carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, anti-CEA TCR retroviral vector-transduced autologous lymphocytes bind to tumor cells expressing CEA, which may result in cytokine expression, activation and proliferation of T-cells, and a specific cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. The tumor-associated antigen (TAA) CEA is overexpressed by a variety of cancer cell types, including those of the gastrointestinal tract, lung, and breast.
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain 100000000 UNT/ML Injectable Suspension;
material entity;Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells Cancer Vaccine;Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities. In vitro, T cells are activated through exposure to the anti-CD3 murine monoclonal antibody OKT3 and low-dose interleukin 2 (Il-2) for 6-14 days and then armed with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi). Upon administration, anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (AATC) attach to CD3-expressing T cells and CD20-expressing tumor cells, selectively cross-linking T cells and tumor cells. This may result in the recruitment and activation of cytotoxic T lymphocyte (CTLs), CTL-mediated specific tumor cell lysis, and the secretion of antitumor cytokines and chemokines. CD20, a cell surface phosphoprotein, is found on normal B cells and most B-cell tumors.
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain 100000000 UNT/ML Injectable Suspension [Dryvax];
material entity;Anti-CD19/CD3 Tetravalent Antibody AFM11 Vaccine;An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.
material entity;Ankara (MVA) and ALVAC(2) Vaccine;Recombinant MVA-gp100M and ALVAC(2)-5T4 were constructed to complement existing ALVAC(2)-gp100M and MVA-5T4 vectors. Recombinant TAA expression in chicken embryo fibroblast cells was confirmed by Western blot analysis. 5T4 expression was approximately equal for both viruses, whereas ALVAC-derived gp100 was quickly degraded, at a time point when MVA-derived gp100 was still stable and expressed at high levels
material entity;Ankara (MVA) Vaccine;A modified vaccinia Ankara (MVA) encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes.
material entity;Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118;A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer. its expression is correlated with poor prognosis.
material entity;Amolimogene Bepiplasmid Vaccine;A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer.
material entity;AML mRNA Positive Lysate Loaded Autologous Dendritic Cell Vaccine;A cancer vaccine consisting of autologous dendritic cells loaded with separate preparations of acute myelogenous leukemia (AML) cell lysate and AML-specific messenger RNA (mRNA) with potential immunostimulatory and antineoplastic activities. Upon administration, AML mRNA plus lysate loaded autologous dendritic cell vaccine may elicit a potent cytotoxic T-cell (CTL) response against AML cells, resulting in tumor cell death. Autologous dendritic cells doubly-loaded with AML cell lysate and AML-specific mRNA may elicit superior primary, recall, and effector lytic immune responses compared to autologous dendritic cells loaded with tumor lysate or tumor mRNA alone.
material entity;ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine;A cancer vaccine consisting of a replication-defective recombinant canarypox virus [ALVAC(2)] encoding the cancer-testis antigen NY-ESO and the TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3. also called TRICOM), with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC(2)/NY-ESO (M)/TRICOM vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells, including bladder, breast, hepatocellular, melanoma, and prostate tumor cells. TRICOM may enhance antigen presentation and activate cytotoxic T-cells. In addition, ALVAC(2) encodes the vaccinia virus (vv) E3L ad K3L genes, which may potentiate the translation of the NY-ESO and TRICOM genes.
material entity;0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2020-2021];
material entity;0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection;
material entity;0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2020-2021];
material entity;0.5 ML influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain 500000000 UNT/ML;
material entity;0.5 ML influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2020-2021];
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain 500000000 UNT/ML [ACAM2000];
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022 Southern Hemisphere];
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain 500000000 UNT/ML Injectable Solution;
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022-2023];
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution;
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2022-2023];
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000];
material entity;0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Suspension;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension;
material entity;anti-PRAME Immunotherapeutic GSK2302032A Vaccine;An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity.
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension [Comirnaty];
material entity;anti-p53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes Vaccine;Human autologous peripheral blood lymphocytes (PBLs) transduced with an anti-p53 T cell receptor gene with potential antineoplastic activity. PBLs are harvested from a patient and pulsed with a retroviral vector that encodes the T-cell receptor gene specific for a mutated form of p53. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these modified PBLs express the anti-p53 T cell receptor which binds to mutant p53-overexpressing tumor cells. PBL-mediated tumor growth inhibition may follow. Many tumor cell types overexpress mutant p53 proteins, which are associated with the loss of apoptosis regulation and abnormal cell proliferation.
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.0075 MG/ML;
material entity;anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes Vaccine;Human autologous CD62L-positive T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T-Lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes. it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy.
material entity;anti-NY-ESO-1 Immunotherapeutic GSK-2241658A Vaccine;An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity.
material entity;anti-idiotypic monoclonal antibody BEC2 vaccine;A murine anti-idiotypic monoclonal antibody (anti-Id MoAb) that is directed against an idiotype mimicking a disialoganglioside GD3. GD3 represents a major surface marker on most human melanoma cells. Due to poor immunogenicity of GD3, anti-Id MoAb BEC2 (Ab2) was raised against a mouse anti-GD3 MoAb, R24 (Ab1). This anti-Id MoAb was shown to be functionally mimicking GD3 in stimulating an immune response to produce Ab3 that may be used in combination with other adjuvants for treatment of melanomas.
material entity;anti-idiotypic mAb MK2-23+BCG;
material entity;Anti-Idiotype Specified Monoclonal Antibody Vaccine;A synthetic antibody produced by a genetically homogenous population of hybrid cells (hybridoma) against determinant idiotypes (Id) which usually mimic human epitopes. Anti-Id vaccines may be effective in the treatment of B-cell lymphomas, resulting in tumor regression. Anti-idiotype vaccine therapy is less likely to induce autoimmunity if the target antigen is not normally expressed on normal tissues. Monoclonal antibodies have become powerful tools for tumor targeting, recognizing different protein markers on certain cancer cells and may be used alone or as delivery agents for drugs, toxins or radioactive material targeted to tumors.
material entity;Anti-idiotype MUC-1 Monoclonal Antibody Vaccine;A monoclonal antibody that functionally mimics MUC-1 antigen, a tumor cell surface antigen. Administration of anti-idiotype MUC-1 monoclonal antibody may elicit an anti-idiotype antibody and corresponding T-cell response against MUC-1 expressing tumor cells.
material entity;Anti-GnRH Vaccine PEP223;A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors.
material entity;Anti-CTLA4 MoAb RNA/GITRL RNA-transfected Autologous Dendritic Cell Vaccine;An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL). expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.
material entity;antigen-targeted Personalized Breast Cancer Vaccine;An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse (""off the shelf"") and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor.
material entity;0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021 Southern Hemisphere];
material entity;0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2020-2021];
material entity;0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2020-2021];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.025 MG/ML;
material entity;0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2020-2021];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.05 MG/ML;
material entity;0.5 ML influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2020-2021];
material entity;SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML;
material entity;0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe;
material entity;SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension;
material entity;0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021];
material entity;SARS-COV-2 (COVID-19) vaccine, vector non-replicating;
material entity;0.5 ML influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe;
material entity;SARS-COV-2 (COVID-19) vaccine, vector non-replicating Injectable Suspension;
material entity;smallpox vaccine live, New York City Board of Health vaccinia strain;
material entity;0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2020-2021];
material entity;Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension;
material entity;Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora];
material entity;yellow fever virus strain 17D-204 live antigen 2000 UNT/ML Injection;
material entity;yellow fever virus strain 17D-204 live antigen 2000 UNT/ML Injection [Stamaril];
material entity;yellow fever virus strain 17D-204 live antigen 4000 UNT/ML Injection;
material entity;yellow fever virus strain 17D-204 live antigen 4000 UNT/ML Injection [YF-Vax];
material entity;Afluria 2010-2011 Formula vaccine;
material entity;Afluria 2011-2012 Formula vaccine;
material entity;Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML [Vaxchora];
material entity;Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML Oral Suspension;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2014-2015 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2013-2014 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2014-2015 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2013-2014 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2014-2015 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2013-2014 Formula];
material entity;varicella zoster virus glycoprotein E Injection;
material entity;varicella zoster virus glycoprotein E Injection [Shingrix];
material entity;varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection;
material entity;varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection [Shingrix];
material entity;varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML Injection;
material entity;varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax];
material entity;varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection;
material entity;varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection [Zostavax];
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Prefilled Syringe;
material entity;Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML;
material entity;0.5 ML influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Solution [TE Anatoxal Berna];
material entity;0.5 ML influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix Quad 2014-2015 Formula];
material entity;tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 5 LFU;
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 5 LFU Injectable Solution;
material entity;tetanus toxoid vaccine, inactivated Injectable Solution [TE Anatoxal Berna];
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution;
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe;
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI];
material entity;Autologous HNSCC DNA-transfected Semi-allogeneic Fibroblasts MRC-5 Vaccine;A vaccine consisting of lethally irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous tumor DNA derived from a head and neck squamous cell carcinoma (HNSCC), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous HNSCC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses HNSCC tumor-associated antigens (TAAs), which may activate the immune system to induce a cytotoxic T-lymphocyte (CTL) response against HNSCC cells. The MRC-5 cell line, established in 1966, is a human diploid lung fibroblast cell line derived from the human lung tissue of a 14-week-old male fetus.
material entity;Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858;A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.
material entity;Autologous GM-CSF-Secreting Lethally Irradiated Leukemia Cell Vaccine;An autologous cancer vaccine composed of lethally irradiated leukemia cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, the autologous GM-CSF-secreting lethally irradiated leukemia cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the immune system to attack tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.
material entity;Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine;A lethally irradiated, autologous colorectal cancer vaccine consisting of patient-specific colorectal cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, the autologous GM-CSF-secreting lethally irradiated colorectal cancer cell vaccine releases GM-CSF. In turn, GM-CSF may increase the body's immune response against tumor cells by promoting the maturation and activation of dendritic cells (DCs), and enhancing tumor-specific antigen presentation to both B- and T-cells, which leads to better recognition of tumors by the immune system. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.
material entity;Autologous GM-CSF-Secreting Breast Cancer Vaccine;An autologous tumor cell vaccine containing irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Autologous breast cancer cells are transduced ex vivo with an adenovirus vector encoding the GM-CSF gene and irradiated and then reintroduced into the patient. Upon repeated subcutaneous administration of the vaccine, autologous GM-CSF-secreting breast cancer cells secrete GM-CSF, which may stimulate a tumor-specific cytotoxic T-lymphocyte (CTL) response.
material entity;Autologous Expanded Mesenchymal Stem Cells OTI-010 Vaccine;Multipotent self-renewing adherent non-hematopoietic stromal cells harvested from a patient's bone marrow and grown in vitro. When injected back into the patient, autologous expanded mesenchymal stem cells OTI-010 may differentiate into various mesenchyme-derived cell types and, in some instances, may augment bone marrow engraftment after whole-body irradiation.
material entity;Autologous Epstein-Barr Virus-Transformed B-Lymphoblastoid Cell Vaccine;A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis.
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Solution;
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2021-2022];
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Solution [Typhim VI];
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection;
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2014-2015 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2013-2014 Formula];
material entity;tetanus toxoid vaccine, inactivated 0.5 ML Injectable Solution;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 10 LFU/ML;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2013-2014 Formula];
material entity;tetanus toxoid vaccine, inactivated 10 MG/ML;
material entity;tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 1000 UNT;
material entity;tetanus toxoid vaccine, inactivated 1000 UNT Injectable Suspension;
material entity;tetanus toxoid vaccine, inactivated 2 UNT/ML;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula];
material entity;tetanus toxoid vaccine, inactivated 2 UNT/ML Injectable Solution;
material entity;tetanus toxoid vaccine, inactivated 20 UNT/ML [TE Anatoxal Berna];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Solution;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2013-2014 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flulaval 2014-2015 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flulaval Quad 2014-2015 Formula];
material entity;Feline leukemia virus protein;
material entity;Canine parvovirus protein;
material entity;Marek's disease virus protein;
material entity;Newcastle disease virus protein;
material entity;Canine coronavirus protein;
material entity;Canine distemper virus protein;
material entity;Bovine herpesvirus 1 protein;
material entity;West Nile virus protein;
material entity;Pseudorabies virus protein;
material entity;Classical swine fever virus protein;
material entity;Chlamydophila abortus protein;
material entity;Mycoplasma synoviae protein;
material entity;Vibrio anguillarum (Listonella anguillarum) protein;
material entity;Streptococcus equi protein;
material entity;Mycoplasma gallisepticum protein;
material entity;Infectious Hematopoietic Necrosis Virus protein;
material entity;Yersinia ruckeri protein;
material entity;Aeromonas salmonicida protein;
material entity;Lawsonia intracellularis protein;
material entity;Porphyromonas gulae protein;
material entity;Vibrio cholerae protein;
material entity;Rift Valley Fever virus protein;
material entity;Cryptosporidium parvum protein;
material entity;Hendra virus protein;
material entity;Burkholderia pseudomallei protein;
material entity;Western equine encephalomyelitis virus protein;
material entity;Rickettsia spp protein;
material entity;Bordetella pertussis protein;
material entity;Dengue Virus protein;
material entity;Nipah virus protein;
material entity;Adenovirus-p53 Transduced Dendritic Cell Vaccine;A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant adenovirus encoding p53 peptide, with potential immunomodulating activity. Intradermal vaccination with adenoviral-p53 transduced dendritic cell vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.
material entity;Adenovirus-mediated Human Interleukin-12 Vaccine;A replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (Ad.hIL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.
material entity;Adenovirus RSV-TK Vaccine;A gene viral vector complex comprised of a replication-defective adenovirus and a herpes simplex virus thymidine kinase gene that activates ganciclovir, causing inhibition of DNA synthesis and apoptosis.
material entity;EBOV NP;
material entity;Adenovirus HER2-Transduced Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, adenovirus HER2-transduced autologous dendritic cell vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers.
material entity;Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy.
material entity;Adenovirus Encoding Rat HER-2/neu Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding HER-2/neu.
material entity;Adenovirus B7-1 Vaccine;A gene-viral vector complex comprised of an adenovirus vector and B7-1 gene targeting the CD80 antigen. Adenovirus B7-1 is used as a component in antineoplastic vaccines to elicit a cytotoxic T-cell response.
material entity;Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine;A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response.
material entity;Adenovirus 5-Fibroblast Growth Factor 2 Vaccine;Fibroblast growth factor-2-retargeted adenoviral vectors may be used to increase the transduction of GBM-derived endothelial cells, enabling a new and efficient antiangiogenesis strategy for the treatment of malignant gliomas.
material entity;Coccidioides spp. protein;
material entity;Adenovirus 5-CD40 Ligand Vaccine;An adenovirus vector engineered to produce CD40 ligand. For use as a possible gene therapy agent. May induce apoptosis through the TNF pathway.
material entity;Trypanosoma brucei protein;
material entity;Yersinia enterocolitica protein;
material entity;Entamoeba histolytica protein;
material entity;Lef from B. anthracis str. A2012;
material entity;EBOV GP;
material entity;Helicobacter pylori protein;
material entity;SodC from B. abortus strain 2308;
material entity;SARS-CoV protein;
material entity;Neospora caninum protein;
material entity;Giardia duodenalis protein;
material entity;Toxoplasma gondii protein;
material entity;Babesia bovis protein;
material entity;Bordetella avium protein;
material entity;Actinobacillus pleuropneumoniae protein;
material entity;Theileria parva protein;
material entity;Theileria annulata protein;
material entity;Eimeria spp. protein;
material entity;Eimeria tenella protein;
material entity;Chlamydophila psittaci protein;
material entity;Leishmania amazonensis protein;
material entity;Trypanosoma cruzi protein;
material entity;Babesia canis protein;
material entity;Leishmania donovani protein;
material entity;Sarcocystis neurona protein;
material entity;Leishmania major protein;
material entity;Leishmania infantum protein;
material entity;Eimeria maxima protein;
material entity;Herpes simplex virus type 1 and 2 protein;
material entity;vaccinia melanoma cell lysates (VMCL) vaccine;A cancer vaccine with VMCL was not associated with a statistically significant improvement in OS or RFS, with CIs not ruling out important gains from such treatment.
material entity;tyrosinase240-251S, 368-376D Vaccine;
material entity;Tyrosinase-KLH Vaccine;A peptide vaccine containing a tyrosinase epitope conjugated with keyhole lymphocyte hemocyanin (KLH) with potential antineoplastic activity. Tyrosinase, one of the melanoma differentiation antigens, is the rate-limiting enzyme for melanin synthesis. This tyrosine epitope is conjugated with KLH, which serves as an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with tyrosinase-KLH peptide vaccine may produce anti-tyrosinase antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response against cells expressing tyrosinase antigen, resulting in decreased tumor growth.
material entity;TRP1(0RF3):1-9 Peptide Vaccine;A recombinant peptide consisting of amino acid residues 1 to 9 of the tyrosinase-related protein 1 (TRP1). Expressed by cells of melanocyte origin, TRP1 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP1(0RF3):1-9 may stimulate cytotoxic T cell responses to melanoma cells.
material entity;TRP-2: 180-188 Peptide Vaccine;A recombinant peptide consisting of amino acid residues 180 to 188 of the tyrosinase-related protein 2 (TRP2). Expressed by cells of melanocyte origin, TRP2 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP-2: 180-188 peptide may induce cytotoxic T lymphocyte (CTL) responses to melanoma cells.
material entity;TriMixDC-MEL Vaccine;
material entity;TLR-9/GM Vaccine;
material entity;Campylobacter jejuni protein;
material entity;Tetravalent RNA-lipoplex Cancer Vaccine;A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding the four melanoma-associated antigens (MAAs), the cancer-testis antigen NY-ESO-1, the human melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and putative tyrosine-protein phosphatase (TPTE), encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine BNT111, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This results in the production of various pro-inflammatory cytokines and induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs NY-ESO-1, MAGE-A3, tyrosinase, and TPTE.
material entity;Escherichia coli protein;
material entity;Synthetic Melanoma-Associated Antigens Vaccine;A cancer vaccine containing synthetic epitope peptides derived from melanoma tumor-associated antigens (TAAs), including melanoma-melanocyte antigen gp100(280-288), melanoma-associated antigen tyrosinase(1-9), and melanoma-associated antigen melan-A(27-35). Upon administration, synthetic melanoma-associated antigens vaccine may stimulate a cytotoxic T-lymphocyte immune response against melanoma cells that express TAAs which share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis.
material entity;Lassa Fever Virus protein;
material entity;Synchrovax SEM Plasmid DNA Vaccine;A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase (1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth.
material entity;Variola virus protein;
material entity;Marburg Virus protein;
material entity;Human Immunodeficiency Virus protein;
material entity;Hantavirus protein;
material entity;Ebola virus protein;
material entity;Clostridium botulinum protein;
material entity;Francisella tularensis protein;
material entity;XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410;A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells.
material entity;WT1 Peptide Vaccine WT2725;A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors.
material entity;WT1 Analog Peptide Vaccine;A peptide vaccine comprised of an epitope of human Wilms tumor 1 (WT-1) with potential antineoplastic activity. WT-1, a transcription factor, is overexpressed in most types of leukemia and in some solid cancers. Vaccination with the WT-1 analog peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against WT-1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation.
material entity;Unconjugated Myeloma Ig Id Vaccine;A vaccine consisting of myeloma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated myeloma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against myeloma cells, resulting in decreased tumor growth.
material entity;Survivin Sur1M2 Peptide Vaccine;A modified recombinant nonapeptide (LMLGEFLKL) derived from the anti-apoptosis protein survivin with potential immunopotentiating and antineoplastic activities. Upon administration, survivin Sur1M2 peptide vaccine may elicit humoral and cellular immune responses against survivin-expressing cancers, resulting in decreased tumor cell proliferation and tumor cell death. The survivin protein inhibits caspase activation and apoptosis. it is undetectable in normal adult tissues but is expressed by several human cancers including lung, colon, breast, pancreas, and prostate cancer as well as hematopoietic malignancies and skin cancers.
material entity;Recombinant Adenovirus-hIFN-beta Vaccine;A recombinant replication-defective adenovirus which encodes the gene for the cytokine human interferon-beta (IFN-beta). Once inserted into and replicating in host tumor cells, recombinant adenovirus-hIFN-beta expresses human IFN-beta, which may stimulate an antiproliferative natural killer (NK) cell response against tumor cells and induce caspase-mediated tumor cell apoptosis.
material entity;Salmonella spp. protein;
material entity;Xenogeneic Tyrosinase DNA Vaccine;A plasmid DNA vaccine, encoding an epitope of mouse tyrosinase, with potential antineoplastic activity. Administered via intramuscular electroporation, vaccination with xenogeneic tyrosinase DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) immune responses against melanoma cells that express tyrosinase, resulting in decreased tumor growth.
material entity;Shigella protein;
material entity;Vaccinia-Tyrosinase Vaccine;A vaccine consisting of recombinant vaccinia virus, based on the modified vaccinia virus Ankara (MVA) that encodes the melanoma-associated antigen tyrosinase. Vaccination with vaccinia-tyrosinase may stimulate the host immune system to mount a cytotoxic T-cell response against tumor cells expressing tyrosinase. Tyrosinase is a melanoma-specific differentiation agent that catalyzes the synthesis of the melanin precursor L-3,4-dihydroxyphenylalanine (L-DOPA).
material entity;VEE Virus protein;
material entity;Vaccinia-GM-CSF Vaccine;A recombinant vaccinia virus that encodes granulocyte-macrophage colony stimulating factor (GM-CSF). By activating T-cells and macrophages, vaccination with recombinant vaccinia GM-CSF may enhance the host immune system response to poorly immunogenic tumors, resulting in decreased tumor growth.
material entity;Clostridium tetani protein;
material entity;Vaccinia Melanoma Oncolysates (VMO) Vaccine;
material entity;Neisseria meningitidis protein;
material entity;Streptococcus pneumoniae protein;
material entity;0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2013-2014 Formula];
material entity;0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2014-2015 Formula];
material entity;Haemophilus influenzae protein;
material entity;0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe;
material entity;Coxiella burnetii protein;
material entity;0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe;
material entity;Mycobacterium tuberculosis protein;
material entity;0.1 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;Plasmodium spp. protein;
material entity;0.1 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;delayed release oral tablet;
material entity;0.1 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;nasal spray;
material entity;oral liquid product;
material entity;Vivotif (Canada);
material entity;Twinrix Junior;
material entity;Typherix vaccine;
material entity;Tripacel vaccine;
material entity;Varivax III;
material entity;Vivaxim vaccine;
material entity;Vaqta vaccine;
material entity;Varilrix vaccine;
material entity;Synchrotope TA2M Plasmid DNA Vaccine;A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchrotope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth.
material entity;Synchotrope TA2M Vaccine;A recombinant plasmid DNA vaccine that encodes two peptides, tyrosinase 207-216 and tyrosinase 1-17, both of which are derived from human tyrosinase.
material entity;Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant;A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine.
material entity;Recombinant Vaccinia-TRP1 Vaccine;A recombinant vaccinia virus encoding the melanocyte differentiation antigen tyrosinase-related protein-1 (TRP-1) with potential use in cancer immunotherapy.
material entity;Recombinant Vaccinia-Multiepitope Melanoma Peptides-B7.1-B7.2 Vaccine;A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis. vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs.
material entity;Recombinant Vaccinia-Mgp100 Vaccine;A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. This recombinant vaccinia Mgp100 encodes a fragment epitope of gp100 bearing 2 amino acids substitution. T->M at position 210 and 288 A ->V at position 210. This modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently.
material entity;Recombinant Vaccinia-gp100:209-217 Vaccine;A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. gp100p209 is a fragment epitope of gp100 in which the threonine in position 2 is replaced with methionine. this modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently.‚Äö√†√∂‚àö¬ß
material entity;Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine;A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock. as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation.
material entity;virus protein;a protein from a virus
material entity;Recombinant Fowlpox-Tyrosinase Vaccine;A recombinant fowlpox virus vaccine with potential antineoplastic activity. Binding to the melanoma antigen tyrosinase, recombinant fowlpox-tyrosinase vaccine generates cellular immune responses against melanoma cells expressing the tyrosinase antigen. this effect is enhanced by the co-administration of interleukin 2 (IL-2). Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
material entity;parasite protein;a protein from a parasite
material entity;Recombinant Fowlpox-Mgp100 Vaccine;A cancer vaccine consisting of a replication-defective recombinant fowlpox virus that encodes for the murine melanoma antigen glycoprotein 100 (mgp100) with potential antineoplastic activity. Vaccination with recombinant fowlpox-mgp100 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
material entity;G+ bacterium protein;
material entity;G- bacterium protein;
material entity;Brucella protein;
material entity;Yersinia pestis protein;
material entity;fungus protein;a protein from fungus
material entity;Bacillus anthracis protein;
material entity;bacterium protein;a protein from a bacterium
material entity;meningococcal group A polysaccharide 0.1 MG/ML Injectable Solution;
material entity;meningococcal group A polysaccharide Injectable Solution;
material entity;mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution;
material entity;pVAXrcPSAv53l DNA Vaccine;A cancer vaccine containing xenogenic DNA from rhesus macaque (Macaca mulatta) that encodes prostate specific antigen (PSA) with potential immunostimulating and antineoplastic activities. Upon repeated intradermal administration via electroporation, pVAXrcPSAv53l vaccine may induce a cytotoxic T-lymphocyte (CTL) response against PSA-expressing prostate cancer cells. Rhesus PSA is 89% homologous to human PSA.
material entity;mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution [Biavax II];
material entity;pTVG-HP Plasmid DNA Vaccine;A cancer vaccine containing plasmid DNA encoding human prostatic acid phosphatase (PAP) (pTVG-HP) with potential immunostimulatory and antineoplastic activities. Upon administration, pTVG-HP plasmid DNA vaccine may stimulate the host immune system to generate a cytotoxic T lymphocyte (CTL) response against PAP-expressing prostate cancer cells. PAP or prostatic specific acid phosphatase (PSAP) is a tumor associated antigen (TAA) that may be overexpressed in prostate cancer.
material entity;mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML [Mumpsvax];
material entity;PSMA/TARP Peptide Vaccine;A peptide-based cancer vaccine containing epitopes of T cell receptor gamma-chain alternate reading frame protein (TARP) and prostate-specific membrane antigen (PSMA) in combination with a Poly IC-LC immunoadjuvant, with potential antineoplastic activity. Upon administration, PSMA/TARP peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP- and PSMA-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP and PSMA are commonly expressed in prostate cancer cells.
material entity;PSA:154-163(155L) Peptide Vaccine;A cancer vaccine comprised of a synthetic peptide with an amino acid sequence corresponding to positions 154-163 of the amino acid sequence for prostate-specific antigen (PSA) with a leucine substitution at position 155. Upon administration, PSA:154-163(155L) peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA.
material entity;PSA:154-163 Peptide vaccine;A synthetic peptide based on sequence corresponding to positions 154-163 of the amino acids of prostate-specific antigen (PSA), VISNDVCAQV. Upon administration, PSA:154-163 peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA.
material entity;PSA/PSMA DNA Plasmid INO-5150 vaccine;A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs.
material entity;PSA/IL-2/GM-CSF Vaccine;A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response.
material entity;PSA-PAP/KLH-pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the prostate-specific tumor associated antigens (TAAs) prostate specific antigen (PSA) and prostate acid phosphatase (PAP), and conjugated to the immunostimulant keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, prostate cancer antigen/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against prostate cancer cells expressing PSA and PAP, which may result in prostate cancer cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy.
material entity;PSA-OP Peptide Vaccine;A 30-residue prostate specific antigen (PSA) oligoepitope peptide (OP) vaccine with potential antineoplastic activity. PSA-OP peptide vaccine contains the PSA-1 and PSA-3 HLA-A2 epitopes and the PSA-9 HLA-class I-A3 epitope joined by peptide linker sequences. In an animal model, vaccination with this agent has been shown to elicit a cytotoxic T-lymphocyte immune response.
material entity;PSA RNA-Pulsed Dendritic Cell Vaccine;An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells.
material entity;Recombinant Fowlpox-Prostate Specific Antigen Vaccine;A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
material entity;0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe;
material entity;0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2013-2014 Formula];
material entity;0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2014-2015 Formula];
material entity;0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML [Biavax II];
material entity;0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injectable Solution;
material entity;0.25 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022];
material entity;mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injectable Solution [Biavax II];
material entity;0.25 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML Injectable Solution [Mumpsvax];
material entity;0.25 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;mumps virus vaccine live, Jeryl Lynn strain Injectable Solution;
material entity;0.25 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.25 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021 Southern Hemisphere];
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain Injection;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain Injection [Attenuvax];
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group W-135 / meningococcal polysaccharide vaccine group Y Injectable Solution [Menomune A/C/Y/W-135];
material entity;Telomerase Peptide Vaccine GV1001;A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution [Meningovax-AC];
material entity;Sipuleucel-T Vaccine;A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.
material entity;Rilimogene-galvacirepvec Vaccine;A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.
material entity;rF-PSA/PSMA/TRICOM Vaccine;A synthetic fowlpox viral vaccine containing the tumor-associated antigens prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3. TRICOM). Vaccination with this viral vaccine may enhance antigen presentation and activate cytotoxic T-cells against PSA- or PSMA-expressing tumor cells.
material entity;Recombinant Vaccinia-PSA/PSMA Vaccine;A recombinant vaccinia virus encoding prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) with potential use in cancer immunotherapy.
material entity;Recombinant Vaccinia-Prostate Specific Antigen Vaccine;A recombinant vaccinia virus encoding prostate-specific antigen (PSA). Vaccination with recombinant vaccinia-PSA may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for PSA, which may decrease tumor growth.
material entity;Recombinant Vaccinia PSA Vaccine;A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA.
material entity;Recombinant Fowlpox-TRICOM Vaccine;A cancer vaccine comprised of a recombinant fowlpox virus vector encoding TRICOM. TRICOM is comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3) that may enhance antigen presentation and activate cytotoxic T-cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
material entity;Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine;A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
material entity;Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Vaccine;An adenovirus type 5 (Ad5) encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with potential apoptosis-inducing and antineoplastic activities. Upon administration of recombinant Ad5 encoding TRAIL, the adenovirus selectively infects tumor cells and expresses TRAIL. The virally expressed TRAIL binds to and activates its receptors TRAIL receptor-1 (TRAIL-R1, death receptor 4, DR4) and TRAIL receptor-2 (TRAIL-R2, death receptor 5, DR5), which subsequently activate caspases and induce apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types.
material entity;UV1 Telomerase Peptide Vaccine;A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.
material entity;0.5 ML acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Pentacel];
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;0.5 ML acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML [Meningovax-AC];
material entity;0.5 ML acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injectable Solution;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe;
material entity;meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection;
material entity;0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe;
material entity;meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection [Menomune A/C/Y/W-135];
material entity;0.25 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula];
material entity;meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML Injectable Solution;
material entity;0.25 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula];
material entity;meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML Injectable Solution [Meningovax-AC];
material entity;0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2012-2013 Formula];
material entity;0.25 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe;
material entity;rF-MUC1(DF3)/TRICOM Vaccine;A fowlpox vaccine containing the tumor-associated antigen mucin-1 (MUC1), found in pancreatic tumor cells, and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3. TRICOM), which is designed to enhance antigen presentation and activation of immune responses critical for tumor destruction. Vaccination with this agent may elicit a host immune response against MUC1-expressing tumor cells.
material entity;Retroviral Vector MFGS-MOv18-gamma Vaccine;A recombinant retrovirus containing the modified murine retroviral vector MFG-S encoding a chimeric construct, MOv18-gamma. MOv18 is a murine monoclonal antibody developed against epitope of human folate binding protein, which is overexpressed on more than 90% of non-mucinous epithelial ovarian neoplasms. The chimeric construct (MOv18-gamma) encodes the variable region of MOv18 antibody, and the gamma chain of human T-cell receptor. This virion might be used to transduce autologous T lymphocytes, and reintroduced back to the patient after expansion ex vivo to invoke specific immune response against ovarian cancer cells.
material entity;L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Injection [Gardasil];
material entity;pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine;A plasmid DNA vaccine containing mammalian expression vector pUMVC3, encoding epitopes of human insulin-like growth factor-binding protein 2 (hIGFBP-2) with potential immunostimulating and antineoplastic activities. Upon vaccination, pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against hIGFBP-2-expressing cells. The tumor associated antigen (TAA) hIGFBP-2, a member of the insulin like growth factor receptor family, is overexpressed in a number of cancer cell types and its expression has been associated with increased invasiveness.
material entity;L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine Injectable Suspension;
material entity;Pexastimogene-devacirepvec Vaccine;An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response.
material entity;L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine Injectable Suspension [Cervarix];
material entity;PA-1-STK Ovarian Carcinoma Vaccine;A cell-based cancer vaccine with potential antineoplastic activity. PA-1-STK ovarian carcinoma vaccine is produced by transducing the ovarian cancer cell line, PA-1, with the herpes simplex thymidine kinase (HSV-tk) gene, resulting in a cell line, PA-1-STK, that permanently expresses the HSV tk gene. Upon transfection into malignant cells, this vaccine is capable of sensitizing tumor cells in response to an antiviral drug such as ganciclovir, which is readily phosphorylated by the TK enzyme to its active form. Administration of ganciclovir following PA-1 STK transfection results in enhanced cytotoxicity of the transfected tumor cells. Additionally, adjacent non-transfected cells are also killed by the activated antiviral drug, a phenomenon referred to as the bystander effect that occurs with this type of suicide-gene transfer technique.
material entity;Poliovirus protein;
material entity;P53-Synthetic Long Peptides Vaccine;A peptide vaccine consisting of 10 synthetic long peptides (SLPs), 25-30 amino acids in size and derived from the middle portion of p53 (amino acids 70-251), mixed with the adjuvant Montanide ISA-51 with potential immunostimulatory and antitumor activities. Upon administration, p53 synthetic long peptide (70-251) vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against p53-expressing tumor cells. p53, a tumor associated antigen (TAA), may be overexpressed in variety of cancer cell types.
material entity;Rabies virus protein;
material entity;Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine;A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with an ovarian tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the ovarian tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells expressing ovarian tumor cell-specific antigens, which may result in ovarian tumor cell lysis.
material entity;Mumps virus protein;
material entity;Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine;A cancer vaccine containing autologous dendritic cells (DCs) that are transfected with mRNAs extracted from amplified ovarian cancer stem cells, and mRNAs of the universal tumor antigens human telomerase reverse transcriptase (hTERT) and survivin with potential immunostimulatory and antineoplastic activities. Upon administration, ovarian cancer stem cell/hTERT/survivin mRNAs-loaded autologous DC-006 vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against ovarian cancer cells expressing hTERT, survivin, and specific ovarian cancer stem cell antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Ovarian cancer stem cells contain a specific range of antigens that are essential for the neoplastic growth and survival of ovarian cancer cells.
material entity;Human papillomavirus protein;
material entity;Ovarian Cancer Peptide Vaccine;A cancer vaccine comprised of synthetic peptides corresponding to naturally-occurring peptides derived from ovarian cancer cell antigens. Ovarian cancer peptide vaccine may elicit a cytotoxic T-cell response against tumor cells expressing the related ovarian cancer cell antigens.
material entity;Ovapuldencel-T Vaccine;A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.
material entity;Rotavirus protein;
material entity;Hepatitis A virus protein;
material entity;0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Japanese encephalitis virus protein;
material entity;0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2019-2020];
material entity;Measles virus protein;
material entity;0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;Hepatitis B virus protein;
material entity;0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Influenza virus protein;
material entity;0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2019-2020];
material entity;0.1 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula];
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection;
material entity;0.25 ML influenza A virus (H3N2) antigen 0.03 MG/ML / influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection;
material entity;0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2012-2013 Formula];
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML [Attenuvax];
material entity;0.1 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Prefilled Syringe;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 25000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injection;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 25000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injection [M-M-R II];
material entity;0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Prefilled Syringe;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML Injection;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML Injection [Attenuvax];
material entity;PSA Prostate Cancer Vaccine;A peptide vaccine containing the prostate specific antigen (PSA) with potential antineoplastic activity. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. Vaccination with PSA peptide vaccine may produce anti-PSA antibodies as well as elicit a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth.
material entity;PROSTVAC-Contaminated W/ BVDV vaccine;A vaccinia virus carrying a copy of the human gene encoding prostate-specific antigen (PSA), contaminated with bovine viral diarrhea virus (BVDV).
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.0000000385 MG/ML [Je-Vax];
material entity;Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine;A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the prostate tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis.
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.0000000385 MG/ML Injectable Suspension;
material entity;Prostate Cancer Vaccine ONY-P1;A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells. in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant.
material entity;Corynebacterium diphtheriae protein;
material entity;Prostate cancer DNA vaccine pDOM-PSMA27 encoding PSMA;This DNA vaccine expressed prostate-specific membrane antigen (PSMA)
material entity;Porcine circovirus 2 protein;
material entity;Primary Prostate Cancer Tissue/hTERT/Survivin mRNA-loaded Autologous Dendritic Cell Vaccine;An autologous dendritic cell (DCs) vaccine targeting prostate cancer with immunostimulating activity. The autologous DC vaccine is prepared via transfecting DCs with mRNAs extracted from primary prostate cancer tissue, and mRNAs of human telomerase reverse transcriptase (hTERT) and survivin. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against prostate cancer cells, resulting in tumor cell death. Both hTERT and survivin are essential in neoplastic growth, and are considered to be universal tumor antigens.
material entity;Yersinia pseudotuberculosis protein;
material entity;NY-ESO-1/LAGE-1 peptide vaccine;A cancer vaccine containing HLA class I- and II-binding peptides derived from the NY-ESO-1/LAGE-1 cancer/testis antigen with potential immunostimulatory and antineoplastic activities. Upon administration, NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine may induce a cytotoxic immune response against tumor cells that over-express NY-ESO-1/LAGE-1. Rarely expressed by normal cells, the NY-ESO-1/LAGE-1 cancer/testis antigen has been shown to be preferentially expressed on the surface of some cancer cell types.
material entity;Bovine Leukemia virus protein;
material entity;VEGFR2-169 Peptide Vaccine;A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types. overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.
material entity;VEGFR1-1084 Peptide Vaccine;A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor 1 (VEGFR1 or Flt-1) with potential immunostimulating, antiangiogenic, and antineoplastic activities. Upon vaccination, VEGFR1-1084 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1-expressing endothelial cells of the tumor microvasculature, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR1, a receptor tyrosine kinase, may be overexpressed on endothelial cells of the tumor microvasculature and is associated with tumor cell proliferation, invasion and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenicity.
material entity;Sargramostim Plasmid DNA Pancreatic Tumor Cell Vaccine;A whole cell vaccine comprised of irradiated allogenic pancreatic tumor cells transfected with a plasmid DNA encoding human sargramostim (GM-CSF). Vaccination results in expression of GM-CSF, which induces proliferation and differentiation hematopoietic lineage cells as well as stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Furthermore, administration of this pancreatic tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth.
material entity;Rubella virus protein;
material entity;Yellow fever virus protein;
material entity;Chlamydophila pneumoniae protein;
material entity;0.25 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2020-2021];
material entity;Chlamydia muridarum protein;
material entity;0.25 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Varicella-zoster virus protein;
material entity;0.25 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021];
material entity;Tick-borne Encephalitis Virus (TBEV) protein;
material entity;0.25 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.25 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2021-2022];
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.0000000385 MG/ML Injectable Suspension [Je-Vax];
material entity;0.25 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe;
material entity;0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro];
material entity;0.25 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe;
material entity;Japanese encephalitis virus vaccine, inactivated Injectable Suspension [Je-Vax];
material entity;0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 31 vaccine / L1 protein, human papillomavirus type 33 vaccine / L1 protein, human papillomavirus type 45 vaccine / L1 protein, human papillomavirus type 52 vaccine / L1 protein, human papillomavirus type 58 vaccine / L1 protein, human papillomavirus type 6 vaccine Prefilled Syringe;
material entity;0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016 Southern Hemisphere];
material entity;L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 31 vaccine / L1 protein, human papillomavirus type 33 vaccine / L1 protein, human papillomavirus type 45 vaccine / L1 protein, human papillomavirus type 52 vaccine / L1 protein, human papillomavirus type 58 vaccine / L1 protein, human papillomavirus type 6 vaccine Injection;
material entity;L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Injection;
material entity;L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Injection;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2019-2020];
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Prefilled Syringe [Ipol];
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Suspension;
material entity;0.5 ML human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe [Ipol];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injection;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injection [RabAvert];
material entity;rabies virus vaccine flury-lep strain Injection [RabAvert];
material entity;rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML Injection;
material entity;Adenoviral Vector Ad5-CEA(6D) Vaccine;A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses.
material entity;Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201;A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.
material entity;Adenovector Encoding MDA7 Vaccine;A nonreplicating adenoviral vector (adenovector) encoding the melanoma differentiation-associated 7 gene (MDA7) with potential antineoplastic activity. After intratumoral injection and adenovector-mediated gene transfer of MDA7 into tumor cells, the expressed MDA7 transgene may inhibit tumor cell proliferation and induce tumor cell apoptosis.
material entity;Ad5-yCD/mutTKSR39rep-hIL12 Vaccine;A replication-competent oncolytic adenovirus encoding the murine pro-inflammatory cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of Ad5-yCD/mutTKSR39rep-hIL12, the adenovirus selectively infects and replicates in tumor cells, which results in direct tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells, which may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. In addition, Ad5-yCD/mutTKSR39rep-hIL12-infected cancer cells express yCD and TKSR39. upon administration of the prodrugs 5-fluorocytosine (5-FC) and valganciclovir (vGCV), the yCD and HSV-1 TKSR39 activate these prodrugs to form 5-fluorouracil (5-FU) and ganciclovir, respectively. 5-FU gets converted to 5-fluoro-uridine monophosphate (5-FUMP) and subsequently to 5-fluoro-deoxyuridine monophosphate (5-FdUMP). 5-FdUMP irreversible inhibits thymidylate synthase, inhibits deoxythymidine triphosphate (dTTP) formation and halts DNA synthesis. Once phosphorylated intracellularly, ganciclovir triphosphate competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis.
material entity;Ad-sig-hMUC-1/ecdCD40L Vaccine;A cancer vaccine consisting of a recombinant adenoviral vector encoding the tumor-associated antigen (TAA) human MUC-1 (hMUC-1) linked to the extracellular domain (ecd) of the co-stimulatory molecule CD40 ligand (CD40L) and an adenovirus signal sequence that encodes a secretory signal peptide (Ad-sig) with potential immunostimulating and antineoplastic activities. Due to the presence of the secretory signal peptide expressed by Ad-sig in the vaccine construct, transfected cells may secrete a fusion protein composed of hMUC-1 and the CD40L ecd. The CD40L moiety part of the fusion protein binds to CD40 receptors on dendritic cells (DCs). Subsequently, DCs may be activated and migrate, T-cells may expand, and a cytotoxic T lymphocyte (CTL) response against tumor cells that overexpress hMUC-1 may follow. MUC-1 is a hypoglycosylated TAA overexpressed by epithelial cancer cells.
material entity;Ad CMV I kappaB alpha Vaccine;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Prefilled Syringe;
material entity;0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Injection;
material entity;rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML Injection [Imovax];
material entity;0.5 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe;
material entity;0.5 ML hepatitis B surface antigen vaccine 0.005 MG/ML Prefilled Syringe [Recombivax];
material entity;0.5 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe;
material entity;0.5 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection;
material entity;0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / meningococcal polysaccharide vaccine group Y 0.01 MG/ML Injection;
material entity;0.5 ML Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML Injection;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2019-2020];
material entity;Brucella melitensis as vaccine component;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe;
material entity;Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;pertussis vaccine 0.0468 MG/ML;
material entity;pertussis vaccine 0.0468 MG/ML Injectable Solution;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;pertussis vaccine 600 UNT/ML Injectable Solution;
material entity;pertussis vaccine 8 UNT/ML;
material entity;pertussis vaccine 8 UNT/ML Injectable Solution;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Suspension;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Suspension [Ipol];
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2019-2020];
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2019-2020];
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Quadracel];
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML [Menquadfi];
material entity;Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection;
material entity;Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection [Menveo];
material entity;Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Prefilled Syringe;
material entity;Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Prefilled Syringe [Trumenba];
material entity;Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine;
material entity;Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML;
material entity;VHL2 (Y12M) Peptide Vaccine;A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL2 (Y12M) peptide is a point mutation variant (from tyrosine to methionine at amino acid position 12) of the VHL protein. Vaccination with this peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.
material entity;VHL16 Peptide Vaccine;A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL16 peptide, also known as S111I, is a point mutation variant of the VHL tumor suppressor protein. the mutation is in amino acid position 111. Vaccination with this agent may stimulate a cytotoxic T-cell response in patients with VHL-associated cancers that express this variant of the VHL tumor suppressor protein.
material entity;VHL14 Peptide Vaccine;A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL14 peptide is a point mutation variant of the VHL protein. the mutation is in amino acid position 166. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation.
material entity;VHL-59: 116-128 Peptide Vaccine;A peptide vaccine consisting of amino acids 116 through 128 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a frameshift mutation. As a cancer vaccine, VHL-59: 116-128(FrSh116-128) peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.
material entity;VHL-42: 65-76(V74G) Peptide Vaccine;A peptide vaccine consisting of amino acids 65 through 76 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a glycine substitution at position 74. As a cancer vaccine, VHL-59: 65-76(V74G) may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.
material entity;Renal Tumor-Reactive Autologous Peripheral Blood Lymphocyte Vaccine;Peripheral blood lymphocytes (PBL) harvested from the blood of a renal cancer patient and exposed in vitro to renal tumor-associated antigens (TAA). Introducing these renal tumor-reactive autologous peripheral blood lymphocytes back to the same patient target tumor cells expressing these TAAs and could induce a cytotoxic T-cell-mediated immune response against renal cell cancer.
material entity;Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003;A cell-based preparation in which autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. Upon electroporation into autologous DCs, the RNA is translated and processed. BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. When AGS-003-BLD is reintroduced to the patient, the MHC-presented peptides interact with and activate CD8-positive T cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs.
material entity;Renal Cell Carcinoma Peptides Vaccine IMA901;A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding). endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens.
material entity;RCAS-Akt Vaccine;A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the AKT Gene. The viral vector RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis.
material entity;PAX3/FKHR Peptide Vaccine;A synthetic peptide vaccine based on the sequences of a translocation mutation of 2 transcriptional factor genes, PAX3 and FKHR. PAX3/FKHR fusion proteins are frequently found in patients with rhabdomyosarcomas. Vaccination with PAX3/FKHR peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this PAX3/FKHR fusion protein.
material entity;Von Hippel-Lindau Peptide Vaccine;A cancer vaccine composed of peptides derived from a tumor-associated protein encoded by a mutated Von Hippel-Lindau (VHL) oncogene. VHL peptide vaccine may stimulate a cytotoxic T cell response against tumor cells expressing the VHL tumor-associated protein.
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Vaxelis];
material entity;Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;Brucella abortus as vaccine component;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Vaxelis];
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML / hepatitis B surface antigen vaccine 0.01 MG/ML Injection;
material entity;mumps virus vaccine live, Jeryl Lynn strain Injectable Solution [Mumpsvax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML Injection [Tdvax];
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Prefilled Syringe;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Prefilled Syringe [Menactra];
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injection;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injection [Menactra];
material entity;Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML [Menactra];
material entity;12MP Vaccine;2 class major histocompatibility complex-restricted melanoma peptides.
material entity;12 Melanoma Peptide Vaccine;
material entity;117-126:FGF-5 Peptide Vaccine;A fragment of fibroblast growth factor-5 (FGF-5). Originally isolated from a renal cell carcinoma cell line that overexpressed FGF-5, FGF-5:117-126 peptide is recognized by tumor infiltrating cytotoxic T lymphocytes. Overexpressed by several cancer cell types, this peptide is being tested as a potential target for antineoplastic immunotherapies. (NCI04)
material entity;1(SOCS1)-silenced dendritic cell (DC) Vaccine;To obtain SOCS1-silenced DCs, DCs derived from mouse bone marrow cells ex vivo were induced to differentiation in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, and then transduced with Len-SOCS1-shRNA or control Len-GFP lentiviruses. The SOCS1-silenced DCs were loaded by TRP2 peptide to prepare the DC vaccine, which was induced to mature by LPS. The DCs were analyzed by flow cytometry (FCM) for surface expressions of MHCII and CD86 and by real-time PCR for the expressions of SOCS1, IL-10 as well as IL-12p40. B16 or IL-10-silenced B16 (IL-10(-/-).) cells were inoculated into C57BL/6 mice.
material entity;4-peptide melanoma vaccine;A cancer vaccine that may stimulate an immune response against 4 different melanoma associated antigens. This may lead to a reduction in tumor cell proliferation of cancer cells expressing these antigens. The vaccine may contain 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a helper tetanus peptide. The peptides may include Melan-A, gp100, MAGE-3, and NA17. The vaccine can be used in combination Ontak, which may produce an immune response in patients with metastatic melanoma, and the Ontak may improve these immune responses and lead to tumor shrinkage.
material entity;Telomerase: 540-548 Peptide Vaccine;A recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT). Telomerase expression has been directly linked to tumor development. its catalytic subunit is expressed in the majority of human cancer cells, but infrequently in normal cells. Vaccination with telomerase:540-548 peptide may stimulate cytotoxic T cells to recognize and kill telomerase-expressing cells.
material entity;RCAS-Ras Vaccine;A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector, RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis.
material entity;Abagovomab;A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.
material entity;851B Gel Vaccine;A topical gel containing a peptide derived from the human papillomavirus (HPV). Application of 851B gel may stimulate the host immune system to trigger a cytotoxic T-lymphocyte response to cells that express HPV.
material entity;27-35(27L):MART-1 Peptide Vaccine;A synthetic peptide consisting of amino acids 27 through 35 of the melanoma differentiation antigen MART-1. 27-35(27L) MART-1 has a leucine substitution at amino acid position 27 to improve binding to HLA-A*0201. Vaccination with this agent may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against melanoma cells expressing MART-1.
material entity;12MP, 12MP/Tet, 12MP/6MHP, or 6MHP Vaccine;4 treatment groups, vaccinated with 12 MHC class I-restricted melanoma peptides to stimulate CTL (12 MP, group A), plus a tetanus peptide (group B), or a mixture of 6 melanoma helper peptides (6 MHP, group C) to stimulate helper T lymphocytes (HTL), or with 6 melanoma helper peptide (6 MHP) alone (group D), in incomplete Freund's adjuvant plus granulocyte macrophage colony-stimulating factor.
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Decavac];
material entity;Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML Injection;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine Injection;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine Injection [Menquadfi];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Quadracel];
material entity;0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Suspension;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Suspension [Comirnaty];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Suspension [Spikevax];
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.025 MG/ML;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.025 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5) 0.025 MG/ML Injectable Suspension;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.05 MG/ML;
material entity;rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injectable Solution;
material entity;rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injectable Solution [Meruvax II];
material entity;rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution [Meruvax II];
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2019-2020];
material entity;0.5 ML influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe;
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000000 UNT/ML Oral Suspension;
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 667000 UNT/ML;
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 667000 UNT/ML [Rotarix];
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 667000 UNT/ML Oral Suspension;
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 667000 UNT/ML Oral Suspension [Rotarix];
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension;
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix];
material entity;rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML [Meruvax II];
material entity;rabies virus vaccine wistar strain PM-1503-3M (human), inactivated Injection;
material entity;rabies virus vaccine wistar strain PM-1503-3M (human), inactivated Injection [Imovax];
material entity;Neisvac-C;
material entity;Menomune A/C/Y/W-135 vaccine;
material entity;Mutacol;A live attenuated V. cholerae vaccine that is manufactured by Berna Biotech, Ltd. This vaccine uses the V. Cholera strain CVD 103-HGR.
material entity;Infanrix-IPV;
material entity;Infanrix -IPV/Hib;
material entity;Infanrix/Hib;
material entity;Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C;
material entity;Menjugate vaccine;
material entity;Liquid Pedvax HIB vaccine;
material entity;Meningitec vaccine;
material entity;Rotarix vaccine;
material entity;Td Adsorbed;
material entity;Pediacel vaccine;
material entity;Pneumo 23;A polyvalent pneumococcal vaccine used to protectsagainst serious infection (e.g., meningitis, bacteria in the blood) due to Streptococcus pneumoniae, and it is manufactured by Sanofi Pasteur.
material entity;Quadracel vaccine;
material entity;Recombivax HB;
material entity;Priorix vaccine;A MMR vaccine that is manufactured by GlaxoSmithKline Biologicals.
material entity;Priorix-Tetra vaccine;A Measles-Mumps-Rubella-Vericella vaccine that is live attenuated and manufactured by GlaxoSmithKline Biologicals.
material entity;Avaxim - Pediatric;
material entity;BCG Vaccine (Freeze-Dried) (by Sanofi Pasteur);
material entity;Actacel;
material entity;Avaxim;
material entity;DT Polio Adsorbed;
process;review of vaccine license application;A vaccine regulatory process that is for vaccine regulatory agent to review vaccine license application from vaccine producer.
process;vaccine saftey regulation;A vaccine regulation for vaccine safety.
material entity;Inactivated Poliomyelitis Vaccine - IPV;A poliovirus vaccine that contains inactivtated Poliomyelitis to prevent disease caused from the vaccine.
material entity;Infanrix-hexa;A combination vaccine that protects infants from diphtheria, tetanus, pertussis (whooping cough), polio, hepatitis B and Haemophilus influenzae type b (Hib).
material entity;Imovax Polio;
material entity;Imovax Rabies (Canada);
material entity;Dukoral;
material entity;Engerix-B vaccine;
material entity;FSME - IMMUN;
material entity;Hiberix vaccine;
material entity;Eolarix;A Measles-Rubella vaccine that is live attenuated and manufactured by GlaxoSmithKline Biologicals.
material entity;Epaxal vaccine;
material entity;Nelipepimut-S Plus GM-CSF Vaccine;A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response.
material entity;VEGFR-2 DNA Vaccine VXM01;An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature.
material entity;Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1;A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively-personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens.
material entity;Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2;A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient‚Äö√†√∂‚àö√òs own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing.
material entity;Recombinant Adenovirus-LacZ Vaccine;
material entity;PF-04948568 Vaccine;A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.
material entity;PEP-CMV Vaccine;A peptide vaccine derived from cytomegalovirus (CMV) antigens with potential immunostimulating activity. Intradermal administration of the PEP-CMV vaccine may stimulate the immune system to mount a specific helper and cytotoxic T-lymphocyte (CTL) response against CMV-infected tumor cells. Infection with the herpesvirus CMV may play a significant role in tumor cell initiation and progression as well as chemoresistance.
material entity;Recombinant Fowlpox GM-CSF Vaccine Adjuvant;A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
material entity;Recombinant Adenovirus-Interferon/Syn3 Vaccine;A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN 2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon with Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFN 2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells.
material entity;Oncolytic Adenovirus Encoding GM-CSF Vaccine;A recombinant oncolytic adenovirus encoding the immunohematopoietic cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cells lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus may promote a cytotoxic T cell response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death.
site;USA;USA is a country that exists in north America.
site;country;
material entity;Rubella virus vaccine;A viral vaccine that protects against infection with Rubella virus.
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 158000000 UNT/ML;
material entity;Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine;A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3. also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone.
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 158000000 UNT/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 158000000 UNT/ML [Flumist 2012-2013 Formula];
material entity;Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207;A whole, heat-killed, recombinant Saccharomyces cerevisiae yeast-based vaccine genetically altered to express the carcinoembryonic antigen (CEA) peptide 610D with potential immunostimulating and antineoplastic activities. Upon administration, recombinant Saccharomyces cerevisia-CEA(610D) vaccine GI-6207 may stimulate a host cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells, which may result in tumor cell lysis. CEA, a tumor associated antigen, is overexpressed on a wide variety of human cancer cells including colorectal, gastric, lung, breast and pancreatic cancer cells. CEA 610D encodes for 9 amino acids (605-613) in which aspartate is substituted for asparagine at position 610 (610D) in order to strengthen the induction of the CTL response against CEA-expressing tumor cells.
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 158000000 UNT/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 158000000 UNT/ML Nasal Spray;
material entity;Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine;A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors.
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 158000000 UNT/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 158000000 UNT/ML Nasal Spray [Flumist 2012-2013 Formula];
material entity;Recombinant Fowlpox-B7.1 Vaccine;A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the stimulatory molecule transgene B7-1. Recombinant fowlpox-B7.1 (rF-B7.1) vaccine may enhance antigen presentation and activate antitumoral cytotoxic T-cells.
material entity;RAS Peptide Cancer Vaccine;A cancer vaccine containing a RAS oncogene-encoded peptide with potential antineoplastic activity. RAS peptide cancer vaccine may stimulate a RAS peptide-specific antitumoral T-cell cytotoxic immune response, resulting in an inhibition of tumor cell proliferation and tumor cell death.
material entity;Poly Microsphere Encapsulated HER2/neu Oral Vaccine;A cancer vaccine consisting of Her2/neu peptides incorporated into microspheres of poly (lactide-co-glycolide) (PLGA), a biodegradable polymer. Poly microsphere encapsulated HER2/neu oral vaccine has been investigated for use in immunotherapy for tumors positive for HER-2/neu, a tumor associated antigen that is overexpressed in various cancers, including breast and ovarian cancer.‚Äö√†√∂‚àö¬ß
material entity;PCLUS 6.1-18MN Vaccine;A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 6.1-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies.
material entity;PCLUS 3-18MN Vaccine;A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies.
material entity;PADRE-CMV Fusion Peptide Vaccine;A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope.
material entity;p53 Peptide Vaccine;A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein.
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 50000000 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 50000000 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML Nasal Spray;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 50000000 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML [Flumist 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 50000000 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML Nasal Spray [Flumist 2014-2015 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Prefilled Syringe;
material entity;TBC-CEA-Contaminated W/ BVDV Vaccine;A cancer vaccine consisting of a recombinant vector encoding the tumor-associated carcinoembryonic antigen (CEA) that is‚Äö√†√∂‚àö¬ßcontaminated‚Äö√†√∂‚àö¬ßwith bovine viral diarrhea virus (BVDV). The carcinoembryonic antigen (CEA) is a prevalent tumor marker expressed by a number of different cancers such as colorectal, breast, lung and ovarian carcinomas. vaccination with vaccinia virus genetically engineered to express‚Äö√†√∂‚àö¬ßCEA‚Äö√†√∂‚àö¬ßmay generate antitumoral T-cell responses.‚Äö√†√∂‚àö¬ßBVDV‚Äö√†√∂‚àö¬ßis an RNA pestivirus that may contaminate vaccines due to its presence in fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production.
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2012-2013 Formula];
material entity;TARP 29-37-9V Peptide Vaccine;A peptide-based cancer vaccine, consisting of amino acid residues 29 through 37 of T cell receptor gamma alternate reading frame protein (TARP) with a leucine-to-valine substitution at position 9, with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 29-37-9V peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against TARP-expressing tumor cells, which may result in decreased tumor cell proliferation. The leucine-to-valine substitution at position 9 of this peptide improves its immunogenicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic.
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML [Fluzone High-Dose 2013-2014 Formula];
material entity;TARP 27-35 Peptide Vaccine;A peptide-based cancer vaccine, containing amino acid residues 27 through 35 of T cell receptor gamma alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 27-35 peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic.
material entity;Synthetic Peptides E-PRA And E-PSM Vaccine;A cancer vaccine consisting of E-PRA and E-PSM, two synthetic peptide analogs of PRAME (PReferential Antigen MElanoma) and PSMA (Prostate Specific Membrane Antigen), with potential immunostimulating activity. Upon direct administration into lymph nodes, synthetic peptides E-PRA and E-PSM vaccine may sitmulate a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing tumor cells. PRAME and PSMA are tumor-associated antigens upregulated and expressed on the cell surfaces of certain tumor cell types.
material entity;Synthetic hTERT DNA Vaccine INO-1400;A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT-encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells.
material entity;SVN53-67/M57-KLH Peptide Vaccine;A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine, this peptide is able to bind both HMC class I and II molecules and may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response against survivin-expressing cancer cells. This may result in decreased tumor cell proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family, expressed during embryonic development while absent in most normal adult cells, is upregulated in a variety of human cancers. its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. KLH may enhance immune recognition and may promote an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune response.
material entity;Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine;An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens.
material entity;Retrovector Encoding Mutant Anti-Cyclin G1 Vaccine;A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur.
material entity;Recombinant Vaccinia-NY-ESO-1 Vaccine;A cancer vaccine consisting of a recombinant vaccinia viral vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with recombinant vaccinia- NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.
material entity;Recombinant Vaccinia-MUC1-B7 Vaccine;An admixture of recombinant vaccinia virus encoding MUC-1 and recombinant vaccinia virus encoding the murine T-cell co-stimulatory molecule B7.1. MUC-1 is a glycosylated mucin that is overexpressed in breast, lung, pancreatic, prostate, stomach, colon, and ovarian carcinomas. Vaccination with MUC-1 in combination with B7.1 may enhance the cytotoxic T cell (CTL) immune response to tumors expressing MUC-1, compared to vaccination with MUC-1 alone.
material entity;Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907;A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival.
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML [Fluzone High-Dose 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2013-2014 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML [Fluzone High-Dose 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML Prefilled Syringe;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2012-2013 Formula];
material entity;Sialyl Tn-KLH Vaccine;A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth.
material entity;Recombinant Vaccinia-MUC-1 Vaccine;A vaccine containing a recombinant vaccinia virus that encodes the gene for human mucin-1, a tumor-associated antigen. Upon administration, recombinant vaccinia-MUC-1 vaccine may elicit a MUC-1-specific cytotoxic T cell response against tumor cells bearing MUC-1.
material entity;Recombinant Vaccinia DF3/MUC1 Vaccine;A vaccinia virus based vaccine expressing human tumor associated epithelial mucin (DF3 antigen. MUC1). MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in various tumors such as breast, prostate, and ovarian cancers. This vaccine could be used in development of immunotherapeutics against cancers expressing MUC1.
material entity;Recombinant Modified Vaccinia Ankara-5T4 Vaccine;A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain incapable of virion assembly.
material entity;Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine;A cancer vaccine containing autologous dendritic cells pulsed with a fusion product of an epitope of human tumor-associated epithelial mucin 1 (MUC1) antigen and the vaccine adjuvant mannan (oxidized mannose), with potential antineoplastic activity. When the modified dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in tumor cell lysis. Addition of manna in this vaccine, enhances immune recognition. MUC1 antigen, a high-molecular-weight transmembrane glycoprotein, is overexpressed on many tumor cells.
material entity;Recombinant dHER2 Vaccine;A cancer vaccine consisting of a truncated recombinant HER2 peptide (dHER2) with potential antineoplastic activity. Upon administration, recombinant dHER2 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. The HER2 protein is a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. dHER2 includes the extracellular domain (ECD) and a part of the intracellular domain (ICD) of the HER2 protein.
material entity;Recombinant Anti-WT1 Immunotherapeutic GSK2302024A Vaccine;An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.
material entity;Recombinant Adenovirus-Cre Recombinase Vaccine;
material entity;pNGVL3-hICD Vaccine;A plasmid DNA cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene. Upon administration and after cellular uptake by skin or muscle cells, the pNGVL3-hICD vaccine plasmid expresses the HER-2/neu protein, which, after intracellular processing, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance.
material entity;Personalized Synthetic Long Peptide Breast Cancer Vaccine;A cancer vaccine consisting of one or more long, synthetic peptides derived from patient-specific breast cancer tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of the personalized synthetic long peptide breast cancer vaccine, the peptides stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TAAs, which results in tumor cell lysis.
material entity;ONYX-015 Vaccine;An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of ONYX-015-mediated tumor cell cytotoxicity.
material entity;NY-ESO-B Vaccine;A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma. and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent.
material entity;NY-ESO-1b peptide vaccine;A recombinant nonapeptide used as an antineoplastic vaccine. NY-ESO-1b peptide vaccine contains the amino acid sequence SLLMWITQC, derived from the cancer-testis tumor antigen (NY-ESO-1), which is expressed on tumor cells of many different types, including melanomas. Vaccination with this peptide vaccine may elicit strong humoral and cellular immune responses to NY-ESO-1-expressing cancers.
material entity;NY-ESO-1/GLA-SE vaccine ID-G305AmN;A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines.
material entity;NY-ESO-1 plasmid DNA cancer vaccine;A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 with potential immunostimulating and antitumor activities. Upon administration, NY-ESO-1 plasmid DNA cancer vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1 is a tumor associated antigen (TAA) found in normal testes and expressed on the surfaces of various tumor cells, including melanoma, breast, bladder, prostate, lung, ovarian, and hepatocellular tumor cells.
material entity;NY-ESO-1 peptide vaccine;A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.
material entity;Natural Killer Cells ZRx101 vaccine;A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma. (NCIT C85466).
material entity;Tn(c)-KLH Conjugate Vaccine;A vaccine containing a clustered pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Alpha-N-acetylgalactosamine (Tn) is a monosaccharide usually O-linked to serine or threonine residues of mucins found on most epithelial cancers with the highest expression on prostate cancer. This vaccine contains the Tn epitope cluster (c) that is synthesized by linking 3 copies of the Tn epitope on a threonine backbone to achieve the essential immunogenic structure. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition. Vaccination with Tn(c)-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing Tn antigen, resulting in decreased tumor growth.
material entity;Synthetic Breast Cancer Peptides-Tetanus Toxoid-Montanide ISA-51 Vaccine;A cancer vaccine comprised of multiple synthetic breast cancer peptides and the adjuvant tetanus toxoid helper peptide emulsified in the adjuvant Montanide ISA-51 with immunopotentiation activity. Vaccination with this cancer vaccine may elicit a specific cytotoxic T-lymphocyte response against breast cancer cells. Synthetic breast cancer peptides may stimulate the immune response against cells that produce breast cancer markers such as erbB2 (HER2/neu) while tetanus toxoid helper peptide binds to class II MHC molecules as a nonspecific vaccine helper epitope, resulting in a long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.
material entity;STn-KLH plus Detox Vaccine;A vaccine comprised of a synthetic Sialyl-Tn antigen linked to the protein carrier, keyhole limpet hemocyanin (KLH), administered with immunostimulant, Detox. Vaccination with STn-KLH plus Detox may elicit an IgG-based anti-STn antibody response and ultimately a cytotoxic T-cell response against STn-expressing cancer cells.
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluvirin 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluzone 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluzone 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Fluzone 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [FluLaval 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Fluvirin 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Afluria 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Fluzone 2011-2012 Formula];
material entity;Remestemcel-L Vaccine;Human mesenchymal stem cells (MSCs) harvested from bone marrow of healthy adult donors and expanded ex vivo, with potential immunosuppressive activity. Remestemcel-L cells are hypo-immunogenic due to lack of major histocompatibility II (MHC II) molecule expression, eliciting little, if any, host immune response upon intravenous infusion. Infusion of allogeneic MSCs may result in: a) increased production of anti-inflammatory cytokines, such as interleukin-10, prostaglandin E, and hepatocyte growth factor. b) decreased mononuclear phagocyte expression of indoleamine 2,3,-dioxygenase, which catabolizes L-tryptophan into its pro-inflammatory metabolites. and c) modulated dendritic cell (DC)maturation and disrupted activities of natural killer (NK) cells and CD8+ and CD4+ T cells. In addition, pluripotent MSCs, upon administration, may be recruited to damaged tissue sites, differentiating along specific lineages when stimulated.
material entity;Recombinant Vaccinia-CEA Vaccine;A recombinant vaccinia virus encoding carcinoembryonic antigen (CEA). CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers. Attenuated vaccinia virus is a highly effective immunizing agent that evokes both humoral and cell-mediated responses. Vaccination with this agent may evoke a cytotoxic immune response to CEA-expressing cells.
material entity;WT1-A10/AS01B Immunotherapeutic GSK2130579A Vaccine;An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence. ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21.
material entity;WT1 Peptide Vaccine OCV-501;A leukemia cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors.
material entity;Tumor Cell Derivative Vaccine;A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens (substances isolated from tumor cells). A tumor antigen vaccine may stimulate the body's immune system to find and kill cancer cells.
material entity;PR1 Leukemia Peptide Vaccine;A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis.
material entity;p.DOM-WT1-37 DNA Vaccine;A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.37, with potential antitumor activity. Upon vaccination with p.DOM-WT1-37 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity.
material entity;Racotumomab Vaccine;An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells.
material entity;PR-151 Peptide Vaccine;A tumor-specific peptide encoded by patient-specific mutant p53 oncogene with potential immunostimulatory properties. The peptide (LPTGQDL) contains a frame shift mutation at amino acid position 134. It was used to pulse dendritic cells, which are then used in the adoptive immunotherapy setting and may stimulate the host immune system to mount a specific cytotoxic T lymphocyte response against tumor cells expressing the p35 mutation.
material entity;EP-2101 Vaccine;A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. OSE 2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes. This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes.
material entity;Telomerase-specific Type 5 Adenovirus OBP-301 Vaccine;A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. OBP-301 contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells.
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Flulaval 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Afluria 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain Nasal Spray [Flumist 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Afluria 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Afluria 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Agriflu 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluarix 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluarix 2011-2012 Formula];
material entity;Oncovax-ID/IL-2 Vaccine;A cancer vaccine consisting of a mixture of a murine lymphoma-derived idiotype and interleukin-2 (IL-2) encapsulated in dimyristoylphosphatidylcholine liposomes. The use of a liposomal carrier confers immunogenicity to the naturally non-immunogenic idiotype.
material entity;Viagenpumatucel-L Vaccine;A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1.
material entity;Tergenpumatucel-L Vaccine;An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, tergenpumatucel-L is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a 'xenograft'. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell xenograft, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes.
material entity;Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine;A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.
material entity;Recombinant DNA-L523S Vaccine;A plasmid DNA encoding human L523S, an RNA-binding protein that belongs to the KOC (K homology domain containing protein overexpressed in cancer) family, with potential antineoplastic activity. Vaccination with L523S DNA may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express the L523S protein. As an oncofetal protein, L523S is normally expressed in early embryonic tissue, but is overexpressed in certain cancer cell types.
material entity;Recombinant Adenovirus-L523S Vaccine;A replication-defective adenovirus containing a gene that encodes the human protein L523S with potential antineoplastic activity. Upon administration, recombinant adenovirus-L523S vaccine expresses L523S, which may stimulate antibody and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing L523S. L523S is an RNA-binding protein that belongs to the KOC (K homology domain containing protein over-expressed in cancer) family of proteins. As an oncofetal protein, L523S is normally expressed in early embryonic tissues and certain normal adult tissues such as colon, fallopian tube, gall bladder, and ovary tissues but may be overexpressed in squamous cell cancers of the lung.
material entity;NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL) and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.
material entity;NA17.A2 peptide vaccine;A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17. A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas.
material entity;NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine;A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3 (MAGE-3.A2) and the cancer-testis antigen (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Upon administration, the NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing NA-17, MAGE-3.A2 and NY-ESO-1, resulting in tumor cell lysis. The tumor-associated antigens (TAAs) NA-17, MAGE-3.A2 and NY-ESO-1 are overexpressed in a variety of cancer cell types.
material entity;Unconjugated Lymphoma Ig Id Vaccine;A vaccine consisting of lymphoma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated lymphoma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth.‚Äö√†√∂‚àö¬ß
material entity;Survivin Antigen Vaccine DPX-Survivac;A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of the maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells. its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [FluLaval 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Flulaval 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluvirin 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Afluria 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Agriflu 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluarix 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluarix 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluvirin 2010-2011 Formula];
material entity;WT1 247-261 Peptide Vaccine;A synthetic peptide vaccine consisting of a HLA-DRw53-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 247 through 261, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 247-261 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluvirin 2011-2012 Formula];
material entity;WT1 235-243 Peptide Vaccine;A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.
material entity;WT1 126-134 Peptide Vaccine;A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation.
material entity;WT1 124-138 Peptide Vaccine;A synthetic peptide vaccine consisting of a HLA-DR15-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 124 through 138, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 124-138 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.
material entity;Vi Capsular Polysaccharide Typhoid Vaccine;A live attenuated bacteria injectable vaccine used to prevent typhoid, which is caused by Salmonella typhi.
material entity;VCL-CB01 Vaccine;A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis.
material entity;Vaccinia Virus DD-CDSR Vaccine;A highly tumor-selective vaccinia virus (vv) with an engineered double deletion (DD) of the thymidine kinase (tk) and vaccinia growth factor genes and additions of both a cytosine deaminase (CD) gene and a somatostatin receptor (SR) gene with potential oncolytic viral activity. The tk and vaccinia growth factor gene deletions in intratumorally administered vaccinia virus (vvDD-CDSR) help to restrict its replication and cytolytic activity to tumor cells with large nucleotide pools and tumor cells with activation of the EGFR-Ras pathway. Addition of the CD gene to the viral genome allows control of oncolytic viral infection through the administration of the prodrug 5-fluorocytosine (5-FC), converted by CD to the antimetabolite 5-fluorouracil (5-FU) in cells infected with this agent. Addition of the SR gene allows anatomical localization of vaccinia virus (vvDD-CDSR) through the use of octreotide scintigraphy.
material entity;URLC10-TTK-KOC1-VEGFR1-VEGFR2 Multipeptide Vaccine;A cancer vaccine containing five peptide epitopes with potential immunostimulatory and antitumor activity. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), KOC1 (IGF II mRNA Binding Protein 3) and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, KCO1, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth.
material entity;URLC10 Peptide Vaccine;A cancer vaccine containing URLC10 (up-regulated lung cancer 10) epitopes with potential immunostimulatory and antineoplastic activities. Upon administration, URL peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. Up-regulated in lung and esophageal cancers, the function of URLC10 is unknown.
material entity;pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccine;An antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death.
material entity;pNGVL4a-CRT/E7(detox) DNA Vaccine;A cancer vaccine consisting of the DNA plasmid pNGVL4a-A encoding calreticulin (CRT) linked to a detox form of human papillomavirus (HPV) type 16 E7 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, this vaccine may generate a potent cytotoxic T-lymphocyte (CTL) response against E7-expressing tumor cells, resulting in tumor cell death. For E7(detox), the amino acids in E7 at positions 24 (cysteine to glycine) and 26 (glutamic acid to glycine) were substituted. CRT, a 46 kDa protein located in the lumen of the cell's endoplasmic reticulum (ER), may potentiate MHC class I presentation of HPV-16 E7 to E7-specific CD8-positive T cells. In addition, pNGVL4a-A contains two short immunostimulatory DNA sequences (ISS) in the noncoding region, which may elicit the production of IFN- and IL-12 in transfected keratinocytes and dermal antigen presenting cells (APCs), resulting in a potent T helper cell type 1 response.
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluzone 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluzone 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain Nasal Spray;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain Nasal Spray [FluMist 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Afluria 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Afluria 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [FluLaval 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Flulaval 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Fluvirin 2010-2011 Formula];
material entity;Recombinant Adenovirus-p53 SCH-58500 Vaccine;A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis.
material entity;RASVAC-V Vaccine;A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine, RASVAC-V is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation.
material entity;RASVAC-C Vaccine;A synthetic vaccine used for cancer immunotherapy also known as Ras(cis 12)-Vaccinia Vaccine, RASVAC-C is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation.
material entity;Verpasep Caltespen Vaccine;A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes.
material entity;Synthetic Long E6/E7 Peptides Vaccine HPV-01;A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells.
material entity;Recombinant Vaccinia Viral Vector RO5217790 Vaccine;A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with MVA-HPV16E6/E7-IL2 vaccine TG4001 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells.
material entity;Recombinant Human Papillomavirus Nonavalent Vaccine;A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.‚Äö√†√∂‚àö¬ß
material entity;Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine;A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) Types 6, 11, 16, and 18 with immunoprophylactic activity. The immunoprohylactic efficacy of L1 VLP vaccines, such as recombinant human papillomavirus quadrivalent vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.
material entity;p.DOM-WT1-126 DNA Vaccine;A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.126, with potential antitumor activity. Upon vaccination with p.DOM-WT1-126 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity.
material entity;URLC10-CDCA1-KOC1 Multipeptide Vaccine;A cancer vaccine containing multiple peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from, URLC10 (up-regulated lung cancer 10), CDCA1 (cell division cycle-associated protein 1), KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-CDCA1-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, CDCA1, KCO1 peptides, resulting in cell lysis and decreased tumor growth.
material entity;Recombinant Human Fusion Protein L19TNFalpha Vaccine;An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Fluvirin 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Fluzone 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Fluzone 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Afluria 2010-2011 Formula];
material entity;influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML;
material entity;influenza B virus vaccine, B-Wisconsin-1-2010-like virus 158000000 UNT/ML;
material entity;influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML;
material entity;influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain;
material entity;influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML;
material entity;Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.0000000385 MG/ML;
material entity;influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML;
material entity;influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML;
material entity;influenza B virus vaccine B/Brisbane/60/2008 antigen 50000000 MG/ML;
material entity;influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML;
material entity;pill;
material entity;delayed release oral capsule;
material entity;oral product;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML [Flumist 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML Nasal Spray;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML Nasal Spray [FluMist 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML Nasal Spray [Flumist 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML Nasal Spray;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 MG/ML;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine Nasal Spray;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML [FluMist 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML [Fluzone 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Prefilled Syringe;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML [Fluzone 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML [Fluzone 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula];
material entity;Recombinant Fowlpox-gp100p209 Vaccine;A melanoma vaccine comprised of a recombinant fowlpox vector construct encoding a modified epitope of the melanoma antigen glycoprotein 100 (gp100), ES-2092M(gp100), containing an endoplasmic reticulum signal sequence targeted to the endoplasmic reticulum apparatus. Vaccination with recombinant fowlpox-gp100p209 vaccine may stimulate the host immune system more efficiently to mount a cytotoxic T lymphocyte response against tumor cells expressing the gp100 antigen.
material entity;prime/boost DC-TRP-2 melanoma vaccine;rime/boost vaccination proved to be of no advantage or even detrimental in therapeutic settings in B16F1 and transgenic adenocarcinoma of the mouse prostate (TRAMP) models, respectively
material entity;Plasmacytoid Dendritic Cell Vaccine;A whole cell vaccine derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology that exhibits immunomodulating activity. Plasmacytoid dendritic cells (pDCs) express a characteristic set of surface markers, such as CD123 (interleukin-3 receptor alpha chain), BDCA-2 (blood dendritic cell antigen 2. CD303) and BDCA-4 (CD304), as well as intracellular toll-like receptors 7 and 9. Upon stimulation, the activated pDCs produce substantial amounts of interferon (IFN) alpha, and to a lesser degree IFN-beta, as well as other cytokines and chemokines, such as tumor necrosis factor alpha and interleukins 1, 6 and 8. In addition, these pDCs, directly or indirectly stimulate T-cells, B-cells and natural killer cells. This may potentially lead to increased immunity against tumor cells.
material entity;PEP-3-KLH Conjugate Vaccine;A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII. this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC).
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula];
material entity;NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine;A cell-based cancer vaccine composed of dendritic cells (DC) pulsed with peptides derived from the tumor-associated antigens human cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1/MART-1 peptide-pulsed DC vaccine may stimulate the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells.
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Fluvirin 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Agriflu 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluarix 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluarix 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Afluria 2010-2011 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluvirin 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Afluria 2011-2012 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluvirin 2010-2011 Formula];
material entity;Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution;
material entity;Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution [Metavirulent];
material entity;pWRG7079 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pWRG7079. This plasmid contains a CMV promoter and a kanamycin resistance gene and differs from pWRG7077 by the insertion of a TPA sequence.
material entity;Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution;
material entity;Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution [Metavirulent];
material entity;pcDNA3.1/Hygro(-) DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/Hygro(-). This plasmid is 5596 base pairs in length and contains a CMV promoter and an ampicillin resistance gene.
material entity;Antigens Surface Of Virus Influenza, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / Switzerland / 9715293/2013, Nib-88;
material entity;pCMV3ISS DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCMV3ISS. This plasmid is a eukaryotic expression vector.
material entity;Antigens Surface Of Virus Influenza, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / Switzerland / 9715293/2013, Nib-88 0.03 MG/ML;
material entity;pUSK DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pUSK.
material entity;pUBIQ DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pUBIQ. This plasmid is derived from pGEM3 and contains a CMV promoter and an ampicillin resistance gene.
material entity;pEGFP-N1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pEGFP-N1. This plasmid is 4733 base pairs in length and contains a CMV promoter and kanamycin resistance gene.
material entity;pCDL-SRa296 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCDL-SRa296. This plasmid is 3700 base pairs in length and contains a SRalpha promoter.
material entity;pUSE- DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pUSE-. This plasmid is a mammalian expression vector derived from pCI-neo.
material entity;APL023 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label APL023.
material entity;p1012 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label p1012.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 10 by Boehringer Ingelheim;
material entity;Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 10;
material entity;Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 100;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 10 by Novartis;
material entity;Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2015-2016];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 1;
material entity;Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2015-2016];
material entity;Antigens Surface Of Virus Influenza, strain B / Brisbane / 9/2014 Wild Type;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol];
material entity;Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;Antigens Surface Of Virus Influenza, strain B / Brisbane / 9/2014 Wild Type 0.03 MG/ML;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 1 by Novartis;
material entity;Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;BCG, Live, Connaught Strain 1 MG/ML;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 1 by Boehringer Ingelheim;
material entity;Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;BCG, Live, Connaught Strain 1 MG/ML Injectable Solution;
material entity;Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2016-2017];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2016-2017];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe;
material entity;Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension Box of 10;
material entity;Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML [Pneumovax 23];
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-Christchurch-16-2010 NIB-74 (H1N1) (A-California-7-2009) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-Christchurch-16-2010 NIB-74 (H1N1) (A-California-7-2009) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension [Fluarix];
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML [INFLUVAC];
material entity;pBC12B1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pBC12B1. This plasmid is a eukaryotic expression vector.
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension;
material entity;pGFP DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pGFP. This plasmid is 3300 base pairs in length and contains a lac promoter and an ampicillin resistance gene.
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension [INFLUVAC];
material entity;pCSIVgag DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCSIVgag.
material entity;pVacc4 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pVacc4. This plasmid is a derivative of pVacc1 and contains a CMV promoter.
material entity;pRc/RSV DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pRc/RSV. This plasmid is 5224 base pairs in length and contains a RSV LTR promoter and ampicillin resistance gene.
material entity;pCI-TPA DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCI-TPA. This plasmid contains the N-terminal signal sequence of TPA.
material entity;pcDNA3.1/V5-His-TOPO DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/V5-His-TOPO. This plasmid is 5523 base pairs in length and contains a CMV promoter and ampicillin resistance gene.
material entity;pIRES1neo DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pIRES1neo. This plasmid is 5257 base pairs in length and contains an ampicillin resistance gene.
material entity;pVR1020 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pVR1020. This plasmid contains a CMV promoter and kanamycin resistance gene.
material entity;nkCMVintpolyli DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label nkCMVintpolyli. This plasmid contains a CMV promoter.
material entity;pCMV-beta DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCMV-beta. This plasmid is 7164 base pairs in length and contains a CMV promoter and ampicllin resistance gene.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 50;
material entity;Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 20;
material entity;Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 1;
material entity;Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 1;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 50 by Boehringer Ingelheim;
material entity;Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension Box of 1;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 100;
material entity;Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML [IMMUGRIP];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 10;
material entity;Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML [VAXIGRIP];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 20;
material entity;Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension;
material entity;Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 50;
material entity;Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 20 by Novartis;
material entity;Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG;
material entity;pRC DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pRC. This plasmid is 7400 base pairs in length and contains CMV and RSV promoters.
material entity;pET11d DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pET11d. This plasmid is 5674 base pairs in length and contains an ampicillin resistance gene.
material entity;50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac] Box of 1;
material entity;pUMVC4b DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pUMVC4b. This plasmid is 4478 base pairs in length and contains a CMV promoter and kanamycin and ampicillin resistance genes.
material entity;multi-epitope HER2 peptide vaccine TPIV100;A cancer vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. The four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. TPIV100 and sargramostim could work in treating patients with HER2 positive, stage II-III breast cancer.
material entity;50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac] Box of 1 by Lamepro;
material entity;pcTPA DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pcTPA. This plasmid is based on pcDNA3 and contains the hTPA signal sequence.
material entity;MUC1 peptide-poly-ICLC vaccine;A cancer vaccine containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1 peptide-poly-ICLC adjuvant vaccine in boosting systemic immunity to MUC1 in women with stage I-III 'triple-negative' [i.e., ER(-) PR(-) HER2/neu(-)] breast cancer. MUC1 peptide-Poly-ICLC vaccine could also work in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.
material entity;50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac] by Lamepro;
material entity;pMV10.1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pMV10.1. This plasmid contains a CMV promoter and a kanamycin resistance gene.
material entity;MT-201-GBM monocyte vaccine;A cancer vaccine consisting of autologous monocytes loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein. UL83) as a fusion protein with the lysosome-associated membrane protein (LAMP), with potential immunostimulatory and antineoplastic activities. The autologous CMV-pp65-LAMP mRNA loaded monocyte vaccine MT-201-GBM exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of LAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. MT-201-GBM (pp65CMV antigen monocytes) are administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O[6]-methylguanine-DNA methyltransferase) (MGMT) gene promoter. The vaccine is made from a type of immune cell called monocytes, which have been engineered to express a cytomegalovirus (CMV) protein. Patients also receive standard radiation therapy combined with temozolomide.
material entity;50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension Box of 1;
material entity;pGT36 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pGT36. This plasmid is a derivative of pcDNA3 and contains a CMV promoter and a kanamycin resistance gene.
material entity;mRNA-based personalized cancer vaccine NCI-4650;A cancer vaccine targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. Up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. The mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. This mRNA vaccine might cause certain tumors to shrink. Immunogenic neoantigens and can predict for neoantigens binding the patient human leukocyte antigen (HLA) molecules from melanoma or epithelial cancer patients and use these epitopes for a personalized therapeutic messenger ribonucleic acid (mRNA) vaccine.
material entity;VR1040 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label VR1040. This plasmid contains four copies of the mouse immunostimulatory sequence and is similar to VR1012.
material entity;mRNA tumor antigen DC vaccine;A cancer vaccine made with dendritic cells (DCs) pulsed with mRNA encoded tumor antigens. These personalized cell vaccines may lead to antitumor specific T cell responses.
material entity;pcDNA1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pcDNA1. This plasmid is 4000 base pairs in length and contains a CMV promoter.
material entity;mRNA neoantigen tumor vaccine;A cancer vaccine with or without PD-1/L1 may help treat patients with advanced gastric cancer. A personalized mRNA tumor vaccine encoding neoantigen may also help treat patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma. The vaccine can also be used in combination with PD-1 for the treatment of advanced solid tumors.
material entity;pCAT DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCAT. This plasmid is 4364 base pairs in length and contains an ampicillin resistance gene.
material entity;mixed bacterial cancer vaccine;A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes. the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12). The mixed bacteria vaccine (MBV) is administered at a starting dose of 250 EU (1 µL) and escalated in each patient to a dose inducing the desired pyrogenic effect, defined as a body temperature of 38°C to 39.5°C. It is given to patients with malignant tumors that expressed the NY-ESO-1 antigen. It is designed to induce immunological effects and tumor response following vaccination.
material entity;melanoma helper peptide vaccine;A cancer vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Vaccines using melanoma peptides from cytotoxic T cells and helper T cells could work in treating patients with metastatic melanoma. This vaccine contains 12 melanoma peptides restricted by Human Leukocyte Antigen (HLA)-A1, -A2, or -A3 and 6 melanoma helper peptides restricted by HLA-DR molecules emulsified with sargramostim (Granulocyte-macrophage colony-stimulating factor, GM-CSF) and Montanide ISA-51 or Montanide ISA-51 VG (ISA-51).
material entity;pUMVC3 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pUMVC3. This plasmid is 4030 base pairs in length and contains a CMV promoter and kanamycin resistance gene.
material entity;MDX-CTLA4 antibody/tyrosinase/gp100/MART-1 melanoma vaccine;A cancer vaccine composed of CTLA-4 antibody. tyrosinase, gp100, and MART-1 peptides. and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.
material entity;MDX-1379 (gp100) melanoma peptide vaccine;A cancer vaccine made up of two peptides that are pieces of a bigger melanoma protein (gp100). These peptides bind to HLA-A2 which is then recognized by T cells. It could be given in combination with MDX-010 (ipilimumab, BMS-734016). MDX-010 (anti-CTLA4) antibodies are designed to keep the immune system running by blocking CTLA-4 from down-regulating T cell activation.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 50 by Boehringer Ingelheim;
material entity;Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 20 by Boehringer Ingelheim;
material entity;Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Prefilled Syringe [FLUAD 2015-2016];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 20;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;Bordetella pertussis as vaccine component;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 50;
material entity;Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax 2015-2016];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 20 by Novartis;
material entity;Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Prefilled Syringe;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 2;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG;
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2016-2017];
material entity;50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension by Lamepro;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 100;
material entity;Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 2 by Novartis;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;Bacillus anthracis as vaccine component;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension [INFLUVAC];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 2 by Boehringer Ingelheim;
material entity;Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML;
material entity;influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension [IMMUGRIP];
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2019-2020];
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension [VAXIGRIP];
material entity;Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;pcDNA DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pcDNA.
material entity;proVAX DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label proVAX. This plasmid contains a CMV promoter and a hCG-beta leader sequence.
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 5;
material entity;pSecTag2A DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSecTag2A. This plasmid is 5159 base pairs in length and contains a CMV promoter and ampicillin reisistance gene.
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 5 by Sanofi;
material entity;pRc/CMV-HBs(S) DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pRc/CMV-HBs(S). This plasmid is 5618 base pairs in length and contains a CMV promoter and ampicillin resistance gene.
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 6;
material entity;V1Jns DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label V1Jns. This plasmid contains the human CMV promoter, enhancer and intron A as well as the polyadenylation sequences of bovine growth hormone.
material entity;pND-14 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pND-14. This plasmid contains a CMV promoter, ampicillin resistance gene, a tissue plasminogen activator leader sequence, a bovine growth hormone terminator, and constitutive transport element from simian retrovirus.
material entity;Auxo-GTU DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label Auxo-GTU.
material entity;pCMN160 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCMN160. This plasmid has a CMV promoter.
material entity;pAK-4 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pAK-4. This plasmid is 6600 base pairs in length and contains a CMV promoter and kanamycin and ampicillin resistance genes.
material entity;pCMVi(-H3)Ubs DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCMVi(-H3)Ubs. This plasmid contains a CMV promoter.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno] by Baxter;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno];
material entity;Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2016-2017 Formula];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension;
material entity;Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno] Box of 10 by Baxter;
material entity;Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2016-2017];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno] Box of 10;
material entity;Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 2;
material entity;Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 6 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 100;
material entity;Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016 Southern Hemisphere];
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 50;
material entity;Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 3;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 20;
material entity;Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2016-2017];
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 5;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 6;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2016 Southern Hemisphere];
material entity;50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 10;
material entity;Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML;
material entity;50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac];
material entity;Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2016 Southern Hemisphere];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 25 by Glaxosmithkline;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 50 by Glaxosmithkline;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 50;
material entity;VLA2001 vaccine;A SARS-CoV-2 inactivated, Vero-cell based vaccine adjuvanted with aluminum and CpG 1018. It uses the manufacturing platform of Valneva's commercial Japanese encephalitis (JE) vaccine
material entity;Soberana 02;A SARS-CoV-2 subunit vaccine developed by Finlay Vaccine Institute (IFV)
material entity;V591;A SARS-CoV-2 vaccine candidate that uses a measles virus vector platform, and is made by Merck. Development of the vaccine was discontinued on January 25, 2021.
material entity;Recombinant SARS-CoV-2 vaccine (Sf9 cell);A SARS-CoV-2 protein subunit vaccine by West China Hospital
material entity;S-268019;A SARS-CoV-2 recombinant protein vaccine¬¨‚Ä†that uses the Baculovirus expression vector system.
material entity;QazVac vaccine;A SARS-CoV-2 inactivated vaccine manufactured by the Research Institute for Biological Safety Problems (Republic of Kazakhstan)
material entity;RBD-HBsAg VLP;A SARS-CoV-2 virus-like particle vaccine that contains the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike (S) protein and is adjuvanted with aluminum.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 20;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 10 by Glaxosmithkline;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 25;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 20 by Glaxosmithkline;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 20;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 10 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 5;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 20 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] by Glaxosmithkline;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] Box of 10 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 50;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Moniarix];
material entity;pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Synflorix];
material entity;AV-COVID-19;A SARS-CoV-2 vaccine consisting of autologous dendritic cells previously loaded ex vivo with spike protein.
material entity;pcDNA3.1(Zeo)+ DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1(Zeo)+. This plasmid is 5015 base pairs in length and contains a zeocin selectable marker, a CMV promoter, and an ampicillin resistance gene.
material entity;pVF DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pVF.
material entity;VR1055 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label VR1055. This plasmid is derived from pUC19 and contains a CMV promoter, kanamycin resistance gene, a cloning polylinker, and a transcriptional terminator region derived from the rabbit beta-globin gene.
material entity;pRSC DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pRSC.
material entity;pGT146-mIL-12 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pGT146-mIL-12.
material entity;pDNAVACC DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pDNAVACC.
material entity;pSW3891 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSW3891. This plasmid contains a CMV promoter.
material entity;pJW4304 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pJW4304. This plasmid is 5132 base pairs in length and contains a CMV promoter.
material entity;Corbevax vaccine;A SARS-CoV-2 vaccine that includes a protein antigen, SARS-CoV-2 Spike RBD, adsorbed to the adjuvant Alhydrogel (Alum), in combination with another approved adjuvant, CpG 1018
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 25;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 10;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Prevnar];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 50;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Pneumovax 23];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 25 by Sanofi;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Pneumopur];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] by Sanofi;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Pnu-Imune];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 50 by Sanofi;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Pneumovax II];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 10;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML [Pneumopur];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML [Pnu-Imune];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 25;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML [Pneumovax II];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 10 by Sanofi;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML [Pneumovax 23];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun] by Glaxosmithkline;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun] Box of 10 by Glaxosmithkline;
material entity;EpiVacCorona vaccine;A SARS-CoV-2 protein subunit vaccine that relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).
material entity;GLS-5310;A SARS-CoV-2 plasmid DNA vaccine developed by GeneOne Life Science.
material entity;DelNS1-2019-nCoV-RBD-OPT1;An influenza virus vector SARS-CoV-2 vaccine administered as an intranasal spray manufactured by University of Hong Kong, Xiamen University, and Beijing Wantai Biological Pharmacy.
material entity;KCONVAC vaccine;A SARS-CoV-2 inactivated virus vaccine by Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Co.
material entity;VAT00002;A stabilised pre-fusion SARS-CoV-2 spike protein vaccine produced in a baculovirus expression system and manufactured by Sanofi Pasteur and GlaxoSmithKline
material entity;Abdala;An authorized SARS-CoV-2 protein subunit vaccine based on recombinant RBD subunits manufactured by the Center for Genetic Engineering and Biotechnology (CIGB).
material entity;CIGB-669;A SARS-CoV-2 protein subunit vaccine based on recombinant RBD subunits manufactured by the Center for Genetic Engineering and Biotechnology (CIGB).
material entity;LV-SMENP-DC;A SARS-CoV-2 recombinant vector vaccine by Shenzhen Geno-Immune Medical Institute
material entity;Nanocovax;A SARS-CoV-2 subunit vaccine with recombinant SARS-CoV-2 spike (S) protein and aluminum phosphate adjuvant
material entity;IIBR-100;A rVSV-SARS-CoV-2-S vaccine developed by the Israel Institute for Biological Research (IIBR).
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun] Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Synflorix];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Prevnar];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.002 MG/ML;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.001 MG;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun];
material entity;pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Pneumorix];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Pneumopur];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun] Box of 10;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Pnu-Imune];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun] Box of 1;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Pneumovax II];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 20;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 10 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 5 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis];
material entity;FVAX vaccine;
material entity;Flagrp170 vaccine;
material entity;ESAT-6-gpi DNA vaccine combined with B16F10-ESAT-6-gpi/IL-21 vaccine;
material entity;electroloading of mature dendritic cells with melanoma whole tumor cell lysate vaccine;
material entity;DNP-modified autologous vaccine;
material entity;DNA Vaccine encoding p42.3;
material entity;gp100:280-288(288V) Peptide Vaccine;
material entity;gp100:209-217(210M) peptide vaccine;
material entity;gp100 Vaccine;
material entity;GM-CSF transfected cells vaccine;
material entity;MCMV-TRP2 vaccine;
material entity;MAGE-A3-genetically modified lymphocyte vaccine;
material entity;MAGE-A3 + AS15 vaccine;
material entity;MAGE-A12:170-178 vaccine;
material entity;mAb PC61 and DC/tumor fusion vaccine;
material entity;long-peptide vaccine and mAb;
material entity;Large Multivalent Immunogen (LMI) vaccine;
material entity;L612 HuMAb vaccine;
material entity;KSA-KLH Conjugate Vaccine;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2022-2023];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2018-2019];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2020-2021];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2021-2022];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2022-2023];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Cc;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2019-2020];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Emra-Med;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2020-2021];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2021-2022];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad Quadrivalent 2022-2023];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension by Evans Vaccines;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension by Sanofi;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injectable Solution;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax] by Merck;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax] by Sanofi;
material entity;mCRT-vGPCR-coated whole-cell vaccine;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution;
material entity;procarbazine, dactinomycin, velba vaccine;
material entity;OVA-TEXO vaccine;
material entity;Oral Bacille Calmette-Guerin for malignant melanoma vaccine;
material entity;Multipeptide melanoma vaccine;
material entity;Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine;
material entity;mouse/human gp10025-33 peptide plus CpG adjuvant. mouse/human gp100. mouse/human gp10025-33 peptide-pulsed DCs vaccine;
material entity;Modified Vaccinia Virus Ankara Vaccine Expressing p53;
material entity;Melanoma-specific Melan-A/Mart-1 peptide + virus-like nanoparticles;
material entity;Melan-A/Mart-1 vaccine;
material entity;Melacine;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2019-2020];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10 by Sanofi;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2022-2023];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 20;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 20 by Evans Vaccines;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2020-2021];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 50;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2022-2023];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 50 by Evans Vaccines;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [FluLaval Quadrivalent 2015-2016];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2020-2021];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2021-2022];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu] Box of 10;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu] Box of 10 by Mylan;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu] by Mylan;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10 by Evans Vaccines;
material entity;HSPPC-96 vaccine;
material entity;Hsp70 chaperone-based gel composition vaccine;
material entity;HSP65-HER2 fusion peptide vaccine;
material entity;hMART-IT vaccine;
material entity;HCA587 protein vaccine;
material entity;hapten dinitrophenyl vaccine;
material entity;GVAX Pancreatic Cancer Vaccine;
material entity;IDD-3 vaccine;
material entity;HUVECs-OK432 vaccine;
material entity;human leukocyte antigen class I-modified peptide vaccine;
material entity;ipilimumab, vemurafenib vaccine;
material entity;Ipilimumab vaccine;
material entity;intralesional bacile Calmette-Guerin (BCG), DTIC, vincristine vaccine;
material entity;intralesional bacile Calmette-Guerin (BCG) vaccine;
material entity;Incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA;
material entity;IMM-101 vaccine;
material entity;IL-12p70 vaccine;
material entity;IFN/tremem vaccine;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad Quadrivalent 2021-2022];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2020-2021];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad Quadrivalent 2020-2021];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2022-2023];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2019-2020];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2020-2021];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2021-2022];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2019-2020];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [FluMist Quadrivalent 2022-2023];
material entity;irradiated melanoma cells plus BCG vaccine;
material entity;irradiated autologous cell vaccine;
material entity;pPA63-LAMP1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pPA63-LAMP1.
material entity;Synchotrope TA2M DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label Synchotrope TA2M. This plasmid is 3683 base pairs in length and has two copies of the murine CpG immune stimulatory sequence AACGTT inserted.
material entity;pCMV/myc/ER DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCMV/myc/ER. This plasmid is 5066 base pairs in length and contains a CMV promoter and ampicillin resistance gene.
material entity;IL-2 peptide and GM-CSF-in-adjuvant melanoma vaccine;A cancer vaccine compromised of melanoma peptides plus GM-CSF-in-adjuvant. It is combined with low-dose IL-2 therapy, which could significantly enhance the immunologic efficacy.
material entity;pNGVL3 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pNGVL3. This plasmid has a CMV promoter and kanamycin and ampicillin resistance genes.
material entity;IDO peptide vaccine;A cancer vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. It may activate the immune system to induce an immune response against IDO-expressing tumor cells, which may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. This vaccine, using a small fragment of IDO, can be used in combination with either Ipilimumab or Vemurafenib to treat malignant melanoma that has metastasized.
material entity;SINCp B-gal DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label SINCp B-gal. This plasmid contains a CMV promoter.
material entity;hyperacute-prostate cancer vaccine;A cancer vaccine composed of irradiated allogeneic prostate cancer cell lines (HAP-1 and HAP-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. It is hoped that the immune response to the foreign substance will stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.. The expression of the murine alpha (1,3) galactosyltransferase [alpha (1,3) GT] gene results in the cell surface expression of alpha (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids.
material entity;WRG/BEN DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label WRG/BEN. This plasmid is based off of pWRG7077. It contains a CMV promoter and a kanamycin resistance gene.
material entity;hyperacute-melanoma vaccine;A cancer vaccine composed of irradiated allogeneic melanoma cell lines (HAM-1, HAM-2 and HAM-3). These cell lines have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha(1,3)GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.
material entity;pNGVL4a DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pNGVL4a. This plasmid has a CMV promoter and kanamycin and ampicillin resistance genes.
material entity;hyperacute - breast cancer vaccine;A cancer vaccine composed of irradiated allogeneic breast cancer cell lines (HAB-1 and HAB-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.
material entity;1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 10;
material entity;pSin-B-gal DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSin-B-gal. This plasmid contains a CMV promoter.
material entity;HPV E6/E7-encoding semliki forest virus vaccine Vvax001;A cancer vaccine consisting of a recombinant, attenuated, replication-incompetent form of the Semliki Forest Virus (SFV) vector encoding the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV), with potential immunomodulating and antineoplastic activities. The vaccine induces expression of the E6/E7 proteins and stimulates both the innate and the adaptive immune system, resulting in a potent cytotoxic T-lymphocyte (CTL) response against and lysis of tumor cells expressing HPV E6 and E7. The vaccine may help to treat patients with a history of (pre) malignant cervical lesions.
material entity;pLXSHD DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pLXSHD. This plasmid has a murine leukemia virus enhancer-promoter LTR.
material entity;hodgkin's antigens-GM-CSF-expressing cell vaccine;A cancer vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. Also, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens. Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. This vaccine contains cells expressing Hodgkin's antigens and GM-CSF, and could cause an immunological response in Hodgkin's lymphoma patients.
material entity;HLA-A1, HLA-A2, and CD40-ligand pulsed dendritic cell vaccine;A cancer vaccine made from a person's white blood cells mixed with tumor proteins (HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens) and CD40-ligand, and may make the body build an immune response to kill tumor cells. This is combined with denileukin diftitox, which
material entity;pSport-B-gal DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSport-B-gal. This plasmid contains a CMV promoter.
material entity;HLA neoantigen vaccine;A cancer vaccine for vaccination with neoantigens that can both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients, tipping the intra-tumoural balance in favour of enhanced tumour control. The vaccine targets up to 20 predicted personal tumour neoantigens. The vaccine induced CD4+ and CD8+ T cells responses. These T cells discriminated mutated from wild-type antigens, and in some cases directly recognized autologous tumour.
material entity;HER2 ICD peptide vaccine;A cancer vaccine made from peptides that may help the body build an effective immune response to kill tumor cells. Patients with HER2 positive locally advanced breast cancer can be vaccinated with a HER2 Intracellular Domain (ICD) peptide-based vaccine administered concurrently with trastuzumab. The vaccine may lead to an immune response (HER2 specific T cell immunity and/or the development of intramolecular epitope spreading).
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Eurim-Pharm;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Emra-Med;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2019-2020];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Kohlpharma;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 5;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2019-2020];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 1;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2019-2020];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Boehringer Ingelheim;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe Box of 1;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2019-2020];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 1;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Flulaval Quadrivalent 2019-2020];
material entity;1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 10 by European;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2019-2020];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur] Box of 1;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution Box of 1;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 5;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2019-2020];
material entity;1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution Box of 10;
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution;
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst];
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 3;
material entity;50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 3 by Sanofi;
material entity;pCI30 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCI30. This plasmid contains a CMV promoter, ampicillin resistance gene, T7 RNA polymerase promoter, a multiple cloning region and a 6xHis tag coding sequence.
material entity;pCP15/60 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCP15/60.
material entity;pMASIA-tgD DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pMASIA-tgD. This plasmid is based off of pMASIA and contains a CMV promoter and kanamycin resistance gene.
material entity;mature dendritic cell melanoma vaccine;A cancer vaccine that may elicit a cytotoxic T-cell (CTL) response against cancer cells. Autologous dendritic cells are pulsed with melanoma tumor-specific peptides. The mature dendritic cell (mDC3/8) vaccine (primer and booster) in patients with stage III and stage IV melanoma is followed by treatment with pembrolizumab (anti-PD-1 therapy). Using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells.
material entity;pCMVi-UB DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCMVi-UB. This plasmid was built from pCMV-5 and contains a CMV promoter.
material entity;MART-1, tyrosinase and MAGE-A6 autologous DC vaccine;A cancer vaccine made with autologous dendritic cells (DC) are transduced with the MART-1, tyrosinase and MAGE-A6 (melanoma associated antigens, MAA) genes for melanoma patients. Some patients also receive interferon-alfa 2b (IFN) intravenously.
material entity;pCMV-TPA/ZS7 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCMV-TPA/ZS7. This plasmid contains a CMV promoter and is generated from pCMV-ZS7 by attaching hTPA to ospC ZS7.
material entity;MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine;A cancer vaccine comprised of multiple peptides derived from MAGE-1A, Her-2/neu, and folate binding protein (FBP), with potential immunostimulating and antineoplastic properties. The MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Vaccination with this cancer vaccine may activate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. The vaccine compromises synthetic ovarian cancer-associated peptides administered with a synthetic tetanus toxoid helper peptide emulsified in Montanide ISA-51 before or after paclitaxel and carboplatin in patients with stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer undergoing optimal cytoreductive surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery.
material entity;pABB-CRS2 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pABB-CRS2. This plasmid is a derivative of pCVD442 and contains a chloramphenicol resistance gene.
material entity;LMP2A-loaded conventional DC vaccine;A cancer vaccine made with Epstein Barr Virus (EBV)-derived tumor antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines are administered alone or co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the setting of autologous stem cell transplant with infusion of mature T cells. It may induce EBV derived tumor antigen specific CD8+ T cell response in patients with EBV+ lymphoma in the setting of autologous stem cell transplant.
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1 by Sanofi;
material entity;pTPA-PA63 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pTPA-PA63.
material entity;KRAS-targeted mRNA vaccine;A cancer vaccine used alone or in combination with PD-1 inhibitor in patients with advanced solid tumors with KRAS mutation (G12C, G12D, or G12V) and HLA type HLA-A11:01 or HLA C08:02. The vaccine is a lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets the most commonly occurring KRAS mutations (G12D, G12V, and G12C). The mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations.
material entity;VR2210 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label VR2210. This plasmid contains a CMV promoter and kanamycin resistance gene. It was created through ligation of fragments of digested plasmid VR1012, hTPA, and B. burgdorferi B31 ospA.
material entity;KLH-pulsed autologous dendritic cell vaccine;A cancer vaccine made with autologous dendritic cells pulsed with KLH for this vaccination, combined with radiation or a gene therapy agent, TNFerade. TNFerade or radiation serves to generate cell death stimulating the immune response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor immune response to achieve a local and systemic clinical benefit.
material entity;pSecTag2B DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pSecTag2B. This plasmid is 5163 base pairs in length and contains a CMV promoter and ampicillin resistance gene.
material entity;KLH-id vaccine;A cancer vaccine made of tumor protein taken from a cancer patient's plasma (liquid part of the blood) and KLH (a protein designed to increase the immune response of the vaccine).
material entity;pTPA-PA63-LAMP1 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pTPA-PA63-LAMP1.
material entity;KLH and tumor lysate pulsed DC vaccine;A cancer vaccine made with dendritic cells pulsed with KLH and tumor lysate for patients with neuroblastoma.
material entity;intracel KLH vaccine;A cancer vaccine that could teach T-cells to detect and kill cancer cells better. Intracel KLH is given without adjuvant subcutaneously and with Tetanus Toxoid 0.5 ml intramuscularly.
material entity;IL15-DC vaccine;A cancer vaccine made with autologous dendritic cells that are manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH. then activated with LPS and CD40 Ligand.IL15 is a T cell growth factor that could have a very important role in cancer immunotherapy. IL15 DCs are particularly efficient at priming functional melanoma specific CD8+ T cells. The use of IL15 in the manufacture of the DC vaccine could result in an improved immunotherapy product for melanoma patients.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 10 by Boehringer Ingelheim;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT Injection [Imovax] by Sanofi;
material entity;1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 1 by European;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 10;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT Injection [RabAvert] by Glaxosmithkline;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML [Fluzone 2019-2020];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 10 by Novartis;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 5 by Boehringer Ingelheim;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 1 by Novartis;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2019-2020];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 1 by Novartis;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur] Box of 1 by Glaxosmithkline;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 1 by Boehringer Ingelheim;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 1 by Sanofi;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2019-2020];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 10 by Baxter;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Orifarm Leverkus;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe Box of 1;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Novartis;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;1 ML BCG, live, Connaught strain 20000 UNT/ML Injectable Solution;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tet Aktiv] Box of 100;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 1 by Boehringer Ingelheim;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;1 ML BCG, live, Connaught strain 20000 UNT/ML Injectable Solution Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tet Aktiv];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 5 by Boehringer Ingelheim;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension;
material entity;1 ML BCG, live, Connaught strain 20000 UNT/ML Injectable Solution Box of 10 by AJ Vaccines;
material entity;1 ML BCG, live, Connaught strain 20000 UNT/ML Injectable Solution by AJ Vaccines;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2019-2020];
material entity;1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution;
material entity;1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix];
material entity;1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 1;
material entity;whole tumor cell cancer vaccine;A whole cell cancer vaccine that uses whole tumor cells to deliver cancer antigen(s).
material entity;whole cell cancer vaccine;A cancer vaccine that uses whole cells to deliver cancer antigen(s).
material entity;therapeutic cancer vaccine;Cancer vaccine that aims to eliminate or control tumor cells.
material entity;preventive cancer vaccine;Cancer vaccine that prevents cancer formation and development.
material entity;tumor antigen;Either a tumor-specific or a tumor-associated antigen.
material entity;HPV infection;An infection that has as part organisms of the human papillomavirus (HPV).
disposition;HPV associated cancer;A cancer that is caused by human papillomavirus (HPV) infection. HPV infection can lead to six types of cancer including anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancer.
material entity;alpha-GalCer-loaded tumor-cell vaccine;
material entity;RIPO(H3.3) vaccine;
material entity;Pulmonary BCG immunotherapy for malignant melanoma vaccine;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT Injectable Solution Box of 5;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT Injection;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur] Box of 1;
material entity;influenza A virus (H3N2) antigen 0.03 MG/ML / influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1 by Merck;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT Injectable Solution Box of 1;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2022 Southern Hemisphere];
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT Injection;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2022-2023];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 5;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2021 Southern Hemisphere];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2021-2022];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 5;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 1;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2020-2021];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2016 Southern Hemisphere];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] by Glaxosmithkline;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2019-2020];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution Box of 1;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT Injection [Imovax];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution Box of 10;
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension;
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax];
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax] by Merck;
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe;
material entity;0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax];
material entity;VR10551 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label VR10551. This plasmid contains a human cytomegalovirus immediate early 1 promoter, a kanamycin resistance gene, intron A and a modified rabbit b-globin terminator.
material entity;VCL-1632 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label VCL-1632. This plasmid contains a CMV promoter, kanamycin resistance gene, the murine Kappa constant region sequence, a translational enhancer, the murine IgG2a heavy-chain sequence, and a translation terminator. This plasmid is derived from pUC-18.
material entity;pPJV7563 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pPJV7563. This plasmid has a human cytomegalovirus immediate early promoter.
material entity;HER-2-neu, CEA peptides, GM-CSF, montanide ISA-51 vaccine;A cancer vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. The vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. Vaccines made from peptides may make the body build an immune response to kill tumor cells. This vaccine is compromised of HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51, and aims to cause an immune response in patients with stage IIB, III, or IV colorectal cancer.
material entity;p188 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label p188. This plasmid is a replication-defective derivative of pP1/H7.
material entity;H3.3K27M-specific peptide vaccine;A cancer vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Following the administration of the vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. A lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3) is a feature mutation in diffuse intrinsic pontine gliomas (DIPGs). This vaccine contains an H3.3-K27M targeted neoantigen peptide that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells.
material entity;pCMV/R DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCMV/R. This plasmid is a mammalian expression vector with a CMV promoter.
material entity;GVAX leukemia vaccine;A cancer vaccine that uses irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) to induce potent immune responses. The vaccine may prevent advanced myelodysplastic syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or acute myeloid leukemia (AML) from relapsing after stem cell transplant. The patients own cancer cells are engineered to produce a protein called GM-CSF, which can be effective in stimulating a powerful immune response specific to that cancer.
material entity;VRC-9123 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label VRC-9123.
material entity;gp100 mature dendritic cell vaccine;A cancer vaccine using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells. Autologous dendritic cells are pulsed with 2 gp100 melanoma peptides (G209-2M and G280-9V) plus up to an additional 10 unique melanoma tumor-specific peptides. Patients also receive cyclophosphamide 300mg/m2 IV in order to deplete regulatory T cells.
material entity;pWRG DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pWRG. This plasmid is a eukaryotic expression plasmid that contains the immediate early promoter and intron A of human cytomegalovirus.
material entity;GM.CD40L cell vaccine;A cancer vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand (CD40L) genes. The vaccine may stimulate an anti-tumoral dendritic cell-mediated host immune response. Universal GM-CSF-producing and CD40L-expressing bystander cell line is used to form an autologous tumor cell-based vaccine for patients with mantle cell lymphoma in order to make the body build an effective immune response to kill cancer cells. It can be used in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, and IL-2. The vaccine can be done with bystander and autologous tumor cells for patients with malignant melanoma. It can also be combined with lenalidomide for patients with myelodysplastic syndrome (MDS).
material entity;pHW2000 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pHW2000. This plasmid is derived from pHW12 and contains part of the human pol I promoter and murine terminator sequences, a CMV promoter, and the polyadenylation signal of the gene encoding bovine growth hormone.
material entity;GM-K562 cell vaccine;A cancer vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. The vaccine can also be combined with stem cell transplantation. The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome.
material entity;pCAGGSP7 DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCAGGSP7. This plasmid has a polylinker containing KpnI, XhoI, ClaI, EcoRV, SmaI, Not1 and Sac1 sites inserted into the EcoRI site of pCAGGS.
material entity;genetically engineered allogeneic prostate carinoma cells secreting interleukin-2 and interferon gamma;A cancer vaccine made with HLA class I-matched allogeneic human prostate carcinoma cells that are genetically engineered to secrete interleukin-2 and interferon gamma for patients with prostate carcinoma. Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer.
material entity;pCAGGS/MCS DNA vaccine plasmid;A DNA vaccine plasmid vector that has the plasmid label pCAGGS/MCS. This plasmid has a chicken beta-actin promoter, contains a multiple cloning site between the EcoRI and BglII sites of the rabbit beta-globin gene, and has restriction sites for the enzymes SacI, ClaI, NsiI, Asp718, SmaI, SphI, XhoI, and NheI.
material entity;GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid KLH conjugate vaccine;A cancer vaccine used to treat patients with small cell lung cancer by using several components (small cell lung cancer targets) that have been tested individually in patients with small cell lung cancer or other cancers (GD2, GD3, Globo H, Fucosyl GM1 and N-propionylated polysialic acid) so that the body will make antibodies to the vaccine which will also react against the cancer. Two other substances (KLH and OPT-821) are added which boost the immune system. Vaccination with the pentavalent KLH conjugate vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing any of these antigens.
material entity;GD2-CAR vaccine;A cancer vaccine made with T cells genetically engineered to express anti-GD2 Chimeric Antigen Receptor to treat patients with children and young adults with GD2+ solid tumors, including neuroblastoma. The T cells may have an antitumor effect. They can be used in combination with AP1903 and Cyclophosphamide. (NCT02107963) There are increased CXCR3- classical monocytes in patients as CAR-T numbers waned.
material entity;DNA cancer vaccine;A cancer vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing the whole of parts of genes encoding one or more vaccine antigen proteins.
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Solution by Aventis;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2019-2020];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Glaxosmithkline;
material entity;1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe [VACCIN RABIQUE INACTIVE MERIEUX] by Sanofi;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Kohlpharma;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 5;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2019-2020];
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Orifarm Leverkus;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2019-2020];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] by Novartis;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Fluad 2019-2020];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe Box of 1;
material entity;influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2019-2020];
material entity;1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension [Tollwut-Impfstoff] by Sanofi;
material entity;influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML Nasal Spray;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur] by Novartis;
material entity;influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML Nasal Spray;
material entity;influenza A virus (H3N2) antigen 0.03 MG/ML / influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;influenza A virus (H5N1) antigen Injectable Suspension;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Eurim-Pharm;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 5;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Kohlpharma;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 1;
material entity;influenza A virus (H3N2) antigen 0.03 MG/ML / influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Orifarm Leverkus;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Cc;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Emra-Med;
material entity;0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Eurim-Pharm;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal] Box of 10;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal] Box of 10 by Crucell;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal] by Crucell;
material entity;DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit];
material entity;DEPDC1/MPHOSH1 Peptide Vaccine;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 10;
material entity;Dendritic Cell-Idiotype-Keyhole Limpet Hemocyanin Vaccine;
material entity;CVB4/p24(73(3)) vaccine;
material entity;CpG 7909/PF3512676 vaccine;
material entity;Contusugene ladenovec vaccine;
material entity;class I HLA-A0201-restricted gp100209-2M peptide vaccine;
material entity;Canvaxin;
material entity;Biolistic DNA vaccine;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus 1000 UNT / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2021 Southern Hemisphere];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2020 Southern Hemisphere];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2020-2021];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2018-2019];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 10 by Glaxosmithkline;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 20;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 TCID / Mumps virus 12500 TCID / Rubella virus 1000 TCID;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2016-2017];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 20 by Glaxosmithkline;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2017-2018];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] by Glaxosmithkline;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2015-2016];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2016 Southern Hemisphere];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone 2015-2016];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl] by bioCSL;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada] Box of 10;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada] Box of 10 by Mylan;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT [Imovax];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML [Rabivac];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2019-2020];
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML [Tollwut-Impfstoff];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2020-2021];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Flublok 2016-2017];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada] by Mylan;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Flublok 2017-2018];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML [Rabipur];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm] Box of 10;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT [RabAvert];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Flublok 2015-2016];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm] Box of 10 by Mylan;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 5000 UNT / Rubella virus 1000 UNT;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2022-2023];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm] by Mylan;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2021-2022];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2022 Southern Hemisphere];
material entity;autologous dendritic cells (DCs) vaccine;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad] by Novartis;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 10;
material entity;ALVAC-CEA (6D)-B7.1 Vaccine;
material entity;Alpha Fetoprotein Plasmid DNA Vaccine;
material entity;Ad5F35-LMP1/LMP2-Transduced Autologous Dendritic Cell vaccine;
material entity;Ad5-yCD/mutTKSR39rep-hIL12 vaccine;
material entity;HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901;A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types.
material entity;FrSh61 (MEA) VHL33 Peptide Vaccine;A peptide derived from the tumor suppressor protein Von Hippel-Lindau (VHL). This peptide, sequence: MEAGRPRPCCAR, was constructed based on a frameshift mutation of one of the VHL gene products. the more abundant protein VHLp18(MEA) (where MEA stands for three amino acids, Met-Glu-Ala). Vaccination with FrSh61(MEA)VHL33 peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2020-2021];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 5000 UNT / Rubella virus 1000 UNT Injection;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2018-2019];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 5000 UNT / Rubella virus 1000 UNT [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2019-2020];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2022-2023];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 5000 UNT / Rubella virus 1000 UNT Injection [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2017-2018];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT Injectable Solution;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2020-2021];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 10 by Glaxosmithkline;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 20;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT Injectable Solution [Priorix] by GSK;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2018-2019];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 20 by Glaxosmithkline;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT Injectable Solution [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] by Glaxosmithkline;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2017-2018];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl] Box of 10;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl] Box of 10 by bioCSL;
material entity;BCG treatment after surgical tumor removal vaccine;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria] Box of 10;
material entity;BCG and Corynebacterium parvum for malignant melanoma vaccine;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria] Box of 10 by bioCSL;
material entity;BCG and chemotherapy for malignant melanoma vaccine;
material entity;bacillus Calmette-Guerin (MER) vaccine;
material entity;Bacillus Calmette-Guerin (BCG), dinitrochlorobenzene (DNCB) vaccine;
material entity;Bacillus Calmette-Guerin (BCG), C. parvum vaccine;
material entity;Bacillus Calmette-Guerin (BCG) vaccine;
material entity;Bacille Calmette Guerin for melanoma of lower extremity vaccine;
material entity;autologous monocyte-derived mature DCs pulsed with p53, survivin and telomerase-derived peptide vaccine;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML [Priorix];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe Box of 1;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluvirin 2016-2017];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix] Box of 1;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluvirin 2017-2018];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flulaval Quadrivalent 2019-2020];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluvirin 2015-2016];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flulaval Quadrivalent 2017-2018];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria] by bioCSL;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe Box of 1;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flulaval Quadrivalent 2018-2019];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [FluLaval Quadrivalent 2015-2016];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal] Box of 10;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flulaval Quadrivalent 2016-2017];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal] Box of 10 by Novartis;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2021-2022];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal] by Novartis;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2022-2023];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix] Box of 1;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad] Box of 10;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad] Box of 10 by Novartis;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac];
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Solution;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT Injectable Solution;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT Injectable Solution;
material entity;rabies virus vaccine flury-lep strain Injection [Verorab];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution;
material entity;1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe;
material entity;1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT Injection [RabAvert];
material entity;1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe [VACCIN RABIQUE INACTIVE MERIEUX];
material entity;1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension [Tollwut-Impfstoff];
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 20;
material entity;rabies virus vaccine flury-lep strain Injectable Solution;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 20 by Sanofi;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 50;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 50 by Sanofi;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] by Sanofi;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu] Box of 10;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [FluMist Quadrivalent 2021-2022];
material entity;rabies virus vaccine flury-lep strain Prefilled Syringe [Rabipur];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [FluMist Quadrivalent 2019-2020];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu] Box of 10 by Crucell;
material entity;rabies virus vaccine flury-lep strain Injectable Suspension [Rabipur];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist Quadrivalent 2020-2021];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu] by Crucell;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Prefilled Syringe [VACCIN RABIQUE INACTIVE MERIEUX];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist Quadrivalent 2017-2018];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu];
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Injectable Suspension [Tollwut-Impfstoff];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist Quadrivalent 2018-2019];
material entity;rabies virus vaccine flury-lep strain Injectable Solution [Rabipur];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist 2015-2016];
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML [VACCIN RABIQUE INACTIVE MERIEUX];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist Quadrivalent 2016-2017];
material entity;rabies virus vaccine flury-lep strain Injectable Solution [Verorab];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2022-2023];
material entity;rabies virus vaccine flury-lep strain Injectable Solution [Rabivac];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray;
material entity;rabies virus vaccine flury-lep strain Injection [Rabipur];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe [VACCIN RABIQUE INACTIVE MERIEUX];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10 by Mylan;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] by Mylan;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel] Box of 10;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel] Box of 10 by Baxter;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension [Tollwut-Impfstoff];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel] by Baxter;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Prefilled Syringe;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP];
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 10;
material entity;rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac];
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 10 by Sanofi;
material entity;rabies virus vaccine flury-lep strain Prefilled Syringe;
material entity;rabies virus vaccine flury-lep strain Injectable Suspension;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Injectable Suspension;
material entity;rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Injectable Solution;
material entity;dendritic cell/​myeloma fusion vaccine;A cancer vaccine onsisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma. This vaccine uses Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy. The dendritic cell myeloma vaccine may improve response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT).
material entity;dendritic cell tumor peptide vaccine;A cancer vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. This vaccine is used to treat diffuse hemispheric glioma with a H3 G34 mutation that has come back (recurrent) and/or is growing, spreading, or getting worse (progressive). It is made with the patient's own white blood cells and peptide-pulsed dendritic cells, which may help the body build an effective immune response to kill tumor cells. It is combined with immunotherapy monoclonal antibodies, such as nivolumab and ipilimumab, which also may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
material entity;dendritic cell survivin vaccine;A cancer vaccine made using the participant's own blood cells. The vaccine will contain a virus called an adenovirus, similar the virus that causes the common cold. The dendritic cells contain survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry. The vaccine is given in combination with G-CSF, T cells, and the CD34 progenitor cells.
material entity;DC/AML fusion vaccine;A cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous acute myeloid leukemia (AML) cells, with potential immunostimulatory and antineoplastic activities. It is generated in vitro by mixing DCs and irradiated AML cells harvested from individual patients, in the presence of polyethylene glycol (PEG), to produce hybrid DC-leukemia fusion cells. The vaccine may elicit a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response against a broad array of AML-associated antigens, which may lead to AML cell lysis. When dendritic cells and tumor cells are brought together, the dendritic cells can stimulate immune responses against the tumor and, in some cases, cause the tumor to shrink. GM-CSF is a drug that stimulates white blood cells and is given with the DC AML Vaccine in an effort to enhance the effect of the vaccine.
material entity;cyclin B1/WT-1/CEF-loaded DC vaccine;A cancer vaccine for patients with Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer to receive ex vivo-generated tumor antigen-loaded dendritic cells (DCs), which can prime lymphocytes and regulate and maintain immune responses. The vaccine may boost T cell immunity targeted against breast cancer, enhance chemotherapy effectiveness and decrease tumor metastagenicity, and decrease the recurrence rates of LA TNBC and ER+/HER2- BC.
material entity;CLL idiotypic DNA vaccine;A cancer vaccine that treats patients with Binet Stage A Chronic Lymphocytic Leukemia (CLL) by using a fragment of Deoxyribonucleic acid (DNA) containing the sequence of their own immunoglobulin gene. The vaccine is designed to generate an immune response and shrink or slow the CLL.
material entity;chimeric exosomal tumor vaccine;A cancer vaccine prepared as tumor cells are isolated from the lesion site of patients with recurrent or metastatic bladder cancer, and dendritic cells or macrophages are isolated from peripheral blood. The vaccine activates an immune response and the microenvironment of bladder cancer lesions, and improves the anti-recurrence treatment effect of bladder cancer.
material entity;CDX-1307 vaccine;A cancer vaccine for bladder cancer designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-β). hCG-β is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. Administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. The human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells.
material entity;dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes;A cancer vaccine made of tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Allogeneic haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells.
material entity;Melanoma DNA vaccine TA2M(TM) encoding tyrosinase peptides;
material entity;Mouse gp100 Plasmid DNA Vaccine;A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis.
material entity;Monoclonal Antibody 4B5 Anti-Idiotype Vaccine;A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities. Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues.
material entity;ESR1 peptide vaccine;A cancer vaccine comprised of estrogen receptor alpha (ERa. estrogen receptor 1. ESR1) mutant peptides, combined with the immunoadjuvants granulocyte-macrophage colony-stimulating factor (GM-CSF) and montanide ISA, with potential immunomodulating and antineoplastic activities. ESR1 mutant peptides in the ESR1 peptides/GM-CSF/montanide ISA vaccine may activate the immune system to induce an immune response against tumor cells expressing these ESR1 mutations. Cancer peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. The vaccine may improve outcomes of patients with endocrine resistant breast cancer.
material entity;MELITAC 12.1 Peptide Vaccine;A multipeptide cancer vaccine comprised of 12 melanoma peptides restricted by Class I MHC (12MP), plus a tetanus helper peptide
material entity;Melapuldencel-T Vaccine;A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, melapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.
material entity;Melanoma Theraccine;A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI). This agent may be combined with immunomodulatory cytokines such as interferon alpha. Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors.
material entity;electrofusion DC vaccine;A cancer vaccine made with PEG fusions generated from allogeneic dendritic cells and autologous tumor-derived cells with GM-CSF and Il-4. The vaccine is irradiated, frozen, and thawed before being administered to patients with AJCC Stage IV Renal Cell Carcinoma. The vaccine could have and effect on the immune system and cancer.
material entity;DIPG and GMB Immunomodulatory DC vaccine;A cancer vaccine based on ex vivo genetic modifications in combination with known tumor-specific antigens may substantially enhance the activation potential of tumor-specific T cells with improved benefit to patients. This DC vaccine is based on autologous DCs pulsed with genetically modified tumor cells or related antigens such as neoantigens to induce a strong anti-tumor immunity. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg).
material entity;dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes;A cancer vaccine from tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Autologous haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells.
material entity;hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe;
material entity;hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe [Vaqta];
material entity;hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection;
material entity;hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection [Vaqta];
material entity;hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML Injectable Suspension;
material entity;hepatitis A vaccine (inactivated) strain HM175 Injectable Suspension;
material entity;hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe;
material entity;hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe [Havrix];
material entity;hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection;
material entity;hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection [Havrix];
material entity;mRNA-Electroporated Dendritic Cells Vaccine;
material entity;MART-1:26-35(27L) Peptide Vaccine;
material entity;MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells Vaccine;Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.
material entity;MART-1 Vaccinia Vaccine;A cancer vaccine consisting of an attenuated recombinant vaccinia virus expressing the melanoma-associated antigen MART-1. Vaccination with this agent may stimulate cytotoxic host immune responses to melanoma cells.
material entity;MART-1 Fowlpox Vaccine;A synthetic cancer vaccine derived from a melanoma-associated antigen, MART-1. Antigenic peptides derived from MART-1 are recognized by CD8+ T lymphocytes and have been used to immunize patients with advanced melanomas. prolonged immunization may result in a reduction in tumor size. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues.
material entity;MART-1 Adenovirus Vaccine;A vaccine consisting of recombinant adenovirus vector encoding MART-1 (melanoma antigen recognized by T-cells 1), an immunogenic protein of unknown function that is expressed by certain types of melanoma. Vaccination with MART-1 adenovirus vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against MART-1 positive melanoma cells, resulting in an antitumor effect.
material entity;MART-1 Vaccine;
material entity;CAR G36-PDL1 vaccine;A cancer vaccine made with chimeric antigen receptor (CAR) T cells that can be used to treat solid tumors. These CAR-T cells are engineered to target carbonic anhydrase IX (CAIX) to secrete anti-PD-L1 monoclonal antibody (mAb), termed immune-restoring (IR) CAR G36-PDL1. The T cells can be used to treat clear cell renal cell carcinoma (ccRCC) with reconstituted human leukocyte antigen (HLA) partially matched human leukocytes derived from fetal CD34+ hematopoietic stem cells (HSCs) and bearing human ccRCC skrc-59 cells under the kidney capsule. The cells can restore active antitumor immunity by promoting tumor-killing cytotoxicity, reducing immunosuppressive cell components such as M2 macrophages and exhausted CD8+ T cells, and enhancing T follicular helper (Tfh)-B cell crosstalk.
material entity;Melan-A/MAGE-3.DP4 Peptide Vaccine;
material entity;Melan-A VLP Vaccine;A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLP) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may activate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is an antigen that is upregulated in most melanomas. VLP stimulates the immune system and promotes the CTL response.
material entity;MART-1:27-35 Peptide Vaccine;A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide may induce cytotoxic host immune responses against melanoma cells that express this peptide
material entity;Light-Emitting Oncolytic Vaccinia Virus GL-ONC1 Vaccine;An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques.
material entity;MOv-PBL Vaccine;Peripheral blood lymphocytes (PBL) transfected to express MOv have been designed for possible use in autologous adoptive cellular immunotherapy of ovarian adenocarcinomas that overexpress folate-binding protein. MOv-PBLs express MOv-gamma (MOv), a chimeric receptor gene product derived from a recombinant gene encoding the variable region of murine monoclonal antibody MOv18 against folate-binding protein (FBP), often overexpressed in human ovarian cancer cells, and the human gene encoding the IgG and IgE Fc receptor gamma subunit. Autologous vaccination with these PBLs stimulates a host cytotoxic T lymphocyte response against ovarian cancer cells that overexpress FBP.
material entity;Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH Conjugate Vaccine;A multivalent vaccine comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32-mer, TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens.
material entity;Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623;A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis.
material entity;HLA-A*0201-Restricted URLC10-VEGFR1-VEGFR2 Multipeptide Vaccine;A cancer vaccine containing three HLA-A0201-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer 10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature expressing VEGFR 1 and 2 peptides. this may result in tumor cell lysis, the inhibition of tumor angiogenesis, and decreased tumor growth. HLA-A0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
material entity;HLA-A0201-Restricted TRP2-gp100-EphA2-HER2 multipeptide Vaccine;A cancer vaccine containing four HLA-A0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein 100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor 2 (HER2). Upon administration, HLA-A0201-restricted TRp2-gp100-EphA2-HER2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
material entity;0.5 ML A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension;
material entity;IMT-1012 Immunotherapeutic Vaccine;A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy.
material entity;Host Dendritic Cell Vaccine-001 MSSM/BIIR;A dendritic cell (DC) vaccine containing ex vivo expanded autologous DCs obtained from a patient with leukemia with potential immunostimulating activity. Upon reintroduction into the host, the host dendritic cell vaccine-001 MSSM/BIIR may stimulate the immune system to mount a leukemia-specific cytotoxic T lymphocyte (CTL) response.
material entity;HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine;A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.
material entity;HLA-A*2404-Restricted RNF43-TOMM34-VEGFR1-VEGFR2 Multipeptide Vaccine;A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from ring finger protein 43 (RNF43). translocase of outer mitochondrial membrane 34 (TOMM34). and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing RNF43, TOMM34, and VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 TCID / Mumps virus 12500 TCID / Rubella virus 1000 TCID Injection;
material entity;human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 TCID / Mumps virus 12500 TCID / Rubella virus 1000 TCID [M-M-R II];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT [M.M.R. VaxPro];
material entity;human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Injectable Suspension;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 TCID / Mumps virus 12500 TCID / Rubella virus 1000 TCID Injection [M-M-R II];
material entity;human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Injectable Suspension [Cervarix];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Prefilled Syringe;
material entity;hepatitis B surface antigen vaccine Injectable Suspension [Recombivax];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection [Priorix];
material entity;hepatitis B surface antigen vaccine Injection [Prehevbrio];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution;
material entity;hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Prefilled Syringe [Priorix];
material entity;hepatitis B surface antigen vaccine Injectable Suspension [HB-VAX];
material entity;hepatitis B surface antigen vaccine 0.04 MG/ML Injection [Heplisav-B];
material entity;0.5 ML A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension [INFLUVAC];
material entity;hepatitis B surface antigen vaccine 0.04 MG/ML Injection [Recombivax];
material entity;0.5 ML A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension Box of 1;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution [Priorix];
material entity;hepatitis B surface antigen vaccine 0.04 MG/ML [Recombivax];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER];
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] Box of 5;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] Box of 5 by Praxis Biologics;
material entity;0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution Box of 5;
material entity;0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension;
material entity;MAGE-A3/HPV 16 Peptide Vaccine;
material entity;Liposomal MUC1/PET-lipid A Vaccine;A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen.
material entity;EF-1 Peptide Vaccine;A synthetic peptide derived from the protein ESW/FLI1 type 1 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-1 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 1 fusion protein.
material entity;G250 Peptide Vaccine;A naturally occurring 9-residue peptide of fibroblast growth factor 5 (FGF-5). Recognized by tumor infiltrating cytotoxic T lymphocytes originally isolated from a renal cell carcinoma that overexpressed FGF-5, FGF-5:172-176/217-220 peptide activates various cytotoxic CD8 lymphocytes in an HLA-restricted manner. Overexpressed in several cancer cell lines, FGF-5 is a tumor-associated antigen that may be useful in cancer immunotherapy.
material entity;HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine;A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens
material entity;Golnerminogene Pradenovec Vaccine;A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties. the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF.
material entity;MUC-2-Globo H-KLH Conjugate Vaccine;
material entity;mRNA-Derived Prostate Cancer Vaccine CV9103;A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is modified and formulated to have enhanced translational potency and adjuvant activities. PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells. their expression in prostate cancer has been correlated with disease progression.
material entity;Fowlpox-PSA-TRICOM Vaccine;A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA) and TRICOM, a combination of three immunostimulants (i.e., B7.1, ICAM-1, and LFA-3). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
material entity;HLA-A*0201-Restricted VEGFR1 Peptide Vaccine;A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT Injectable Solution [Priorix-Tetra];
material entity;0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] by Mylan;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT Injectable Solution;
material entity;0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria 2018-2019];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT Injectable Solution [Priorix-Tetra] by GSK;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2016-2017 Formula];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus 1000 UNT / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU Injection;
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria 2016-2017];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus 1000 UNT / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria 2017-2018];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT [Priorix-Tetra];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus 1000 UNT / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU Injection [Priorix];
material entity;influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria 2015-2016];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT Injectable Suspension;
material entity;human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq];
material entity;0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist];
material entity;human-bovine reassortant rotavirus strain G1 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G2 vaccine 1400000 UNT/ML / human-bovine reassortant rotavirus strain G3 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G4 vaccine 1000000 UNT/ML / human-bovine reassortant rotavirus strain P1A[8] vaccine 1150000 UNT/ML Oral Suspension;
material entity;0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist] Box of 5;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT Injectable Suspension [M.M.R. VaxPro] by MSD;
material entity;human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe [Cervarix];
material entity;0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist] Box of 5 by Astrazeneca;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT Injectable Suspension [M.M.R. VaxPro];
material entity;human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension;
material entity;0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray Box of 5;
material entity;0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension;
material entity;0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC];
material entity;0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10;
material entity;0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10 by Mylan;
material entity;MAGE-A3 Peptide Vaccine;A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.
material entity;MAGE-1 Vaccinia Contaminated with BVDV;A cancer vaccine consisting of a recombinant vaccinia virus encoding the tumor-associated gene MAGE-1 that is contaminated with bovine viral diarrhea virus (BVDV). The MAGE-1 gene is a member of the melanoma antigen-encoding gene family which is expressed in various malignant tumors such as hepatocellular carcinoma and germ cell tumors in addition to melanoma. Vaccination with vaccinia virus expressing human MAGE-1 may generate antitumoral T-cell responses. BVDV is an RNA pestivirus that may contaminate vaccines due to its presence in the fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production.
material entity;Folate-FITC vaccine;A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.
material entity;Indoleamine 2,3-dioxygenase Peptide Vaccine;A peptide vaccine against the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), with potential immunomodulating and antineoplastic activities. Vaccination with indoleamine 2,3-dioxygenase peptide vaccine may activate the immune system to induce an immune response against IDO-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and may eradicate IDO-expressing tumor cells. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system
material entity;Fowlpox Virus Vaccine;A recombinant virus-based vaccine that contains various peptide antigens. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Strong CD8 T cell responses may be induced after prolonged immunization and have been associated with tumor regression.
material entity;ESO-1:157-165(165V) Peptide vaccine;A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers.
material entity;ESO-1 (161-180) Peptide Vaccine;A recombinant 19-residue peptide vaccine consisting of amino acids 161 through 180 of the cancer/testis (CT) antigen. ESO-1 (161-180) peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04) (NCIT C28775).
material entity;hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1;A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and LAMP.
material entity;Murine TYRP2 Plasmid DNA Vaccine;A plasmid DNA vaccine encoding the mouse tumor associated antigen tyrosinase-related protein-2 (TYRP2) with potential immunostimulating and antineoplastic activities. Upon administration, murine TYRP2 plasmid DNA vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing TYRP2. this vaccine may also induce an immune response against tyrosinase-related protein-1 (TYRP1). TYRP2 and TYRP1, melanosomal membrane glycoproteins upregulated in melanoma cells, are involved in melanin synthesis.
material entity;follicular lymphoma, patient-specific, soluble protein idiotype vaccine;A cancer vaccine directed against the soluble protein idiotype of an individual follicular lymphoma with potential antineoplastic activity. The vaccine may induce an idiotype-specific cytotoxic T-lymphocyte (CTL) response against follicular lymphoma cells expressing the idiotype, resulting in tumor cell lysis. Idiotypic vaccinations have the capacity of inducing an idiotype- and tumor-specific immune response, inducing specific immune responses able to kill in vivo follicular lymphoma cells, and prolonging survival of responding patients. This vaccine may contribute to preventing relapse indefinitely in responding patients.
material entity;hepatitis B surface antigen vaccine 0.0025 MG/ML Prefilled Syringe [Recombivax];
material entity;hepatitis B surface antigen vaccine 0.0025 MG/ML [Recombivax];
material entity;0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray [FluMist Quadrivalent];
material entity;hepatitis B surface antigen vaccine 0.0025 MG/ML Prefilled Syringe;
material entity;0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray [FluMist Quadrivalent] by Astrazeneca;
material entity;hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection [Prehevbrio];
material entity;0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray;
material entity;hepatitis B surface antigen vaccine 0.0025 MG/ML;
material entity;hepatitis A virus strain CR 326F antigen, inactivated Prefilled Syringe [Vaqta];
material entity;hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection;
material entity;hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta];
material entity;hepatitis A virus strain CR 326F antigen, inactivated Prefilled Syringe;
material entity;hepatitis A virus strain CR 326F antigen, inactivated Injection;
material entity;hepatitis A virus as vaccine component;
material entity;hepatitis B virus as vaccine component;
material entity;poliovirus as vaccine component;
material entity;Vibrio cholerae as vaccine component;
material entity;0.1 ML BCG, Live, Connaught Strain 1 MG/ML Injectable Solution;
material entity;0.1 ML BCG, Live, Connaught Strain 1 MG/ML Injectable Solution by Sanofi;
material entity;0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray;
material entity;GM2/GD2/GD3 Lactone-KLH Conjugate Trivalent Vaccine;A trivalent cancer vaccine containing the ganglioside lactones GM2, GD2 and GD3 conjugated with the immunostimulant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with GM2 lactone/GD2 lactone/GD3 lactone-KLH conjugate trivalent vaccine may elicit antibodies against tumor cells expressing any of these epitopes, resulting in an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these gangliosides. GM2, GD2 and GD3 are tumor associated antigens (TAAs) that are overexpressed in a variety of tumor cell membranes.
material entity;MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine;A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types.
material entity;LMP-2:419-427 Peptide Vaccine;A peptide vaccine containing amino acids residues from 419 through 427 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:49-427 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.
material entity;LMP-2:340-349 Peptide Vaccine;A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation
material entity;MVA-EBNA1/LMP2 Vaccine;A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. (NCIT C91076).
material entity;MVA-PSA/PAP Prostate Cancer Vaccine;A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation.
material entity;FRAME-001 personalized vaccine;A cancer vaccine made from tumor-specific neopeptides resulting from frameshift mutations in tumor cells, so-called Frames, present potentially potent targets for the immune system and can be utilized in therapeutic anti-cancer vaccination with the intention to synergize in their effect with immune checkpoint inhibitors. The personalized vaccine FRAME-001 based on a patient's Framome and selection of Frame peptides in advanced NSCLC cancer patients after standard first line treatment consisting of immune checkpoint inhibitor pembrolizumab as monotherapy or combined with chemotherapy (carboplatin/cisplatin and pemetrexed/paclitaxel) could help treat patients with non-small cell lung cancer.
material entity;Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with tumor-derived clonal immunoglobulin (Ig) with potential immunostimulatory and antineoplastic activities. Upon administration, idiotype-pulsed autologous dendritic cell vaccine APC8020, containing idiotype (Id) protein structures that can be recognized by antibodies and by CD41 T lymphocytes and CD81 T lymphocytes, may stimulate antitumoral cytotoxic T lymphocyte (CTL) and antibody responses against Id-expressing tumor cells. The Id represents the unique antigenic determinants in the variable regions of the clonal Ig.
material entity;hTERT I540/R572Y/D988Y Multipeptide Vaccine;A peptide vaccine consisting of multiple epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. hTERT I540/R572Y/D988Y multipeptide vaccine contains strongly antigenic peptide epitopes I540 (9-mer), R572Y (9-mer) and D988Y (10-mer). Vaccination with this agent may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells. Directly linked to tumorigenesis, telomerase is expressed in the majority of human cancer cells but is infrequently expressed in normal cells.
material entity;MAGE-A3-expressing Adenovirus Type 5 Vaccine;An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.
material entity;hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [HB-VAX];
material entity;Rickettsia prowazekii as vaccine component;
material entity;hepatitis B surface antigen vaccine 0.04 MG/ML;
material entity;rubella virus as vaccine component;
material entity;hepatitis B surface antigen vaccine 0.01 MG/ML Prefilled Syringe [Recombivax];
material entity;Yersinia pestis as vaccine component;
material entity;hepatitis B surface antigen vaccine 0.02 MG/ML [HB-VAX];
material entity;Haemophilus influenzae type b as vaccine component;
material entity;hepatitis B surface antigen vaccine 0.005 MG/ML Prefilled Syringe [Recombivax];
material entity;hepatitis B surface antigen vaccine 0.01 MG/ML Injection [Recombivax];
material entity;hepatitis B surface antigen vaccine 0.005 MG/ML [Recombivax];
material entity;hepatitis B surface antigen vaccine 0.005 MG/ML Injectable Suspension [Recombivax];
material entity;hepatitis B surface antigen vaccine 0.003 MG/ML;
material entity;hepatitis B surface antigen vaccine 0.003 MG/ML Injectable Solution;
material entity;hepatitis C virus as vaccine component;
material entity;influenza A virus as vaccine component;
material entity;influenza B virus as vaccine component;
material entity;Japanese encephalitis virus as vaccine component;
material entity;Neisseria meningitidis as vaccine component;
material entity;rabies virus as vaccine component;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 1;
material entity;GM-CSF-encoding Oncolytic Adenovirus CGTG-102 vaccine;A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus enhances antigen presentation, promotes natural killer (NK) cell-mediated killing and causes a cytotoxic T cell (CTL) response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. CGTG-102 is designed to replicate only in cells with defects in the p16/Rb/E2F pathway, attributed to a mutation common in many solid tumors. Replacement of the Ad5 capsid protein knob with a knob domain from serotype 3 causes higher transduction in cancer cells as compared to normal cells.
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 10;
material entity;GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccine;Used C57BL/6 mice and irradiated B16 tumor cells expressing granulocyte and macrophage colony-stimulating factor (GM-CSF), interleukin-12 (IL-12) or both. Tumor was transplanted by the injection of wild-type B16 cells. Tumor growth and survival were measured to evaluate the efficacy of vaccination. Specific humoral response and immunoglobulin G (IgG) switch were evaluated measuring total IgG and IgG1 and IgG2a subtypes against tumor membrane proteins of B16 cells
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 100;
material entity;GITRL RNA-transfected Autologous Dendritic Cell Vaccine;An autologous dendritic cell (DC) cancer vaccine with GITRL RNA-transfected that has potential immunostimulatory activity.
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 50;
material entity;Gag:267-274 Peptide Vaccine;A cancer vaccine containing of a synthetic form of the renal cell carcinoma (RCC)-associated antigen G250 with potential antineoplastic activity. Vaccination with G250 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the G250 antigen, resulting in decreased tumor growth. Found in the majority of renal cell carcinomas, G250 is a cell surface tumor-associated antigen (TAA) that contains an HLA-A2.1-restricted epitope that is recognized by CTLs.
material entity;Fowlpox Virus Vector Vaccine;A recombinant fowlpox virus-based vaccine vector designed to express various tumor-associated peptide antigens. Strong CD8 cytotoxic T cell responses may be induced after prolonged immunization with fowlpox virus vaccines and have been associated with tumor regression. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues.
material entity;ESO-1 Reactive Autologous Peripheral Blood Lymphocyte vaccine;Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated protein ESO-1 in vitro, and then transferred back to the same patient to target tumor cells expressing ESO-1. ESO-1 is a human self-antigen expressed by melanomas. The ESO-1 gene encodes several MHC class I- and MHC class II-restricted epitopes that may activate cytotoxic T-cell-mediated tumor destruction
material entity;Indium In 111-Labeled Autologous Polymorphonuclear Leukocytes Vaccine;A preparation of autologous peripheral polymorphonuclear (PMNLs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PMNLs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PMNLs localized in lymphoma tissue.
material entity;Indium In 111-Labeled Autologous Peripheral Blood Mononuclear Cells Vaccine;A preparation of autologous peripheral blood mononuclear cells (PBMCs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PBMCs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PBMCs localized in lymphoma tissue.
material entity;KLH-Lymphoma Ig Vaccine;A chimeric lymphoma vaccine generated by combining the recipient's Ig idiotype (Id) protein with keyhole limpet hemocyanin (KLH), an immune stimulant, with potential antineoplastic activity. Vaccination with KLH-Lymphoma Ig Vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth.
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Vaccine / Rubella virus / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Decavac];
material entity;Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injection [Priorix];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Tenivac];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Tenivac];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Vaccine / Rubella virus / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Priorix-Tetra];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injection;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe Box of 1;
material entity;Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injectable Solution [Priorix];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Decavac];
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 1 by Glaxosmithkline;
material entity;Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injection [M-M-RVAXPRO];
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 10 by Glaxosmithkline;
material entity;Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injection [M-M-R II];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Decavac];
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 100 by Glaxosmithkline;
material entity;diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 50 by Glaxosmithkline;
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML;
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Sanofi;
material entity;Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injectable Solution [M-M-RVAXPRO];
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 1;
material entity;gp100/IFA vaccine;To understand why cancer vaccine-induced T cells often do not eradicate tumors, we studied immune responses in mice vaccinated with gp100 melanoma peptide in incomplete Freund's adjuvant (peptide/IFA), which is commonly used in clinical cancer vaccine trials (Hailemichael et al., 2013). Immunization Route: Intramuscular injection (i.m.)
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 10;
material entity;gp100-Reactive Autologous Peripheral Blood Lymphocyte vaccine;Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the same patient to target tumor sites expressing gp100. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas.
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 100;
material entity;gp100-Pulsed Peripheral Blood Mononuclear Cell vaccine;Peripheral blood lymphocytes (PBL) harvested from host blood and stimulated in vitro with tumor-specific gp 100 antigen. 'Pulsing' PBL with gp100, a tumor associated antigen (TAA) commonly expressed by melanoma cells, may increase melanoma-reactive cytotoxic lymphocytes (CTL) in the PBL cell population. Autologous gp100-pulsed PBL have been administered to melanoma patients in order to augment cytotoxic immune responses to melanoma.
material entity;gp100-Fowlpox Vaccine;A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the melanoma antigen glycoprotein 100 (gp 100) with potential antineoplastic activity. The expression of gp100 may generate a cellular immune response to melanoma cells. this effect is enhanced by the co-administration of interleukin 2
material entity;gp100 Vaccinia Vaccine;A cancer vaccine consisting of a recombinant vaccinia virus encoding the gp100 melanoma-melanocyte antigen. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas.
material entity;gp100 Protein (184V) vaccine;A recombinant peptide derived from the human melanoma antigen glycoprotein 100 (gp100) with potential use in cancer immunotherapy. gp100 protein(184V) has a valine substitution at position 184. Vaccination with this peptide may evoke a cytotoxic T lymphocyte (CTL) response against tumor cells expression the gp100 antigen.
material entity;gp100 and GM-CSF DNA/Gold Vaccine;A vaccine consisting of microscopic gold particles coated with plasmid DNA encoding the glycoprotein 100 (gp100) melanoma antigen and granulocyte-macrophage colony-stimulating factor (GM-CSF). Vaccination with gp100 and GM-CSF DNA/gold vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against gp100 positive cells, resulting in decreased tumor growth. GM-CSF is thought to increase the induction and activation of antigen-presenting cells (APC), allowing for a reduction in the dose of gp100 administered.
material entity;gp100 Adenovirus Vaccine;A vaccine consisting of a replication-defective recombinant adenovirus that encodes the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100 adenovirus vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
material entity;gp100 + Mart-1 + Mart-3 vaccine;A vaccine that injected peptides of gp100, MART-1, MAGE-3
material entity;cancer stem cell-loaded dc vaccine;A cancer vaccine made of peripheral blood and tumor specimen harvested from patients with metastatic adenocarcinoma of the pancreas to generate cancer stem cell (CSC)-loaded denritic cell (DC) vaccines. CSC-primed antibodies and T cells are capable of selective targeting CSCs and conferring antitumor immunity.
material entity;gp100: ES209-217(210M) Peptide vaccine;A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution;
material entity;Haemophilus capsular oligosaccharide / Neisseria meningitidis Injectable Suspension;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML [Priorix-Tetra];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 50 UNT/ML Injectable Solution;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Priorix-Tetra];
material entity;Haemophilus capsular oligosaccharide / Neisseria meningitidis Injectable Solution;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Suspension;
material entity;BCG, live, Tice strain;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 50;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution [Priorix];
material entity;diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML Injection [Tdvax];
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Suspension [M-M-RVAXPRO];
material entity;diphtheria toxoid vaccine, inactivated 5 MG/ML / tetanus toxoid vaccine, inactivated 10 MG/ML Injectable Suspension;
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML [Tdvax];
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML Injection;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix] Box of 1;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution [M-M-RVAXPRO];
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI] Box of 1;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution [M-M-R II];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension;
material entity;Leukemic Apoptotic Corpse-Pulsed Autologous Dendritic Cells Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with corpses of apoptotic leukemic cells, with potential immunostimulatory and antineoplastic activities. Upon vaccination, autologous dendritic cells pulsed with leukemic apoptotic corpse may activate the immune system to mount an anti-tumoral cytotoxic T-lymphocyte (CTL) response against leukemic cells expressing leukemia-associated antigens, which may result in leukemic cell lysis and inhibition of tumor cell growth. Apoptotic tumor cell corpses contain an array of tumor associated antigens
material entity;Human Myeloid Progenitor Cells CLT-008 vaccine;Early-to late-stage myeloid progenitor cells derived from adult human stem cells with potential hematopoietic activity. Upon infusion, human myeloid progenitor cells CLT-008 proliferate into mature myeloid cells, including granulocytes, macrophages, platelets, and erythrocytes. These myeloid progenitor cells die within forty-five days after a burst of hematopoiesis. This agent cannot create lymphoid cells, including T cells associated with graft-versus-host disease
material entity;Mouse Prostate-Specific Membrane Antigen Plasmid DNA Vaccine;A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis
material entity;Human Prostate-Specific Membrane Antigen Plasmid DNA Vaccine;A vaccine consisting of a plasmid DNA encoding the human prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express this antigen, resulting in tumor cell lysis.
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe Box of 1;
material entity;HPV E6/E7 DNA Vaccine GX-188E;A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] by Glaxosmithkline;
material entity;HPV 16 E7:12-20 Peptide Vaccine;A peptide based vaccine consisting of amino acids 12 through 20 of the E7 gene of the Human Papilloma Virus type 16. HPV-16 E7 12-20 peptide vaccine may elicit a specific CD8 T-cell response to the E7 oncogene protein, thereby inhibiting the abrogation of p53 and pRb function and thus prevent tumorigenesis.
material entity;Human Papillomavirus Vaccine V503;A vaccine consisting of noninfectious, recombinant virus-like particles (VLP) containing the major viral capsid protein L1 of nine strains of human papillomavirus (HPV), with potential immunoprotective activity. Vaccination with HPV V503 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against cells positive for any of these nine strains of HPV, thereby preventing cervical infection upon exposure to certain HPV subtypes.
material entity;Human Papillomavirus Tumor Antigen Vaccine;A vaccinia viral based vaccine, encoding epitopes of E6 and E7 proteins from human papillomavirus (HPV) types 16 and 18, with immunostimulatory and antineoplastic activities. HPV types 16 and 18 account for approximately 70% of cervical cancers. Vaccination with this HPV-TA (tumor antigen) vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for E6 and E7 from either type 16 or 18 HPV, resulting in decreased tumor growth.
material entity;Human Papillomavirus 16/18 L1 virus-like particle/AS04 vaccine;A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.
material entity;human Papillomavirus 16 E7 Peptide/Padre 965.10 Vaccine;A synthetic agent derived from human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms. HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator. This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas. PADRE(R) is a proprietary family of molecules that enhances the immune systems response against an administered immunogen such as the HPV E7 nuclear protein.
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix] by Glaxosmithkline;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix];
material entity;diphtheria toxoid vaccine, inactivated 0.2 UNT/ML;
material entity;1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 0.2 UNT/ML Injectable Solution;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus capsular oligosaccharide 0.02 MG/ML Injectable Suspension;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus capsular oligosaccharide 0.02 MG/ML Injectable Suspension [HibTITER];
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 0.036 MG/ML / Haemophilus capsular oligosaccharide 0.05 MG/ML Injectable Solution [Prohibit];
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10 by Merck;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus capsular oligosaccharide 0.02 MG/ML [HibTITER];
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix] Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 0.036 MG/ML / Haemophilus capsular oligosaccharide 0.05 MG/ML [Prohibit];
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] by Sanofi;
material entity;diphtheria toxoid vaccine, inactivated 0.036 MG/ML / Haemophilus capsular oligosaccharide 0.05 MG/ML Injectable Solution;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] by Sanofi;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax];
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] by Waymade;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix] Box of 1 by Glaxosmithkline;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Decavac];
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] by Waymade;
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 10 by Glaxosmithkline;
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 20 by Glaxosmithkline;
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 50 by Glaxosmithkline;
material entity;Typhoid Vaccine Live Ty21a 10000000000 UNT Delayed Release Oral Capsule [Vivotif] by Paxvax Berna;
material entity;Interleukin-2 Anti-Idiotype Vaccine;A vaccine based on anti-idiotype (Id) monoclonal antibodies combined with interleukin-2 (IL-2). Anti-Id vaccines have been shown to be effective in treatment of B-cell lymphoma in animal models and in clinical trials, resulting in tumor regression. the addition of interleukin-2 (IL-2) may augment the therapeutic effect of anti-Id vaccines.
material entity;Interferon-gamma-expressing Adenovirus Vaccine ASN-002;A replication-defective adenoviral serotype 5 vector encoding a recombinant form of the human cytokine interferon-gamma (IFN-g), with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the sustained expression of IFN-g by IFN-g-expressing adenovirus vaccine ASN-002 promotes a T-helper type 1 (Th1) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs). activates macrophages, cytotoxic T-cells, and natural killer (NK) cells. upregulates major histocompatibility complex (MHC) molecules. and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in both an inhibition of tumor cell proliferation and tumor cell death. Compared to IFN-g injections, the prolonged local production of IFN-g at the tumor site allows for higher efficacy and a reduction of systemic toxicity
material entity;GVAX Cancer Vaccine;GVAX cancer vaccines are autologous cell vaccines comprised of tumor cells which have been irradiated and genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the body's immune response to vaccines.
material entity;Immunotherapeutic GSK1572932A;An immunotherapeutic containing a proprietary adjuvant system combined with a melanoma-associated antigen peptide MAGE-A3 epitope with potential immunomodulating and antineoplastic activities. Intramuscular administration with GSK1572932A may stimulate the immune system to exert both humoral and cellular immune responses against MAGE-A3-expressing tumor cells. MAGE-A3, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, and bladder cancer.
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1;
material entity;IL-2/Lptn Gene-Modified Allogeneic Neuroblastoma Tumor Cell Vaccine;A cancer vaccine consisting of allogeneic neuroblastoma tumor cells have been genetically modified to secrete the human cytokine interleukin-2 (IL-2) and the human chemokine lymphotactin (Lptn) with potential immunostimulating and antineoplastic activities. Upon administration, IL-2 and Lptn are secreted by the IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine, potentially enhancing the cytotoxic T lymphocyte (CTL) response elicited by vaccine neuroblastoma tumor-associated antigens (TAAs) against host neuroblastoma tumor cells. Produced by activated progenitor T cells, Lptn belongs to the C chemokine subfamily and is a potent chemotactic factor for lymphocytes. IL-2 stimulates natural killer (NK) cells and may enhance a vaccine-elicited CTL immune response against tumor cells.
material entity;HLA-A2402-Restricted VEGFR1/2 Multipeptide Vaccine;A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
material entity;HLA-A*2402-Restricted VEGFR1 Peptide Vaccine;A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
material entity;bivalent neuroblastoma vaccine with adjuvant OPT-821;A cancer vaccine that is a bivalent vaccine with the antigens GD2L and GD3L for patients with High-Risk Neuroblastoma. The antigens are linked to KLH and mixed with OPT-821. It is given in combination with oral β-glucan, which can help white blood cells kill cancer.
material entity;GVAX Lung Cancer Vaccine;This is an autologous lung cancer vaccine consisting of patient-specific lung cancer cells genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), an immunostimulatory cytokine (NCIT C1979). GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias.
material entity;Multi-peptide CMV-Modified Vaccinia Ankara Vaccine;
material entity;Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injectable Solution [M-M-R II];
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 50;
material entity;Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 25 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 25 LFU/ML;
material entity;1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution Box of 100;
material entity;diphtheria toxoid vaccine, inactivated 25 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension;
material entity;Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [ProQuad];
material entity;diphtheria toxoid vaccine, inactivated 20 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension;
material entity;Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Priorix];
material entity;diphtheria toxoid vaccine, inactivated 20 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix] Box of 100;
material entity;diphtheria toxoid vaccine, inactivated 15 UNT/ML;
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1;
material entity;1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix];
material entity;diphtheria toxoid vaccine, inactivated 18 UNT/ML;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10;
material entity;1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix] by Glaxosmithkline;
material entity;diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution;
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10;
material entity;1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix] Box of 100 by Glaxosmithkline;
material entity;diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix] Box of 1;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI] Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 13.2 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 1;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 10;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 100;
material entity;Fluzone Quadrivalent 2020 Southern Hemisphere vaccine;
material entity;Fluzone Quadrivalent 2020-2021 vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution Box of 20;
material entity;Fluzone Quadrivalent 2021 Southern Hemisphere vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution Box of 10;
material entity;Fluzone Quadrivalent 2021-2022 vaccine;
material entity;Fluzone Quadrivalent 2022 Southern Hemisphere vaccine;
material entity;Fluzone Quadrivalent 2022-2023 vaccine;
material entity;Fluzone Quadrivalent 2023 Southern Hemisphere vaccine;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-1273;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 20;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution;
material entity;hepatitis A vaccine (inactivated) strain HM175 / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Prefilled Syringe;
material entity;SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML [Priorix];
material entity;hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.025 MG/ML Prefilled Syringe;
material entity;Haemophilus influenzae as vaccine component;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 10;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group Y Injection [MenHibrix];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix];
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injection [Hiberix];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension;
material entity;Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML Injection [Hiberix];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group Y Injection;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML;
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection [ActHIB];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension Box of 1;
material entity;Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML Injection;
material entity;measles virus vaccine live, Enders' attenuated Edmonston strain Injectable Solution [Attenuvax];
material entity;Fluzone 2012-2013 Formula vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Injectable Solution [Priorix];
material entity;Fluzone 2013-2014 Formula vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Injectable Solution [Mmr Priorix];
material entity;Fluzone 2014-2015 Formula vaccine;
material entity;Fluzone 2019-2020 vaccine;
material entity;Fluzone High-Dose 2013-2014 Formula vaccine;
material entity;Fluzone High-Dose 2014-2015 Formula vaccine;
material entity;Fluzone Intradermal 2013-2014 Formula vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix] Box of 100;
material entity;Fluzone Intradermal 2014-2015 Formula vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix];
material entity;Fluzone Quadrivalent 2016 Southern Hemisphere vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Injectable Solution;
material entity;Fluzone Quadrivalent 2019-2020 vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution Box of 100;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 6 CELLS/ML;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML [Priorix];
material entity;Haemophilus capsular oligosaccharide 0.03 MG/ML / Neisseria meningitidis 0.5 MG/ML Injectable Solution;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI];
material entity;Fluvirin 2011-2012 Formula vaccine;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe;
material entity;Fluvirin 2012-2013 Formula vaccine;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI];
material entity;MAGE-3.A1 Peptide Vaccine;A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe;
material entity;Long Peptide Vaccine 7;A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types.
material entity;hTERT/Survivin/Melanoma Tumor Cell-Derived mRNA-Transfected Dendritic Cell Vaccine;A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival.
material entity;HLA-A2-Binding TYR/MART-1/gp100 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen peptides tyrosinase (TYR), MART-1(melanoma antigen recognized by T-cells) and melanoma antigen glycoprotein 100 (gp100), with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against Tyr-, MART-1 and gp100-expressing cancer cells, resulting in tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.
material entity;HLA-A1-Binding MAGE-1/MAGE-3 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A1-binding melanoma-associated antigen peptides MAGE-1 and MAGE-3 with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against MAGE1- and MAGE-3-expressing cancer cells, resulting in tumor cell lysis. HLA-A1 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells. epitope design restricted to epitopes that bind most efficiently to HLA-A1 may improve antigenic peptide immunogenicity.
material entity;Hexapeptide melanoma vaccine;
material entity;gp100:280-288 Peptide Vaccine;A vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100:280-288 peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
material entity;gp100:209-217 Peptide vaccine;A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth.
material entity;gp100:154-162 Peptide Vaccine;A peptide consisting of amino acid residues 154 through 162 of the melanoma-melanocyte antigen gp100. Vaccination with gp100:154-162 peptide may enhance tumor-specific T-cell immunity. gp100 antigen is a self-antigen expressed by melanocytes, pigmented retinal cells, and most melanoma lesions and is recognized via class I and II HLA-restricted mechanisms.
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 25;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 20;
material entity;Haemophilus capsular oligosaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.048 MG/ML Injectable Solution;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 40;
material entity;Haemophilus capsular oligosaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.048 MG/ML Injectable Solution [OmniHIB];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix];
material entity;Haemophilus capsular oligosaccharide 0.015 MG/ML / Neisseria meningitidis 0.25 MG/ML Injectable Suspension [Liquid PedvaxHIB];
material entity;Fluvirin 2013-2014 Formula vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution;
material entity;Haemophilus capsular oligosaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.048 MG/ML [OmniHIB];
material entity;Fluvirin 2014-2015 Formula vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 100;
material entity;Haemophilus capsular oligosaccharide 0.015 MG/ML / Neisseria meningitidis 0.25 MG/ML Injectable Solution;
material entity;Fluzone 2010-2011 Formula vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 10;
material entity;Haemophilus capsular oligosaccharide 0.015 MG/ML / Neisseria meningitidis 0.25 MG/ML Injectable Suspension;
material entity;Fluzone 2011-2012 Formula vaccine;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Injectable Suspension Box of 1;
material entity;Haemophilus capsular oligosaccharide / tetanus toxoid vaccine, inactivated Injectable Solution [OmniHIB];
material entity;Haemophilus capsular oligosaccharide 0.015 MG/ML / Neisseria meningitidis 0.25 MG/ML [Liquid PedvaxHIB];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML [Priorix-Tetra];
material entity;Haemophilus capsular oligosaccharide / Neisseria meningitidis Injectable Suspension [Liquid PedvaxHIB];
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML [Mmr Priorix];
material entity;Haemophilus capsular oligosaccharide / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / meningococcal polysaccharide vaccine group Y 0.01 MG/ML Injection [MenHibrix];
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 50;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Sanofi;
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Waymade;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Waymade;
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10 by Sanofi;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10 by Sanofi;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 40;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 25;
material entity;Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / meningococcal polysaccharide vaccine group Y 0.01 MG/ML Injection;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 10;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML Injection;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10 by Waymade;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 50;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML Injection [PedvaxHIB];
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10 by Waymade;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 20;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML / hepatitis B surface antigen vaccine 0.01 MG/ML Injection;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix] Box of 1 by Glaxosmithkline;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 100;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML / hepatitis B surface antigen vaccine 0.01 MG/ML Injection [COMVAX];
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI] Box of 1 by Sanofi;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 10;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.015 MG/ML;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra];
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.015 MG/ML Injectable Solution;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 20;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine Injection;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 100;
material entity;Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine Injection [COMVAX];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Injectable Solution;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine / Varicella Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Priorix-Tetra];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Injectable Suspension;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Injectable Solution [Priorix];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus Injection [Priorix];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus Injection [M-M-R II];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine / Varicella Virus Vaccine Live (Oka-Merck) strain Injectable Solution;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection;
material entity;Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Injectable Solution [Priorix-Tetra];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus Injection;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [Priorix];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Priorix-Tetra];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Prefilled Syringe;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Injectable Suspension [M.M.R. VaxPro];
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution;
material entity;MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Prefilled Syringe [Priorix];
material entity;Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809 Vaccine;A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809 is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.
material entity;Inalimarev Vaccine;A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.
material entity;Inactivated Vaccinia Virus Vaccine;A poxvirus made non-infectious by ultraviolet light or other inactivation methods in order to reduce its pathogenicity. In cancer gene therapy, inactivated vaccinia virus may be used as a vector to express a protein that kills tumor cells or elicits specific anti-tumor immunity. In a cancer vaccine application, tumor cells taken from the host may be adsorbed with inactivated vaccinia virus and returned to the host, where the modified tumor cells may stimulate an anti-tumor immune response.
material entity;hTERT Vaccine V934/V935;
material entity;hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301;A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens.
material entity;hTERT mRNA/Survivin Peptide-double-loaded Autologous Dendritic Cell Vaccine;A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding human telomerase reverse transcriptase (hTERT) and survivin peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT mRNA/survivin peptide-double-loaded autologous dendritic cell vaccine may elicit an immune response against cancer cells expressing hTERT and survivin by activating cytotoxic T-cells (CTLs), natural killer cells (NKs), and B-lymphocytes. The tumor associated antigens (TAAs) hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and play key roles in tumor cell growth and survival.
material entity;E1M(184V) Peptide Vaccine;A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor. (NCIT C62801).
material entity;Bcr-Abl peptide vaccine;A cancer vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. The bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine is used in combination with GM-CSF. The peptides may help the body build an effective immune response to kill cancer cells, and the GM-CSF may increase the number of immune cells found in bone marrow or peripheral blood. This combination is used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia. It can also be used in combination with imatinib mesylate to decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease
material entity;Lapuleucel-T Vaccine;A cell-based vaccine targets tumors expressing the HER2/neu marker. HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers. APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient. These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu.
material entity;KLH-FITC Vaccine;A conjugate consisting of keyhole-limpet hemocyanin (KLH) and fluorescein isothiocyanate (FITC) with potential immunostimulating activity. Vaccination with KLH-FITC may elicit an immune response against fluorescein and the production of anti-fluorescein IgG antibodies. KLH, a natural protein isolated from the marine mollusk keyhole limpet, is an immunostimulant carrier protein.
material entity;nexavant vaccine adjuvant;A nucleic acid vaccine adjuvant that targets on TLR3 agonist to induce a mixed Th1/Th2 response.
material entity;nucleic acid vaccine adjuvant;A vaccine adjuvant that is primarily composed of nucleic acid.
material entity;MiHA-loaded PD-L1/L2-silenced Dendritic Cell Vaccine;A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipient's minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing miHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion. silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipient's hematopoietic tumor cells.
material entity;ACM-CpG vaccine adjuvant;An emulsion vaccine adjuvant that targets on TLR-agonist. It is a nucleic acid-based adjuvant for chemical nature.
material entity;IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051;Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells.
material entity;cowpea mosaic virus vaccine adjuvant;A particulate antigen delivery system vaccine adjuvant derived from Cowpea mosaic virus that is able to induce a Th1-biased response.
material entity;HLA-Matched Donor Mononuclear Cell-Enriched Leukocytes Apocell vaccine;A preparation of allogeneic HLA-matched leukocytes treated with a derivative of placental protein 14 (PP14) with potential immunomodulating activity. PP14 derivative-treated HLA-matched donor mononuclear cell-enriched leukocytes contain at least fifty-five percent early-apoptotic T cells. after infusion and when processed by recipient dendritic cells, early-apoptotic T cells may help induce a decrease in the donor effector T-cell responses against the recipient of an allogeneic hematopoietic stem cell (HSC) transplant, thereby minimizing allogeneic HSC transplant-related graft-versus-host disease (GVHD). PP14, a 162 amino acid glycosylated protein secreted by the late secretory phase endometrium, binds to T cells in a carbohydrate fashion and has been shown to induce T-cell apoptosis. maternal immune tolerance to the fetus and pregnancy-related remissions of autoimmune disease may involve PP14-induced T cell apoptosis.
material entity;S-540956 vaccine adjuvant;An oligonucleotide vaccine adjuvant that is a TLR9-agonistic adjuant containing a CpG oligonucleotide annealed to a complementary strand with an amphiphilic chain unit, acts as a potent cancer vaccine adjuvant by targeting draining lymph nodes.
material entity;Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells
material entity;precision vaccines program-057 vaccine adjuvant;A vaccine adjuvant which is a small molecule adjuvant that is able to induce a mixed Th1/Th2 response and active innate immunity.
material entity;EF-2 Peptide Vaccine;A synthetic peptide derived from the protein ESW/FLI1 type 2 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-2 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 2 fusion protein. (NCIT C49064).
material entity;oligonucleotide vaccine adjuvant;A nucleic acid vaccine adjuvant that is primarily composed of oligonucleotide.
material entity;Globo H-DT Vaccine OBI-833;A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen.
material entity;A-910823 vaccine adjuvant;An emulsion vaccine adjuvant that is squalene-based adjuvant, induces T follicular helper cells and humoral immune responses via alpha-tocopherol component.
material entity;LY6K/VEGFR1/VEGFR2 Multipeptide Vaccine;A multipeptide vaccine consisting of peptides derived from lymphocyte antigen 6 complex locus K (LY6K) and type I and II vascular endothelial growth factor receptors (VEGFRs) with potential antineoplastic activity. Upon administration, LY6K/VEGFR1/VEGFR2 multipeptide vaccine may elicit an antitumor cytotoxic T-lymphocyte (CTL) immune response against LY6K-expressing tumor cells and/or VEGFR-expressing vascular endothelial cells involved in tumor angiogenesis. LY6K is a tumor-associated antigen (TAA) that occurs singly in glycosylphosphatidyl-inositol (GPI)-linked cell-surface glycoproteins or as three-fold repeated domain in the urokinase-type plasminogen activator receptor. VEGFRs are cell surface receptors that stimulate endothelial cell proliferation, invasion, angiogenesis, and vasculogenesis upon ligand binding and receptor activation.
material entity;SLA-Alum vaccine adjuvant;A combination vaccine adjuvant of a synthetic TLR4 agonist and aluminum salt.
material entity;Monoclonal Antibody 105AD7 Anti-idiotype Vaccine;A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis.
material entity;Stable Emulsion (SE) vaccine adjuvant;An emulsion vaccine adjuvant that includes squalene-based oil-in-water emulsion.
material entity;Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101;
material entity;Human Papilloma Virus L1 Virus-Like Particle V504 Vaccine;A vaccine formulation consisting of several types of human papillomavirus (HPV)-derived noninfectious virus-like particles (VLPs) with potential immunoprophylactic activity. Upon administration, HPV L1 VLP vaccine V504 may generate humoral immunity against various HPV L. major capsid proteins, thereby preventing cervical infection upon exposure to the associated HPV types. VLPs are composed of self-assembling L. major capsid proteins or functional L. major capsid protein derivatives.
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 100;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.069 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.0016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.0032 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0064 MG/ML / diphtheria toxoid vaccine, inactivated 18 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 50;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.0468 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0468 MG/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.0468 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0468 MG/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension [Tripedia];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Quadracel];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.0468 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0468 MG/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Tripedia];
material entity;BCG, Live, Tice Strain Injection;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Vaxelis];
material entity;Bacillus anthracis strain V770-NP1-R antigens Injectable Suspension [Biothrax];
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI];
material entity;BCG, live, Tice strain 50 MG Injection;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix];
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 10;
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 20;
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 50;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 1;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 10;
material entity;HPV-11 Vaccine;A vaccine directed against Human Papillomavirus Type 11 that causes majority of the genital warts and anogenital cancers.
material entity;HPV DNA plasmids therapeutic vaccine VGX-3100;A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV DNA plasmids therapeutic vaccine VGX-3100 expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis.
material entity;HPV 18 L1-VLP vaccine;Noninfectious, synthetic, virus-like particles (VLP) containing the major viral capsid protein, L1, of the human papillomavirus type 18 with potential immunoprotective activity. Vaccination with HPV 18 L1-VLP may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) response against cells positive for HPV 18, thereby preventing cervical infection upon exposure to HPV type 18.
material entity;HPV 18 E6:13-21 peptide vaccine;A synthetic peptide vaccine consisting of amino acids 13 through 21 of the viral oncoprotein human papillomavirus (HPV) 18 E6. The HPV 18E6 peptide cross-reacts immunologically with both HPV type 16 and HPV type 18, the most common HPV types involved in cervical cancer. Vaccination with HPV-18 E6:13-21 peptide may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV 16 and 18.
material entity;HPV 16 L1-VLP vaccine;A vaccine consisting of human papillomavirus-derived noninfectious virus-like particles (VLPs), containing the L. major capsid protein. Vaccination with HPV 16 L1-VLP results in increases in T cell-proliferative response to HPV 16 L1-VLP, as well as significant increases in cytokine (interferon-gamma, interleukin-5 and -10) responses to L1 VLP. This agent may reduce the incidence of persistent HPV-16 infection, which may be responsible for half of all cases of cervical cancer including high-grade cervical intraepithelial neoplasia.
material entity;HPV 16 E7:86-93 peptide vaccine;A synthetic peptide vaccine consisting of amino acids 86 through 93 (TLGIVCPI) of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination with HPV-16 E7:86-93 peptide, which binds to HLA-A* 0201 molecule, may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 E7.
material entity;HPV 16 E6 (18-26) peptide vaccine;A peptide derived from the oncogenic human papillomavirus (HPV) early gene product E6. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions and has a high affinity for the most common human lymphocyte antigen (HLA), HLA-A2. Immunogenic peptides from the HPV 16 E6 may be used to trigger a T-cell-mediated immune response to HPV.
material entity;HIVgP160 vaccine;A synthetic HIV vaccine based on a recombinant canary pox virus vector expressing the human immunodeficiency virus (HIV) glycoprotein gp160. HIVgP160 vaccine has been used to generate in vivo primary T lymphocyte response against HIV antigens.
material entity;MVA-FCU1 TG4023 vaccine;A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1TG4023 enters tumor cells where FCU1 is expressed. Subsequently, the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT. 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase and, so, DNA synthesis through deprivation of deoxythymidine triphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly
material entity;HCV DNA Vaccine INO-8000;A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC)
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Decavac];
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 50;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix];
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus capsular oligosaccharide Injectable Suspension;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI];
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus capsular oligosaccharide Injectable Suspension [HibTITER];
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus capsular oligosaccharide Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus capsular oligosaccharide Injectable Solution [Prohibit];
material entity;Bordetella pertussis toxoid vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML Injectable Suspension;
material entity;Bordetella pertussis toxoid vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML Injectable Suspension [Certiva];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.069 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.0016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.0032 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0064 MG/ML / diphtheria toxoid vaccine, inactivated 18 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension [ACEL-IMUNE];
material entity;Bordetella pertussis toxoid vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML [Certiva];
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 50;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Typhim V] by Sanofi;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.069 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.0016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.0032 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0064 MG/ML / diphtheria toxoid vaccine, inactivated 18 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [ACEL-IMUNE];
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] by Glaxosmithkline;
material entity;Typhoid Vaccine Live Ty21a 10000000000 UNT Oral Powder [Vivotif] by Berna Biotech;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 1000000000 UNT/ML Injectable Suspension by Aventis;
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 10;
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 20;
material entity;MSCV-MGMT(P140K) Vaccine;
material entity;Montanide ISA-51/Survivin Peptide Vaccine;
material entity;Monoclonal Antibody GD2 Anti-Idiotype Vaccine;An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells.
material entity;Monoclonal Antibody A1G4 Anti-Idiotype Vaccine;An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells
material entity;Monoclonal Antibody 3H1 Anti-Idiotype Vaccine;A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA). This agent is used as a cancer vaccine against tumors that express CEA.
material entity;Monoclonal Antibody 11D10 Anti-Idiotype Vaccine;A vaccine consisting of a monoclonal antibody (MoAb) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope. Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.
material entity;Mimotope-P10s-PADRE Peptide Vaccine;
material entity;Methanol Extraction Residue of BCG;A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy.
material entity;Mesothelioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine consisting of autologous dendritic cells (DCs) pulsed with mesothelioma tumor lysate with potential immunostimulating and antineoplastic activities. Upon administration, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount a specific cytotoxic T lymphocyte (CTL) response against mesothelioma tumor cells, resulting in tumor cell lysis.
material entity;MUC-1 Peptide Vaccine;A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein.
material entity;MVF-HER-2(597-626)/MVF-HER-2 (266-296) Peptide Vaccine;A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope derived from measles virus fusion protein (MVF. amino acid residues 288-302) co-synthesized with B-cell epitopes derived from the HER-2/neu a.a. 597-626 and HER-2/neu a.a. 266-296, with potential antineoplastic activity. Vaccination with MVF-HER-2(597-626)/MVF-HER-2(266-296) peptide vaccine may be capable of inducing an active specific immune response, mounting a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress the HER-2 protein. The oncogenic protein HER-2, a member of the human epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in a variety of cancers and is correlated with increased tumor growth, progression and a poor prognosis. HER-2(597-626) corresponds to the binding site of trastuzumab on the extracellular domain IV of HER-2. HER-2 (266-296) corresponds to the binding site of pertuzumab on the dimerization loop of domain II of HER-2
material entity;MVA-MUC1-IL2 Vaccine;A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells.
material entity;Mutant p53 Peptide Pulsed Dendritic Cell Vaccine;A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation.
material entity;Multipeptide Vaccine S-588210;A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K. LY6K. URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2. NUF2. CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3. KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B. MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.
material entity;Multi-epitope Folate Receptor Alpha Peptide Vaccine;
material entity;MUC1-targeted Peptide GO-203-2C Vaccine;
material entity;MUC1-KLH Vaccine/QS21;A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21, with potential antineoplastic activity. MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition. the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen. Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers.
material entity;MUC1-KLH Conjugate Vaccine;A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH conjugate vaccine may stimulate humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. In this vaccine, MUC1 antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, and ovary.
material entity;MUC1 Antigen/SB AS-2 Vaccine;
material entity;MUC-2-KLH Vaccine;A peptide vaccine containing human mucin 2 (MUC2) protein conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. MUC2, a secretory or gel forming glycoprotein expressed predominantly in goblet cells of the gastrointestinal and respiratory tracts, is overexpressed as an aberrant or deglycosylated form in various tumors such as gastric carcinomas and some hormone-refractory prostate cancers. MUC2 protein is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with MUC2-KLH may result in the production of antibodies as well as elicit a cytotoxic T- lymphocyte (CTL) response against tumor cells expressing MUC2
material entity;Bacillus anthracis strain V770-NP1-R antigens Injectable Suspension;
material entity;Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML [Biothrax];
material entity;Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Pentacel];
material entity;Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML;
material entity;acellular pertussis vaccine, inactivated 8 UNT/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated 8 UNT/ML / diphtheria toxoid vaccine, inactivated 25 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated 600 UNT/ML;
material entity;acellular pertussis vaccine, inactivated 600 UNT/ML Injectable Solution;
material entity;acellular pertussis vaccine, inactivated 0.936 UNT/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;meningococcal A polysaccharide vaccine (non-US);
material entity;Junin virus vaccine;
material entity;CEA RNA-pulsed Autologous Human Cultured Dendritic Cells Vaccine;Autologous human dendritic cells pulsed with RNA encoding the carcinoembryonic antigen (CEA) are being studied for possible use in the treatment of cancer expressing CEA.
material entity;leprosy vaccine;
material entity;CD80 Breast Cancer Vaccine;A vaccine comprised of CD80-transfected allogenic breast cancer cells to induce T-cell response.
material entity;Flucelvax 2014-2015 Formula vaccine;
material entity;influenza virus vaccine whole virus;
material entity;CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells. it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.
material entity;Flucelvax Quadrivalent 2018-2019 vaccine;
material entity;Japanese Encephalitis vaccine unspecified formulation;
material entity;CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine;A plasmid DNA vaccine containing the mammalian expression vector pUMVC3 (pNGVL3) encoding epitopes of CD105 (Endoglin), Y-box binding protein 1 (Yb-1), SRY-box 2 (SOX2), cadherin 3 (CDH3), and murine double minute 2 (MDM2) proteins, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of pUMVC3-CD105/Yb-1/SOX2/CDH3/MDM2-epitopes plasmid DNA vaccine, the plasmid transfects cells and the peptides are expressed. This generates a specific memory Th1 (T-helper) cell immune response, stimulates secretion of cytokines by the T cells and leads to a cytotoxic T-lymphocyte (CTL) response against CD105/Yb-1/SOX2/CDH3/MDM2-expressing tumor cells. CD105/Yb-1/SOX2/CDH3/MDM2 proteins are highly immunogenic tumor associated antigens that are overexpressed in breast cancer. Additionally, these antigens are associated with breast cancer stem cells and with epithelial to mesenchymal transformation (EMT).
material entity;Flucelvax Quadrivalent 2019-2020 vaccine;
material entity;influenza virus vaccine split virus (incl. purified surface antigen);
material entity;Bcr-Abl (b2a2)-derived peptide vaccine;A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. (NCIT C61309) The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.
material entity;influenza virus vaccine unspecified formulation;
material entity;Carcinoembryonic Antigen RNA-pulsed DC Cancer Vaccine;A vaccine comprised of autologous dendritic cells pulsed with mRNA-encoded Carcinoembryonic Antigen (CEA) targeting tumor cells expressing CEA.
material entity;Human Rabies vaccine from human diploid cell culture;
material entity;Carcinoembryonic Antigen Peptide-1 Vaccine;A cancer vaccine comprised of an epitope from the Carcinoembryonic Antigen obtained from cancer cells that can stimulate an immune response against tumor cells.
material entity;influenza nasal unspecified formulation;
material entity;Carcinoembryonic Antigen Peptide 1-6D Virus-Like Replicon Particles Vaccine;A cancer vaccine, consisting of alphavirus vector-derived virus-like replicon particles expressing the 9-amino-acid carcinoembryonic antigen peptide (CAP) 1-6D, with potential antineoplastic activity. Vaccination with this agent may elicit a cytotoxic T lymphocyte (CTL) immune response against CEA-expressing tumor cells.
material entity;Carcinoembryonic Antigen Peptide 1-6D Vaccine;9-residue human leukocyte antigen (HLA)-restricted fragment of carcinoembryonic antigen (CEA). Vaccination with carcinoembryonic antigen peptide 1-6D, which has the amino acid sequence YLSGANLNL, may elicit a cytotoxic T lymphocyte (CTL) immune response against tumors expressing CEA.
material entity;HPV unspecified formulation;
material entity;CAP-3 (CEA Peptide 9-mer) Vaccine;
material entity;Poliomyelitis Virus Type 1 (Sabin Strain (Ls-C, 2ab)) Live Attenuated Oral Vaccine;
material entity;Human poliovirus 160 BAU/ML;
material entity;0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Prefilled Syringe;
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection [Adacel];
material entity;0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Injection;
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection;
material entity;0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Injection [Menactra];
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection [Quadracel];
material entity;0.5 ML meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection;
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection [Boostrix];
material entity;0.5 ML meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Prefilled Syringe;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5;
material entity;0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML Injection;
material entity;Flucelvax Quadrivalent 2020-2021 vaccine;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution;
material entity;0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML Injection [Attenuvax];
material entity;Flucelvax Quadrivalent 2021-2022 vaccine;
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection;
material entity;0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 25000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injection;
material entity;Flucelvax Quadrivalent 2022-2023 vaccine;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5 by Sanofi;
material entity;0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML / varicella-zoster virus vaccine live (Oka-Merck) strain 20000 UNT/ML Injection;
material entity;FluLaval 2010-2011 Formula vaccine;
material entity;Flulaval 2011-2012 Formula vaccine;
material entity;0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Prefilled Syringe;
material entity;Flulaval 2012-2013 Formula vaccine;
material entity;Flulaval 2013-2014 Formula vaccine;
material entity;Novel influenza-H1N1-09 injectable;
material entity;Novel Influenza-H1N1-09 live virus for nasal administration;
material entity;Dendritic Cell-Autologous Lung Tumor Vaccine;A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells. The dendritic cells are transduced with the gene encoding an antigen specific to the patient's cancer and then returned to the patient. In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen. Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy.
material entity;Meningococcal MCV4 unspecified conjugate formulation(groups A C Y and W-135);
material entity;Dendritic Cell Tumor Cell Lysate Vaccine;A vaccine composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response.
material entity;Fluarix Quadrivalent 2019-2020 vaccine;
material entity;Novel influenza-H1N1-09 all formulations;
material entity;Cytokine-Induced Killer Cells Vaccine;A preparation of autologous lymphocytes with potential immunopotentiating and antineoplastic activities. Cytokine-induced killer (CIK) cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T lymphocytes, generated ex-vivo by incubation of peripheral blood lymphocytes (PBLs) with anti-CD3 monoclonal antibody, interleukin (IL)-2, IL-1, and interferon gamma (IFN-gamma) and then expanded. When reintroduced back to patients after autologous stem cell transplantation, CIK cells may recognize and kill tumor cells associated with minimal residual disease (MRD). CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells.
material entity;Fluarix Quadrivalent 2020-2021 vaccine;
material entity;meningococcal vaccine of unknown formulation and unknown serogroups;
material entity;Cyclin B1 Peptide-pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with cyclin B1 peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, cyclin B1 peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and anti-cyclin B1 antibody responses against cyclin B1-expressing cancer cells, resulting in tumor cell lysis. Cyclin B1, a key regulator of the cell cycle and cell division, is overexpressed in a variety of cancer cells.
material entity;meningococcal polysaccharide (groups A C Y W-135) tetanus toxoid conjugate vaccine 0.5mL dose preservative free;
material entity;CTP-37-DT Vaccine;A vaccine composed of synthetic peptides derived from beta-human chorionic gonadotropin (hCG) conjugated to diphtheria toxoid. Vaccination with this peptide may elicit the host immune response against hCG-producing cancer cells.
material entity;meningococcal B unspecified formulation;
material entity;Bcr-Abl (b3a2)-derived peptide vaccine;A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.
material entity;meningococcal C conjugate vaccine;
material entity;CMVpp65/gB Plasmid Vaccine ASP0113;A poloxamer-formulated, bivalent DNA vaccine containing two plasmids encoding both the human cytomegaloviral (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with potential immunostimulatory properties. Upon intramuscular injection of CMVpp65/gB plasmid vaccine ASP0113, the expressed proteins may activate the immune system to mount both cellular and humoral immune responses against CMV-positive cells. This results in cell lysis of CMV-infected cells and prevents both viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients exposed to infected donor cells or tissues in transplant recipients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants. The poloxamer-based delivery system enhances DNA delivery.
material entity;meningococcal AC polysaccharide vaccine (non-US);
material entity;CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the human cytomegalovirus (CMV) phosphoprotein pp65, with potential immunostimulatory and antineoplastic activities. Upon administration, the CMV pp65 peptide-pulsed autologous DC vaccine exposes the immune system to the CMV pp65 peptide, which may result in a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to cell lysis. The CMV pp65 protein, also called the 65 kDa lower matrix phosphoprotein, is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types, such as glioblastoma
material entity;meningococcal ACWY vaccine unspecified formulation;
material entity;Chimeric Ad11p/Ad3 Oncolytic Virus Vaccine;A complex, replication-selective, E1B and partial E3 gene deleted, adenovirus type 11p (Ad11p)/Ad3 chimeric oncolytic virus with potential antineoplastic activity. Upon intralesional injection of enadenotucirev, the adenovirus selectively and rapidly replicates in cancer cells. however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation in host cells, which promotes viral replication. Deletion of E1B prevents replication in normal, healthy cells that express wild-type p53. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of the E3 gene, which encodes the adenovirus death protein, enhances the safety profile of the administered adenovirus.
material entity;CEA/Tetanus Toxoid T Helper Epitope Fusion Protein-Expressing DNA Plasmid Vaccine;A plasmid vaccine encoding wild type human carcinoembryonic antigen (CEA) fused to a tetanus toxoid T helper epitope, with potential antineoplastic activity. Upon vaccination and subsequent intradermal electroporation, CEA/tetanus toxoid T helper epitope fusion protein-expressing DNA plasmid vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA, a tumor associated antigen, is overexpressed in a variety of cancer cell types. The tetanus toxoid helper peptide epitope, obtained from the bacterial Clostridium tetani toxoid, binds to class II MHC molecules and increases the helper T-cell response thereby inducing an increased and long-term immune response.
material entity;Poliomyelitis Virus Type 2 (Sabin Strain (P712, Ch, 2ab)) Live Attenuated Oral Vaccine 100000 UNT;
material entity;poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution;
material entity;0.5 ML Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Prefilled Syringe;
material entity;poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML [Poliovaccine Ssi];
material entity;0.5 ML Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Prefilled Syringe [Prevnar];
material entity;Poliomyelitis Virus Type 2 (Sabin Strain (P712, Ch, 2ab)) Live Attenuated Oral Vaccine;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe [Ipol];
material entity;poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution [Poliovaccine Ssi];
material entity;0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Prefilled Syringe;
material entity;poliomyelitis virus type 1 brunhilde / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Solution;
material entity;0.5 ML Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Prefilled Syringe;
material entity;Fluarix Quadrivalent 2021-2022 vaccine;
material entity;poliomyelitis virus type 1 brunhilde;
material entity;0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe;
material entity;Fluarix Quadrivalent 2022-2023 vaccine;
material entity;poliomyelitis virus type 1 brunhilde 80 UNT/ML;
material entity;0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML Injection [Menquadfi];
material entity;Flublok Quadrivalent 2019-2020 vaccine;
material entity;poliomyelitis virus type 1 brunhilde / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Solution [Poliovaccine Ssi];
material entity;0.5 ML Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML Injection;
material entity;Flublok Quadrivalent 2020-2021 vaccine;
material entity;0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Prefilled Syringe [Menactra];
material entity;Flublok Quadrivalent 2021-2022 vaccine;
material entity;0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML Injection;
material entity;Flublok Quadrivalent 2022-2023 vaccine;
material entity;Poliomyelitis Virus Type 1 (Sabin Strain (Ls-C, 2ab)) Live Attenuated Oral Vaccine 1000000 UNT;
material entity;Flucelvax 2012-2013 Formula vaccine;
material entity;Flucelvax 2013-2014 Formula vaccine;
material entity;hepatitis A vaccine adult dosage;
material entity;Haemophilus influenzae type b vaccine PRP-D conjugate;
material entity;autologous dendritic cell vaccine loaded with personalized peptide vaccine (pep-dc vaccine);A cancer vaccine made of dendritic cells (DCs) loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide for patients with advanced or recurrent metastatic NSCLC.
material entity;Hep A live attenuated-IM;
material entity;autologous CMV-pp65-flLAMP mRNA loaded dendritic cell vaccine;A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein. UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. The vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a powerful adjuvant capable of stimulating macrophage function, inducing proliferation and maturation of DCs, and is able to enhance T-lymphocyte stimulatory function. The vaccine can be used in combination with monoclonal antibodies, such as basiliximab, that can block tumor growth in different ways, as well as temozolomide, and radiation therpay. The combination of treatments may kill more tumor cells.
material entity;diphtheria antitoxin;
material entity;autologous cancer testis antigen specific dendritic cell vaccine;A cancer vaccine that uses autologous cancer testis (CT) antigen specific dendritic cell (DC) preceded by decitabine as a demethylating chemotherapy for patients with high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma. The mature DC is pulsed with overlapping peptides mixes derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3.
material entity;Haemophilus influenzae type b vaccine conjugate unspecified formulation;
material entity;autologous CLL tumor cell vaccine;A cancer vaccine that consists of of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. The CD8+ T cells can react against CLL-associated antigens. Autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
material entity;cholera BivWC;
material entity;autolgous DC vaccine pulsed with autologous tumor homogenate for metastatic rcc;A cancer vaccine that uses dendritic cells pulsed with autologous tumor homogenate in combination With High Dose-IL2 and immunomodulating radiotherapy for patients with Metastatic RCC.
material entity;cholera live attenuated;
material entity;Canarypox-hIL-12 Melanoma Vaccine;A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis.
material entity;Fluad 2020-2021 vaccine;
material entity;botulinum antitoxin;
material entity;rMVA-PSA/PSMA/TRICOM vaccine;A cancer vaccine consisting of recombinant modified vaccinia Ankara (rMVA) encoding the prostate specific antigen (PSA), the prostate-specific membrane antigen (PSMA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Vaccination with PSA/PSMA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells over-expressing PSA or PSMA.
material entity;IreA;
material entity;cholera vaccine unspecified formulation;
material entity;Brain Tumor Initiating Cell Vaccine;A cell-based cancer vaccine comprised of brain tumor initiating cells (BTICs), with potential immunostimulating and antineoplastic activity. BITCs are from the glioblastoma multiforme (GBM) cell line GBM-6 and contain glioma stem-like cell-associated antigens. Upon administration, the BITC vaccine may stimulate a specific anti-tumoral cytotoxic T-lymphocyte (CTL) response against brain tumor cancer cells and brain tumor stem like cells, resulting in tumor cell lysis. BITC have unique antigenicity and have the ability to self-renew. vaccination against BITC antigens may kill these cells and may prevent tumor recurrences.
material entity;IutA;
material entity;Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine;A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation.
material entity;GNA1030;
material entity;adenovirus vaccine unspecified formulation;
material entity;Berzofsky Ras/P53 Peptide Vaccine;A synthetic vaccine combining the peptide antigens of two proteins, ras oncoprotein and tumor suppressor p53
material entity;Hma;
material entity;C0393;
material entity;FimH;
material entity;IroN from Escherichia coli;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluarix 2011-2012 Formula];
material entity;Fluarix Quad 2014-2015 Formula vaccine;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Agriflu 2010-2011 Formula];
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula];
material entity;GNA1870;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluvirin 2010-2011 Formula];
material entity;GNA2091;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Afluria 2010-2011 Formula];
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula];
material entity;NadA;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluarix 2010-2011 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML Prefilled Syringe;
material entity;Fluad Quadrivalent 2020-2021 vaccine;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2012-2013 Formula];
material entity;Fluad Quadrivalent 2021-2022 vaccine;
material entity;Fluad Quadrivalent 2022-2023 vaccine;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2014-2015 Formula];
material entity;Fluarix 2010-2011 Formula vaccine;
material entity;Fluarix 2011-2012 Formula vaccine;
material entity;Fluarix 2012-2013 Formula vaccine;
material entity;Fluarix 2013-2014 Formula vaccine;
material entity;Fluarix 2014-2015 Formula vaccine;
material entity;herpes simplex virus type 2 vaccine;
generically dependent continuant;Historical record of a typhus vaccination;
material entity;CAP-2 (CEA Peptide 9-mer) Vaccine;
material entity;hepatitis C vaccine;
material entity;Bcl-Xl 42-CAF09b vaccine;A cancer vaccine made up of Bcl-xl 42 and the adjuvant CAF09b for patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases. B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases, Bcl-xl 42 is a peptide fragment of the full protein and can lead to the death of cancer cells. CAF09b improves the activation of the immune system.
material entity;hepatitis E vaccine;
material entity;BC-819 vaccine;A cancer vaccine made with BC-819 (also known as DTA-H19), which is a double-stranded DNA plasmid, 4,560 base pairs (bp) in length, carrying the gene for the Diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter. The DT-A chain expression is triggered by the presence of H19 transcription factors that are only up-regulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell, enabling highly targeted cancer treatment. It is used in combination with intravenously administered gemcitabine for patients with Locally Advanced Pancreatic Adenocarcinoma. The activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells.
material entity;hepatitis B vaccine adolescent/high risk infant dosage;
material entity;B7.1/​IL-2 leukaemia cell vaccine;A cancer vaccine containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein. It uses B7.1 (CD80)/IL-2 immune gene therapy for high risk MDS RAEB-2 and acute myeloid leukaemia (AML) patients who are unsuitable for an allogeneic haematological stem cell transplant.
material entity;hepatitis B vaccine unspecified formulation;
material entity;autologous, dnp-modified ovarian cancer vaccine;A cancer vaccine made from the patient's own tumor tissue may stimulate an immune response against the patient's tumor cells. O-Vax nay induce a DTH response to autologous, DNP-modified ovarian cancer cells. The vaccine includes DNP-modified autologous ovarian tumor cells followed by cyclophosphamide then weekly doses of DNP-modified autologous ovarian tumor cells mixed with Bacillus of Calmette and Guérin (BCG).
material entity;hepatitis A vaccine unspecified formulation;
material entity;autologous tumor cell lysate vaccine;A cancer vaccine made from the patient's cancer cells that may make the body build an immune response and kill their tumor cells. The autologous tumor cell vaccine will be given together with adjuvant interferon gamma or sargramostim (GM-CSF) in patients with advanced cancer (breast, lung, prostate, colorectal, sarcoma, renal, melanoma). The vaccine uses irradiated autologous tumor cells and tumor lysate.
material entity;IpaD;
material entity;Hepatitis B vaccine (recombinant) 3-antigen Al(OH)3 adjuvanted;
material entity;autologous total tumor mrna and CMV-pp65-flLAMP mRNA loaded liposome vaccine;A cancer vaccine consisting of total tumor RNA (TTRNA) derived and amplified from autologous tumor cells and mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein. UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), formulated in DOTAP lipid particles, with potential immunostimulatory and antineoplastic activities. he autologous total tumor mRNA and CMV-pp65-flLAMP mRNA loaded liposome vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs). This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these tumor antigens. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine is used to treat patients with Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM). The vaccine is also used for for the treatment of early melanoma recurrence following adjuvant Anti-PD-1 antibody therapy.
material entity;IroN from Salmonella spp.;
material entity;hepatitis A vaccine pediatric dosage unspecified formulation;
material entity;autologous oxidized ovarian tumor cell lysate vaccine;A cancer vaccine that is composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. The autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response. Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally.
material entity;IpaB;
material entity;hepatitis A vaccine pediatric/adolescent dosage 3 dose schedule;
material entity;autologous neuroblastoma cell vaccine;A cancer vaccine that uses autologous neuroblastoma cells, irradiated and genetically modified by adenoviral vectors to secrete interleukin-2 (IL-2) for patients with high-risk neuroblastoma. The adenoviral vector are used to transduce the cells ex-vivo, patients are not treated with the viral vector.
material entity;IpaC;
material entity;autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine;A cancer vaccine that encodes macrophage inflammatory protein 3 alpha (MIP3a)-fused lymphoma idiotype in single chain format for patients with atients with Asymptomatic Phase Lymphoplasmacytic Lymphoma.
material entity;GroEL from Salmonella spp.;
material entity;SopB;
material entity;Agriflu 2012-2013 Formula vaccine;
material entity;Fluad 2019-2020 vaccine;
material entity;0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Prefilled Syringe;
material entity;0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Injection;
material entity;Spa32;
material entity;0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe;
material entity;ECSE P3-0034;
material entity;0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Injection;
material entity;C4424;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula];
material entity;C3389;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula];
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluvirin 2011-2012 Formula];
material entity;Afluria 2012-2013 Formula vaccine;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe;
material entity;Afluria 2013-2014 Formula vaccine;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Afluria 2011-2012 Formula];
material entity;Afluria 2014-2015 Formula vaccine;
material entity;0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe;
material entity;Afluria Quadrivalent 2019-2020 vaccine;
material entity;Afluria Quadrivalent 2020-2021 vaccine;
material entity;Afluria Quadrivalent 2021-2022 vaccine;
material entity;Afluria Quadrivalent 2022-2023 vaccine;
material entity;Agriflu 2010-2011 Formula vaccine;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 1000000000 UNT/ML;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Injectable Suspension;
material entity;Typhoid Vaccine Live Ty21a Extended Release Oral Capsule;
material entity;Typhoid Vaccine Live Ty21a Oral Capsule;
material entity;Typhoid Vaccine Live Ty21a Oral Powder;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension;
material entity;SARS-COV-2 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine Product (Comirnaty Bivalent) Pfizer-BioNTech;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Intramuscular Solution;
material entity;Typhoid Vaccine Live Ty21a 10000000000 UNT Oral Powder [Vivotif];
material entity;SARS-COV-2 (COVID-19) vaccine UNSPECIFIED;
material entity;Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine;A cancer vaccine consisting of a proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family. it plays a significant role in the pathogenesis of some breast cancers
material entity;SARS-COV-2 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine (Spikevax Bivalent) Moderna;
material entity;Mammaglobin-A DNA Vaccine;A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers.
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free pediatric 25 mcg/0.25 mL dose;
material entity;hTERT/Survivin/CMV Multipeptide Vaccine;
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free pediatric 50 mcg/0.5 mL dose;
material entity;HER2-pulsed Autologous Type-1 Polarized Dendritic Cell Vaccine;A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers.
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 30 mcg/0.3mL dose tris-sucrose formulation;
material entity;Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH Conjugate Vaccine;A multivalent vaccine againt breast cancer that comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32(aa), TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens.
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 50 mcg/0.5 mL dose;
material entity;ICT-121 Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells. its overexpression is correlated with increased resistance to chemotherapy.
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 3 mcg/0.2mL dose tris-sucrose formulation;
material entity;Fas-Chimera Transgene-expressing Endothelial Tumor Cell-targeting Adenovector VB-111 Vaccine;
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 30 mcg/0.3mL dose;
material entity;EGFRvIII Peptide Vaccine;An antineoplastic vaccine directed against a peptide found in the epidermal growth factor receptor class III variant (EGFRvIII), a constitutively activated mutant of the wild-type tyrosine kinase. This protein variant is present in a substantial proportion of malignant gliomas and other human cancers.
material entity;SARS-COV-2 COVID-19 Non-US Vaccine Specific Product Unknown;
material entity;SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention);
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Priorix-Tetra];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Vaxelis];
material entity;poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection [Vaxelis];
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix];
material entity;poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Typhim V];
material entity;poliomyelitis virus type 1 brunhilde / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett);
material entity;1.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B];
material entity;Typhoid Vaccine Live Ty21a Delayed Release Oral Capsule [Vivotif Berna];
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett);
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection;
material entity;poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML;
material entity;1 ML rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML Injection [Imovax];
material entity;poliovirus vaccine inactivated, type 2 (MEF-1) 100000 CELLS;
material entity;1.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe;
material entity;poliovirus vaccine inactivated, type 3 (Saukett) 300000 CELLS;
material entity;1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injection;
material entity;poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML;
material entity;1 ML rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML Injection;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Daptacel];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 25 by Glaxosmithkline;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML [Typherix];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 25;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Tripedia];
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML [Typhim V];
material entity;Typhoid Vaccine Live Ty21a Extended Release Oral Capsule [Vivotif];
material entity;Typhoid Vaccine Live Ty21a Oral Capsule [Typhoral L];
material entity;Typhoid Vaccine Live Ty21a Oral Capsule [Vivotif Berna];
material entity;Typhoid Vaccine Live Ty21a Oral Capsule [Vivotif];
material entity;Tick-borne encephalitis vaccine (non-US);
material entity;Tick-borne encephalitis vaccine inactivated preservative free 0.25mL dose;
material entity;tetanus toxoid not adsorbed;
material entity;tetanus toxoid unspecified formulation;
material entity;SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA) CanSino Biological Inc./Beijing Institute of Biotechnology;
material entity;SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light);
material entity;SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology Chinese Academy of Sciences);
material entity;SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Zifivax);
material entity;Tick-borne encephalitis vaccine unspecified;
material entity;Typhoid conjugate vaccine (non-US);
material entity;Tick-borne encephalitis vaccine inactivated preservative free 0.5mL dose;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 20 by Glaxosmithkline;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 100;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [ACEL-IMUNE];
material entity;Typhoid Vaccine Live Ty21a Oral Powder [Vivotif];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 10 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Certiva];
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension [Hepatyrix];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 20;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection [Quadracel];
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Intramuscular Solution [Typhim V];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 100 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Quadracel];
material entity;Typhoid Vaccine Live Ty21a 10000000000 UNT;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Injectable Suspension Box of 1;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 10;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injectable Suspension [Pediarix];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;Flumist 2014-2015 Formula vaccine;
material entity;rheumatic fever vaccine;
material entity;FluMist Quadrivalent 2019-2020 vaccine;
material entity;Flumist Quadrivalent 2020-2021 vaccine;
material entity;respiratory syncytial virus monoclonal antibody (motavizumab) intramuscular;
material entity;DNA Vector pPRA-PSM Vaccine;A cancer vaccine consisting of a DNA plasmid encoding epitopes of the human preferential antigen of melanoma (PRAME) and the prostate specific membrane antigen (PSMA) with potential immunostimulating activity. Upon direct administration of this vaccine into lymph nodes, peptides expressed by DNA plasmid vector pPRA-PSM may activate the immune system, resulting in a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing cells. PRAME and PSMA are tumor associated antigens upregulated in a number of cancer cell types. As part of the MKC1106-PP regimen exploiting the 'prime-boost strategy', this plasmid is responsible for priming the immune response and is used in conjunction with a peptide vaccine consisting of PRAME and PSMA that boosts the immune system against PRAME- and PSMA-expressing tumor cells.
material entity;FluMist Quadrivalent 2021-2022 vaccine;
material entity;respiratory syncytial virus monoclonal antibody (palivizumab) intramuscular;
material entity;DNA Vaccine VB10.16;A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, the DNA vaccine VB10.16 expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer.
material entity;FluMist Quadrivalent 2022-2023 vaccine;
material entity;rabies vaccine for intradermal injection;
material entity;DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112;A DNA-based combination immunotherapeutic, INO-3112, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone.
material entity;rabies vaccine unspecified formulation;
material entity;DNA Plasmid Encoding Interleukin-12 INO-9012 Vaccine;A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of DNA plasmid encoding interleukin-12 INO-9012, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.
material entity;pneumococcal conjugate vaccine 10 valent;
material entity;Dinitrophenyl-Modified Autologous Renal Cell Carcinoma Tumor cell Vaccine;A cancer vaccine consisting of autologous renal cell carcinoma (RCC) tumor cells modified with the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of DNP-modified autologous renal cell carcinoma tumor cell vaccine may induce a cytotoxic T-lymphocyte (CTL) response against renal cell carcinoma tumor cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens.
material entity;Pneumococcal Conjugate unspecified formulation;
material entity;Dendritic Cell-targeting Lentiviral Vector ID-LV305 Vaccine;An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.
material entity;Pneumococcal conjugate vaccine 15-valent (PCV15) polysaccharide CRM197 conjugate adjuvant preservative free;
material entity;Dendritic Cell-Recombinant Prostate-Specific Membrane Antigen Vaccine;A vaccine comprised of autologous dendritic cells pulsed with a recombinant prostate specific membrane antigen.
material entity;Pneumococcal conjugate vaccine 20-valent (PCV20) polysaccharide CRM197 conjugate adjuvant preservative free;
material entity;Dendritic Cell-MART-1 Peptide Vaccine;A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of MART-1 (melanoma antigen recognized by T-cells), an antigen expressed by melanoma cells. When the altered dendritic cells are returned to the patient, they stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing MART-1.
material entity;Dendritic Cell-gp100-MART-1 Antigen Vaccine;An autologous dendritic cells vaccine with antineoplastic property. Dendritic cells harvested from cancer patients are pulsed with human gp100 melanoma antigen and MART-1 (melanoma antigen recognized by T-cells) antigen. both antigens are up-regulated in melanomas. Vaccination with this vaccine may elicit the host immune response against MART-1 or gp100 expressing cells.
material entity;Novel influenza-H1N1-09 preservative-free injectable;
material entity;Dendritic Cell-CEA Peptide Vaccine;A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of carcinoembryonic antigen (CEA), a tumor-associated antigen expressed by a wide range of cancers. When the altered dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing CEA.
material entity;Falimarev vaccine;A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML;
material entity;0.7 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022];
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 1000000 CELLS / poliovirus vaccine inactivated, type 2 (MEF-1) 100000 CELLS / poliovirus vaccine inactivated, type 3 (Saukett) 300000 CELLS Injectable Suspension [Polio Sabin-Rit Multi];
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML Injectable Suspension;
material entity;0.7 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML [Polio Sabin-S];
material entity;0.7 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021];
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 1000000 CELLS;
material entity;0.7 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe;
material entity;Fluvirin 2010-2011 Formula vaccine;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injection;
material entity;0.7 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022-2023];
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 1000000 CELLS / poliovirus vaccine inactivated, type 2 (MEF-1) 100000 CELLS / poliovirus vaccine inactivated, type 3 (Saukett) 300000 CELLS Injectable Suspension;
material entity;0.7 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 1000000 CELLS / poliovirus vaccine inactivated, type 2 (MEF-1) 100000 CELLS / poliovirus vaccine inactivated, type 3 (Saukett) 300000 CELLS [Polio Sabin-Rit Multi];
material entity;0.7 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;Typhoid Vaccine Live Ty21a 10000000000 UNT [Vivotif];
material entity;0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML [Hepatyrix];
material entity;0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection;
material entity;Poliomyelitis Virus Type 3 (Sabin Strain (Leon 12a1b)) Live Attenuated Oral Vaccine 600000 UNT;
material entity;Poliomyelitis Virus Type 3 (Sabin Strain (Leon 12a1b)) Live Attenuated Oral Vaccine;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;1 ML hepatitis B surface antigen vaccine 0.04 MG/ML Injection [Recombivax];
material entity;Flulaval 2014-2015 Formula vaccine;
material entity;Flulaval Quad 2013-2014 Formula vaccine;
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent preservative free 3 mcg/0.2 mL dose tris-sucrose formulation;
material entity;Flulaval Quad 2014-2015 Formula vaccine;
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 10 mcg/0.2mL dose tris-sucrose formulation;
material entity;IDH1R132H Mutation-targeting IDH1 Peptide Vaccine;
material entity;Flulaval Quadrivalent 2019-2020 vaccine;
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 30 mcg/0.3 mL dose tris-sucrose formulation;
material entity;HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine;
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 50 mcg/0.5 mL or 25 mcg/0.25 mL dose;
material entity;Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701;A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis.
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 10 mcg/0.2 mL dose;
material entity;Glioma-Associated Antigen Peptide-Pulsed Autologous Dendritic Cell Vaccine;A cancer vaccine comprised of autologous dendritic cells pulsed with synthetic glioma-associated antigen (GAA) peptides with potential antineoplastic activity. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against GAA peptide-expressing glioma cells, resulting in tumor cell lysis.
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 10 mcg/0.2 mL dose tris-sucrose formulation;
material entity;Fowlpox-NY-ESO-1 Vaccine;A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.
material entity;SARS-COV-2 (COVID-19) vaccine D614 prefusion spike recombinant protein subunit (CoV2 preS dTM) AS03 adjuvant added preservative free 10mcg/0.5mL dose;
material entity;gp96-secreting Allogeneic Bladder Cancer Cell Vaccine HS-410;An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of the gp96-Ig-secreting allogeneic bladder cancer cell vaccine HS-410, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells.
material entity;SARS-COV-2 (COVID-19) vaccine D614 prefusion spike recombinant protein subunit (CoV2 preS dTM) AS03 adjuvant added preservative free 5mcg/0.5mL dose;
material entity;Emepepimut-S Vaccine;A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells. (NCIT C2195).
material entity;rotavirus vaccine unspecified formulation;
material entity;HPV-6-targeting Immunotherapeutic Vaccine INO-3106;A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies.
material entity;rotavirus live tetravalent vaccine;
material entity;hVEGF26-104/RFASE Peptide Vaccine;A therapeutic cancer vaccine containing a truncated, synthetic peptide mimic of the human angiogenic activator vascular endothelial growth factor (VEGF), consisting of 79 amino acids (amino acids 26-104 of VEGF), and emulsified in the immunoadjuvant RFASE, with potential immunostimulatory and antitumor activities. Upon intramuscular vaccination, the hVEGF26-104 moiety of hVEGF26-104/RFASE acts as an antigen and induces an immune response against VEGF, which results in anti-VEGF antibody binding to and neutralization of endogenous VEGF. This prevents the binding of endogenous VEGF to the VEGF receptor (VEGFR) and blocks VEGFR-mediated endothelial cell signaling, resulting in an inhibition of both angiogenesis and tumor cell proliferation. VEGF plays a key role in angiogenesis, tumor cell proliferation and invasion. RFASE, which belongs to the group of sulpholipopolysaccharides (SLPs), is a synthetic polysaccharide covalently coupled to lipid groups and sulphate groups, and is able to induce a strong humoral immune response upon antigen administration.
material entity;Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from malignant glioma cells with potential immunostimulatory and antineoplastic activities. Upon administration, malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine exposes the immune system to undefined malignant glioma tumor-associated antigens (TAAs), which may result in anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against glioma cells and glioma cell lysis.
material entity;SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 100 mcg/0.5mL dose or 50 mcg/0.25mL dose;
material entity;IDH1R132H-Specific Peptide Vaccine PEPIDH1M;A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection Box of 10;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection;
material entity;1 ML hepatitis B surface antigen vaccine 0.0025 MG/ML Prefilled Syringe [Recombivax];
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5;
material entity;1 ML hepatitis B surface antigen vaccine 0.04 MG/ML Injection;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution [Ipol];
material entity;1 ML hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection [Prehevbrio];
material entity;Flulaval Quadrivalent 2020-2021 vaccine;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution;
material entity;1 ML hepatitis B surface antigen vaccine 0.0025 MG/ML Prefilled Syringe;
material entity;Flulaval Quadrivalent 2021-2022 vaccine;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution Box of 10;
material entity;1 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe;
material entity;Flulaval Quadrivalent 2022-2023 vaccine;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution [Ipol] Box of 10;
material entity;1 ML hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection;
material entity;FluMist 2010-2011 Formula vaccine;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML Injectable Suspension [Polio Sabin-S];
material entity;1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe;
material entity;Flumist 2011-2012 Formula vaccine;
material entity;1 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection;
material entity;Flumist 2012-2013 Formula vaccine;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML [Ipol];
material entity;0.7 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML;
material entity;1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.025 MG/ML Prefilled Syringe;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution Box of 20;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution Box of 10;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix];
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] by Glaxosmithkline;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 20 by Glaxosmithkline;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 20;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 10 by Glaxosmithkline;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 10;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix];
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix] Box of 1 by Glaxosmithkline;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix] Box of 1;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe;
material entity;0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe Box of 1;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 20;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix];
material entity;typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 50;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 20 by Glaxosmithkline;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 10;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 20;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 50;
material entity;Typhoid Vaccine Live Ty21a 10000000000 UNT Delayed Release Oral Capsule;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 10;
material entity;Venezuelan equine encephalitis inactivated;
material entity;Vaccinia smallpox monkeypox vaccine live attenuated preservative free subcutaneous or intradermal injection;
material entity;Venezuelan equine encephalitis vaccine unspecified formulation;
material entity;typhoid vaccine unspecified formulation;
material entity;vaccinia (smallpox) vaccine diluted;
material entity;typhoid vaccine parenteral acetone-killed dried (U.S. military);
material entity;typhoid vaccine parenteral other than acetone-killed dried;
material entity;Typhoid Vaccine Live Ty21a 10000000000 UNT Delayed Release Oral Capsule [Vivotif];
material entity;LMQ vaccine adjuvant;A combination vaccine adjuvant that is liposome-based adjuvant of a synthetic TLR agonist and saponin induced a Th1-biased immune response.
material entity;CPDI-02 vaccine adjuvant;A vaccine adjuvant that is a peptide which is able to induce Th1/Th2/Th17 immune responses through the mechanism of selectively activates C5aR1 on mononuclear phagocytes vs neutrophils.
material entity;dengue fever vaccine;
material entity;Ebola unspecified;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 10 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated 0.936 MG/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 20;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 10;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 100 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 100;
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension [Pediarix];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 40 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML Injectable Solution;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 40;
material entity;acellular pertussis vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML Injectable Suspension;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra];
material entity;acellular pertussis vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 15 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 18 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Solution [Typherix];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 50;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Prefilled Syringe [Typherix];
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension Box of 1 by Sanofi;
material entity;Typhoid Vaccine Live Ty21a 10000000000 UNT Oral Powder;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension Box of 1;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution;
material entity;Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 1000000000 UNT/ML Injectable Suspension;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Typhim V];
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix];
material entity;2G053 vaccine adjuvant;A vaccine adjuvant, a small molecule TLR agonist that drives a mixed Th1/Th2 response.
material entity;GLA-Alum vaccine adjuvant;A combination vaccine adjuvant of a synthetic TLR agonist and aluminum salt.
material entity;ALFQ vaccine adjuvant;A combination vaccine adjuvant that is an AS01-mimic, liposomal adjuvant of a TLR4 agonist and saponin.
material entity;2G023A vaccine adjuvant;A vaccine adjuvant which is a small molecule TLR agonist that drives a mixed Th1/Th2 response.
material entity;CpG55.2 vaccine adjuvant;A vaccine adjuvant with a Toll-like receptor 9 (TLR9)-active oligonucleotide that is able to induce Th1/Th2 immune responses.
material entity;SMNP vaccine adjuvant;A combination vaccine adjuvant that includes AS01-mimic, Immune Stimulating Complex (ISCOM) with a TLR4 agonist.
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 25;
material entity;0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 20;
material entity;1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 40;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] by Glaxosmithkline;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 50 by Glaxosmithkline;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 100;
material entity;0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 10;
material entity;ORF;
material entity;B. abortus strain 19 L7/L12;
material entity;MOMP from C. psittaci;
material entity;ABRA;
material entity;VP35 from Marburg Virus;
material entity;TRAP from P. falciparum;
material entity;AMA1 from P. falciparum 3D7;
material entity;OmpA from C. psittaci;
material entity;LolC/E;
material entity;PotF;
material entity;StxB2;
material entity;Omp31;
material entity;Ag85A;
material entity;Env Gp160;
material entity;P1 from Coxiella burnetii;
material entity;NP from Zaire ebolavirus;
material entity;HspB from Coxiella burnetii;
material entity;H3L;
material entity;GP from Marburg Virus;
material entity;NP Marburgvirus - Ravn;
material entity;BoNT/C(Hc50);
material entity;HAVgp2;
material entity;BoNT/A1 from C. botulinum A str. Hall;
material entity;BoNT/B;
material entity;TTC;
material entity;Bfr from B. abortus S19;
material entity;RplL;
material entity;FHc;
material entity;BotA;
material entity;BoNT/A1 from C. botulinum;
material entity;Hap from H. influenzae;
material entity;P4 from Haemophilus influenzae;
material entity;Pal;
material entity;Omp26;
material entity;EsxA;
material entity;NP;
material entity;YscF from Y. pestis CO92;
material entity;GP from Zaire ebolavirus;
material entity;GP from Sudan ebolavirus;
material entity;Autologous Tumor Cell Vaccine;A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro. the vaccine is then administered to the individual from whom the tumor cells were isolated. Typically combined with an adjuvant immunostimulant, an autologous cell vaccine may elicit a cytotoxic T-lymphocytic immune response to cell surface-expressed tumor-associated antigens (TAAs), resulting in tumor cell death.
material entity;Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine;An autologous chronic lymphocytic leukemia cancer vaccine consisting of patient-specific membrane proteins directly extracted from patient autologous tumor cells and incorporated into liposomes along with Interleukin 2 (IL-2) to produce membrane-patched proteoliposomes, with potential immunostimulating and antineoplastic activities. After subcutaneous injection of the autologous tumor cell proteoliposomes chronic lymphocytic leukemia vaccine, liposomes deliver the encapsulated tumor antigens into the cytosol of antigen presenting cells (APCs). Subsequently, the APCs process the antigens and present antigen-derived peptides to the immune system. This may enhance recognition of tumors by the immune system, and activate both cytotoxic CD8+ T cells and CD4+ helper T cells against tumor cells. IL-2 is incorporated into the vaccine to leverage its ability to expand activated T cells.
material entity;ags-003-bld vaccine;A cancer vaccine composed of autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. The RNA is translated and processed, and BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. The MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. The vaccine can be used in combination with gemcitabine hydrochloride and cisplatin which stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, while the vaccine helps the body build an effective immune response to kill tumor cells. In combination, they may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery in patients with bladder cancer.
material entity;Tig;
material entity;Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine;A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with autologous T cell receptor gamma-chain alternate reading frame protein (TARP) peptide with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous TARP peptide-pulsed dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is commonly expressed in breast and prostate cancer cells.
material entity;Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous sarcoma lysate-pulsed dendritic cell vaccine exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis.
material entity;Autologous Renal Cell Carcinoma Tumor Lysate-Pulsed Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with renal cell carcinoma (RCC) tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous renal cell carcinoma tumor lysate-dendritic cell vaccine may stimulate anti-tumoral cytotoxic T-lymphocyte (CTL) and antibody responses against RCC tumor cells expressing RCC TAAs, resulting in RCC tumor cell lysis.
material entity;Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101;A genetically-modified autologous dendritic cell-based vaccine expressing a drug-inducible costimulatory CD40 receptor (iCD40) with potential immunomodulating and antineoplastic activities. Autologous dendritic cells (DCs) are genetically modified to express the iCD40 receptor and are pulsed with the tumor antigen prostate-specific membrane antigen (PSMA). Upon intradermal administration, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizer agent AP1903 is administered. AP1903 binds to and activates iCD40 receptors presented on DC surfaces, thus activating the DCs and stimulating a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. This delayed activation strategy optimizes DC accumulation in local draining lymph nodes prior to DC activation. iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to a drug-binding domain.
material entity;Autologous Pluripotent ALDHbr Stem Cells ALD-451 Vaccine;A specific population of autologous, pluripotent bone marrow derived cells that express high levels of the cytosolic enzyme aldehyde dehydrogenase (ALDH) with potential protective and neuro-cognition improving activity. Expression of high levels of ALDH is an indicator of the biological activity in heterogenous early stage stem cells. Upon intravenous administration, these ALDH bright cells may protect normal cells and may repair damaged cells. These cells may also protect brain cells from damage and may improve neurocognition.
material entity;Autologous Ovarian Tumor Cell Lysate-Pulsed Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous, irradiated dendritic cells (DCs) pulsed with ovarian tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian tumor cells expressing the patients ovarian tumor cell-specific TAAs, which may result in ovarian tumor cell lysis.
material entity;RpsL;
material entity;Autologous OFA-iLRP RNA-Transfected Dendritic Cell Vaccine;A cancer vaccine consisting of autologous, mature monocyte-derived dendritic cells (DCs) transfected with oncofetal antigen immature laminin receptor protein (OFA-iLRP) RNA, with potential antineoplastic activity. Upon administration, DCs in the OFA-iLRP RNA-transfected autologous dendritic cell vaccine express, process, and present OFA-iLRP to the host immune system, which may mount a potent cytotoxic T-cell (CTL) response against OFA-iLRP-expressing tumor cells. As a highly conserved protein, OFA-iLRP is preferentially expressed in fetal tissues and in many types of cancer, including hematopoietic malignancies, but is not detectable in normal differentiated adult cells.
material entity;Iss;
material entity;GP from Lake Victoria marburgvirus;
material entity;Bp26;
material entity;IalB;
material entity;Bfr from B. melitensis biovar Abortus 2308;
material entity;FyuA;
material entity;Omp25;
material entity;S nucleocapsid protein from Dobrava-Belgrade virus;
material entity;Belagenpumatucel-L Vaccine;A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation. vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.
material entity;Bcl-Xs Adenovirus Vaccine;A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis.
material entity;BCG, Cell Wall Skeleton Vaccine;
material entity;anti-HER2/HER3 dendritic cell vaccine;A cancer vaccine that uses anti-HER2/HER3 dendritic cells in combination with Pembrolizumab in patients with Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC). The dendritic cells boost the immune system, and the Pembrolizumab enhances cancer immune responses, in combination they may shrink the cancer.
material entity;allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine;A cancer vaccine that consists of an allogeneic cell line that has a high expression level of melanoma molecules (HLA A2/4-1BB Ligand), and has been genetically modified to induce a strong immune response. Stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease.
material entity;allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine;A cancer vaccine made of allogeneic pancreatic tumor cells are transfected with a GM-CSF gene to treat ocally advanced, unresectable or metastatic pancreatic adenocarcinoma. It may be in combination with Ipilimumab (an antibody that blocks negative signals to T cells).
material entity;alk peptide vaccine;A cancer vaccine that restored priming of Anaplastic lymphoma kinase (ALK)-specific CD8+ T cells, eradicated lung tumors in combination with ALK tyrosine kinase inhibitors (TKIs) and prevented metastatic dissemination of tumors to the brain. Human ALK peptides are displayed by HLA-A*02:01 and HLA-B*07:02 molecules. The peptides are immunogenic and recognized by CD8+ T cells from individuals with non-small cell lung cancer (NSCLC).
material entity;Autologous-Cell Melanoma Vaccine;An autologous-cell vaccine for melanoma.
material entity;GNA1946;
material entity;Autologous-Cell Leukemia Vaccine;An autologous therapeutic vaccine for the treatment of acute myelogenous leukemia. This vaccine is prepared from blood samples of patients following their first relapse. Tumor cells extracted from blood sample are modified with hapten, a process that makes the cells appear foreign to the patient's body and results in stimulating immune response against the cancer.
material entity;GNA1220;
material entity;Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine;A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with specific tumor-associated peptide antigens (TAPA), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous TAPA-pulsed DC vaccine exposes the immune system to the specific TAPAs, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the TAPA-expressing cancer cells. This leads to cancer cell lysis. This vaccine is specific towards peptides derived from the following proteins: sperm autoantigenic protein 17 (SP17), ropporin, A-kinase anchor protein 4 (AKAP4), pituitary tumor-transforming 1 (PTTG1) and SPANX family member B (SPANX-B).
material entity;Omp19;
material entity;Omp16;
material entity;GNA33;
material entity;NspA from N. meningitidis MC58;
material entity;GNA1162;
material entity;GNA992 (hsf);
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2013-2014 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2012-2013 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2012-2013 Formula];
material entity;DnaK from Brucella;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2012-2013 Formula];
material entity;SurA;
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2012-2013 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2012-2013 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Agriflu 2012-2013 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2014-2015 Formula];
material entity;0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe;
material entity;Gag protein from SIV-mnd 2;
material entity;GNA2001;
material entity;B. melitensis M5 P39;
material entity;CS1;
material entity;FlaA from C. jejuni NCTC 11168;
material entity;Tir;
material entity;FimH from E. coli UTI89;
material entity;GNA2132;
material entity;EltB;
material entity;Eae;
material entity;Autologous NSCLC DNA-Transfected Semi-Allogeneic Fibroblasts MRC-5 Vaccine;A vaccine consisting of irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous non-small cell lung cancer (NSCLC)-derived DNA with potential immunostimulatory and antineoplastic activities. Upon administration, autologous NSCLC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses NSCLC tumor-associated antigens (TAAs) in addition to MHC class I-determinants and the co-stimulatory molecule B7.1, which may induce a cytotoxic T-lymphocyte (CTL) response against NSCLC cells. The MRC-5 cell line is a human diploid lung fibroblast cell line extablished in 1966.
material entity;Autologous Melanoma Lysate/NY-ESO-1-pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.
material entity;Autologous Melanoma Lysate/KLH-Pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and conjugated to the immunostimulant Keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy.
material entity;MSP1 from P. falciparum;
material entity;Autologous Melanoma Lysate-Pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis.
material entity;RESA;
material entity;Autologous Lymphoma Cell/Autologous Dendritic Cell Electrofusion Hybrid Vaccine;A cell-based cancer vaccine consisting of hybrid cells created by electrofusing autologous dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis.
material entity;Autologous Lymphoma Cell/Allogeneic Dendritic Cell Electrofusion Hybrid Vaccine;A cell-based cancer vaccine consisting of hybrid cells created by electrofusing allogeneic dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis.
material entity;Autologous Lymphoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine;A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous lymphoma cells with potential immunostimulatory and antineoplastic activities. Upon intranodal administration, autologous lymphoma cell lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against lymphoma cells, which may result in lymphoma cell lysis.
material entity;Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine;A cancer vaccine composed of tumor-specific idiotype determinants derived from an individual's tumor cells which are conjugated to keyhole limpet hemocyanin, an immunostimulant carrier protein. When injected into the individual from whom the tumor cells were isolated, this vaccine may stimulate an antitumoral cytotoxic T-lymphocytic immune response.
material entity;Autologous IL-2-expressing B-CLL Vaccine;A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced ex vivo with an adenoviral vector encoding the gene for the human cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous IL-2-expressing B-CLL vaccine expresses IL-2, stimulates natural killer (NK) cells, and may enhance the cytotoxic T-lymphocyte (CTL) immune response against the patient's B-CLL cells.
material entity;FbpA;
material entity;PepA;
material entity;SecA2;
material entity;EsxB;
material entity;CjaA from C. jejuni;
material entity;Pvs25;
material entity;PPE18;
material entity;CjaA from C. jejuni RM 1221;
material entity;Autologous NSCLC Peptide-specific Dendritic Cell Vaccine;A personalized cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with immunogenic peptides derived from autologous non-small cell lung cancer (NSCLC) cells, with potential immunostimulating and antineoplastic activities. During leukapheresis, mature DCs are loaded with autologous NSCLC-derived peptides. Upon re-administration of the NSCLC peptide-specific DC vaccine, the immune system is exposed to NSCLC-associated antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against NSCLC cells and tumor cell lysis.
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Gerke;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Emra-Med;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Orifarm Leverkus;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Aca Mueller;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Axicorp;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Cc;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Kohlpharma;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Mevita;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Mtk;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Aca Mueller;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Emra-Med;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Gerke;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Kohlpharma;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Mevita;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Mtk;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Orifarm Leverkus;
material entity;P. aeruginosa DNA Vaccine encoding OprF;
material entity;B. burgdorferi DbpA and OspA Protein Vaccine;
material entity;Salmonella DNA vaccine encoding SopB Protein;
material entity;Salmonella IroN Protein Vaccine;
material entity;Measles Virus vaccine VEE/SIN-H;
material entity;S. typimurium Vi4072;
material entity;T. annulata Tams1 Protein Vaccine;
material entity;Leishmania vaccine using recombinant L. tarentolae strain expressing A2 antigen;
material entity;S. typhi GroEL Protein Vaccine;
material entity;S. typhi DnaJ Protein Vaccine;
material entity;P. aeruginosa OprI Protein Vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 2;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 100;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Kohlpharma;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 50;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 2;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 100;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Gerke;
material entity;L. amazonensis CP Protein Vaccine;
material entity;P. falciparum DNA Vaccine encoding EBA-175;
material entity;P. falciparum CS expressed in irradiated P. berghei as Vaccine;
material entity;VVr expressing L. infantum P36/LACK;
material entity;pcDNA3-LiP0;
material entity;S. aureus DNA Vaccine encoding PBP2a Protein;
material entity;P. aeruginosa PcrV Protein Vaccine;
material entity;P. chabaudi AMA1 Protein Vaccine;
material entity;P. falciparum LSA-3 Protein Vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Emra-Med;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by GSK;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Aca Mueller;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Axicorp;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Cc;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Glaxosmithkline;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Glaxosmithkline;
material entity;mRNA-1273.214;A SARS-CoV-2 bivalent mRNA vaccine by Moderna that contains the mRNA-1273 COVID-19 vaccine and the mRNA-1273.214 Omicron booster
material entity;mRNA-1273.529;A SARS-CoV-2 mRNA booster vaccine by Moderna that targets the Omicron variant
material entity;GEMCOVAC-19;A SARS-CoV-2 mRNA vaccine by Gennova Biopharmaceuticals Limited
material entity;LVRNA009;A SARS-CoV-2 mRNA vaccine by AIM Vaccine Co., Ltd.
material entity;UNAIR Inactivated COVID-19 Vaccine;A SARS-CoV-2 inactivated vaccine developed by Airlangga University
material entity;V-01-351/V-01D Bivalence Vaccine;A SARS-CoV-2 protein subunit vaccine manufactured by Livzon Pharmaceutical Group Inc.
material entity;SYS6006;A SARS-CoV-2 mRNA vaccine by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typhim VI] Box of 10;
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typhim VI];
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection Box of 10;
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection;
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution Box of 1;
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typherix] Box of 10;
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typherix];
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution;
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1;
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI];
material entity;MicroCrystalline Tyrosine vaccine adjuvant;
material entity;Omicron COVID-19 inactivated vaccine by China National Biotec Group Company Limited;A SARS-CoV-2 inactivated vaccine developed by China National Biotec Group Company Limited
material entity;authorized COVID-19 virus-like particle vaccine;
material entity;colorectal cancer vaccine;A cancer vaccine that is used against colorectal cancer
material entity;lymphoma vaccine;A cancer vaccine that is used against lymphoma.
material entity;GLA-AF vaccine adjuvant;
material entity;prostate cancer vaccine;A cancer vaccine that is used against prostate cancer.
material entity;SLA-LSQ vaccine adjuvant;
material entity;SLA-SE vaccine adjuvant;
material entity;GLA-SE vaccine adjuvant;
material entity;GLA-SLQ vaccine adjuvant;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;Salmonella Typhi Inactivated Antigen 8 X;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Revaxis];
material entity;Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule Box of 3;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis];
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension Box of 5;
material entity;Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule [Vivotif Berna];
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension;
material entity;Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule;
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection Box of 10;
material entity;Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule [Vivotif Berna] Box of 3 by Paxvax Berna;
material entity;diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection;
material entity;Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule [Vivotif Berna] Box of 3;
material entity;diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML [Tri-Immunol Im];
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution [Typherix];
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution;
material entity;diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im];
material entity;Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS [Vivotif Berna];
material entity;diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution;
material entity;Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS;
material entity;brain cancer vaccine;A cancer vaccine that is used against brain canceer.
material entity;liver cancer vaccine;A cancer vaccine that is used against liver canceer.
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 UNT Injectable Solution by Iaf Biovac;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension Box of 1;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension [RUDIVAX] Box of 1 by Sanofi;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 UNT Injectable Solution;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 UNT;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID [RUDIVAX];
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension [RUDIVAX] Box of 1;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension [RUDIVAX];
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID;
material entity;VXS-1223;A SARS-CoV-2 protein subunit vaccine manufactured by Vaxxas Pty Ltd
material entity;AAHI-SC2;A SARS-CoV-2 RNA vaccine by ImmunityBio, Inc.
material entity;RQ3013;A SARS-CoV-2 RNA vaccine by Walvax Biotechnology and Shanghai RNACure Biopharma
material entity;RVM-V001;A SARS-CoV-2 RNA vaccine by RVAC Medicines
material entity;Prime-2-CoV-Beta;A SARS-CoV-2 protein subunit vaccine manufactured by Speransa Therapeutics.
material entity;RH109;A SARS-CoV-2 RNA vaccine by Wuhan Recogen Biotechnology Co., Ltd.
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML;
material entity;Salmonella Typhi Inactivated Antigen 0.025 MG/ML;
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML [Typhim VI];
material entity;Salmonella Typhi Inactivated Antigen 0.05 MG/ML [Typherix];
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Suspension [RUDIVAX];
material entity;Salmonella Typhi Inactivated Antigen;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection [Ervevax];
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Suspension;
material entity;Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution [Ervevax];
material entity;EG-COVID;A SARS-CoV-2 RNA vaccine by EyeGene Inc.
material entity;mRNA-1073;A SARS-CoV-2 mRNA vaccine by Moderna that combines the mRNA-1273 COVID-19 vaccine and the mRNA-1010 influenza vaccine.
material entity;Betuvax-CoV2;A SARS-CoV-2 protein subunit vaccine manufactured by Human Stem Cell Institute
material entity;COVID-19 mRNA vaccine by CanSino Biologics;A SARS-CoV-2 RNA vaccine by CanSino Biologics Inc.
material entity;Irradiated MBGV antigen;
material entity;Diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation;
material entity;Recombinant VEE Replicons expressing MBGV NP;
material entity;Q-VAX;
material entity;DTP-Haemophilus influenzae type b conjugate and hepatitis B vaccine;
material entity;Marburg virus glycoprotein expressed by baculovirus recombinants;
material entity;influenza, injectable, Madin Darby Canine Kidney, quadrivalent with preservative;
material entity;M. tuberculosis DNA vaccine pAK4-sod;
material entity;varicella zoster immune globulin (Investigational New Drug);
material entity;BCG auxotroph expressing HIV-1 clade immunogen;
material entity;Diphtheria-Pertussis-Tetanus-Haemophilus B-Hepatitis B vaccine,(Pentavalent);
material entity;Recombinant VEE Replicons expressing MBGV GP;
material entity;vaccinia immune globulin passive vaccine;
material entity;deltaphoP/Q S. typhimurium strains expressing PEB1-ss;
material entity;varicella zoster immune globulin;
material entity;Rho(D) Unspecified formulation;
material entity;tetanus immune globulin;
material entity;Avirulent Salmonella vaccine strain carrying C. jejuni cjaA gene;
material entity;Chimaeric HBV core particles carrying Puumala virus nucleocapsid protein fragments;
material entity;Rho(D) Immune globulin- IV or IM passive vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Aca Mueller;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Eurim-Pharm;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injectable Solution;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML [Hiberix];
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain Injectable Suspension [Stamaril];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Mtk;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection [Hiberix];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50 by Merck;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.015 MG / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.25 MG [PedvaxHIB];
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injectable Suspension;
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML;
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Emra-Med;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.015 MG / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.25 MG Injectable Solution;
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension Box of 1;
material entity;yellow fever virus strain 17D-204 live antigen Injectable Suspension [Arilvax];
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injectable Solution [PedvaxHIB];
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injectable Solution;
material entity;Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension;
material entity;CVD 909;
material entity;Heterologous MARV Protein VLP;
material entity;tetanus and diphtheria toxoids, not adsorbed, for adult use;
material entity;CVD 915;
material entity;trivalent poliovirus vaccine, live, oral;A poliovirus vaccine that contains three types of poliovirus and uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
material entity;Coxevac;
material entity;tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid);
material entity;P1-HspB (fusion of protein 1 and heat-shock protein B);
material entity;tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified;
material entity;VSV-based vaccine expressing MBGV GP;
material entity;Non-US bivalent oral polio vaccine (types 1 and 3);A poliovirus vaccine that contains two types of poliovirus and uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
material entity;Chlamyvax FQ;
material entity;Non-US monovalent oral polio vaccine, unspecified formulation;A poliovirus vaccine that contains one type of poliovirus and uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
material entity;Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus;
material entity;influenza, injectable, quadrivalent, preservative free, pediatric;
material entity;influenza, intradermal, quadrivalent, preservative free, injectable;
material entity;Chloroform-methanol residue (CMR);
material entity;DTP-Haemophilus influenzae type b conjugate vaccine;
material entity;M-44;
material entity;influenza, high-dose seasonal, quadrivalent, 0.7ml dose, preservative free;A viral vaccine that protects against infection with influenza virus and with high-dose seasonal,quadrivalent,0.7ml dose,preservative free.
material entity;0.5 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Organon;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Sanofi;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Solution [HibTITER];
material entity;acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Sanofi;
material entity;meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y / tetanus toxoid vaccine, inactivated Injectable Solution [Nimenrix];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Eurim-Pharm;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection [ActHIB];
material entity;acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Gerke;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection;
material entity;acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Merck;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Solution [Hiberix];
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Mtk;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Solution;
material entity;acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Axicorp;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injectable Solution;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Cc;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML [ActHIB];
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML;
material entity;Live attenuated vaccine TC-83;
material entity;SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose;A Comirnaty COVID-19 mRNA vaccine utilizing Lipid Nanoparticle-Self-amplifying RNA technology against the original strain of COVID-19 without preservative ,which is produced by Pfizer (PF) with a dose of 30 mcg/0.3 mL.
material entity;VEE virus complex-specific monoclonal antibody;
material entity;BCG expressing MSP;
material entity;SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech;A Comirnaty COVID-19 mRNA vaccine produced by Pfizer-BioNTech,which is a bivalent vaccine that is effective against the original strain of COVID-19 as well as the Omicron BA.1 variant.A non-US vaccine product.
material entity;MVA85A prime and BCG boost;
material entity;SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation;A Comirnaty COVID-19 mRNA vaccine utilizes Lipid Nanoparticle-Self-amplifying RNA technology, available as a bivalent boosters against the original strain of COVID-19 as well as the Omicron BA.1 variant produced by Pfizer (PF) with a dose of 30 mcg/0.3 mL to provide enhanced protection.
material entity;MBP fused on Campylobacter FlaA (MBP-FlaA);
material entity;Inactivated C. jejuni whole-cell (CWC);
material entity;PVSRIPO vaccine vector;A recombinant viral vaccine vector that uses PVSRIPO, a recombinant nonpathogenic polio-rhinovirus chimera. PVSRIPO is an engineerable oncolytic virus whereas its internal ribosomal entry site element can be substituted to demolish its cytopathogenic effect. PVSRIPO has a natural inherent tropism for antigen-presenting cells (including dendritic cells and macrophages) due to the presence of the CD-155 receptor on their cellular surfaces. This enables it of inducing CD8+ T-cell mediate immune responses.
material entity;Truncated Recombinant DoBV Nucleocapsid Proteins (Dob-N rNp);
material entity;Recombinant DOBV nucleocapsid protein (rDOBV N);
material entity;pancreatic cancer vaccine;A cancer vaccine that is used against pancreatic canceer.
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux];
material entity;Salmonella Typhi Inactivated Antigen Injection [Typhim VI];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Td-Impfstoff Merieux];
material entity;Salmonella Typhi Inactivated Antigen Injectable Solution [Typhim VI];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Adt Vaccine];
material entity;Salmonella Typhi Inactivated Antigen Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;Salmonella Typhi Inactivated Antigen Injection [Typherix];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Td-Pur];
material entity;Salmonella Typhi Inactivated Antigen Injection;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;Salmonella Typhi Inactivated Antigen 8 X Oral Tablet Box of 1 by Staufen;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Boostrix];
material entity;Salmonella Typhi Inactivated Antigen 8 X Oral Tablet Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Adt Booster];
material entity;Salmonella Typhi Inactivated Antigen Delayed Release Oral Capsule [Vivotif Berna];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix];
material entity;Salmonella Typhi Inactivated Antigen Delayed Release Oral Capsule;
material entity;Salmonella Typhi Inactivated Antigen 8 X Oral Tablet;
material entity;Recombinant RNA replicons from attenuated VEE virus;
material entity;Mtb72f fusion protein;
material entity;passive vaccine;A vaccine that is made of immune globulin and used to immunize an individual against some disease(s).
material entity;Defective adenovirus expressing VEEV E2 glycoprotein;
material entity;respiratory syncytial virus immune globulin passive vaccine, intravenous;
material entity;Non-typeable H. influenzae dLOS-P6 vaccine;
material entity;Rho(D) Immune globulin - IM;
material entity;Adenovirus vectors expressing Marburg virus glycoprotein;
material entity;immune globulin, unspecified formulation;
material entity;Marburg virus-like particles;
material entity;rabies immune globulin;
material entity;Live attenuated VEE vaccines;
material entity;immune globulin, intramuscular;
material entity;Chimeric SIN/VEE Virus SIN-83;
material entity;immune globulin, intravenous;
material entity;Nontypeable H. influenzae outer membrane recombinant P4 vaccine;
material entity;Hepatitis A immune globulin passive vaccine;Hepatitis A Immune Globulin passive vaccine is a passive vaccine that provides protection against hepatitis A through the passive transfer of an antibody. Hep A, IG provides temporary immunity to the virus for two to three months, if administered prior to exposure or within two weeks after exposure.
material entity;Live attenuated V3526 virus;
material entity;hepatitis B immune globulin passive vaccine;
material entity;anthrax immune globulin passive vaccine;
material entity;cytomegalovirus immune globulin passive vaccine, intravenous;
material entity;Nontypeable H. influenzae Outer Membrane Protein P1 vaccine;
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide Injectable Solution [Menitorix];
material entity;diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution;
material entity;Vaccine, Typh.-Paratyph.A & B;
material entity;diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution;
material entity;Tick-borne encephalitis virus inactivated Injectable Suspension [Ticovac];
material entity;Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide Injectable Solution;
material entity;Vaccine, Typh.-Paratyph.A & B Injectable Solution [Tab Impfstoff];
material entity;diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution;
material entity;Vaccine, Typh.-Paratyph.A & B Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Booster] Box of 5;
material entity;Tick-borne encephalitis virus inactivated;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Booster];
material entity;Salmonella Typhi Inactivated Antigen Oral Tablet;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection Box of 5;
material entity;Tick-borne encephalitis virus inactivated Injectable Suspension [Fsme Immun];
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Vaccine];
material entity;Tick-borne encephalitis virus inactivated Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection;
material entity;Salmonella Typhi Inactivated Antigen Intramuscular Solution [Typherix];
material entity;Salmonella Typhi Inactivated Antigen Intramuscular Solution;
material entity;DNA vaccine encoding ANDV glycoproteins;
material entity;influenza virus DNA vaccine encoding HA of Equine influenza virus H3N8;
material entity;hepatocellular carcinoma vaccine;A cancer vaccine that is developed against hepatocellular carcinoma.
material entity;C. botulinum DNA vaccine pSCARSA/BHc;
material entity;Recombinant baculovirus encoding HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1));
material entity;head and neck cancer vaccine;A cancer vaccine that is developed against head and neck cancer.
material entity;Recombinant vesicular stomatitis virus encoding HA from Influenza A virus (A/WSN/1933(H1N1));
material entity;nasopharyngeal cancer vaccine;A cancer vaccine that is developed against nasopharyngeal cancer.
material entity;N. caninum DNA vaccine encoding NcSAG1 and NcSRS2, combined with recombinant NcSAG1 and NcSRS2 Proteins;
material entity;sarcoma cancer vaccine;A cancer vaccine that is developed against sarcoma cancer.
material entity;P. yoelii DNA vaccine encoding PyHEP17 Protein;
material entity;esophageal cancer vaccine;A cancer vaccine that is developed against esophageal cancer.
material entity;CCPS-P64kR;
material entity;ovarian cancer vaccine;A cancer vaccine that is developed against ovarian cancer.
material entity;N. caninum MIC10 and p24 protein vaccine;
material entity;renal cancer vaccine;A cancer vaccine that is developed against renal cancer.
material entity;mesothelioma cancer vaccine;A cancer vaccine that is developed against mesothelioma cancer.
material entity;myeloma cancer vaccine;A cancer vaccine that is developed against myeloma cancer.
material entity;Rotavirus VP4/VP7 Protein Vaccine;
material entity;Rotavirus VP2/VP 6 Protein Vaccine;
material entity;gastric cancer vaccine;A cancer vaccine that is developed against gastric cancer
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Kohlpharma;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Cc;
material entity;tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Europharma;
material entity;tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Gerke;
material entity;tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [Tetanol];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Orifarm Leverkus;
material entity;tetanus toxoid vaccine, inactivated 12.5 LFU/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1;
material entity;tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Europharma;
material entity;tetanus toxoid vaccine, inactivated 10 UNT/ML [Tetanol];
material entity;AdH5-FluA NP;
material entity;influenza virus DNA vaccine encoding M1 from influenza A virus (A/chicken/Henan/12/2004(H5N1));
material entity;L. donovani LD31 Protein Vaccine;
material entity;BacHA derived from Influenza A virus (A/Indonesia/CDC669/2006(H5N1));
material entity;pCAGGoptiHA;
material entity;L. major H1 Protein Vaccine;
material entity;Flagellin-based HA globular head fusion vaccine using HA protein from Influenza A virus (A/Viet Nam/1203/2004(H5N1));
material entity;Recombinant vaccinia virus encoding HA from Influenza B virus (Strain B/England/222/82);
material entity;L. major DNA Vaccine encoding SP;
material entity;L. major DNA Vaccine encoding LACKp24, TSA, LmSTI1 and CPa;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tet Aktiv] Box of 100;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tet Aktiv];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML [T-Immun Immuno];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 10;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 1;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML [T Immun];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Sanofi;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML [Tetanol];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 150 UNT/ML [Tet Aktiv];
material entity;Recombinant vaccinia A27L, D8L, and B5R Proteins with adjuvant MPL-TDM;
material entity;DNA vaccine co-expressing A85A and caspase-3;
material entity;Plasmodium knowlesi vaccine;a malaria vaccine that protects against malaria caused by Plasmodium knowlesi.
material entity;Shiga Toxin 2 B Subunit Vaccine;
material entity;Giardia spp. protein;
material entity;E. coli heat-labile enterotoxin B-subunit (LB-T) Vaccine;
material entity;PFS25/28 in Matrix M;
material entity;Live, Attenuated Rifampin-Resistant Rough Mutants of Brucella melitensis;
material entity;NanoAlum vaccine adjuvant;A vaccine adjuvant that reformulates Alhydrogel as a stable nanoparticle with the anionic polymer polyacrylic acid (PAA), leading to the induction of structure-dependent TH1 response.
material entity;Brucella ovis Microparticle Subunit Vaccine;
material entity;Nanostructured Lipid Carrier (NLC) vaccine adjuvant;A vaccine adjuvant is a small molecule adjuvant that induces Th1-based immune response and is designed for use with self-amplifying RNA antigens.
material entity;Zoosaloral H.;
material entity;CAF09b vaccine adjuvant;A vaccine adjuvant that is a lipid-based vaccine adjuvent based on cationic surfactant dimethyl-dioctadecyl ammonium (DDA) combined with C-type lectin agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I:C. CAF09b is able to induce CD8+ T-cell response.
material entity;Broilact Chick Salmonella vaccine;
material entity;3M-052-AF vaccine adjuvant;A vaccine adjuvant that is a lipid-based nanosuspension of a synthetic TLR7/8 ligand that facilitates adsorption to aluminum oxyhydroxide via the structural properties of the helper lipid employed.
material entity;S. flexneri 2a strain CVD 1205;
material entity;MAS-1 vaccine adjuvant;A vaccine adjuvant 30:70 (w/w) Water-in-Oil (W/O) emulsion that stimulates a mixed Th1/Th2 response.
material entity;Salmonella vacT;
material entity;ProLNG-S vaccine adjuvant;A vaccine adjuvant that induces CD8 T cells and provides innate protection.
material entity;Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine.;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 50 by Eurim-Pharm;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [T Polio Adsorbed];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 50 by Sanofi;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [T Polio Adsorbed];
material entity;diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10 by Eurim-Pharm;
material entity;Neisseria meningitidis polysaccharide group Y tetanus toxoid conjugate;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10 by Sanofi;
material entity;meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension [Neisvac C];
material entity;Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 25 by Eurim-Pharm;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 25 by Sanofi;
material entity;Neisseria meningitidis polysaccharide group Y tetanus toxoid conjugate 0.01 MG/ML;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;meningococcal group C polysaccharide / tetanus toxoid vaccine, inactivated Injectable Suspension [Neisvac C];
material entity;Neisseria meningitidis 0.25 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 20 by Eurim-Pharm;
material entity;meningococcal group C polysaccharide / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;Haemophilus capsular oligosaccharide 0.03 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1 by Eurim-Pharm;
material entity;meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension;
material entity;Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1 by Sanofi;
material entity;meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML [Neisvac C];
material entity;Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML;
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML;
material entity;RASV expressing Y. pestis Psn;
material entity;Pseudorabies recombinant vector vaccine encoding gp50 and gII protein;
material entity;cervical cancer vaccine;A cancer vaccine that is developed against cervical cancer.
material entity;Pseduorabies Subunit Glycoprotein C Vaccine;
material entity;colon cancer vaccine;A cancer vaccine that is developed against colon cancer.
material entity;Y. pestis DNA vaccine encoding dfF1 Protein;
material entity;lung cancer vaccine;A cancer vaccine that is developed against lung cancer.
material entity;Y. pestis YscF Protein Vaccine;
material entity;leukemia cancer vaccine;A cancer vaccine that is developed against leukemia.
material entity;vP869;
material entity;breast cancer vaccine;A cancer vaccine that is developed against breast cancer.
material entity;Yellow Fever NS1 Protein Vaccine;
material entity;bladder cancer vaccine;A cancer vaccine that is developed against bladder cancer.
material entity;TBEV DNA vaccine encoding E protein;
material entity;SLA-AF vaccine adjuvant;A vaccine adjuvant is an oil-in-water emulsion that induces Th1-based immune response.
material entity;Varicella Subunit Vaccine encoding gI and gE glycoproteins;
material entity;CAF01 vaccine adjuvant;A vaccine adjuvant is a gadoteridol-loaded cationic adjuvant formulation 01 that induced a Th1/Th17 type of immune response.
material entity;Plasmodium chabaudi vaccine;a malaria vaccine that protects against malaria caused by Plasmodium chabaudi.
material entity;Killed Vaccinia Virus with Adjuvant NanoEmulsion;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Emra-Med;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 50 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution;
material entity;Human Papillomavirus 16/18 L1 virus vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Aca Mueller;
material entity;tetanus toxoid vaccine, inactivated 1.5 UNT/ML [Tetanol];
material entity;diphtheria toxoid vaccine, inactivated Injectable Solution;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Axicorp;
material entity;tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Cc;
material entity;tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution [Tetanol];
material entity;Human Papillomavirus 6/11/16/18 L1 virus vaccine;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 0.04 MG/ML;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Mtk;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed];
material entity;diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10 by Kohlpharma;
material entity;tetanus toxoid vaccine, inactivated 1.5 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 50 by Eurim-Pharm;
material entity;tetanus toxoid vaccine, inactivated 0.088 MG/ML;
material entity;diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML;
material entity;poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 50 by Sanofi;
material entity;ACAM1000;
material entity;V-LSGPC;
material entity;ML29;
material entity;YFV17D/LAS-GPC;
material entity;VSV[Delta]G/LVGPC;
material entity;V-LSG + V-LSN;
material entity;V-LSG1 + V-LSG2;
material entity;HC of type C and D;
material entity;V-LSG/N;
material entity;LC16m8;
material entity;CCSV;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10 by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 25 by Sanofi;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 5;
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Booster];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Kohlpharma;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Boehringer Ingelheim;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Vaccine];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Sanofi;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Booster] Box of 5;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3;
material entity;diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection Box of 10;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Adt Vaccine];
material entity;10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Adt Booster];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Cc;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Emra-Med;
material entity;MVA-BN;
material entity;Smallpox DNA Vaccine;
material entity;pABFHc2;
material entity;LC16m0;
material entity;NYVAC;
material entity;MVA;
material entity;IMV-EEV;
material entity;dVV-L;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Aca Mueller;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Gerke;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Mtk;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Aca Mueller;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Axicorp;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Cc;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Emra-Med;
material entity;S. pneumoniae GtS Protein Vaccine;
material entity;L. donovani HASPB1 Protein Vaccine;
material entity;MIPSCo-mRNA-RBD-1;A SARS-CoV-2 RNA vaccine by the University of Melbourne.
material entity;S. pneumoniae 6PGD Protein Vaccine;
material entity;Osvid-19;A SARS-CoV-2 inactivated vaccine developed by Osve Pharmaceutical Company.
material entity;N. meningitidis TbpA Protein Vaccine;
material entity;EgyVax;A SARS-CoV-2 inactivated vaccine developed by Eva Pharma.
material entity;S. pneumoniae PhpA-79 Protein Vaccine;
material entity;GRT-R912;A SARS-CoV-2 RNA vaccine by Gritstone Bio, Inc.
material entity;L. infantum SMT Protein Vaccine;
material entity;Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1;A synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine
material entity;P. berghei MSP1 Protein Vaccine;
material entity;DoCo-Pro-RBD-1 + MF59;A SARS-CoV-2 protein subunit vaccine manufactured by the University of Melbourne.
material entity;H. pylori HspA Protein Vaccine;
material entity;ACM-001;A SARS-CoV-2 protein subunit vaccine manufactured by ACM Biolabs.
material entity;Almansour-001;A SARS-CoV-2 DNA vaccine developed by Imam Abdulrahman Bin Faisal University.
material entity;H. pylori GltA Protein Vaccine;
material entity;LQ vaccine adjuvant;
material entity;H. pylori HspB Protein Vaccine;
material entity;ABO1009-DP;A SARS-CoV-2 RNA vaccine by Suzhou Abogen Biosciences Co., Ltd.
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Repevax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 100;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Dt Wellcovax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 250;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Td Impfstoff];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 25;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Diftavax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 250;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Di Tetasorbat];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 3;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Dt Vaccinol];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Dt Impfstoff];
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxin Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Boostrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 100;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxin Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 12.5 LFU/ML / tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension;
material entity;V-LSN;
material entity;VRP;
material entity;PBT;
material entity;BoNT/A(Hc);
material entity;BoNT/B(Hc);
material entity;BoNT/F(Hc);
material entity;S. pneumoniae RASV synthesizing PsaA;
material entity;S. pneumoniae PiaA Protein Vaccine;
material entity;GP and NP;
material entity;Ebola virus recombinant adenovirus vector vaccine ADV-GP/NP;
material entity;V-LSG;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Repevax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 25;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 100;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Boostrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 25;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Adt Vaccine];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 250;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Dt Rix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 3;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Diftavax];
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Td-Impfstoff Merieux];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 3;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Diftavax];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Adt Booster];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Td-Pur];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Mtk;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 50 by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Mtk;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Sanofi;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Emra-Med;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Cc;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Gerke;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone 2013-2014 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluvirin 2013-2014 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluvirin 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Flucelvax 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Flulaval 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluarix 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Flucelvax 2013-2014 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Afluria 2014-2015 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluarix 2013-2014 Formula];
material entity;Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 700000 PFU/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula];
material entity;Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 698000 PFU/ML;
material entity;Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 805000 PFU/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Flulaval Quad 2013-2014 Formula];
material entity;Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 2290000 UNT;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone Quadrivalent 2014-2015 Formula];
material entity;Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 770000 PFU/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2013-2014 Formula];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Vaxigrip Junior];
material entity;Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 2220000 UNT;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flulaval Quad 2013-2014 Formula];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [VAXIGRIP];
material entity;Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 2040000 UNT;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2013-2014 Formula];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.0075 MG/ML;
material entity;Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 772000 PFU/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.00752 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluzone Intradermal 2012-2013 Formula];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.009 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension;
material entity;Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 980000 PFU/ML;
material entity;Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 2840000 UNT;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluzone High-Dose 2012-2013 Formula];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Agrippal];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Fluarix];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Fluvax];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [INFLUVAC];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Intanza];
role;TLR3 receptor role;A role of a material entity that binds to TLR3 and activates the receptor for pathogen recognition and activation of innate immunity.
role;TLR8 receptor role;A role of a material entity that binds to TLR8 and activates the receptor for pathogen recognition and activation of innate immunity.
material entity;2F52 vaccine adjuvant;
role;TLR4 receptor role;A role of a material entity that binds to TLR4 and activates the receptor for pathogen recognition and activation of innate immunity.
material entity;Alhydroxiquim-II vaccine adjuvant;
material entity;Adjuplex+GLA vaccine adjuvant;
material entity;AlT3 vaccine adjuvant;
material entity;Japanese encephalitis virus Prefilled Syringe [Ixiaro];
material entity;Japanese encephalitis virus Prefilled Syringe;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluvirin 2013-2014 Formula];
material entity;Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML [Jespect];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluvirin 2014-2015 Formula];
material entity;Japanese encephalitis virus Injection;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flucelvax 2014-2015 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.00752 MG/ML;
material entity;Japanese encephalitis virus Injectable Suspension [Ixiaro];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flulaval 2013-2014 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.009 MG/ML;
material entity;Japanese encephalitis virus Injection [Ixiaro];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluarix 2014-2015 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.015 MG/ML;
material entity;Japanese encephalitis virus Injection [Imojev];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flucelvax 2013-2014 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.09 MG/ML;
material entity;Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 807000 PFU/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Afluria 2014-2015 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 50000000 UNT/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluarix 2013-2014 Formula];
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection;
material entity;Japanese encephalitis virus Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2014-2015 Formula];
material entity;Japanese encephalitis virus Injectable Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Afluria 2013-2014 Formula];
process profile;Th1-biased immune profile;A biased immune profile that is characterized by the presense of T help cells Type 1 T helper (Th1) cells that produce interferon-gamma, interleukin (IL)-2, and tumour necrosis factor (TNF)-beta, which activate macrophages and are responsible for cell-mediated immunity and phagocyte-dependent protective responses.
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [VAXIGRIP];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Live Attenuated, A-California-7-2009 (H1N1) strain Nasal Spray;
role;TLR2 receptor role;A role of a material entity that binds to TLR2 and activates the receptor for pathogen recognition and activation of innate immunity.
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Live Attenuated, A-California-7-2009 (H1N1) strain Nasal Spray [Fluenz];
process profile;immune response profile;
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.0075 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension [Fluvirin 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension [Afluria 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension [Flulaval 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Solution [Flublok 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone Intradermal 2014-2015 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Solution;
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Agrippal];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone High-Dose 2014-2015 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Fluarix];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone Intradermal 2013-2014 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Fluvax];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [INFLUVAC];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone High-Dose 2013-2014 Formula];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Intanza];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Vaxigrip Junior];
material entity;Influenza A virus Injectable Suspension [VAXIGRIP];
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain Injectable Suspension;
material entity;Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain Injectable Suspension [Intanza];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluvirin 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluzone 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluarix 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Flucelvax 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Afluria 2012-2013 Formula];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Xanaflu];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Agriflu 2012-2013 Formula];
material entity;Influenza A virus / Influenza B virus Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Nasal Spray [Flumist 2012-2013 Formula];
material entity;Influenza A virus / Influenza B virus Injectable Suspension [Alpha RIX Tetra];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe;
material entity;Influenza A virus / Influenza B virus Injectable Suspension [INFLUVAC];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension [Fluzone 2012-2013 Formula];
material entity;Influenza A virus / Influenza B virus Injectable Suspension [VAXIGRIP];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Nasal Spray;
material entity;Influenza A virus Injectable Suspension;
material entity;Influenza A virus Injectable Suspension [Alpha RIX Tetra];
material entity;Influenza A virus Injectable Suspension [INFLUVAC];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [VAXIGRIP];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Viroflu];
material entity;S. pneumoniae ClpP protein Vaccine;
material entity;SCTV01C;A SARS-CoV-2 subunit vaccine by Sinocelltech Ltd.
material entity;S. pneumoniae CbpA Protein Vaccine;
material entity;Ad5-triCoV/Mac;A SARS-CoV-2 replication deficient human adenovirus vector vaccine expressing the spike, nucleocapsid and RNA polymerase proteins.
material entity;S. pneumoniae SrtA Protein Vaccine;
material entity;AAV5-RBD-S;A SARS-CoV-2 recombinant viral vector vaccine by Biocad
material entity;S. pneumoniae PspA Protein Vaccine;
material entity;UM-3005 vaccine adjuvant;A vaccine adjuvant that includes UM-3005, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.
material entity;Brucella melitensis omp31 mutant vaccine;
material entity;SII Bivalent;A SARS-CoV-2 bivalent protein subunit vaccine by Novavax containing antigen for both the ancestral strain and B.1.351 (Beta) variant.
material entity;Brucella melitensis omp25 mutant vaccine;
material entity;SII B.1.617.2;A SARS-CoV-2 monovalent protein subunit vaccine by Novavax immunizing against the B.1.617.2 (Delta) variant and containing the Matrix-M1 adjuvant
material entity;BoNT/C;
material entity;ARCT-165;A SARS-CoV-2 RNA vaccine by Arcturus Therapeutics, Inc., named as ARCT-165.
material entity;Pseudorabies recombinant vector vaccine encoding gp50 protein;
material entity;SII B.1.351;A SARS-CoV-2 monovalent protein subunit vaccine by Novavax immunizing against the B.1.351 (Beta) variant and containing the Matrix-M1 adjuvant
material entity;Influenza Virus Fragmented, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / South Australia / 55/2014 Ivr-175 0.03 MG/ML;
material entity;CPDI-01 vaccine adjuvant;
material entity;recombinant viral vector vaccine;A recombiant vector vaccine that is has a viral vector.
material entity;Brucella melitensis bp26 mutant vaccine;
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus B Conjugate Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Hibdt];
material entity;Diphtheria Antitoxin / diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;L1 protein, Human papillomavirus type 11 Vaccine 0.04 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension [Afluria 2012-2013 Formula];
material entity;Influenza Virus Surface Antigen, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / South Australia / 55/2014 Type Wild 0.03 MG/ML;
material entity;Candida albicans extract / diphtheria toxoid vaccine, inactivated / Glycerin / Proteus mirabilis / Purified Protein Derivative of Tuberculin / tetanus toxin Injectable Solution [Multitest Cmi];
material entity;L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Prefilled Syringe [Silgard];
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus B Conjugate Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Injection [Cervarix];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Fluzone 2012-2013 Formula];
material entity;Diphtheria Antitoxin / diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix];
material entity;L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Injection;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension;
material entity;Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;Japanese encephalitis virus vaccine, inactivated Prefilled Syringe [Japanese encephalitis GCVC];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Flulaval 2012-2013 Formula];
material entity;Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Boostrix];
material entity;Japanese encephalitis virus vaccine, inactivated Injection [Je-Vax];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Fluvirin 2012-2013 Formula];
material entity;Candida albicans extract / diphtheria toxoid vaccine, inactivated / Glycerin / Proteus mirabilis / Purified Protein Derivative of Tuberculin / tetanus toxin Injectable Solution;
material entity;L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Injectable Suspension [Gardasil];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Fluarix 2012-2013 Formula];
material entity;Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix];
material entity;L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Flucelvax 2012-2013 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Afluria 2012-2013 Formula];
material entity;Influenza Virus Fragmented, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / Switzerland / 9715293/2013, Nib-88;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Agriflu 2012-2013 Formula];
material entity;Influenza Virus Fragmented, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / Switzerland / 9715293/2013, Nib-88 0.03 MG/ML;
material entity;Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension [Adacel];
material entity;Japanese encephalitis virus vaccine, inactivated Injection [Jespect];
material entity;Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013;
material entity;Japanese encephalitis virus vaccine, inactivated Injection;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2014-2015 Formula];
material entity;Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013 0.0075 MG/ML;
material entity;Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013 0.00752 MG/ML;
material entity;N. caninum NcPDI Protein Vaccine;
material entity;Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013 0.015 MG/ML;
material entity;Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013 0.03 MG/ML;
material entity;Influenza Virus Surface Antigen, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / South Australia / 55/2014 Type Wild;
material entity;influenza virus HA protein vaccine (influenza A virus (A/Yamagata/120/1986(H1N1)));
material entity;Covi Vax;A SARS-CoV-2 inactivated vaccine developed by the National Research Centre of Egypt
material entity;influenza virus DNA vaccine encoding HA from influenza A virus (A/environment/Hong Kong/156/1997(H5N1));
material entity;influenza virus DNA vaccine encoding HA from influenza B virus (B/Ibaraki/2/85);
material entity;ARCT-154;A SARS-CoV-2 RNA vaccine by Arcturus Therapeutics, Inc., named as ARCT-154.
material entity;influenza virus HA protein vaccine (influenza A virus (A/Fukuoka/C29/85(H3N2)));
material entity;LYB001;A COVID-19 virus-like particle vaccine developed by Yantai Patronus Biotech Co., Ltd.
material entity;N. meningitidis NspA Protein Vaccine;
material entity;PIKA Recombinant COVID-19 Vaccine;A SARS-CoV-2 subunit vaccine by Yisheng Biopharma
material entity;N. meningitidis LctP Protein Vaccine;
material entity;COVID-19 DNA vaccine by the University of Hong Kong and Immuno Cure 3 Limited;A SARS-CoV-2 DNA vaccine developed by University of Hong Kong and Immuno Cure 3 Limited
material entity;influenza virus DNA vaccine encoding HA from influenza A virus (A/Hong Kong/1/68(H3N2));
material entity;COVID-19 subunit vaccine by PT Bio Farma;A SARS-CoV-2 subunit vaccine by PT Bio Farma
material entity;N. miningitidis TBP2 Protein Vaccine;
material entity;COVIDITY;A SARS-CoV-2 DNA vaccine developed by Scancell Ltd.
material entity;VB10.2210;A SARS-CoV-2 T-Cell-based DNA vaccine developed by Vaccibody AS
material entity;ChAd-triCoV/Mac;A SARS-CoV-2 replication deficient chimpanzee adenovirus 68 vector vaccine expressing the spike, nucleocapsid and RNA polymerase proteins.
material entity;N. meningitidis ExbB Protein Vaccine;
material entity;N. caninum NcDG1 protein vaccine;
material entity;VB10.2129;A SARS-CoV-2 DNA vaccine developed by Vaccibody AS encoding the receptor-binding domain
material entity;diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection Box of 20;
material entity;Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.015 MG/ML;
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Solution;
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection Box of 10;
material entity;Influenza Virus Fragmented, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / South Australia / 55/2014 Ivr-175;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2012-2013 Formula];
material entity;diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [Revaxis];
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix] Box of 1;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2012-2013 Formula];
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2012-2013 Formula];
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix-Hib];
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2012-2013 Formula];
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix-Hib];
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix] Box of 20;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2012-2013 Formula];
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Act-HIB DTP];
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix] Box of 10;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Agriflu 2012-2013 Formula];
material entity;L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Prefilled Syringe [Cervarix Grk];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension [Fluzone 2012-2013 Formula];
material entity;Influenza B virus vaccine, B-Brisbane-60-2008-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain / Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injection;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe;
material entity;Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.0075 MG/ML;
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Act-HIB DTP];
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML [Cervarix];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension [Flulaval 2012-2013 Formula];
material entity;Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.00752 MG/ML;
material entity;diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension [Fluvirin 2012-2013 Formula];
material entity;Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.009 MG/ML;
material entity;Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.015 MG/ML;
material entity;Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.0075 MG/ML;
material entity;Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.00752 MG/ML;
material entity;Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.009 MG/ML;
material entity;Noora;A SARS-CoV-2 subunit vaccine by Bagheiat-allah University of Medical Sciences
material entity;Baiya SARS-CoV-2 Vax 1;A SARS-CoV-2 subunit vaccine by Baiya Phytopharm Co., Ltd.
process profile;Th1/Th17 mixed immune profile;An immune profile that is characterized by the presense of both Type 1 and Type 17 T helper (Th1 and Th17) cells.
material entity;SCB-2020S;A SARS-CoV-2 subunit vaccine by Clover Biopharmaceuticals AUS Pty Ltd that contains the S protein from the B.1.351 variant.
process profile;Th17 immune profile;An immune profile that is characterized by the presense of T helper 17 cells (Th17) that a subset of pro-inflammatory T helper cells defined by their production of interleukin 17 (IL-17). They are related to T regulatory cells and the signals that cause Th17s to differentiate actually inhibit Treg differentiation.
process profile;Th2-biased immune profile;A baised immune profile that is characterized by the presense of T type 2 Th (Th2) cells that produce IL-4, IL-5, IL-10, and IL-13, which are responsible for strong antibody production, eosinophil activation, and inhibition of several macrophage functions, thus providing phagocyte-independent protective responses.
process profile;Th1/Th2 mixed immune profile;An immune profile that is characterized by the presense of both Type 1 and Type 2 T helper (Th1 and Th2) cells.
material entity;Japanese encephalitis virus vaccine, inactivated 1 UNT Injectable Suspension [Je-Vax];
material entity;Japanese encephalitis virus vaccine, inactivated 1 UNT Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluzone 2014-2015 Formula];
material entity;Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injection [Jespect];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluvirin 2014-2015 Formula];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injection;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluzone 2013-2014 Formula];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Boostrix];
material entity;Japanese encephalitis virus vaccine, inactivated 1 UNT [Je-Vax];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Flulaval 2013-2014 Formula];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;Japanese encephalitis virus vaccine, inactivated 1 UNT;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluvirin 2013-2014 Formula];
material entity;Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Afluria 2013-2014 Formula];
material entity;Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Afluria 2014-2015 Formula];
material entity;Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension Box of 1;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone 2014-2015 Formula];
material entity;Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] Box of 1;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone 2013-2014 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist] Box of 5;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray Box of 5;
material entity;influenza B virus antigen 160000000 /ML;
material entity;CVXGA1;A SARS-CoV-2 recombinant vector vaccine manufactured by CyanVac LLC
material entity;influenza B virus antigen 50000000 /ML;
material entity;AZD2816;A SARS-CoV-2 recombinant vector vaccine by AstraZeneca and Oxford University against variant strain B.1.351
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Boostrix];
material entity;rOv-ASP-1 vaccine adjuvant;A vaccine adjuvant that is a potent adjuvant for antibody and cellular responses to protein, polypeptide and small peptide antigens. rOv-ASP-1 stands for Recombinant Onchocerca volvulus activation-associated secreted protein-1.
material entity;VSA-2 vaccine adjuvant;A vaccine adjuvant that is synthesized by derivatizing a natural Momordica saponin in one step. VSA-2 is chemically stable. VSA-2 is much less toxic than QS-21. VSA-2 is more Th1-biased than QS-21. Momordica saponins are isolated from widely available and sustainable sources.
material entity;VSA-1 vaccine adjuvant;A vaccine adjuvant that is prepared by derivatizing a natural Momordica saponin in one chemical step. VSA-1 is chemically more stable than QS-21. VSA-1 is much less toxic than QS-21. The Momordica saponins are from sustainable sources and widely available.
material entity;authorized COVID-19 DNA vaccine;
material entity;Advax-CpG55.2 vaccine adjuvant;An Advax-CpG vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide CpG55.2.
material entity;COVID-19 subunit vaccine by HIPRA;A SARS-CoV-2 protein subunit vaccine by Laboratorios HIPRA
material entity;AG0302-COVID19;A SARS-CoV-2 DNA vaccine developed by AnGes, named as AG0302-COVID19.
material entity;202-CoV;A SARS-CoV-2 subunit vaccine manufactured by Shanghai Zerun Biotechnology, Walvax Biotechnology, and CEPI
material entity;Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension;
material entity;Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML [Adacel];
material entity;Japanese encephalitis virus vaccine, inactivated Injectable Suspension [Japanese encephalitis GCVC];
material entity;Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML [Tripacel];
material entity;Japanese encephalitis virus vaccine, inactivated Injectable Solution [Ixiaro];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2014-2015 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray;
material entity;Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Tripacel];
material entity;Japanese encephalitis virus vaccine, inactivated Injectable Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2013-2014 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray [FluMist Quadrivalent];
material entity;Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension [Tripacel];
material entity;Japanese encephalitis virus vaccine, inactivated Injectable Suspension [Ixiaro];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2014-2015 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML;
material entity;Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension;
material entity;Japanese encephalitis virus vaccine, inactivated Injectable Solution [Japanese encephalitis GCVC];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2013-2014 Formula];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML [Flumist];
material entity;Bordetella pertussis / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix];
material entity;Japanese encephalitis virus vaccine, inactivated 12 BAU/ML [Ixiaro];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2014-2015 Formula];
material entity;Bordetella pertussis / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;Japanese encephalitis virus vaccine, inactivated 12 BAU/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2013-2014 Formula];
material entity;Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Adacel];
material entity;Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension [Ixiaro];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2014-2015 Formula];
material entity;Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2013-2014 Formula];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2013-2014 Formula];
material entity;Japanese encephalitis virus vaccine, inactivated 1 UNT Injectable Suspension [Je-Vax] by The Res.Found.For Microb.Dis.Osaka University;
material entity;Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.015 MG/ML;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus antigen Nasal Spray;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus antigen Nasal Spray [FluMist Quadrivalent];
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus antigen Nasal Spray [Flumist];
material entity;dmLT vaccine adjuvant;A vaccine adjuvant that includes double mutant of heat-labile E. coli toxin (LT) at R192G/L211A or LT(R192G/L211A)
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML;
material entity;influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML [FluMist Quadrivalent];
material entity;S. aureus FnbA Protein Vaccine;
material entity;L. major DNA Vaccine encoding Gp63;
role;NLRP3 receptor role;A role of a material entity that binds to NLRP3.
material entity;L. major H2B Protein Vaccine;
material entity;PIKA vaccine adjuvant;
material entity;S. aureus CNA Protein Vaccine;
process profile;Th1/Th2/Th17 mixed immune profile;An immune profile that is characterized by the presense of Type 1 Type 2, and Th17 T helper cells.
material entity;S. aureus ClfA Protein Vaccine;
material entity;S. neurona SAG1 Protein Vaccine;
process;therapeutic vaccination;A vaccination process that involves adding a vaccine into a host after a disease has occurred.
material entity;Pseudorabies Subunit gB Protein Vaccine;
material entity;T-vant vaccine adjuvant;A vaccine adjuant that is derived from Salmonella enterica serovar typhimurium and is able to induce Th1/Th2/Th17 immune responses through the mechanism of action of TLR4, inflammasome, and DC activation.
material entity;L. major PSA-2 Protein Vaccine;
material entity;Vaxfectin vaccine adjuvant;A vaccine adjuvant that is equimolar mixture of the cationic lipid GAP-DMORIE [(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-1-propanaminium bromide)] and a neutral colipid DPyPE (1,2-diphytanoyl-sn-glydero-3-phosphoethanolamine).
material entity;Rotavirus VP6 Protein Vaccine;
process;prophylactic vaccination;A vaccination process that involves adding a vaccine into a host prior to disease.
material entity;glycerol vaccine adjuvant;A vaccine adjuvant that includes naturally occurring trivalent alcohol.
material entity;Pam3Cys vaccine adjuvant;A vaccine adjuvant includes three palmitic acid groups that are bound in an ester and amide linkage to a cysteine residue.
material entity;Pseudorabies Subunit gI Protein Vaccine;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 2;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Hibdpt Vaccinol];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML [Rotarix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix] Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Tri-Immunol Im];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Dpt Merieux];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Di Te Tuss Asid];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Hib Dpt Merieux];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Dpt Vaccinol];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Acel Imune];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML [Rotarix];
material entity;S. pyogenes Sib35 Protein Vaccine;
material entity;SQ vaccine adjuvant;
material entity;S. pyogenes SfbI Protein Vaccine;
material entity;M. tuberculosis HBHA Protein Vaccine;
material entity;3M-052-Alum vaccine adjuvant;
material entity;M. tuberculosis DNA Vaccine encoding KatG;
material entity;SWE vaccine adjuvant;
material entity;S. pyogenes Emm1 Protein Vaccine;
material entity;GLA-3M-052-LS vaccine adjuvant;
material entity;S. agalactiae Sip Protein Vaccine;
material entity;3M-052-SE vaccine adjuvant;
material entity;S. pyogenes FBP54 Protein Vaccine;
material entity;BECC470s vaccine adjuvant;
material entity;S. pyogenes FbaA Protein Vaccine;
material entity;TRAC478 vaccine adjuvant;
material entity;Mast cell activator small molecules vaccine adjuvant;
material entity;Precision Vaccines Program (PVP)-037 vaccine adjuvant;
material entity;S. agalactiae Rib Protein Vaccine;
material entity;S. agalactiae BPS Protein Vaccine;
material entity;Mastoparan 7 vaccine adjuvant;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Revaxis];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain Powder for Oral Suspension;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension Box of 1;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20;
material entity;diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Revaxis];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 3;
material entity;diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain Powder for Oral Suspension [Rotarix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe [Infanrix];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension [Rotarix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe [Dtp Rix];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 20;
material entity;diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxin Injectable Suspension [Revaxis];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension [Rotarix] Box of 1 by Glaxosmithkline;
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxin Injectable Suspension;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension [Rotarix] Box of 1;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU [Rotarix];
material entity;1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 3;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU;
material entity;B. burgdorferi OspA Protein Vaccine;
material entity;B. burgdorferi DbpA Protein Vaccine;
material entity;AS01B vaccine adjuvant;A combination vaccine adjuvant includes 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) purified from plant extract Quillaja saponaria Molina, combined in a liposomal formulation consisting of dioleoyl phosphatidylcholine (DOPC) and cholesterol in phosphate-buffered saline solution.
material entity;B. burgdorferi OspB Protein Vaccine;
material entity;AS02A vaccine adjuvant;An AS02 vaccine adjuvant contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL.
material entity;T. pallidum GlpQ Protein Vaccine;
material entity;Adjuvax vaccine adjuvant;A carbohydrate vaccine adjuvant that is a glucan carbohydrate microcapsules with a beta(1-3)/beta(1-6) - linked glucan structure to allow targeting of antigens to macrophages or neutrophils through interactions with the beta-glucan receptor found uniquely on the surface of these cell types. Adjuvax- ligand complexes are formed by physically entrapping or crosslinking the ligand within the beta-glucan.
material entity;L. donovani Beta-tubulin Protein Vaccine;
material entity;Advax-CpG vaccine adjuvant;A vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide (ODN).
material entity;Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88 0.00752 MG/ML;
material entity;T. pallidum Tp92 Protein Vaccine;
material entity;UM-3003 vaccine adjuvant;A vaccine adjuvant that includes UM-3003, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.
material entity;Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88 0.015 MG/ML;
material entity;T. pallidum TmpB Protein Vaccine;
material entity;LTA1 vaccine adjuvant;A vaccine adjuvant made from the A subunit of heat-labile (LT) enterotoxin of Enterotoxigenic Escherichia coli (ETEC). This LTA1 adjuvant is able to induce Th1, Th2, and Th17 immune responses.
material entity;Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88 0.03 MG/ML;
material entity;influenza virus DNA vaccine encoding HA from influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1));
material entity;VLPCOV-01;A SARS-CoV-2 RNA vaccine manufactured by VLP Therapeutics Japan, LLC
material entity;UM-3004 vaccine adjuvant;A vaccine adjuvant that includes UM-3004, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.
material entity;L. donovani GRP-78 Protein Vaccine;
material entity;naNO-COVID;A SARS-CoV-2 subunit vaccine containing a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle.
material entity;influenza virus DNA vaccine encoding HA from influenza A virus (A/equine/Kentucky/1/1981(H3N8));
material entity;IN-B009;A SARS-CoV-2 subunit vaccine by HK inno.N Corporation
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 50;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Suspension [Pediacel];
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG Oral Suspension;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG [Rotarix];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Injectable Solution;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injection [Infanrix];
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2014-2015 Formula];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injection [Act-HIB DTP];
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML [Mumpsvax];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML [Fluzone Intradermal 2012-2013 Formula];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Pediacel];
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 25;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2013-2014 Formula];
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Act-HIB DTP];
material entity;L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Fluzone Intradermal 2014-2015 Formula];
material entity;Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.0075 MG/ML;
material entity;L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension Box of 1;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Injectable Solution;
material entity;Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.00752 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 50;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injection;
material entity;Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula];
material entity;Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.009 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix];
material entity;L1 protein, Human papillomavirus type 6 Vaccine 0.02 MG/ML;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Fluzone Intradermal 2013-2014 Formula];
material entity;Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.015 MG/ML;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 PFU;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe;
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 PFU [Varivax];
material entity;Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 PFU Injection;
material entity;Psuedorabies DNA vaccine encoding IE180 protein;
material entity;Nontypeable H. influenzae NucA Protein vaccine;
material entity;dibutyl phthalate vaccine adjuvant;A vaccine adjuvant that diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of butan-1-ol.
material entity;M. tuberculosis DNA vaccine ESAT-6;
material entity;MPL + TDM vaccine adjuvant;A microbial derivative vaccine adjuvant that is monophosphoryl lipid A (detoxified endotoxin) from S. minnesota (MPL) and synthetic trehalose dicorynomycolate (TDM) in 2% oil (squalene)-Tween 80-water.
material entity;F. tularensis FopB Protein Vaccine;
material entity;Syntex Adjuvant Formulation;A muramyl dipeptide vaccine adjuvant that muramyl dipeptide derivative (threonyl-MDP) in an oil-in-water (o/w) emulsion vehicle.
material entity;Ebola virus EBOV NP;
material entity;Zymosan vaccine adjuvant;A carbohydrate vaccine adjuvant that polysaccharide prepared from the cell wall of Saccaromyces cerevisiae (bakers' yeast).
material entity;Influenza Virus Surface Antigen, Inactivated, Strain B / Phuket / 3073/2013 & ndash. Analogue strain B / Utah / 9/2014, Wild Type;
material entity;Ebola virus DNA vaccine EBOV GP;
material entity;XtendIII vaccine adjuvant;An emulsion vaccine adjuvant that is oil-based adjuvant (Adjuvant XtendIII®. Grand Laboratories, Larchwood, IA).
material entity;Influenza Virus Surface Antigen, Inactivated, Strain B / Phuket / 3073/2013 & ndash. Analogue strain B / Utah / 9/2014, Wild Type 0.03 MG/ML;
material entity;L. monocytogenes DNA Vaccine encoding hly;
material entity;Montanide ISA 50 vaccine adjuvant;A Montanide vaccine adjuvant that Mannide oleate derivative in a mineral oil solution ( Seppic SA, France).
material entity;B. burgdorferi OspC Protein Vaccine;
material entity;Tomatine vaccine adjuvant;A carbohydrate vaccine adjuvant that is tomatidine in which the hydroxy group at position 3 is linked to lycotetraose, a tetrasaccharide composed of two units of D-glucose, one unit of D-xylose, and one unit of D-galactose.
material entity;L. donovani Hsp70 Protein Vaccine;
material entity;Montanide IMS 1313 vaccine adjuvant;A Montanide vaccine adjuvant that is a water-dispersed liquid IMS 1313 nanoparticle combined with an immuno-stimulating compound.
material entity;L. monocytogenes p60 Protein Vaccine;
material entity;Montanide ISA 206 vaccine adjuvant;A water-dispersed liquid nanoparticle combined with an immuno-stimulating compound.
material entity;chitosan vaccine adjuvant;A carbohydrate vaccine adjuvant that is aminoglycan consisting of beta-(1->4)-linked D-glucosamine residues.
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 25;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 50;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Repevax];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Boostrix];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension [Rotarix] Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 25;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension [Rotarix];
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Quatro Virelon No];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension Box of 1;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Infanrix];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension [Rotarix] Box of 1 by Glaxosmithkline;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000;
material entity;Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 10;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Pediacel];
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG Oral Suspension [Rotarix] by Glaxosmithkline;
material entity;Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.0075 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 25;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Repevax];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension;
material entity;Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.00752 MG/ML;
material entity;0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1;
material entity;diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix];
material entity;Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 [Rotarix];
material entity;Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.009 MG/ML;
material entity;Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.015 MG/ML;
material entity;Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.03 MG/ML;
material entity;rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG Oral Suspension [Rotarix];
material entity;Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88;
material entity;Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88 0.0075 MG/ML;
material entity;acellular pertussis vaccine, inactivated 0.0105 MG / Bordetella pertussis 0.008 MG / diphtheria toxoid vaccine, inactivated 2 UNT / tetanus toxoid vaccine, inactivated 20 UNT Injection;
material entity;AlT4 vaccine adjuvant;
material entity;BECC438s vaccine adjuvant;
material entity;BECC438b vaccine adjuvant;
material entity;CaPNP (CaPtivant)(TM) vaccine adjuvant;
material entity;BECC470b vaccine adjuvant;
material entity;Em vaccine adjuvant;
material entity;defective viral genome-derived oligonucleotide vaccine adjuvant;
material entity;Fos47 vaccine adjuvant;
material entity;EmT4 vaccine adjuvant;
material entity;acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 10;
material entity;acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Boostrix] Box of 10;
material entity;acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Boostrix];
material entity;acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT Injectable Solution [Infanrix] by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Boostrix];
material entity;acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT [Infanrix];
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis];
material entity;acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT Injectable Solution [Infanrix];
material entity;acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT Injectable Solution;
material entity;acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Boostrix];
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix];
material entity;acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection Box of 5;
material entity;acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Tripacel] Box of 5;
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML [Infanrix];
material entity;acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Tripacel];
material entity;acellular pertussis vaccine, inactivated 0.013 MG / Bordetella pertussis 0.01 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT Injection;
material entity;acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Tripacel];
material entity;acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection;
material entity;mRNA-1273.211;A multivalent SARS-CoV-2 mRNA booster vaccine which combines mRNA-1273, Moderna's authorized vaccine against ancestral strains, and mRNA-1273.351 in a single vaccine at the 50 ug dose level and lower.
material entity;(H115D)VHL35 Peptide Vaccine;A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. In (H115D)VHL35 peptide, histidine is substituted for an aspartic acid in position 115. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation.
role;Th2 immunity stimulatory role;
material entity;LNP-nCOV saRNA-02;A SARS-CoV-2 self-amplifying RNA vaccine sponsored by MRC/UVRI and LSHTM Uganda Research Unit
material entity;QazCoVac-P;A SARS-CoV-2 protein subunit vaccine manufactured by the Research Institute for Biological Safety Problems in Kazakhstan
role;Th1 immunity stimulatory role;
material entity;2B182C vaccine adjuvant;
role;TLR7 receptor role;A role of a material entity that binds to TLR7 and activates the receptor for pathogen recognition and activation of innate immunity.
material entity;1V270 vaccine adjuvant;A vaccine adjuvant that includes IV270, which is a low-molecular weight TLR7 agonist conjugated to a phospholipid and is a highly potent and stable immune activator.
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix];
material entity;5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Covaxis];
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension Box of 1;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Triaxis];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix];
material entity;5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension [Biothrax];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Boostrix];
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Tetravac];
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix] Box of 1 by Glaxosmithkline;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Repevax];
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix] Box of 1;
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix] Box of 1;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Repevax];
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension Box of 1;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix] Box of 1 by Glaxosmithkline;
material entity;INI-4001 vaccine adjuvant;
material entity;INI-2004 vaccine adjuvant;
material entity;Mannadjuvant;
material entity;LiT4 vaccine adjuvant;
material entity;NanoVax/NE01 vaccine adjuvant;
material entity;MiT4 vaccine adjuvant;
material entity;UM-1098 vaccine adjuvant;
material entity;TQL-1055 vaccine adjuvant;
material entity;2E151 vaccine adjuvant;
material entity;INI-2002 vaccine adjuvant;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Covaxis];
material entity;Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 772000 PFU/ML;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 5;
material entity;Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 770000 PFU/ML;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;Bacillus anthracis Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Adacel];
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adacel] Box of 5;
material entity;Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 2210000 UNT;
material entity;acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adacel];
material entity;Bacillus anthracis Injectable Suspension [Biothrax];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Covaxis];
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.0075 MG/ML;
material entity;5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension [Biothrax] by Emergent Sales And Marketing;
material entity;acellular pertussis vaccine, inactivated 0.0055 MG / Bordetella pertussis 0.01 MG / diphtheria toxoid vaccine, inactivated 2 UNT / tetanus toxoid vaccine, inactivated 20 UNT Injection;
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.015 MG/ML;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Triaxis];
material entity;A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.00752 MG/ML;
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML [Infanrix];
material entity;Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix];
material entity;acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML [Tetravac];
material entity;acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix];
material entity;acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetravac];
material entity;acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2018-2019];
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Pentacel];
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2018-2019];
material entity;acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Pentacel];
material entity;influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [FluMist Quadrivalent 2019-2020];
material entity;acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray [FluMist Quadrivalent 2019-2020];
material entity;acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection;
material entity;influenza A virus A/Indonesia/05/2005 (H5N1) antigen 0.0075 MG/ML Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen Injectable Solution;
material entity;influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray;
material entity;diphtheria toxoid vaccine, inactivated / influenza B virus antigen Injectable Solution [HibTITER];
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [PEDIARIX];
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe;
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [Kinrix];
material entity;acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe;
material entity;influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray;
material entity;influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2018-2019];
material entity;BCG, Live, Tice Strain 800000000 UNT Injectable Solution [OncoTICE] by Merck;
material entity;influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2018-2019];
material entity;BCG, Live, Tice Strain Injectable Solution;
material entity;influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray;
material entity;BCG, Live, Tice Strain Injectable Solution [OncoTICE];
material entity;influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2018-2019];
material entity;BCG, Live, Tice Strain Injectable Suspension;
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe;
material entity;BCG, Live, Tice Strain Injectable Suspension [OncoTICE];
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2018-2019];
material entity;BCG, Live, Tice Strain Injection [Oncotice Bcg];
material entity;BCG, live, Tice strain Injection [OncoTICE];
material entity;influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2018-2019];
material entity;BCG, Live, Tice Strain 800000000 UNT [OncoTICE];
material entity;BCG, Live, Tice Strain 800000000 UNT Injectable Solution;
material entity;BCG, Live, Tice Strain 800000000 UNT Injectable Solution [OncoTICE];
material entity;influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2019-2020];
material entity;influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2019-2020];
material entity;influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2019-2020];
material entity;influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2017-2018];
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection [Flublok 2017-2018];
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018];
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro];
material entity;0.5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension [Biothrax];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML Nasal Spray;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix];
material entity;0.5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML [FluMist Quadrivalent 2021-2022];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 10;
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML [Fluzone Quadrivalent 2021-2022];
material entity;0.5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension [Biothrax] by Emergent Sales And Marketing;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML [Flublok Quadrivalent 2021-2022];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 10;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2021-2022];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 1;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2021-2022];
material entity;pneumococcal capsular polysaccharide type 1 vaccine Injectable Product;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2021-2022];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 20;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2021-2022];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Xanaflu];
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria] Box of 10;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal] Box of 10;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad] Box of 10;
material entity;ChAdV68-S;A SARS-CoV-2 Chimpanzee Adenovirus serotype 6 vector vaccine manufactured by Gritstone Oncology and the National Institute of Allergy and Infectious Diseases
material entity;COVIran Barakat;A SARS-CoV-2 inactivated vaccine by Shifa Pharmed
material entity;Razi Cov Pars;A SARS-CoV-2 protein subunit vaccine manufactured by the Razi Vaccine and Serum Research Institute with a Spike protein antigen
material entity;BBV154;A SARS-CoV-2 recombinant adenoviral vector vaccine that is manufactured by Bharat Biotech International Ltd. and administered intranasally
material entity;1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin] by Baxter;
material entity;1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin];
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension [Ixiaro];
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Flulaval Quad 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Preflucel];
material entity;1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution;
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [VAXIGRIP];
material entity;1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin] Box of 1 by Baxter;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection;
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Viroflu];
material entity;1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin] Box of 1;
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension [Ixiaro] by Eco.Pharma.Supply;
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flulaval Quad 2014-2015 Formula];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 20 by Sanofi;
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension Box of 1;
material entity;influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix Quad 2014-2015 Formula];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 20;
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] by Valneva;
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML;
material entity;1 ML tetanus toxoid vaccine, inactivated 2000 IU/ML Injectable Solution by SK Chemical;
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injection [Jespect];
material entity;influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluarix Quad 2014-2015 Formula];
material entity;1 ML tetanus toxoid vaccine, inactivated 2000 IU/ML Injectable Solution;
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injection;
material entity;influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe;
material entity;influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluarix Quad 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Fluarix];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 100;
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] Box of 1 by Valneva;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Grippe-Impfstoff Csl];
material entity;0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] Box of 1;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML Nasal Spray [FluMist Quadrivalent 2021-2022];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Grippe-Impfstoff Stada];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Grippeimpfstoff Ratiopharm];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Inflexal];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Influsplit];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [INFLUVAC];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 10;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 1;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 20;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2018-2019];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus antigen 0.03 MG/ML Prefilled Syringe;
material entity;Haemophilus influenzae type b Injectable Solution;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus antigen 0.03 MG/ML Prefilled Syringe [Afluria 2018-2019];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Afluria];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2017-2018];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Begripal];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus antigen 0.03 MG/ML [Afluria 2018-2019];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML [Fluad];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20 by Sanofi;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution;
material entity;influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [FluMist Quadrivalent 2022-2023];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution;
material entity;influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray [FluMist Quadrivalent 2022-2023];
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution Box of 5;
material entity;Haemophilus influenzae 0.01 MG Injection;
material entity;Haemophilus influenzae Injection;
material entity;Haemophilus influenzae type b 0.035 MG Injectable Solution;
material entity;Haemophilus influenzae type b 0.04 MG Injectable Solution;
material entity;Haemophilus influenzae type b 0.05 MG Injectable Solution;
material entity;Matrix-M vaccine adjuvant;A saponin vaccine adjuvant comprised of 40 nm nanoparticles composed of Quillaja saponins, cholesterol and phospholipid.
material entity;Advax vaccine adjuvant;A carbohydrate vaccine adjuvant derived from delta inulin
material entity;COVID-19 live, attenuated vaccine;
material entity;COVID-19 virus-like particle vaccine;
material entity;COVID-19 subunit vaccine;
material entity;COVID-19 DNA vaccine;
material entity;COVID-19 recombinant adenoviral vector vaccine;
material entity;COVID-19 inactivated vaccine;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Flulaval Quadrivalent 2021-2022];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by European;
material entity;influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by Emra-Med;
material entity;influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluarix Quadrivalent 2021-2022];
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML [HibTITER];
material entity;pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2018-2019];
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution;
material entity;pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2018-2019];
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1 by European;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Injectable Suspension;
material entity;diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] Box of 5;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1 by Emra-Med;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10 by European;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2018-2019];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10 by Emra-Med;
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2018-2019];
material entity;influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Daptacel];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Adacel];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Adacel];
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection;
material entity;COVID-19 rNDV vector vaccine by Laboratorio Avi-Mex;A recombinant Newcastle Disease Virus vectored vaccine for SARS-CoV-2 by Laboratorio Avi-Mex
material entity;COVID-19 inactivated vaccine by the Scientific and Technological Research Council of Turkey;A SARS-CoV-2 inactivated virus vaccine by the Scientific and Technological Research Council of Turkey adjuvanted by aluminum hydroxide and CpG ODN
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Fluad];
material entity;MF59-adjuvanted SARS-CoV-2 Sclamp vaccine;An MF59-adjuvanted SARS-CoV-2 subunit vaccine based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a novel molecular clamp (spike glycoprotein-clamp [sclamp])
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Fluarix];
material entity;ABNCoV2;A COVID-19 virus-like particle vaccine developed by Radboud University
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Grippe-Impfstoff Csl];
material entity;HDT-301;A SARS-CoV-2 Lipid-Inorganic Nanoparticle (LION(TM)) formulated replicating mRNA vaccine that encodes for a full-length spike (S) protein of the SARS-CoV-2 virus
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Grippe-Impfstoff Stada];
material entity;Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine;A SARS-CoV-2 inactivated virus vaccine by Kocak Farma
material entity;SC-Ad6-1;A SARS-CoV-2 recombinant adenoviral vector vaccine by Tetherex Pharmaceutical Corporation
material entity;COVID-19 VLP vaccine by the Scientific and Technological Research Council of Turkey;A COVID-19 virus-like particle vaccine developed by the Scientific and Technological Research Council of Turkey
material entity;ReCOV;A SARS-CoV-2 subunit vaccine by Jiangsu Rec-Biotechnology Co., Ltd.
material entity;KD-414;A SARS-CoV-2 inactivated vaccine developed by KM Biologics Co., Ltd.
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b / Hepatitis B Surface Antigen Vaccine / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [HEXYON];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution [Typherix] by GSK;
material entity;acellular pertussis vaccine, inactivated / Bordetella Pertussis Filamentous Haemagglutinin Antigen / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / tetanus toxoid vaccine, inactivated Injection [Boostrix];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection Box of 10;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe;
material entity;acellular pertussis vaccine, inactivated / Bordetella Pertussis Filamentous Haemagglutinin Antigen / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / tetanus toxoid vaccine, inactivated Injection;
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typhim VI] Box of 10;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Afluria 2013-2014 Formula];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b / Hepatitis B Surface Antigen Vaccine / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution [Typherix];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluzone 2013-2014 Formula];
material entity;acellular pertussis vaccine, inactivated / Bordetella Pertussis Filamentous Haemagglutinin Antigen / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / tetanus toxoid vaccine, inactivated Injection [Infanrix];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluzone 2014-2015 Formula];
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Adacel];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typherix];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluvirin 2013-2014 Formula];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Grippeimpfstoff Ratiopharm];
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection;
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluvirin 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Inflexal];
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tripacel];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typhim VI];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Flulaval 2013-2014 Formula];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Influsplit];
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Boostrix];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typherix] Box of 10;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Flulaval 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [INFLUVAC];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Afluria 2013-2014 Formula];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Pandemrix];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Afluria 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Preflucel];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution Box of 1;
material entity;authorized COVID-19 recombinant adenoviral vector vaccine;
material entity;authorized COVID-19 subunit vaccine;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu];
material entity;authorized inactivated COVID-19 vaccine;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu] Box of 10;
material entity;authorized COVID-19 recombinant vector vaccine;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu];
material entity;authorized COVID-19 vaccine;A COVID-19 vaccine that is authorized for emergent use, which is typically authorized based on an Emergency Use Authorization (EUA).
material entity;authorized COVID-19 RNA vaccine;
material entity;MVA-SARS-2-ST;A SARS-CoV-2 recombinant viral vector vaccine by the German Center for Infection Research
material entity;CoV2-OGEN1;A SARS-CoV-2 subunit vaccine that is orally administered and manufactured by Syneos Health
material entity;COVID-19 mRNA vaccine by Shanghai East Hospital and Stemirna Therapeutics;A SARS-CoV-2 mRNA vaccine by Shanghai East Hospital and Stemirna Therapeutics
material entity;CoVepiT;A SARS-CoV-2 subunit vaccine by OSE Immunotherapeutics
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [Tetravac];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension Box of 10;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe [Eurim Pharm];
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension Box of 1;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix];
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix];
material entity;1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Hibdt];
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 1 by Sanofi;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu] Box of 10;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 1;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe [Anrix];
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 10 by Sanofi;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 20;
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe;
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 10;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 50;
material entity;influenza A virus (H1N1) antigen Injectable Suspension;
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Afluria];
material entity;acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix Hexa];
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril];
material entity;influenza A virus (H1N1) antigen Injectable Suspension [Begripal];
material entity;0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension;
material entity;FAKHRAVAC;A SARS-CoV-2 inactivated vaccine developed by Organization of Defensive Innovation and Research in Iran
material entity;SpFN;A SARS-CoV-2 protein subunit vaccine manufactured by Walter Reed Army Institute of Research
material entity;VBI-2902a;A SARS-CoV-2 virus-like particle vaccine that expresses a modified version of the SARS-CoV-2 spike (S) glycoprotein and is equipped with an aluminum phosphate adjuvant. It is manufactured by VBI Vaccines Inc. and is delivered intramuscularly.
material entity;NDV-HXP-S;A SARS-CoV-2 recombinant viral vector vaccine by Mahidol University
material entity;PTX-COVID19-B;A SARS-CoV-2 mRNA vaccine by Providence Therapeutics
material entity;mRNA-1273.351;A SARS-CoV-2 lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 10;
material entity;NBP2001;A SARS-CoV-2 protein subunit vaccine by SK Bioscience
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 20;
material entity;COVIGEN;A SARS-CoV-2 DNA vaccine manufactured by University of Sydney, Bionet Co., and Technovalia
material entity;EuCorVac-19;A SARS-CoV-2 protein subunit vaccine by EuBiologics Co., Ltd.
material entity;COVID-eVax;A SARS-CoV-2 plasmid DNA vaccine manufactured by Takis and Rottapharm Biotech
material entity;50 ML tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix] Box of 1 by Glaxosmithkline;
material entity;50 ML tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution [Tetanol];
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix] Box of 1;
material entity;7.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluzone Quadrivalent 2013-2014 Formula];
material entity;50 ML tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension Box of 1;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Flulaval Quad 2013-2014 Formula];
material entity;10 ML tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection Box of 20;
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flulaval 2014-2015 Formula];
material entity;10 ML tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution [Tetanol];
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection Box of 10;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension;
material entity;50 ML tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix];
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Flulaval 2014-2015 Formula];
material entity;10 ML tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension;
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix];
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flulaval 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC];
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10;
material entity;10 ML tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix] Box of 20;
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel];
material entity;1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix] Box of 10;
material entity;influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flulaval Quad 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel] Box of 10;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 10;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 20;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 50;
material entity;COVID-19 subunit vaccine by National Vaccine and Serum Institute of China;A SARS-CoV-2 subunit vaccine developed by the National Vaccine and Serum Institute of China
material entity;EXG-5003;A SARS-COV-2 temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.
material entity;COVIVAC;A SARS-CoV-2 recombinant Newcastle Disease Virus vector vaccine expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein
material entity;V-01;A SARS-CoV-2 subunit vaccine developed by Livzon Mabpharm Inc.
material entity;Soberana Plus;A SARS-CoV-2 protein subunit vaccine manufactured by Instituto Finlay de Vacunas. It is used as a booster dose for the Soberana 02 COVID-19 vaccine
material entity;DS-5670a;A SARS-CoV-2 mRNA vaccine manufactured by Daiichi Sankyo Co., Ltd.
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 20;
material entity;CoviVac;A SARS-CoV-2 inactivated whole virus vaccine developed by the Chumakov Centre at the Russian Academy of Sciences
material entity;MV-014-212;A SARS-CoV-2 live, attenuated vaccine manufactured by Meissa Vaccines, Inc. that expresses the spike (S) protein of SARS-CoV-2.
material entity;MRT5500;A SARS-CoV-2 mRNA vaccine that is manufactured by Sanofi Pasteur
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Covaxis];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI] by Sanofi;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit];
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension;
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Sanofi;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension;
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix];
material entity;7.5 ML tetanus toxoid vaccine, inactivated 5.33 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Solution [Flublok 2013-2014 Formula];
material entity;7.5 ML tetanus toxoid vaccine, inactivated 5.33 UNT/ML Injectable Solution;
material entity;0.5 ML Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution by Aventis;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Solution [Flublok 2014-2015 Formula];
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix];
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Flulaval Quad 2014-2015 Formula];
material entity;acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution;
material entity;0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Solution;
material entity;7.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [Tetanol];
material entity;0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Nasal Spray [Flumist 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl];
material entity;0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl] Box of 10;
material entity;7.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluzone Quadrivalent 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada];
material entity;7.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax] by Merck;
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Nasal Spray;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada] Box of 10;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm];
material entity;influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Flulaval Quad 2014-2015 Formula];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm] Box of 10;
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal];
material entity;influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal] Box of 10;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Emra-Med;
material entity;adenovirus serotype 26 vaccine vector;
material entity;lipid nanoparticle vector;A nanoparticle vector composed of lipids.
material entity;gorilla adenovirus vector;an adenovirus vaccine vector that uses a gorilla adenovirus.
material entity;bacTRL-Spike;A SARS-CoV-2 oral DNA vaccine that delivers plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
material entity;ChulaCov19;A SARS-CoV-2 mRNA vaccine manufactured by Chulalongkorn University
material entity;INO-4800;A DNA vaccine that expresses S protein from the pGX9501 vector
material entity;AdimrSC-2f;A SARS-CoV-2 protein subunit vaccine developed by Adimmune Corporation. AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
material entity;GX-19;A SARS-CoV-2 DNA vaccine expressing the SARS-CoV-2 S protein
material entity;KBP-COVID-19;A SARS-CoV-2 subunit vaccine that is made of a protein subunit made of the RBD domain of the S protein.
material entity;nanoparticle vector;A vaccine component composed of a synthetic component that is solid and spherical structures ranging to around 100 nm in size and prepared from natural or synthetic polymers.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 10;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Axicorp;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 10 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] Box of 25;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Eurim-Pharm;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Emra-Med;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] by Glaxosmithkline;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Orifarm Leverkus;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] Box of 25 by Glaxosmithkline;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Merck;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 50 by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Merck;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Emra-Med;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 80;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Novartis;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] by Novartis;
material entity;hAd5-COVID-19;A SARS-CoV-2 human adenovirus serotype 5 (hAd5) vector vaccine with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
material entity;COVI-VAC vaccine;A SARS-CoV-2 live, attenuated vaccine manufactured by Codagenix, Inc.
material entity;Turkovac;A SARS-CoV-2 inactivated vaccine developed by Health Institutes of Turkey
material entity;mRNA-1283;A SARS-CoV-2 refrigerator-stable mRNA vaccine by Moderna that encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD)
material entity;Covigenix VAX-001;A prophylactic plasmid DNA Vaccine for SARS CoV-2 by Entos Pharmaceuticals
material entity;CORVax12;A SARS-CoV-2 DNA vaccine developed by Providence Health & Services.
material entity;COVID-19 aAPC vaccine;A SARS-CoV-2 recombinant vector vaccine employing the lentiviral vector system and developed by Shenzhen Geno-Immune Medical Institute.
material entity;chimpanzee adenovirus Oxford1 vaccine vector;A chimpanzee adenovirus vaccine vector that patented by Oxford and derived from ChAd serotype Y25 that exchanges the native E4 orf4, orf6 and orf6/7 genes for those from HAdV-C5
material entity;chimpanzee adenovirus Oxford2 vaccine vector;A chimpanzee adenovirus vaccine vector developed by Oxford by deleting E1/E3 from ChAd68 with a modified E4 region.
material entity;IMP CoVac-1;A SARS-CoV-2 subunit vaccine developed by University Hospital Tuebingen
material entity;MVA-SARS-2-S;A SARS-CoV-2 recombinant vector vaccine that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein (S)
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 20 by Novartis;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 20;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20 by Merck;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 10 by Novartis;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 10;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1 by Merck;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 2 by Novartis;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 2;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10 by Merck;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 20 by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Merck;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 20;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Eurim-Pharm;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Orifarm Leverkus;
material entity;BCG, Live, Tice Strain 500000000 CFU Injection;
material entity;Oxford-AstraZeneca COVID-19 vaccine;A SARS-CoV2 recombinat vector vaccine made of a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein
material entity;BCG, Live, Tice Strain 500000000 CFU Injection [Oncotice Bcg];
material entity;Ad26.COV2.S vaccine;A SARS-CoV-2 recombinant viral vector vaccine composed of Ad26 vector expressing S protein.
material entity;BCG, Live, Tice Strain 500000000 CFU Injection [Oncotice Bcg] Box of 3;
material entity;CoV2 SAM;A SARS-CoV-2 RNA vaccine that has a lipid nanoparticle (LNP) platform and Spike protein antigen
material entity;BCG, Live, Tice Strain 500000000 CFU Injection Box of 3;
material entity;Moderna COVID-19 vaccine;A SARS-CoV2 RNA vaccine made of lipid nanoparticle with mRNA which encodes the S-2P antigen, made of the SARS-CoV-2 glycoprotein with a transmembrane anchor and intact S1-S2 cleavage site.
material entity;BCG, Live, Tice Strain 800000000 CELLS;
material entity;SARS-CoV pCI-N DNA vaccine;A plasmid pCI-N, encoding the full-length N gene of SARS-CoV, was constructed and expressed in Escherichia coli DH5alpha
material entity;NVX-CoV2373 vaccine;A SARS-CoV 2 (rSARS-CoV-2) subunit vaccine made of nanoparticles composed of a trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M1 adjuvant.
material entity;MVA-MERS-S vaccine;A MERS recombinant vector made of recombinant modified vaccinia virus Ankara (rMVA) vaccine vector carrying full MERS-CoV spike glycoprotein.
material entity;AdCOVID;A SARS-CoV-2 single dose intranasal vaccine manufactured by Altimmune in collaboration with the University of Alabama-Birmingham. This vaccine was discontinued after a Phase 1 trial.
material entity;rMV-S + rMV-N vaccine;A SARS DNA vaccine made up of arecombinat vector vaccine made from recombinant measles virus expressing S protein and recombinant measles virus expressing N protein.
material entity;SARS-CoV Baculovirus S protein Vaccine;A SARS-CoV recombinant vector made from a baculovirus vector expressing SARS-CoV S protein.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 20 by Novartis;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 2;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Cc;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2017-2018];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 10;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Axicorp;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 20;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Gerke;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2017-2018];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 2 by Novartis;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Eurim-Pharm;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax] Box of 1 by Ribosepharm;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe;
material entity;BCG, Live, Tice Strain 800000000 CELLS [OncoTICE];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax] Box of 1;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 20;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2017-2018];
material entity;BCG, Live, Tice Strain 800000000 CELLS Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 1;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2017-2018];
material entity;BCG, Live, Tice Strain 800000000 CELLS Injectable Suspension [OncoTICE];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension;
material entity;BCG, Live, Tice Strain 800000000 CELLS Injectable Suspension [OncoTICE] by Organon;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;BCG, Live, Tice Strain 800000000 UNT;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2017-2018];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 10;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 1;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;GRAd-COV2;A SARS-CoV 2 recombinant viral vector using Gorilla Adenovirus that encodes for SARS-CoV-2 Spike protein.
material entity;BCG, Live, Tice Strain 200000000 ORGANISMS;
material entity;BCG, Live, Tice Strain 200000000 ORGANISMS [OncoTICE];
material entity;Chinese Academy of Medical Sciences COVID-19 vaccine;A SARS-CoV-2 inactivated whole virus vaccine that is developed by the Chinese Academy of Medical Sciences .
material entity;BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension;
material entity;CVnCoV;A SARS-CoV-2 mRNA vaccine developed by CureVac AG and CEPI.
material entity;BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension [OncoTICE];
material entity;AG0301-COVID19;A SARS-CoV-2 DNA vaccine developed by AnGes, named as AG0301-COVID19.
material entity;BBIBP-CorV vaccine;A SARS-CoV-2 inactivated whole virus vaccine that produced in Vero cells that is developed by the Beijing Institute of Biological Products.
material entity;Sputnik V vaccine;A SARS-CoV-2 recombinant viral vector vaccine composed of Ad26 and Ad5 vectors expressing S protein that lyophilised.
material entity;ARCT-021;A SARS-CoV-2 investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle
material entity;ARCoV;A SARS-CoV-2 mRNA vaccine made of lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 manufactured by Academy of Military Science (AMS), Walvax Biotechnology, and Suzhou Abogen Biosciences.
material entity;ZyCoV-D vaccine;A SARS-CoV-2 plasmid DNA vaccine that encodes the envelope protein.
material entity;WIBP-CorV;A SARS-CoV-2 inactivated whole virus vaccine that is developed by the Wuhan Institute of Biological Products.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 20;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20 by Gerke;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 2;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20 by Cc;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 50;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 20 by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20 by Kohlpharma;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 10;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Cc;
material entity;BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension [OncoTICE] Box of 1;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 1 by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Axicorp;
material entity;BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension [OncoTICE] Box of 1 by MSD;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 100;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Kohlpharma;
material entity;BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension [OncoTICE] by MSD;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 10 by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Gerke;
material entity;BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension Box of 1;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Kohlpharma;
material entity;BCG, Live, Tice Strain 500000000 CFU;
material entity;BCG, Live, Tice Strain 500000000 CFU [Oncotice Bcg];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 1;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Abacus Medicine;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 80;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Orifarm Leverkus;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 1 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 10 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 20;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 10 by Novartis;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 1;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 20 by Novartis;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat] Box of 10 by Glaxosmithkline;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat] Box of 10;
material entity;COVID-19 RNA vaccine;
material entity;COVID-19 recombinant vector vaccine;
material entity;VXA-CoV2-1;A SARS-CoV-2 adenoviral vector-based oral vaccine by Vaxart expressing a SARS-CoV-2 antigen and dsRNA adjuvant
material entity;SKYCovione;A SARS-CoV-2 protein subunit vaccine manufactured by SK Bioscience Co., Ltd., and equipped with an aluminum hydroxide adjuvant
material entity;COVAC;A SARS-CoV-2 subunit vaccine with the S1 component of the SARS-CoV-2 spike (S) protein and SWE adjuvant.
material entity;V590;A SARS-CoV-2 vaccine that uses a recombinant vesicular stomatitis virus (rVSV) platform, and is made by Merck. Development of the vaccine was discontinued on January 25, 2021.
material entity;MVC-COV1901 vaccine;A SARS-CoV-2 subunit vaccine that contains the Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
material entity;COVAX-19;A SARS-CoV-2 protein subunit vaccine developed by Vaxine Pty Ltd and CinnaGen Co. and adjuvanted with Advax
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 50;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 20 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 50 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 20;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 10 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 1;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 1 by Novartis;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 50;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 25;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 10;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat] by Glaxosmithkline;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 20;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 2;
material entity;oral cancer vaccine V3-OVA;A cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. The ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells. Ovarian cancer patients can be given one pill a day for three months.
material entity;OCDC and NeoDC vaccine;A cancer vaccine made with autologous DCs that are pulsed with HOCl-oxidized autologous tumor lysate (OCDC) and administered in prime phase, along with a personal neoantigen-sensitized DC(NeoDC) vaccine administered in the boost phase for Esophageal Squamous Cell Carcinoma.
material entity;NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine;A cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. As proteins are degraded in cells, peptides are presented on the surface of these cells as a complex with tissue type molecules (HLA molecules). T-cells may then recognize the peptide-HLA complexes, via its T-cell receptor, potentially resulting in tumor-cell killing, if sufficient priming takes place. Cancer testis antigens (CTA's) are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination. The CTA's chosen were NY-ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein has proven to be an important antigen in hematological malignancies. It is combined with azacitidine for treatment of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.
material entity;NY-ESO-1, MAGE-A1, and MAGE-A3 dendritic cell vaccine;A cancer vaccine that is made from the subject's blood cells and is designed to interact in the patient's body with cells that are programmed to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3). The vaccine can be given in combination with decitabine which may increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. The dendritic cells may stimulate CD4 and CD8 antigen specific T cells in patients with relapsed or refractory pediatric high grade gliomas, medulloblastomas, and central nervous system primitive neuroectodermal tumors (CNS PNETs).
material entity;neoantigen-loaded autologous dendritic cell vaccine;A cancer vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM).
material entity;neoantigen synthetic long peptide vaccine;A cancer vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells. This vaccine is a optimized neoantigen synthetic long peptide (SLP) vaccines for pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. It can be used in combination with chemoradiation with temozolomide for patients with newly diagnosed glioblastoma.
material entity;pancreatic tumor personalized neoantigen vaccine;A cancer vaccine based on next-generation sequencing and major histocompatibility complex affinity prediction algorithm, which may help treat patients with pancreatic ductal adenocarcinoma. This vaccine may elicit measurable neoantigen-specific immunologic responses in patients.
material entity;P501-AS15 vaccine;A cancer vaccine made up of CPC-P501 protein formulated with the adjuvant AS15. Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, can be treated with the P501-AS15 vaccine.
material entity;P30-linked EphA2/CMV pp65/survivin peptide vaccine P30-EPS;A cancer vaccine comprised of three immunogenic tetanus toxoid epitope P30-linked tumor-associated antigen (TAA) peptides, P30-linked Ephrin receptor A2 (EphA2), P30-linked cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein. UL83) and P30-linked survivin, with potential immunostimulating and antineoplastic activities. The vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EphA2, CMV pp65 and survivin. Hiltonol is used as an adjuvant to stimulate or enhance the activation of your immune system. The vaccine and adjuvant may help treat HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.
material entity;oral therapeutic vaccine V3-X;A cancer vaccine consisting of the tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9. sialylated Lewis A antigen. carbohydrate antigen 19-9. cancer antigen 19-9), with potential immunostimulating and antineoplastic activities. Oral therapeutic vaccine V3-X induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CA19-9. Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. This immunotherapeutic formulation is made from pooled heat- and chemically-inactivated blood from donors with CCA for a pill for cholangiocarcinoma patients.
material entity;PolyPEPI1018 CRC vaccine;A cancer vaccine that contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.
material entity;personalized neoantigen melanoma vaccine;A cancer vaccine for melanoma. Melanomas have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. These proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the melanoma to come back in the future. NeoVax is a long-peptide vaccine targeting up to 20 personal neoantigens per patient for patients with surgically resected stage IIIB/C or IVM1a/b melanoma. There was long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype, as well as diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. There was also tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma.
material entity;personalized mature dendritic cell vaccine;A cancer vaccine that may stimulate the immune system to react to lung cancer cells, in combination with Cyclophosphamide.
material entity;personalized follicular lymphoma vaccine;A cancer vaccine co-administered with poly-ICLC, nivolumab, and rituximab (or another monoclonal antibody against CD20) to treat Follicular Lymphoma. The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D).
material entity;personal neoantigen cancer vaccine;A cancer vaccine designed to target the unique immunogenic mutations arising in each patient's tumor. Peptide binding to MHC is a critical gateway to both the initiation of a T-cell immune response by the antigen presenting cell (APC), and to the detection and elimination of tumor cells presenting the particular peptide by the stimulated cytotoxic T lymphocyte (CTL). The attraction of neoantigens as cancer targets for the immune system results from the structural and geographical features of the mutation. Neoantigen peptides are only found in tumor cells, so CTLs should show exquisite specificity, reducing the opportunity for autoimmune disease.
material entity;PD-L1/IDO peptide vaccine IO102-103;A cancer vaccine composed of IO103, a peptide derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation. The the programmed death 1 (PD-1) regulatory antibody Nivolumab may further help treat patients with metastatic melanoma.
material entity;PD-L1 peptide vaccine;A cancer vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. The vaccines aims to stimulate PD-L1 specific T-cells, hence eliminating both PD-L1 positive tumor cells as well as PD-L1 positive immunosuppressive and antigen presenting cells in the tumor microenvironment. It has been used in clinical trials for patients with multiple melanoma.
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection [Flublok 2016-2017];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [FluLaval Quadrivalent 2015-2016];
material entity;pUMVC3-IGFBP2-HER2-IGF1R plasmid DNA vaccine;A cancer vaccine containing the mammalian expression vector pUMVC3 encoding epitopes derived from three tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2. ERBB2) and insulin-like growth factor 1 receptor (IGF1R), with potential immunostimulating and antineoplastic activities. The vaccine This activates the immune system to mount a combined response from specific T helper type 1 (Th1) cells, memory T-cells and cytotoxic T-lymphocytes (CTL) against IGFBP2-, HER2-, and IGF1R-expressing tumor cells. This vaccine may prevent cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast cancer in which all signs and symptoms have disappeared. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells. It is given in combination with sargramostim.
material entity;prodencel;A cancer vaccine made with autologous dendritic cells targeting prostate cancer (PC)-specific antigen(s), with potential immunostimulatory and antineoplastic activities. Upon administration of prodencel, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against PC cells expressing the antigen(s), resulting in tumor cell lysis. (NCIT C192174) The vaccine could help treat patients with metastatic castration-resistant prostate cancer (mCRPC) after novel androgen-deprived therapy and docetaxel chemotherapy failure.
material entity;polyvalent melanoma vaccine;A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. Treatment with this combination may help treat melanoma.
material entity;mutated neopeptide vaccine;A cancer vaccine with neopeptides designed with single amino acid mutations to enhance their immunogenicity and bind to HLA class I and II molecules. Exome and RNA sequencing as well as in silico HLA-binding predictions to autologous HLA molecules were used to identify candidate neopeptides. Subsequently, in silico HLA-anchor placements were used to deduce putative T-cell receptor (TCR) contacts of peptides. Single amino acids of TCR contacting residues were then mutated by amino acid replacements. TIL-derived CD4+ T-cell clones showed strong responses and tumor cell lysis not only against the designed neopeptide but also against the unmutated natural peptides of the tumor. Turning tumor self-peptides into foreign antigens by introduction of designed mutations is a promising strategy to induce strong intratumoral CD4+ T-cell responses in a cold tumor like glioblastoma.
material entity;multiple signals loaded dendritic cells vaccine;A cancer vaccine that can efficiently present T cells with antigens of HCC sensitize their antitumor properties meanwhile low dose cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Multiple signals loaded dendritic cells vaccine combined low dose of cyclophosphamide combining with radical surgery or TACE or targeted agents for patients with hepatocellular carcinoma coul prolong their survival time.
material entity;multipeptide XS15 vaccine;A cancer vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological malignancies without any approved treatment options.
material entity;multiantigen liposome loaded dendritic cell vaccine;A cancer vaccine for which Advanced Renal Cell Carcinoma patients undergo total nephrectomy to harvest primary tumor for vaccine preparation. Dendritic cells are then pulsed with multiantigens or tumor cells. Some patients also receive vaccination with irradiated autologous tumor lysate. The vaccine may make the body build an immune response to kill tumor cells.
material entity;multi-epitope melanoma peptide vaccine;A cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. This vaccine may stimulate a broader CTL response compared to single-antigen vaccines. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells in patients with stage IIC-IV melanoma. This vaccine is a tyrosinase/gp100/MAGE-3 class I peptide vaccine combined with Montanide ISA 51 or ISA 51 VG with CpG adjuvant 7909 in human leukocyte antigen (HLA) class I A1, A3 or A11 and B44 matched patients with surgically resected stages IIC, III and IV melanoma.
material entity;neoantigen peptide vaccine;A cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Personalized neo-antigen peptide vaccine is a product combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor. Patients also receive nivolumab.
material entity;neoantigen DNA vaccine;A cancer vaccine that may enhance anti-tumor immune response in Renal Cell Carcinoma in combination with checkpoint inhibitors ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody).
material entity;NEO-PV-01 vaccine;A cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Both metastatic squamous non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) are incurable with current therapies, but due to mutations induced by cigarette smoke, typically express a large number of altered proteins that can be recognized as foreign by the immune system. Targeting the immune system against tumor specific antigens using a peptide vaccine could lead to improved response rate and prolonged overall survival with no additional toxicity when combined with Pembrolizumab (monoclonal antibodies that block PD-1/PD-L1 interactions) and standard of care chemotherapy.
material entity;MVF-HER-2(628-647)-CRL 1005 vaccine;A cancer vaccine of a chimeric peptide immunogen of human epidermal growth factor-2 (HER-2) with antineoplastic property. MVF-HER-2(628-647)-CRL 1005 vaccine, coated with poloxamer CRL-1005 to form microparticles, consists of a mutated HER-2 B-cell epitope, HER-2(628-647), and a promiscuous T cell epitope (amino acid sequence 288-302) of the measles virus fusion protein (MVF). The vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. MVF-HER-2(628-647)-CRL 1005 vaccine may induce anti-HER-2 antibody in patients with metastatic or recurrent cancer (Breast, Ovarian, Non-small cell lung cancer, Gastric adenocarcinoma).
material entity;MVA-BN-CV301 vaccine;A cancer vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301 may lead to a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1). therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CV301 is a poxviral-based vaccine comprised of recombinant Modified vaccinia Ankara (MVA-BN-CV301, prime) and recombinant fowlpox (FPV-CV301, boost). CV301 contains transgenes encoding two (2) tumor-associated antigens (TAA), mucin 1 (MUC1) and carcinoembryonic antigen (CEA), as well as three costimulatory molecules (B7.1, intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 3 (LFA-3), designated TRICOM). It is given in combination with SX-682 and M7824 for patients with Triple Negative Breast Cancer (TNBC) and Human papilloma virus (HPV) negative head and neck squamous cell carcinoma (HNSCC).
material entity;pneumococcal capsular polysaccharide type 4 vaccine 0.004 MG;
material entity;pneumococcal capsular polysaccharide type 23F vaccine 0.002 MG/ML;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;pneumococcal capsular polysaccharide type 19F vaccine 0.004 MG;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2022-2023];
material entity;BCG, Live, Connaught Strain Injectable Suspension;
material entity;pneumococcal capsular polysaccharide type 18C vaccine 0.006 MG/ML;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2022-2023];
material entity;BCG, Live, Connaught Strain Injectable Suspension [ImmuCyst];
material entity;pneumococcal capsular polysaccharide type 23F vaccine 0.001 MG;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2022-2023];
material entity;BCG, live, Connaught strain Injectable Suspension [InterVax];
material entity;pneumococcal capsular polysaccharide type 19F vaccine 0.006 MG/ML;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;pneumococcal capsular polysaccharide type 14 vaccine 0.001 MG;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2022-2023];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML;
material entity;influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluad Quadrivalent 2022-2023];
material entity;pneumococcal capsular polysaccharide type 18C vaccine 0.004 MG;
material entity;influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Injectable Suspension;
material entity;pneumococcal capsular polysaccharide type 14 vaccine 0.002 MG/ML;
material entity;influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2022-2023];
material entity;influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2022-2023];
material entity;BCG, Live, Connaught Strain 81 MG Injectable Suspension [ImmuCyst];
material entity;BCG, Live, Connaught Strain 81 MG Injectable Suspension [ImmuCyst] Box of 1;
material entity;BCG, Live, Connaught Strain 81 MG Injectable Suspension [ImmuCyst] Box of 1 by Sanofi;
material entity;BCG, Live, Connaught Strain 81 MG Injectable Suspension [ImmuCyst] by Sanofi;
material entity;BCG, Live, Connaught Strain 81 MG Injectable Suspension Box of 1;
material entity;BCG, Live, Connaught Strain Injectable Solution;
material entity;BCG, Live, Connaught Strain Injectable Solution [ImmuCyst];
material entity;Salmonella-tPA-S SARS DNA vaccine;A SARS DNA vaccine made from CTLA4HingeSARS800 DNA with SARS-CoV S protein
material entity;SARS MA-ExoN vaccine;A SARS recombinant vector vaccine that is made from of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S
material entity;SARS CTLA4-S DNA vaccine;A SARS DNA vaccine that is made from CTLA4HingeSARS800 DNA with SARS-CoV S protein
material entity;SARS tPA-S DNA vaccine;A SARS DNA vaccine that is made from tpa-optimize800 DNA with SARS-CoV S protein
material entity;Salmonella-CTLA4-S SARS DNA vaccine;A SARS DNA vaccine that is made from oral live-attenuated auxotrophic S. typhimurium aroA strain SL7207 that contained CTLA4HingeSARS800 with SARS-CoV S protein.
material entity;Recombinant SARS spike polypeptide vaccine;A SARS DNA vaccine that is made from intraperitoneal recombinant spike polypeptide generated by amplififying gene encoding amino acids residues 14-667 of S protein that was cloned BamHI and KpnI sites of vector pQE-31 that was generated by Escherichia coli
material entity;SARS N + SARS M DNA vaccine;A SARS DNA combination vaccine that is made from recombinant plasmids' containing membrane protein (M) and nucleocapsid protein (N) sequences constructed then expressed and purified from E. coli bacteria.
material entity;SARS M protein DNA vaccine;A SARS DNA vaccine that is made from recombinant plasmid containing membrane protein (M) sequence constructed then expressed and purified from E. coli bacteria.
material entity;SARS N protein DNA vaccine;A SARS DNA vaccine that is made from recombinant plasmid containing nucleocapsid protein (N) sequence constructed then expressed and purified from E. coli bacteria.
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pneumovax 23];
material entity;pneumococcal capsular polysaccharide type 7F vaccine 0.002 MG/ML;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2022 Southern Hemisphere];
material entity;BCG, Live, Connaught Strain 81 MG Injectable Solution [ImmuCyst] Box of 1 by Alliance;
material entity;pneumococcal capsular polysaccharide type 7F vaccine 0.001 MG;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2022-2023];
material entity;BCG, Live, Connaught Strain 81 MG Injectable Solution [ImmuCyst] by Alliance;
material entity;pneumococcal capsular polysaccharide type 9V vaccine 0.002 MG/ML;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2022-2023];
material entity;BCG, Live, Connaught Strain 81 MG Injectable Solution Box of 1;
material entity;pneumococcal capsular polysaccharide type 9V vaccine 0.001 MG;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;BCG, Live, Connaught Strain 81 MG Injectable Suspension;
material entity;pneumococcal capsular polysaccharide type 5 vaccine 0.002 MG/ML;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2022-2023];
material entity;pneumococcal capsular polysaccharide type 5 vaccine 0.001 MG;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2022 Southern Hemisphere];
material entity;pneumococcal capsular polysaccharide type 6B vaccine 0.002 MG/ML;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;pneumococcal capsular polysaccharide type 6B vaccine 0.001 MG;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;pneumococcal capsular polysaccharide type 4 vaccine 0.006 MG/ML;
material entity;BCG, Live, Connaught Strain 660000000 CFU Injection [ImmuCyst];
material entity;BCG, Live, Connaught Strain 81 MG;
material entity;BCG, Live, Connaught Strain 81 MG [ImmuCyst];
material entity;BCG, Live, Connaught Strain 81 MG Injectable Solution;
material entity;SARS rMA15-ΔE vaccine;A SARS recombinant vector vaccine that is made from recombinant MA15 virulent mouse-adapted SARS-CoV (MA15) background of E-deleted vaccine candidate (rMA15-DeltaE).
material entity;BCG, Live, Connaught Strain 81 MG Injectable Solution [ImmuCyst];
material entity;BCG, Live, Connaught Strain 81 MG Injectable Solution [ImmuCyst] Box of 1;
material entity;transgenic lymphocyte immunization vaccine;A cancer vaccine made as patient's lymphocytes are rendered transgenic for a gene coding for selected portion of telomerase an enzyme expressed in the vast majority of cancer cells. Transgenic cells are then returned to the patient to produce an immune response targeted at cancer cells expressing telomerase. The transgenic cells serve as antigen- presenting cells (APCs) with the dual function of antigen synthesis and presentation. Vaccination produces an immune response targeting cancer cells expressing telomerase.
material entity;total tumor RNA-loaded dendritic cell vaccine;A cancer vaccine containing autologous dendritic cells (DCs) that are loaded with total tumor RNA (TTRNA) from a specific tumor, with potential immunostimulatory and antineoplastic activities. The vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA. The vaccine can be given in combination with Temozolomide (TMZ) and Autologous Hematopoietic Stem Cells (HSC).
material entity;TGFβ2 antisense-GMCSF gene modified autologous tumor cell vaccine;A cancer vaccine made with GMCSF transgene that directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. This vaccine integrates enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression. Autologous cancer cells are harvested from patients with advanced refractory cancer, and a TGFβ2 antisense / GMCSF expression vector plasmid is constructed. The autologous cancer tissue is irradiated and electrocorporated with the vector.
material entity;tetanus peptide melanoma vaccine;A cancer vaccine consisting of peptides derived from melanoma-associated antigens and a modified T-cell epitope derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic and helper T-cell response against tumor cells expressing melanoma-associated antigens, resulting in decreased tumor growth. This vaccine is compromised of multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant).
material entity;sialyl lewis-keyhole limpet hemocyanin conjugate vaccine;A cancer vaccine that consists of the oligosaccharide antigen sialyl Lewis (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. The sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewis antigen. The vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.
material entity;secPD-L1 vaccine;A cancer vaccine made with secPD-L1, a splice variant of PD-L1 (programmed death ligand-1, an immune checkpoint pathway) that does not splice into the transmembrane domain, but instead produces a secreted form of PD-L1 that has a unique 18 amino acid tail containing a cysteine that allows it to homodimerize and more effectively inhibit lymphocyte function than monomeric soluble PD-L1. Recombinant secPD-L1 can dimerize and inhibit T-cell proliferation and IFN-gamma production in vitro. SecPD-L1 may function as a paracrine negative immune regulator within the tumor, since secPD-L1 does not require a cell-to-cell interaction to mediate its inhibitory effect. This could lead to improved survival for patients with numerous types of cancers, including lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma.
material entity;SCIB1 DNA vaccine;A cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. The melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs). upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen. SCIB1 can be used in combination with either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma.
material entity;RAS peptide cancer vaccine TG01;A cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. The vaccine may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. The vaccine can be given in combination with Balstilimab and QS-21 for patients with pancreatic cancer to increase efficacy.
material entity;influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Injectable Suspension;
material entity;influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Fluad Quadrivalent 2021-2022];
material entity;influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2021-2022];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2015-2016];
material entity;BCG, live, Connaught strain 20000 UNT/ML Injectable Solution;
material entity;influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Afluria Quadrivalent 2021-2022];
material entity;BCG, live, Connaught strain 20000 UNT/ML Injectable Solution Box of 10;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2016-2017];
material entity;BCG, Live, Connaught Strain 660000000 CFU;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Prefilled Syringe;
material entity;BCG, Live, Connaught Strain 660000000 CFU [ImmuCyst];
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Injection [Flublok 2015-2016];
material entity;BCG, Live, Connaught Strain 660000000 CFU Injection;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe;
material entity;influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Injection;
material entity;BCG, Live, Connaught Strain 1920000000 CFU;
material entity;BCG, Live, Connaught Strain 1920000000 CFU [ImmuCyst];
material entity;BCG, Live, Connaught Strain 1920000000 CFU Injection;
material entity;tumor antigen-sensitized DC vaccine;A cancer vaccine that can be used in combination with Neo-antigen DC vaccine and their sensitized T cells for the treatment of esophageal cancer, advanced malignant melanoma, bladder cancer and colorectal cancer.
material entity;BCG, Live, Connaught Strain 1920000000 CFU Injection [ImmuCyst];
material entity;TriAd cancer vaccine;A cancer vaccine of 3 adenoviral vaccines (ETBX-011, ETBX-051 & ETBX-061). ETBX-011 uses a replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA). ETBX-051 is composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded. ETBX-061 composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded. The three of these vaccines act against tumor associated antigens and have potential immunostimulating and antineoplastic activities. The TriAd vaccine can be used in combination with Anti-PD-L1/TGF-beta trap (M7824) and Anktiva (N-803) to shrink previously untreated head and neck tumors before surgery or stop the tumors from coming back after all treatment.
material entity;BCG, live, Connaught strain 20000 UNT/ML;
material entity;USA licensed veterinary vaccine;USA licensed vaccine for veterinary uses approved by USDA.
role;authorized vaccine role;Vaccine role that indicates a vaccine has received emergency use authorization (EUA) from regulatory authorities for distribution and administration to the public.
material entity;whole tumor cell-based leukemia vaccine;A cancer vaccine administered within the first 2 to 3 months after allogeneic stem cell transplantation may enhance graft-vs.-leukemia responses. Irradiated autologous cancer cells provide a source of tumor antigens at the vaccination site. Granulocyte macrophage colony-stimulating factor (GM-CSF) secreted by irradiated bystander cells stimulates the recruitment, maturation and immunostimulatory activity of dendritic cells (DCs) at the vaccination site. Autologous whole tumor cell-based vaccination may tip the balance between leukemia-specific and alloreactive T cell responses in favor of a graft-vs.-leukemia (GvL) effect.
material entity;TVI-Brain-1 vaccine;A cancer vaccine made as the patient's cancer will be surgically removed to provide cells for the vaccine, then the patient will be vaccinated twice with those cells and GM-CSF. After, the patient's blood will be filtered for white cells which will then be cultured and stimulated to reach a higher (killer) activity level. Next, the activated white blood cells will be infused into the patient's bloodstream so that they will be able to attack the cancer. Lastly, the entire process starting with vaccination will be repeated, for a total of two rounds of therapy. The autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T-cells TVI-Brain-1 recognize and bind to tumor cells expressing the cancer neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.
material entity;tumor lysate/KLH pulsed dendritic cell vaccine;A cancer vaccine made from proteins from the patient's tumor cells may boost the body's immune response against the tumor. The effects of chemotherapy on the immune system can potentially make immunotherapy more effective if administered soon after completion of chemotherapy. The addition of recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7)) may make the immunotherapy more effective. Alpha cluster of differentiation 25 (CD25) and 8H9 depleted autologous lymphocytes plus tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccines plus or minus r-hIL7 (CYT107) may induce immune responses to tumor lysate in patients (with Ewing's sarcoma, rhabdomyosarcoma or neuroblastoma).
material entity;tumor lysate-pulsed dendritic cell vaccine;A cancer vaccine that is composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. It can be used in combination with high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). The combination may increase overall survival and progression-free survival for patients with high-risk pediatric and young adult tumors (localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor).
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2015-2016];
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2015-2016];
material entity;BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 3;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 5;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2016-2017];
material entity;BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 6;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 3;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension;
material entity;BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 5;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe;
material entity;BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 6;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2016-2017];
material entity;BCG, Live, Connaught Strain 1.62 MG/ML;
material entity;BCG, Live, Connaught Strain 1.62 MG/ML [ImmuCyst];
material entity;BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution;
material entity;licensed duck vaccine;
material entity;BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst];
material entity;CRT-N SARS vaccine;A SARS DNA vaccine made from encoding calrectulin linked to a SARS-CoV N protein
material entity;rSARS-CoV-ΔE vaccine;A SARS recombinant vector vaccine made from a line attenuated and recombinant SARS-CoV lacking the E gene
material entity;Ad41.MERS vaccine;A MERS recombinant vector made of Adenovirus type 41 used as vector for MERS-CoV S protein.
material entity;MVA-MERS vaccine;A MERS VLP vaccine made from a recombinant baculovirus co-expresssing the spike S, envelope (E), and membrane (M) proteins of MERS.
material entity;BCG, live, Tice strain 12.5 MG Injection [OncoTICE] by MSD;
material entity;MVvac2-MERS-N vaccine;A MERS recombinant vector vaccine made of live-attenuated measles virus (MV) vaccine encoding the MERS-CoV nucleocapsid protein (MERS-N).
material entity;BCG, live, Tice strain 12.5 MG Injection [OncoTICE] by Organon;
material entity;ChAdOx1-MERS-S vaccine;A MERS recombinant vector made of Chimpanzee adenovirus Oxford 1 vector expressing S protein from MERS-CoV.
material entity;BCG, live, Tice strain 12.5 MG Injection [OncoTICE] by Schering-Plough;
material entity;rVV-SARS vaccine;A MERS DNA vaccine made of plasmid vaccines that encoded S1 subunit only
material entity;MVvac2-MERS-S(H) vaccine;A MERS recombinant vector vaccine made of live-attenuated measles virus (MV) vaccine encoding the MERS-CoV spike protein (MERS-S).
material entity;VRP-MERS-N vaccine;A MERS recombinant vector made from Venezuelan equine encephalitis replicons bearing epitopes of N protein from MERS. Crosslisted as SARS vaccine (VIOLINID:5754). Efficacy higher intranasally than subcutaneously.
material entity;VRP-SARS-N vaccine;A SARS recombinant vector vaccine made from Venezuelan equine encephalitis replicons (VRP) encoding a SARS-CoV CD4+ T cell epitope vaccinated intranasally. Crosslisted as MERS vaccine (VIOLINID:5789). Efficacy higher intranasally than subcutaneously.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 20;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 2;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 20 by Sanofi;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 10;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 10;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2021 Southern Hemisphere];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] by Novartis;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 1;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 10 by Statens Serum Institut;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2020-2021];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 10 by Glaxosmithkline;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 20;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2021 Southern Hemisphere];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 10 by Novartis;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Fluad 2020-2021];
material entity;BCG, Live, Tice Strain 200000000 CELLS;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe;
material entity;BCG, Live, Tice Strain 200000000 CELLS [OncoTICE];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 2 by Novartis;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Injectable Suspension;
material entity;BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 2;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2020-2021];
material entity;BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension [OncoTICE];
material entity;BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension [OncoTICE] Box of 1;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Fluad Quadrivalent 2020-2021];
material entity;BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension [OncoTICE] Box of 1 by MSD;
material entity;BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension Box of 1;
material entity;rDNA-expressed S SARS protein vaccine;A SARS DNA vaccine made from rDNA-expressed ectodomain of the S protein.
material entity;SARS NDV-BC/S vaccine;A SARS-CoV recombinant vector vaccine that is made from the Newcastle disease virus from the mesogenic Beaudette C strainexpressing SARS-CoV S protein.
material entity;SARS NDV-VF/S vaccine;A SARS-CoV recombinant vector vaccine that is made from the Newcastle disease virus from the lentogenic LaSota strain expressing SARS-CoV S protein.
material entity;MERS GLS-5300 vaccine;A MERS DNA Vaccine that is made of the plasmid pGX9109 expressing MERS S protein.
material entity;BCG, Live, Tice Strain 12.5 MG Injectable Solution;
material entity;VRC-SRSDNA015-00-VP vaccine;A SARS DNA vaccine made of a single closed plasmid DNA marcromolecule (VRC-8138) that produces a deletion mutant of the SARS Spike glycoprotein
material entity;BCG, Live, Tice Strain 12.5 MG Injectable Solution [OncoTICE];
material entity;LNP-nCoVsaRNA;A SARS-CoV-2 RNA vaccine made of self-coding RNA encoding SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle.
material entity;Ad5-nCoV;A SARS-CoV-2 vaccine made from a recombinant adinvorius type-5 expressing SARS-CoV-2 S protein.
material entity;CoronaVac vaccine;A SARS-CoV-2 whole virus vaccine made from a purified inactivated SARS-CoV-2 virus.
material entity;ZF2001;A SARS-CoV-2 subunit vaccine composed of the SARS-CoV-2 S protein receptor-binding domain produced in Chinese hamster ovary (CHO) cells and adjuvant aluminum hydroxide.
material entity;MVvac2-MERS-solS vaccine;A MERS recombinant vector made of MVvac2 (measle virus) expressing a soluble, truncated version of spike glycoprotein of MERS-CoV in its full length cloned into the MVvac2 genome and rescued.
material entity;0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Statens Serum Institut;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 50;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Prefilled Syringe;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 5 by Statens Serum Institut;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2017-2018];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2017-2018];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Glaxosmithkline;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 25;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur] Box of 10;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension;
material entity;BCG, Live, Tice Strain 12.5 MG Injectable Solution [OncoTICE] Box of 1;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 20 by Statens Serum Institut;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune] by Lederle Products;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;BCG, Live, Tice Strain 12.5 MG Injectable Solution [OncoTICE] Box of 1 by Merck;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 5 by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe;
material entity;BCG, Live, Tice Strain 12.5 MG Injectable Solution [OncoTICE] by Merck;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 5;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur] Box of 20;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018];
material entity;BCG, Live, Tice Strain 12.5 MG Injectable Solution Box of 1;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;BCG, Live, Tice Strain 12.5 MG Injectable Suspension;
material entity;influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2017-2018];
material entity;BCG, Live, Tice Strain 12.5 MG Injectable Suspension [OncoTICE];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pneumovax 23] by Merck;
material entity;BCG, live, Tice strain 12.5 MG Injection;
material entity;BCG, live, Tice strain 12.5 MG Injection [OncoTICE];
material entity;MERS England1 S1 protein subunit Vaccine;A MERS DNA vaccine made of plasmid that encoded S1 subunit only
material entity;MERS England1 S DNA + England1 S protein subunit vaccine;A MERS combination vaccine made of made of the VRC8400 plasmid that encodes the full-length, membrane anchore MERS spike protein and a DNA vaccine that is a plasmid that encoded S1 subunit
material entity;Ad5.MERS-S1 vaccine;A MERS recombinant vector vaccine made of a recombinant adenoviral vector encoding the the S1 extracellular domain of S protein
material entity;Ad5.MERS-S vaccine;A MERS recombinant vector vaccine made of a recombinant adenoviral vector encoding the full-length MERS-CoV S protein (Ad5.MERS-S)
material entity;beta-propiolactone-inactivated SARS-CoV vaccine;A SARS inactivated vaccine made from whole killed (inactivated by beta-propiolactone) SARS-CoV
material entity;SARS Ad S/N vaccine;A SARS recombinant vector vaccine made of combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein
material entity;Inactivated whole MERS-CoV (IV) vaccine with CpG and Alum;A MERS inactivated whole virus vaccine that has a combined adjuvant that has a combined adjuvant of aluminum hydroxide and CpG oligodeoxynucleotides.
material entity;SARS MVA/S vaccine;A SARS recombinant vector vaccine made from a recombinant form of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S
material entity;BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac];
material entity;SARS ADS-MVA vaccine;A SARS recombinant vector vaccine that is made from a recombinant live-attenuated modified vaccinia virus Ankara (MVA) that had a full-length SARS-CoV envelope Spike (S) glycoprotein gene introduced into the deletion III region of the MVA genome.
material entity;MERS-CoV S vaccine adjuvanted with CpG and Alum;A MERS subunit vaccine that has a combined adjuvant of aluminum hydroxide and CpG oligodeoxynucleotides.
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution;
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluarix Quadrivalent 2020-2021];
material entity;BCG, Live, Tice Strain 12.5 MG [OncoTICE];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pneumovax 23];
material entity;influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe;
material entity;influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2020-2021];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML [Fluzone Quadrivalent 2022-2023];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23];
material entity;influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2020-2021];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022 Southern Hemisphere];
material entity;BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac] Box of 1;
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML [Fluzone Quadrivalent 2023 Southern Hemisphere];
material entity;BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension Box of 1;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur];
material entity;BCG, Live, Montreal Strain Injectable Solution;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune];
material entity;influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection;
material entity;BCG, Live, Montreal Strain Injectable Solution [Pacis];
material entity;BCG, Live, Montreal Strain Injectable Suspension;
material entity;BCG, Live, Montreal Strain Injectable Suspension [Bcg Medac];
material entity;BCG, Live, Montreal Strain Injection;
material entity;BCG, Live, Tice Strain 12.5 MG;
material entity;UV-Inactivated SARS vaccine;A SARS inactivated vaccine made from SARS-CoV inactivated by ultraviolet radiation
material entity;Viral-like-particle S-MHV SARS vaccine;A SARS VLP vaccine made from the SARS-CoV spike protein (S) and the Nucleocapsid (N), envelope (E) and membrane (M) proteins from mouse hepatitis coronavirus (MHV)
material entity;UV-Inactivated SARS + TLR agonist vaccine;A SARS inactivated vaccine made from SARS-CoV inactivated by ultraviolet radiation and a Toll-Like Receptor Agonist Adjuvant is added to prevent eosinophilic immunopathology
material entity;inactivated whole (formalin and UV radiation) SARS-CoV vaccine;A SARS inactivated vaccine made from inactivated whole virus by formalin and Ultraviolet radiation, hence Double Inactivated (DI) Vaccine
material entity;recombinant SARS DNA spike protein vaccine;A recombinant SARS DNA vaccine made from rDNA-expressed ectodomain of the S protein.
material entity;VSVΔG-MERS vaccine;A MERS recombinant vector virus made from chimeric virus based on the vesicular stomatitis virus (VSV) in which the G gene was replaced by MERS-CoV S gene (VSV≈í√ÆG-MERS).
material entity;MERS rNTD vaccine;A MERS subunit vaccine made of a neutralizing monoclonal antibodiesagainst MERS-CoV which bind to the N-terminal domain (NTD) of the MERS-CoV S1 subunit that was expressed by baculovirus-insect cell sf9-derived recombinant MERS-CoV.
material entity;MERS rRBD plus alum vaccine;A MERS subunit vaccine made of neutralizing monoclonal antibodiesagainst MERS-CoV which bind to the ribosomal binding domain (RBD) of the MERS-CoV S protein that was expressed by baculovirus-insect cell sf9-derived recombinant MERS-CoV.
material entity;MERS-CoV pcDNA3.1-S1 DNA vaccine;A MERS DNA vaccine made of plasmid that encodes the first 725 amino acids of S from MERS-CoV
material entity;MERS England1 S DNA Vaccine;A MERS DNA vaccine made of the VRC8400 plasmid that encodes the full-length, membrane anchore MERS spike protein
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] by Sanofi;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1;
material entity;BCG, Live, Montreal Strain 4000000 ORGANISMS/ML [Bcg Medac];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20 by Sanofi;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur] Box of 20;
material entity;BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 10;
material entity;influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML [Flublok Quadrivalent 2020-2021];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur];
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10;
material entity;influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Afluria Quadrivalent 2020-2021];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur];
material entity;influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML Nasal Spray;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II];
material entity;influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML [Flumist Quadrivalent 2020-2021];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20;
material entity;pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur] Box of 10;
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML [Fluzone Quadrivalent 2020-2021];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10 by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II];
material entity;influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML Nasal Spray [Flumist Quadrivalent 2020-2021];
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2020-2021];
material entity;BCG, Live, Connaught Strain Injection;
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2020-2021];
material entity;BCG, Live, Connaught Strain Injection [ImmuCyst];
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Flulaval Quadrivalent 2020-2021];
material entity;BCG, Live, Montreal Strain 120 MG;
material entity;0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 20 by Sanofi;
material entity;0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur];
material entity;influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension;
material entity;BCG, Live, Montreal Strain 120 MG [Pacis];
material entity;BCG, Live, Montreal Strain 120 MG Injectable Solution;
material entity;BCG, Live, Montreal Strain 120 MG Injectable Solution [Pacis];
material entity;BCG, Live, Montreal Strain 120 MG Injectable Solution [Pacis] by ID bio;
material entity;BCG, Live, Montreal Strain 4000000 ORGANISMS/ML;
